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ABSTRACT

Protein kinase CK2 is a constitutively active, acidophilic protein serine/threonine kinase
with an extensive array of protein substrates that have been implicated in the regulation of
many cellular events including those that maintain the delicate balance between
proliferation and survival. Although numerous substrates of CK2 have been identified,
bioinformatic analysis predicts that 20% of the phosphoproteome can be attributed to
CK2, suggesting that our understanding of CK2 is greatly underappreciated. Not
surprisingly, CK2 levels are elevated in multiple cancers, and therapeutics targeting CK2
are in development. In order to realize the full potential of these therapies, it is essential to
have robust methods to monitor CK2 activity as well as interrogate the specificity of CK2
to further understand the cellular role of CK2.
In this thesis, we developed three complementary chemical biology strategies to
investigate the activity and substrate specificity of CK2. First, we generated a novel antiFc antibody to perform a detailed biochemical analysis of the ability of CK2 to utilize 5’γ-ferrocenyl-ATP (FcATP), an electroactive ATP analog. CK2 effectively uses FcATP
compared to ATP and our biochemical assays recapitulate electrochemical data,
providing a strong foundation upon which to develop a multiplexed kinosensor to stratify
patients. Second, to study the substrate specificity of CK2 we genetically engineered an
analog-sensitive CK2 to utilize N6-(2-phenylethyl)ATP, to specifically phosphorylate and
label a direct CK2 substrate, EEF1D. Finally, we performed a systematic analysis of
hierarchical CK2 phosphorylation, where priming phosphorylation is required for
subsequent CK2 phosphorylation. Phosphoserine oriented peptide arrays were used to
define optimal consensus sequences for hierarchical CK2 phosphorylation. Subsequent
bioinformatic analysis revealed over 2000 candidates involved in diverse signaling
pathways, and a fraction of these candidates were known to be phosphorylated in cell.
Collectively, our results will greatly aid in the continued development and clinical
usage of targeted-CK2 inhibitors in personalized medicine. These strategies have
provided insight into the complexity of the signaling pathways that CK2 intricately
regulates and using these strategies will increase our knowledge of the cellular roles and
ii

decipher the kinase-substrate relationships of CK2 to identify biomarkers for CK2
activity.
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CHAPTER ONE: INTRODUCTION1

1.1 General introduction
Cells exist in a dynamic state; they require the ability to rapidly adapt to their constantly
changing environment. Responses to these changes are mediated by signal transduction
involving a number of distinct mechanisms including the reversible phosphorylation of
proteins. Protein phosphorylation is an important regulatory mechanism with a critical
role in signal transduction pathways controlling cell growth, death, survival, and
differentiation (Hunter, 2000; Manning et al., 2002). Protein kinases catalyze the transfer
of the γ-phosphate from ATP to serine, threonine, and tyrosine residues on target proteins,
modulating substrate structure, function, and/or activity. There are 518 putative protein
kinases encoded in the human genome and these kinases are highly conserved in protein
sequence and structure, especially in the catalytic domain (Hanks et al., 1988; Hanks and
Hunter, 1995; Manning et al., 2002). In fact, phosphorylation is so prevalent that it is
estimated that over one-third of the proteome can be phosphorylated and most
phosphoproteins are multiply phosphorylated (Ahn and Resing, 2001; Sharma et al.,
2014).
Unregulated or enhanced protein kinase activity can result in aberrant signalling
pathways and is linked to many human diseases, including cancer (Manning et al., 2002).
Hence, protein kinases have emerged as attractive targets for molecular therapeutics
(Cohen, 2002). One very successful example of targeted inhibition is Gleevec (Imatinib)

1

A modified version of this chapter has been published: Gabriel M and Litchfield DW. (2013) Protein
Kinase CK2: At the Crossroads of Pathways Controlling Cell Proliferation and Survival in Protein Kinase
CK2. Ed. Pinna LA. John Wiley & Sons, Inc. pp 169-189.

2
in the treatment of Chronic Myelogenous Leukemia (CML) (Capdeville et al., 2002). By
binding the ATP binding site of the Bcr-Abl chimeric mutant kinase, Gleevec inhibits
substrate phosphorylation.

1.2 Protein Kinase CK2
Protein kinase CK2 (formerly casein kinase II) was discovered by Burnett and Kennedy
in 1954 (Burnett and Kennedy, 1954). CK2 is a conserved, ubiquitously expressed,
protein serine/threonine kinase. The CK2 family consists of two catalytic subunits, CK2α
and CK2α’, and one regulatory subunit, CK2β. The catalytic subunits are both members
of the CMGC family of kinases, and are closely related to cyclin-dependent kinases
(Cdks) (Manning et al., 2002). Although CK2α and CK2α’ are the products of two
independent genes localized to different chromosomes, they share 90% sequence identity
in the N-terminal 330 amino acids (Litchfield, 2003). The C-termini, however, are
completely different, with CK2α having a 20 amino acid extended tail not present in
CK2α’ (Lozeman et al., 1990).
CK2 is involved in numerous signaling pathways including cell proliferation,
differentiation, and apoptosis (Glover, 1998; Litchfield, 2003). Experiments in yeast and
mice have shown that CK2 is essential for viability. In yeast, simultaneous disruption of
the genes encoding both catalytic subunits of CK2, namely CKA1 together with CKA2,
results in loss of viability (Glover, 1998; Rethinaswamy et al., 1998). Studies in mouse
models have also demonstrated that when either CK2β or CK2α are knocked out, the
result is embryonic lethal, aborting at day E7.5 and E11.5, respectively (Buchou et al.,
2003; Lou et al., 2008). By comparison, when CK2α’ is knocked out the mice are viable
but the males are sterile due to a defect in spermatogenesis where an apoptotic defect

3
leads to oligospermia (Xu et al., 1999; Escalier et al., 2003). This observation suggests a
functional specialization between CK2α and CK2α’ catalytic subunits, where CK2α can
partially but not completely compensate for the loss of CK2α’. Studies have provided
further evidence to support this specialization, although no major differences in the
catalytic properties of CK2α and CK2α’ have yet been identified. Temperature-sensitive
mutants in yeast display distinct phenotypes. Loss of CKA1 revealed a defect in cell
polarity whereas loss of CKA2 resulted in cell cycle arrest (Hanna et al., 1995;
Rethinaswamy et al., 1998). Inducible expression of kinase-inactive forms of CK2α and
CK2α’ in U2-OS cells also reveal a significant attenuation of proliferation with only
CK2α’K69M (Vilk et al., 1999).

1.2.1 Substrate specificity of CK2
CK2 is largely distinguishable from many other protein kinases by its somewhat unique
ability to use not only ATP, but also GTP as a phosphate donor as well as its ability to
phosphorylate serine, threonine, and tyrosine residues within clusters of acidic residues
(Pinna, 1990; Niefind et al., 1999). CK2 is an acidophilic kinase and through an
examination of CK2 substrates, the minimal consensus sequence for CK2 has been
defined as S/T-X-X-D/E, where X is any amino acid (Meggio and Pinna, 2003). The
acidic determinants appear to have an additive effect as many known CK2 sites consist of
a serine/threonine residue followed by a string of acidic residues (Meggio and Pinna,
2003; Salvi et al., 2009). Intriguingly, CK2 has also been shown to use phosphoserine
(pS) and phosphotyrosine (pY), but not phosphothreonine (pT) as acidic determinants for
phosphorylation, suggesting that CK2 could be a participant in hierarchical
phosphorylation events (Kuenzel et al., 1987; Hrubey and Roach, 1990; Litchfield et al.,
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1990; Pinna, 1990; Perich et al., 1992; Marin et al., 1996). In fact, roles for CK2 as both
the priming and primed kinase have been demonstrated by examples published in the
literature (DePaoli-Roach et al., 1981; DePaoli-Roach, 1984; Woodgett and Cohen, 1984;
Watanabe et al., 2005; Koseoglu et al., 2008; Yata et al., 2012; Cesaro et al., 2013;
Venerando et al., 2014).
CK2 is a pleiotropic kinase and is predicted to have a plethora of protein
substrates that are involved in numerous cellular pathways (Litchfield, 2003). Over a
decade ago, a review of the literature identified 307 protein substrates of CK2 (Meggio
and Pinna, 2003). These substrates are as diverse as the pathways CK2 is involved in and
include proteins involved in not only signaling pathways, but transcription factors,
RNA/DNA processes, protein synthesis, cytoskeleton, structure, and metabolism as well.
More recent unbiased studies have identified 138 phosphosites in 105 putative yet high
confidence CK2 substrates using proteome-derived tryptic peptides (Wang et al., 2013).
While a second study using dephosphorylated and immobilized proteomes as substrates
identified 605 phosphopeptides matching the CK2 consensus sequence in 356 proteins
(Bian et al, 2013). In fact, this may represent only a fraction of cellular CK2 substrates as
bioinformatic studies predict that an estimated 20% of the phosphoproteome can be
attributed to CK2 based on matching the consensus sequence to phosphosites present in
the human phosphoElm database (Salvi et al., 2009, 2010). Most of these substrates are
only predicted; some have been confirmed in vitro, and even fewer in vivo, suggesting
that the current repertoire of CK2 substrates is incomplete.

1.2.2 Structural aspects of CK2
In mammalian cells, CK2 exists primarily as a holoenzyme, which is a tetramer
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consisting of a dimer of two regulatory CK2β subunits each interacting with a catalytic
subunit, either CK2α or CK2α’ (CK2α2β2, CK2α’2β2, or CK2αα’β2) (Figure 1-1) (Gietz et
al., 1995; Graham and Litchfield, 2000; Niefind et al., 2001). The catalytic subunit is
bilobal in shape and composed of an N-terminal lobe, rich in β-sheets, connected through
an interdomain hinge to a C-terminal lobe, rich in α-helices (Figure 1-1) (Niefind et al.,
2001). Based on crystal structures solved with purine analogs, the active site is a deep
cleft positioned between these two lobes. The nucleotide-binding pocket is lined with
hydrophobic residues contributed by both lobes, including a glycine rich segment, that
interact with the adenosine ring of ATP through many hydrophobic and Van der Waals
interactions. Additional hydrogen bonding between ATP and the backbones of E114 and
V116 in the interdomain hinge further stabilize binding. For catalysis, two Mg2+ ions are
positioned by N161 and D175 to help neutralize the negative charges from the phosphates
on ATP, and E81 contributes ionic interactions to orient K68 in the correct position for
alignment with the phosphates. Interestingly, the ATP analog, adenylyl-imidodiphosphate
(AMP-PNP) is only bound to one catalytic subunit in this structure.
While CK2 contains many elements that are conserved between other kinases and
are required for catalysis, the nucleotide-binding pocket of CK2 is also quite structurally
unique from other kinases. First, CK2 is a dual specificity kinase and can utilize both
ATP and GTP. Two water molecules that are coordinated within the nucleotide-binding
pocket mediate GTP binding (Niefind et al., 1999). Second, the pocket of CK2 is much
thinner in one dimension, than in other kinases. This is a result of larger hydrophobic
residues that are not conserved and substituted with smaller residues in other kinases;
namely V66, I174, H160, and M163 (Figure 1-2) (Hanks and Hunter, 1995). Notably,
F113 is another large hydrophobic residue in the back of the pocket that acts as a natural

6

Figure 1-1

CK2α

CK2α
AMP-PNP

N-terminal lobe

C-terminal lobe

CK2β

CK2β

Figure 1-1. Crystal structure of the CK2 holoenzyme. Catalytic CK2α subunits are
shown in red and green and regulatory CK2β subunits are shown in blue and cyan. A
non-hydrolyzable ATP analog, adenylyl-imidodiphosphate (AMP-PNP), coloured in
black is positioned in the active site of one of the catalytic CK2α subunits. Image was
prepared with PyMol. PDB: 1JWH.
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barrier to ATP analogs and produces hydrophobic interactions with ATP. A
phenylalanine in this position is only present in 15% of kinases, and is most frequently a
methionine or leucine (Zuccotto et al., 2010).
Additionally, CK2 contains two clusters of basic residues positioned just outside
the nucleotide-binding pocket that confer substrate selectivity and binding (Figure 1-2). In
the absence of a crystal structure solved with a peptide substrate, mutational studies have
mapped the substrate-binding cleft in CK2 to the lysine-rich segment in helix αC (K7479, R80, K83) and the p+1 loop (R191, 195, K198), which interact with acidic residues
on CK2 substrates (Sarno et al., 1996, 1997, 1999; Niefind et al., 2007). In these studies,
mutations of these basic amino acids to neutral alanine residues increased the affinity of
CK2 for its substrate peptide (Sarno et al., 1996, 1997). Additionally, a model generated
by aligning CK2 with the structure of PKA and a bound substrate by changing the PKA
substrate to resemble a CK2 peptide substrate further implicates these basic residues as
they directly interact with individual acidic residues at the n+1, n+2, n+3, and n+4
positions on the substrate (Sarno et al., 1999). This model was further supported by the
observation of two sulfate anions bound to the lysine-rich segment and p+1 loop in a
crystal structure of CK2 (Niefind et al., 2007).

1.2.3 Regulation of CK2 activity
CK2 is largely regarded as constitutively active, and unlike many other protein
serine/threonine kinases, is not susceptible to second messenger regulation or activating
or inhibitory phosphorylation (Litchfield, 2003; St-Denis and Litchfield, 2009). While
there is not yet a unifying model to explain how CK2 activity is controlled within cells,
its regulation appears to involve a number of more subtle means including localization,
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Figure 1-2

Helix αC
(K74-79,R80,K83)
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AMP-PNP

M163
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P+1 loop
(R191,195,K198)

H160

Figure 1-2. The structure of the active site of CK2. The nucleotide binding site is
positioned in a deep cleft between the N- and C-terminal lobes. Selected residues are
highlighted. The p+1 loop and helix αC interact with substrates and are coloured in
yellow. F113 acts as a natural barrier to ATP analogs and is coloured in green. The
catalytic residue, K68, is coloured in blue. Large hydrophobic residues that line the
nucleotide-binding pocket are coloured in red. AMP-PNP is coloured in black. Image
was prepared with PyMol. PDB: 1JWH.
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phosphorylation, and protein-protein interactions (reviewed in Litchfield, 2003; St-Denis
and Litchfield, 2009; St-Denis et al., 2011). Notably, both CK2α and CK2β subunits are
phosphorylated (Phosida). Amongst a number of identified phosphorylation sites, CK2β
is autophosphorylated following tetramer assembly at serines 2, 3, and/or 4 (Litchfield et
al., 1991). Additionally, S209 is phosphorylated by Cdk1 in a cell cycle dependent
manner (Litchfield et al., 1991). CK2α is also phosphorylated by Cdk1 in a cell cycle
dependent manner at threonines 344 and 360 and serines 362 and 370, all contained
within the unique C-terminal tail (Litchfield et al., 1992, Bosc et al., 1995).
Phosphorylation at these sites has no effect on kinase activity (Bosc et al., 1999), but
suggests functional specialization between CK2α and CK2α’ during the cell cycle as they
may be important for different protein-protein interactions (Messenger et al., 2002; StDenis et al., 2009, 2011).

1.3 CK2 in cancer
In line with its participation in many cellular processes, it may not be unexpected that
CK2 has been implicated in a number of diseases including cancer. In this respect,
elevated levels of CK2 have been observed in numerous cancers, including breast
(Landesman-Bollag et al., 2001), prostate (Laramas et al., 2007), lung (Daya-Makin et al.,
1994), head and neck (Faust et al., 1996), colorectal (Lin et al., 2011), gastric (Lin et al.,
2010), hematological (Kim et al., 2007; Martins et al., 2010; Pizzi et al., 2015),
mesothelioma (Zhang et al., 2014), and kidney (Stalter et al., 1994). Studies in mouse
models further reinforce the direct role of CK2 in tumorigenesis. Targeted expression of
CK2 in transgenic mouse models resulted in mammary gland tumorigenesis and thymus
cell transformation (Landesman-Bollag et al., 2001). Tumorigenicity also appears co-
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operative when CK2 is overexpressed in mice completely deficient in p53 (LandesmanBollag et al., 1998) or overexpressing other oncogenes, Tal-1 (Kelliher et al., 1996) or cMyc (Channavajhala and Seldin, 2002) in thymus cells as demonstrated by a synergistic
increase in oncogenic activity and progression of tumorigenesis. Furthermore, it has been
demonstrated that overexpression of CK2 in many cancers, both solid and hematopoietic,
results in a significantly unfavorable prognosis and poor overall survival when compared
with tumours with lower CK2 expression levels (Laramas et al., 2007; Giusiano et al.,
2010; Lin et al., 2010, 2011; Piazza et al., 2012; Bae et al., 2015).

1.3.1 CK2 as a “druggable” target
Considering the direct link between CK2 and tumorigenesis and the correlation of these
levels and survival, several studies have investigated the effect of modulating CK2
activity. Downregulation of CK2 in HT29 colon cancer (Izeradjene et al., 2005), HeLa
cervical cancer (Yamane and Kinsella, 2005a), PC-3 and ALVA-41 prostate cancer
(Wang et al., 2006; Gang et al., 2015), A549 and H2030 lung cancer (Zhao et al., 2013),
and PANC-1 pancreatic cancer cell lines (Hamacher et al., 2007; Kreutzer et al., 2010)
resulted in sensitization to apoptotic stimuli, both intrinsic (ionizing and ultraviolet (UV)
radiation) and extrinsic (TRAIL-induced). Downregulation of CK2 on its own, using
antisense RNA, RNA interference (RNAi), overexpression of kinase-inactive mutants, or
pharmacological inhibitors resulted in the spontaneous induction of apoptosis in
numerous prostate, pancreatic, breast, liver, and leukemia cell lines as well as mouse
xenografts (Slaton et al., 2004; Wang et al., 2005; Di Maira et al., 2007; Hamacher et al.,
2007; Silva et al., 2008; Kreutzer et al., 2010; Martins et al., 2010; Gray et al., 2014; Wu
et al., 2014). Interestingly, inhibiting CK2 in cells from several leukemias resulted in
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significantly reduced cell viability (Kim et al., 2007; Silva et al., 2008; Martins et al.,
2010). In these studies, cell death was higher in Acute Myeloid Leukemia (AML) cells
with high CK2α expression than with AML cells with low CK2α expression and healthy
thymus and bone cells were not significantly affected in Chronic Lymphocytic Leukemia
(CLL) and T-cell Acute Lymphoblastic Leukemia (T-ALL). Clearly, reducing CK2
activity in cancer cells promotes cell death and indicates an anti-apoptotic role for CK2.
Perhaps even more exciting, CK2 inhibition is also effective in inducing cell death in
multidrug resistant and chemorefractory cell lines and in combination can increase the
sensitivity of these previously insensitive cells to vinblastine, imatinib, and doxorubicin
(Di Maira et al., 2007; Zanin et al., 2012; Wang et al., 2015; So et al., 2015).
Furthermore, several studies have demonstrated that CK2 inhibition acts synergistically
with other chemotherapeutic agents including paclitaxil and cisplatin (Perera et al., 2014),
nocodazole (Seeber et al., 2005), gemcitabine (Kreutzer et al., 2010), erlotinib (Bliesath et
al., 2012), doxorubicin (Wang et al., 2015), and 6-thioguanine (Yamane and Kinsella,
2005b).
These observations demonstrate the anti-apoptotic roles of CK2 in cancer which
can be neutralized by downregulating CK2 activity, and sensitizing the cells to die. This
highlights the propensity of CK2 as an attractive therapeutic target and has spurred
immense interest into CK2-targeted drug development. As such, numerous compounds
have been synthesized in an attempt to inhibit CK2 activity (Figure 1-2). Several
compounds

have

been

synthesized

using

a

5,6-dichloro-1-(β-d-ribofura-

nosyl)benzimidazole (DRB) parent molecule and have shown success in inhibiting CK2
activity. These structurally related compounds are 4,5,6,7-tetrabromobenzotriazole
(TBB),

4,5,6,7-tetrabromobenzimidazole

(TBBz),

and

2-dimethylamino-4,5,6,7-
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Figure 1-3

A

C

B

D

E

Figure 1-3. Selected examples of CK2 inhibitors. The structure of ATP (A) and four
commonly used CK2 inhibitors are shown: (B) CX-4945, (C) TBB, (D) TBBz, and (E)
DMAT.
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tetrabromo-1H-benzimidazole (DMAT) and inhibit CK2 with Ki values of 0.4, 0.51, and
0.04 µM, respectively (Sarno et al., 2001; Zien et al., 2003; Pagano et al., 2004; Zien et
al., 2005). Recently, one compound, CX-4945, has been developed by Cylene and is a
potent and selective inhibitor of CK2 (Ki 0.38 nM) that is emerging into Phase I/II
clinical trials (Pierre et al., 2011; Chon et al., 2015; www.clinicaltrials.gov). Interestingly,
these compounds all have some structural resemblance to the adenosine rings ATP, and
are composed of aromatic rings that generate a very planar one-dimensional structure to
exploit the uniquely thin binding-pocket of CK2.

1.4 Involvement of CK2 in signaling pathways controlling death and proliferation
The hallmarks of cancer include deregulated cell growth and proliferation along with
evasion of cell death and apoptosis (Hanahan and Weinberg, 2000). Consistent with the
importance of CK2 in cancer and tumorigenesis, perhaps it is not surprising that CK2 is
an essential component in both cell proliferation and death.

1.4.1 CK2 in apoptosis
Apoptosis is a form of programmed cell death orchestrated by a network of proteases with
a major role in the regulation of cell survival through initiation and execution of
apoptosis. The process is tightly regulated through multiple mechanisms, as perturbations
result in tumorigenesis and have been linked to cancer (Vermeulen et al., 2005).
CK2 has recently emerged as an anti-apoptotic effector protein with increasing
evidence in support of this anti-apoptotic role. First, CK2α’ knockout mice are viable, yet
the males are infertile due to an apoptotic defect during spermatogenesis suggesting that
CK2α’ is necessary for anti-apoptotic regulation (Xu et al., 1999; Escalier et al., 2003).
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Second, induction of apoptosis in cells following downregulation of CK2 provides further
evidence of this anti-apoptotic role. Many proteins become phosphorylated during
apoptosis, and this phosphorylation contributes to both positive and negative regulation
(Kurokawa and Kornbluth, 2009). CK2 regulates apoptosis through phosphorylation of
proteins which are components of the apoptotic machinery as illustrated in Figure 1-4.
CK2 phosphorylates PTEN, a tumor suppressor protein resulting in perpetuation of the
pro-survival signal from PI3K/Akt (Torres et al., 2003). Bid, an important regulator of
cytochrome c release from the mitochondria, apoptosome formation, and consequent
activation of apoptosis is also phosphorylated by CK2 (Desagher et al., 2001). p53, a
transcription factor that transcribes apoptotic genes and regulates cytochrome c release, is
also a CK2 substrate (Shen and White, 2001). Additionally, overexpression of CK2
results in upregulated expression of survivin, a member of the inhibitor of apoptosis (IAP)
family (Tapia et al., 2006). At a molecular level these substrates reiterate the importance
of CK2 in regulating apoptosis, and thus, cell survival.
Many studies have also implicated a role for CK2 in regulating cleavage by
caspases (cysteine-dependent aspartic acid-directed proteases). Caspases are classified
into initiator (2, 8, 9, and 10) and executioner caspases (3, 6, and 7), are synthesized as
inactive pro-enzymes, and require activation. Both extrinsic and intrinsic pathways
converge on the executioner caspases, including caspase 3, which is activated through
cleavage by the upstream initiator caspases. The executioner caspases then efficiently
cleave cellular proteins eventually culminating in the death of the cell (Cohen, 1997;
Chowdhury et al., 2008).
Proteins that are protected from caspase cleavage when phosphorylated by CK2
include Bid (Desagher et al., 2001), Max (Krippner-Heidenreich et al., 2001), HS1
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Figure 1-4
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Figure 1-4. The role of CK2 and convergence with caspases in apoptosis. Proteins with
CK2 phosphorylation sites proximal to caspase cleavage sites, which have been shown
to be protected from caspase-mediated cleavage by phosphorylation, are depicted in
orange. Other proteins with critical roles in caspase pathways and the control of
apoptosis that have been identified as CK2 substrates are highlighted in yellow. CK2 is
coloured in green. See the text for more details.
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(Ruzzene et al., 2002), Presinilin-2 (Walter et al., 1999), Connexin 45.6 (Yin et al., 2001),
YY1 (Riman et al., 2012), and PTEN (Torres et al., 2003). Phosphorylation of Bid
protects against caspase 8 cleavage which attenuates activation of the mitochondrial
apoptotic machinery (Desagher et al., 2001). Phosphorylation of transcription factor YY1
prevents cleavage by caspase 7 and continued transcription of pro-survival, growth, and
proliferative genes (Riman et al., 2012). ARC phosphorylation by CK2 has been
demonstrated to inhibit caspase 8 activation (Li et al., 2002). By preventing caspase
cleavage, CK2 phosphorylation can protect against activation or execution of apoptosis.
These results suggest that CK2 phosphorylation can modulate the activity of caspase
pathways. Notably, CK2 phosphorylation of pro-caspase 2 itself has also been shown to
prevent caspase activation by inhibiting pro-caspase 2 dimerization (Shin et al., 2005).
Perhaps even more interesting, was the identification and in cell confirmation of a CK2
phosphorylation site in murine caspase 9. Phosphorylation at S348 was shown to prevent
cleavage by caspase 8 (McDonnell et al., 2009). Functionally, given that caspase 9 is an
initiator caspase, this indicates that protection of caspase 9 from caspase 8 cleavage by
CK2 phosphorylation prevents activation and in turn, reduces cleavage and activation of
downstream effector caspases including caspase 3 resulting in the attenuation of
apoptosis. Phosphorylation of caspase 9 at S348 was also particularly intriguing as S348
is located within the cleavage motif, suggesting that phosphorylation of residues proximal
to the caspase cleavage site blocks cleavage. This has been further demonstrated with
other substrates (Riman et al., 2012). Most importantly, a recent study has demonstrated
that phosphorylation at T174 and S176 on pro-caspase 3 by CK2 blocks cleavage at a
proximal site by caspases 8 and 9 and subsequent caspase 3 activation (Duncan et al.,
2011; Turowec et al., 2013). This is particularly intriguing because both the extrinsic and
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intrinsic pathways mediated by caspases 8 and 9, respectively, converge on caspase 3
cleavage and apoptosis. Taken together, these observations indicate that CK2 converges
on caspase signalling through phosphorylation and protection of caspase targets or direct
phosphorylation of caspases themselves to regulate apoptosis.
It is apparent that CK2 is critical in maintaining the delicate balance between cell
survival and apoptosis through phosphorylation of pro- and anti-apoptotic proteins.

1.4.2 CK2 in the cell cycle
The cell cycle is a tightly regulated cellular process that allows cells to proliferate through
the division of one cell into two identical daughter cells. There are several lines of
evidence that demonstrate a role for CK2 in the cell cycle. Genetic and biochemical
experiments in slime mould, yeast, and mammalian cells provide evidence for the
requirement of CK2 at the G0/G1, G1/S, and G2/M transitions for proper cell division and
mitotic progression (Kikkawa et al., 1992; Pepperkok et al., 1994; Hanna et al., 1995;
Glover, 1998; St-Denis et al., 2009). This implicates CK2 in every stage of the cell cycle.
Additionally, CK2α and CK2β are both phosphorylated in a cell cycle dependent manner
(Litchfield et al., 1991, 1992).
Progression through the cell cycle is largely mediated through the highly
controlled activation and subsequent deactivation of Cyclin-dependent protein kinases
(Cdks). Each Cdk/cyclin pair is differentially activated throughout the cell cycle, with
Cdk4/Cyclin D and Cdk2/Cyclin E at the G1/S transition, Cdk1/cyclin A during S phase,
and Cdk1/Cyclin B at the G2/M transition (Nasmyth, 1996). Temporal activation of these
Cdks is regulated by the Cdk-activating kinase (CAK), a multicomplex enzyme composed
of Cdk7, Cyclin H, and ménage à trois 1 (MAT1) (Lolli and Johnson, 2005). As
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illustrated in Figure 1-5a, CK2α interacts with Cyclin H to form a complex which
facilitates phosphorylation of S315 on the cyclin by CK2 (Faust et al., 2002). Although
this phosphorylation has no effect on CAK complex formation, it is essential for full
CAK activity (Schneider et al., 2002).

1.4.3 G1/S
During G1/S, the cell prepares for division and begins DNA replication. Activation of the
G1/S Cdks results in pRB hyperphosphorylation leading to the release of the E2F
transcription factor and consequent transcription of critical cell cycle dependent genes
(Sherr and McCormick, 2002). Perhaps, the most extensively studied role of CK2 in G1/S
is its regulation of the critical tumour suppressor protein and transcription factor p53
(Figure 1-5b). Indirect evidence of this regulation has been demonstrated using CK2
inhibitors. Cells treated with CK2 inhibitors show p53 induction and target gene
transcription (Allende-Vega et al., 2005). In healthy cells, p53 is constantly produced and
through its interaction with murine double minute clone 2 (MDM2), p53 is targeted to the
26S proteasome and degraded. In cells with DNA damage, the interaction between p53
and MDM2 is disrupted and p53 is no longer degraded and thus accumulates, leading to
cell cycle arrest (Sherr and McCormick, 2002). At a mechanistic level CK2
phosphorylates MDM2 at both serine 267 and 269 which is required for p53 interaction
and subsequent degradation. In response to UV damage, these sites become
hypophosphorylated which results in stabilization of p53 (Gotz et al., 1999; Hjerrild et al.,
2001; Allende-Vega et al., 2005; Gotz et al., 2005). Furthermore, p53 has been reported
to be a substrate of CK2 and phosphorylation at serine 392 results in increased DNA
binding by p53 and transcriptional activation (Kapoor and Lozano, 1998; Keller and
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Figure 1-5. Involvement of CK2 in different stages of the cell cycle. (A) CK2 promotes
Cdk/cyclin activation through regulation of the Cdk-activating kinase complex. (B) CK2
is involved in regulation of G1/S transition through phosphorylation of p53, MDM2, and
the p21 and p27 Cdk inhibitors. (C) Schematic illustration highlighting the involvement
of CK2 at G2/M. More details of each of these illustrations are provided in the text. P,
phosphate; Ub, ubiquitin.
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Lu, 2002). Overall the regulation of p53 by CK2 is complex and currently not well
defined. Additionally, in response to UV damage, CK2 also interacts with

the

FACT complex, composed of SSRP1 and hSPT16 which results in increased CK2
phosphorylation of p53 (Keller et al., 2001, 2002). SSRP1 is also a CK2 substrate and
phosphorylation decreases SSRP1 binding to DNA causing transcription and replication
to stop (Li et al., 2005).
In addition to its role in Cdk activation through Cyclin H phosphorylation, CK2
can also regulate Cdk activity through CK2β-dependent phosphorylation of Cdk2
inhibitory proteins p21WAF1/CIP1 and p27KIP1 (Gotz et al., 1996; Romero-Oliva and
Allende, 2001; Tapia et al., 2004) (Figure 1-5b). These inhibitor proteins are both
transcriptional targets of p53, however, the effects of CK2 phosphorylation are currently
unknown.
Collectively, it is clear that CK2 has important roles in the G1/S transition,
demonstrated by its regulation through multiple mechanisms to ensure that the cell and
DNA is undamaged before committing itself to DNA replication and division.

1.4.4 G2/M
Mitosis is the stage of cell proliferation where one cell divides into two identical cells.
The process occurs through DNA condensation, formation of a bipolar mitotic spindle
between two centrosomes, chromosomal attachment to the spindle, chromosomal
alignment at the midline, and finally, equal separation of the chromosomes into two cells.
The onset of mitosis is driven by activation of Cdk1/cyclin B, which triggers a massive
wave of phosphorylation (Lindqvist et al., 2009). Increasing evidence supports an
essential role for CK2 in mitosis. For example, attenuation of CK2 activity or knockdown
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of CK2 results in improper mitotic progression attributed to abrogation of the spindle
assembly checkpoint (Sayed et al., 2001).
Immunofluorescence and proteomic studies have localized CK2 with the mitotic
spindle and centrosomes (Yu et al., 1991, Krek et al., 1992; St-Denis et al., 2009, 2011).
Notably, CK2 has the ability to regenerate numerous phosphoepitopes lost during
phosphatase treatment as detected using the mitosis protein monoclonal-2 (MPM-2)
antibody, suggesting that CK2 phosphorylates a number of mitotic proteins (Escargueil et
al., 2000). To date, several CK2 substrates involved in mitosis have been identified. As
illustrated in Figure 1-5c, these include Topoisomerase IIα (Daum and Gorbsky, 1998;
Escargueil et al., 2000), protein serine/threonine kinase Wee1A (Watanabe et al., 2005),
and dual-specificity phosphatases CDC25B (Theis-Febvre et al., 2003) and CDC25C
(Schwindling et al., 2004). CK2 phosphorylation of Wee1A is absolutely required for
Wee1A degradation, activation of Cdk1, and the onset of mitosis (Watanabe et al., 2005).
Priming phosphorylation by Cdk1/cyclin B on Wee1A at S123 primes subsequent
phosphorylation by CK2 at a proximal site, S121, as well as accelerates phosphorylation
of S53 by Plk1. Once phosphorylated these sites produce two binding sites for an E3
ligase, promoting ubiquitin-mediated degradation of Wee1A and the onset of mitosis.
However, for the most part, the effects of CK2 phosphorylation are unknown. A few CK2
interacting proteins have also been identified in mitosis, including β-Tubulin, a structural
component of the mitotic spindle (Faust et al., 1999) and Pin1, a peptidyl-prolyl
isomerase (Messenger et al., 2002) (Figure 3C). Interestingly, Pin1 has been shown to
only interact with CK2α and not CK2α’ and this interaction is mediated through the four
phosphorylation sites unique to the C-terminal tail of CK2α. This interaction has recently
been shown to be critical to the localization of CK2α to the mitotic spindle, where it has
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many mitotic protein substrates (St-Denis et al., 2011). In other studies, phospho-specific
antibodies directed to these sites determined that CK2α is maximally phosphorylated in
prophase and metaphase and decreasing in anaphase. Using phosphorylation site mutants,
it was demonstrated that reversible phosphorylation is critical for precise temporal
regulation of CK2α and proper mitotic progression. Non-phosphorylatable mutants show
decreased mitotic arrest at the spindle assembly checkpoint. Phospho-mimetic mutations
result in aberrant centrosomal amplification leading to abnormal chromosomal
segregation, multipolar spindles as well as lagging chromosomes upon separation and
ultimately mitotic catastrophe (St-Denis et al., 2009).
Taken together, CK2 has an essential role in mitosis mediated through
phosphorylation of mitotic substrates, protein-protein interactions, as well as reversible
phosphorylation of CK2α, which is critical for precise temporal regulation of CK2α and
proper mitotic progression.

1.5 Objectives
Protein kinase CK2 is a ubiquitously expressed protein serine/threonine kinase with a
plethora of protein substrates involved in a complex series of cellular responses including
progression through various stages of the cell cycle and pathways that maintain the
delicate balance between survival and apoptosis. Largely regarded as constitutively
active, CK2 has also been shown to be a crucial constituent in many tightly regulated
cellular processes. Many of these cellular substrates are currently unidentified, as an
estimated 20% of the phosphoproteome may be attributed to CK2, while others have not
been validated as bona fide cellular substrates. Deregulated proliferation and evasion of
apoptosis are two hallmarks of cancer. Not surprisingly, given its numerous substrates
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that are involved in pathways that control cell proliferation and survival, CK2 has been
found elevated in numerous cancers. In light of these observations, CK2 has emerged as
an attractive candidate for molecular-targeted cancer therapy. Therefore, with the entry of
CK2 inhibitors into clinical trials, it will be immensely important to have robust methods
to monitor CK2 activity as well as interrogate the cellular specificity and substrates of
CK2 to further understand the cellular role of CK2 and identify potential biomarkers of
CK2 activity to guide future drug development.
The activity of a single kinase within the complexity of hundreds of structurally
conserved kinases remains a central challenge in the field. To overcome this challenge,
the overall goal of the experimental work that was performed in this thesis is to exploit
chemical biology approaches to elucidate the substrate specificity and activity of protein
kinase CK2.
An electrochemical kinosensor has been proposed as robust method and utilizes
an electroactive 5’-γ-ferrocenyl-ATP (FcATP) analog to directly monitor the transfer of
ferrocene (Fc) to substrate peptides by protein kinases. First, we assessed the ability of
CK2 to utilize FcATP to monitor CK2 activity. To do so, we developed a novel anti-Fc
antibody to facilitate the direct detection of Fc-phosphorylation using traditional
biochemical assays to complement electrochemical measurements. These results are
presented in chapter 2.
Second, we used two approaches to evaluate the substrate specificity of CK2 to
further discern the substrate-kinase relationships. In chapter 3, we engineered a mutant
form of CK2 with an expanded nucleotide-binding pocket by substituting a large residue
with a smaller residue. This mutant is selectively sensitive to both modified ATP analogs
and inhibitors that wild-type CK2 is resistant to. Using this strategy in cell lysate, specific
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phosphorylation of CK2 substrate, EEFID, was observed. In chapter 4, we used a
synthetic phosphoserine oriented peptide array to systematically investigate CK2
hierarchical phosphorylation and subsequently assess candidate peptides identified by
bioinformatic analysis of the human proteome.
Overall, these studies exploit complementary chemical biology approaches to
expand our ability to monitor the activity and substrate selectivity of CK2. Collectively,
the work in this thesis may contribute to the continued development and clinical use of
targeted CK2 therapies.
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CHAPTER TWO: Biochemical characterization of electroactive 5’-γferrocenyl-ATP to monitor CK2 activity2

2.1 Introduction
Over 500 protein kinases orchestrate complex and dynamic signal transduction pathways
to regulate essential cellular pathways including cell growth, death, and survival (Hunter,
2000; Manning et al., 2002). Protein kinases catalyze the transfer of the γ-phosphate from
ATP to serine, threonine, and tyrosine residues on substrate proteins to modulate their
activity and/or function.
Unregulated or enhanced protein kinase activity can result in aberrant signaling
pathways and are linked to many human diseases, including cancer (Manning et al.,
2002). The revelation that kinase activity can be downregulated with the aid of smallmolecule inhibitors has classified kinases as druggable targets (Cohen, 2002). A
milestone achievement in this respect was the remarkable success of Gleevec (Imatinib),
a targeted inhibitor used in the treatment of Chronic Myelogenous Leukemia (CML). By
binding the ATP binding site of the mutant Bcr-Abl fusion protein, Gleevec inhibits ATP
from being utilized to phosphorylate substrates (Capdeville et al., 2002). Together, this
success along with the prevalence of kinase alterations in disease has spurred the rapid
and exponential design and development of inhibitors for other kinases. To date, there are
thousands of patents filed and 20 licensed kinase inhibitors in the clinic (Fabbro, 2015;
Savage and Mahmoud, 2015).

2

A modified version of this chapter has been published: Martic S, Gabriel M, Turowec J, Litchfield DW
and Kraatz HB. (2012) Versatile Strategy for Biochemical, Electrochemical and Immunoarray Detection of
Protein Phosphorylations. JACS 134:17036-17045.
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Protein kinase CK2 is a constitutively active protein serine/threonine kinase that
promotes cell growth and survival, while protecting against apoptosis (Litchfield, 2003).
Given these roles, it is perhaps not surprising that CK2 levels are elevated in numerous
cancers. Overexpression of CK2 in both solid and hematopoietic malignancies also result
in a significantly unfavorable prognosis and poor overall survival when compared with
tumours with lower CK2 expression levels (Daya-Makin et al., 1994; Stalter et al., 1994;
Faust et al., 1996; Landesman-Bollag et al., 2001; Kim et al., 2007; Laramas et al., 2007;
Giusiano et al., 2010; Lin et al., 2010; Lin et al., 2011; Piazza et al., 2012). Thus, CK2
has become an attractive target for drug development and currently there is one CK2
inhibitor emerging into Phase I/II clinical trials (Pierre et al., 2011; Chon et al., 2015;
www.clinicaltrials.gov).
For both diagnostic and drug screening purposes, it is absolutely critical to detect,
monitor, and quantify protein kinase activity. Existing methods to detect protein kinase
activity include surface-plasmon resonance (Mori et al., 2008), phospho-specific
antibodies (Ciaccio et al., 2010), radioactivity (Houseman et al., 2002; Asensio and
Garcia, 2003), fluorescence (Shults et al., 2005), nanoparticles (Wang et al., 2013), and
mass spectrometry (Kubota et al., 2009; Kunz et al., 2012). Although effective, these
techniques have many limitations including availability, high expense, low throughput,
low sensitivity and resolution, and hazardous nature.
As an alternative to these methods, an electrochemical kinosensor has been
proposed as a direct detection method, which is sensitive and non-hazardous, and has the
potential to monitor the activities of multiple kinases simultaneously (Kerman et al.,
2008; Song et al., 2008; Martic et al., 2011b). Central to this kinosensor is electroactive
5’-γ-ferrocenyl-ATP (FcATP), which has been shown with electrochemical assays to be a
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suitable co-substrate for protein kinases (Figure 2-1) (Kerman et al., 2008; Song et al.,
2008). First, the substrate peptide is immobilized on to the surface of a gold electrode.
Upon incubation with a kinase, the ferrocene-phosphate (Fc-phosphate) group from
FcATP is transferred to the substrate. This generates a redox active ferrocenephosphorylated substrate in close proximity to the gold electrode, which produces an
electric current that is measured by electrochemical methods. However, complementary
biochemical assessment of the utility of FcATP in kinase-catalyzed phosphorylation is
lacking.
To enable a direct comparison of electrochemical measurements of ferrocenephosphorylation (Fc-phosphorylation) with established biochemical assays, we developed
an antibody raised against the ferrocene (Fc) epitope and monitored the ability of
FcC6ATP (FcATP with a 6-carbon linker) to be used as a phosphate donor in kinasecatalyzed phosphorylation by CK2α. The novel anti-Fc antibody is both specific and
highly sensitive for the Fc epitope. Using this antibody to detect and characterize Fcphosphorylation indicated that CK2α had a 10-fold lower affinity for FcC6ATP compared
to ATP, but showed no difference in affinity for its protein substrate. Additionally, CK2α
showed no major difference in substrate specificity between FcC6ATP and ATP.
Furthermore, CK2α showed a similar sensitivity to CK2 inhibitors with both FcC6ATP
and ATP. Importantly, endogenous protein kinases can utilize FcC6ATP to phosphorylate
protein substrates in a cell extract. Collectively, these results show that the novel anti-Fc
antibody specifically detects Fc-phosphorylation and FcC6ATP can be efficiently
transferred to substrates by CK2α as well as other kinases.
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Figure 2-1. FcC6ATP and kinase-catalyzed Fc-phosphorylation. The chemical structure
of ATP (A) and FcC6ATP (B). The phosphates are labeled above and the γ-phosphate
and Fc-phosphate are highlighted in grey. (C) An illustration of kinase-catalyzed Fcphosphorylation. Incubation of a substrate with a protein kinase will transfer the Fcphosphate from FcATP to the S/T/Y phosphoacceptor site. S, serine; T, threonine; Y,
tyrosine; X, any amino acid.
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2.2 Methods and Materials
2.2.1 Anti-Fc antibody development- Rabbit polyclonal anti-ferrocene (Fc) antibodies
were produced by YenZym Antibodies, LLC. (San Francisco, California, USA) using
monosubstituted ferrocene-amide-alkylamine conjugated to Keyhole Limpet Hemocyanin
(KLH). Antisera from immunized rabbits were used without further purification.
2.2.2 Anti-Fc antibody characterization- Fc was chemically conjugated to bovine serum
albumin (BSA) (Dr. HB Kraatz, University of Toronto Scarborough, Canada) to generate
Fc-BSA. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry
(MALDI-TOF MS) analysis was performed using a 5800 TOF/TOF System (AB Sciex)
to determine the number of conjugated Fc molecules (Figure 2-2). Sample was mixed 1:1
with α-cyano-4-hydroxycinnamic acid (CHCA), prepared as 5 mg/mL in 6 mM
ammonium phosphate monobasic, 50% acetonitrile, 0.1% trifluoroacetic acid and the data
was acquired using linear mode. Data acquisition and data processing were respectively
done using a TOF/TOF Series Explorer and Data Explorer (both from AB Sciex). The
observed mass/charge ratios for the +1, +2, +3, and +4 charge state indicated that four Fc
molecules were coupled to one molecule of BSA.
For Fc-BSA,
m / z = (MFc-BSA + H) / z , where the m/z observed for the +1 charge state is 67 280.3438
67 280.3438 = (MFc-BSA + 1H) / 1 , where the average mass of H is 1.00794 Da
= (MFc-BSA + 1(1.00794)) / 1
MFc-BSA = 67 279.3358 Da
For BSA,
66 422.5313 = (MBSA + 1H) / 1
= (MBSA + 1(1.00794)) / 1
MBSA = 66 421.5234 Da
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Figure 2-2
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Figure 2-2. Analysis of Fc-BSA by mass spectrometry. (A) BSA and (B) Fs-BSA were
mixed 1:1 with CHCA matrix and analyzed by MALDI-TOF MS.
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Therefore the difference in mass is 67 279.3358 – 66 421.5234 = 857.8124 Da
The mass of one Fc coupled to BSA is 213 Da,
Therefore the number of Fc molecules on BSA is 846.3758 / 213 4
To test for antibody specificity, 30 µg of HeLa lysate was supplemented with 100 ng BSA
or Fc-BSA. To test for linearity, Fc-BSA was serially diluted in water.
2.2.3 Recombinant protein purification- N-terminal GST-tagged CK2α kinase was
expressed in Escherichia coli and affinity purified as previously described (Turowec et
al., 2010). C-terminal His-tagged pro-caspase 3 (C163A) (Addgene plasmid 11822), Nterminal His-tagged caspase 8 (ΔDED C360A) (Addgene plasmid 11828), and N-terminal
His-tagged caspase 8 (ΔDED C360A) T373A were expressed in E. coli and affinity
purified as previously described (Zhou et al., 1997; Denault and Salvesen, 2003).
2.2.4 Kinase assays with recombinant protein substrates- GST-CK2α was diluted in CK2
dilution buffer (5 mM MOPS pH 7.0, 200 mM NaCl, 1 mg/ml BSA) immediately before
use. To test for phosphorylation, 1 µg of purified protein substrates α-casein (Dr. EH.
Ball, University of Western Ontario, Canada), pro-caspase 3-His, His-caspase 8, and Hiscaspase 8 T373A were incubated with 100 ng GST-CK2α in CK2 kinase assay buffer (50
mM TrisHCl pH 7.5, 150 mM NaCl, 10 mM MgCl2) and either 100 µM ATP, 100 µM
ATP supplemented with 0.2 µCi [γ32P]ATP (3000 Ci/mmol, Perkin Elmer) or 100 µM
FcC6ATP (Dr. HB. Kraatz, University of Toronto Scarborough, Canada; Song et al., 2008)
for 30 min at 30°C with shaking.
For kinetic analyses, kinase assays were conducted as described above with either
increasing concentrations of caspase 3-His (0-25 µM) or increasing concentrations of
ATP and FcC6ATP (10-500 µM). The reactions were incubated for 15 min at 30°C with
shaking.
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For inhibition assays, kinase assays were conducted in the presence of CK2
inhibitors

4,5,6,7-tetrabromobenzotriazole

(TBB,

Sigma),

4,5,6,7-

tetrabromobenzimidazole (TBBz, Sigma), and 2-dimethylamino-4,5,6,7-tetrabromo-1Hbenzimidazole (DMAT, Sigma) in increasing concentrations (0-60 µM). GST-CK2α was
incubated with the inhibitor on ice for 18 min before being diluted 5-fold into the kinase
assay. The reactions were incubated for 30 min at 30°C with shaking.
2.2.5 Cell extract kinase assay- HeLa cells were cultured in Dulbecco's Modified Eagle
Medium (DMEM, Corning) supplemented with 10% fetal bovine serum (FBS,
Invitrogen) and antibiotic supplements (0.1 mg/mL streptomycin and 100 units/ml
penicillin, Life Technologies, Inc.) and were grown to 90% confluence. Cells were
harvested in Lysis Buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 µg/mL Pepstatin A,
2 µg/mL Aprotinin, 10 µg/mL Leupeptin, 1 mM PMSF, 1 mM NaF, 1 mM Na2VO4),
lysed by sonicating 3x 15 sec on ice, and centrifuged for 30 min at 55 000xg at 4°C.
Protein concentration was determined by bicinchoninic acid (BCA) assay (Pierce) using
BSA standards and absorbance measured at 565 nm on a Victor3 V 1420 multilabel
counter (Perkin Elmer). Kinase assays were performed with 10 µg lysate in CK2 kinase
assay buffer supplemented with either 1 mM ATP and 10 µCi [γ32P]ATP (3000 Ci/mmol,
Perkin Elmer) or 1 mM FcC6ATP for 1 hour at 30°C with shaking. As a control, 500 mM
EDTA was added to the reaction to a final concentration of 50 mM to inhibit kinasecatalyzed phosphorylation.
2.2.6 Gel electrophoresis, immunoblotting, and phosphorimaging- Reactions were
stopped by boiling samples in 2x Laemmli Buffer and proteins were separated by 12%
sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) (Laemmli, 1970).
Proteins were transferred to polyvinylidene difluoride (PVDF) membrane (Millipore) for
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1 hour at 15 V and 300 mA using the Trans-blot Semi-Dry Electrophoretic transfer
apparatus (Bio-Rad). Gels were stained with Coomassie (0.1% Coomassie Blue R250 in
10% acetic acid, 50% methanol) and membranes were stained with Ponceau (0.1%
Ponceau S in 5% acetic acid). Membranes were blocked in 5% BSA/TBST for 1 hour at
room temperature with rocking. Phosphorylation was analyzed by immunoblotting with
either anti-Fc antibody (1:10 000 in 1% BSA/TBST), anti-phospho-caspase 3
pT174/pS176 antibody (1:10 000 in 1% BSA/TBST), anti-caspase-3 antibody (1:20 000
in 1% BSA/BST, Cell Signalling), or anti-caspase 8 antibody (1:1 000 in 1%BSA/PBST,
Cell Signalling). All primary antibodies were incubated with the membrane overnight at
4°C with rocking. Secondary antibodies (1:10 000 GAR800 or GAM680 in 5%
BSA/TBST, Mandel) were incubated with the membrane for 45 min at room temperature
with rocking. The membranes were scanned and quantified using the LiCor near-infrared
fluorescent scanner using Odyssey v3.0 software (LI-COR Biosciences).
For radioactive assays, reactions were separated by 12% SDS-PAGE, stained with
Coomassie, soaked in 20% PEG-400/50% methanol for 15 min, dried under vacuum at
80°C for 4 hours, and phosphorylation was detected by phosphorimaging using a STORM
820 Phosphorimager (Molecular Dynamics). Phosphate incorporation was quantified
using ImageQuant TL software (Amersham Biosciences).
Experiments were performed three times, except where noted, and the data
graphed using GraphPad Prism version 4.0 for Macintosh (GraphPad Software, San
Diego, Ca; www.graphpad.com). KM values were determined by nonlinear regression
analysis fit to a Michaelis-Menten model for enzyme kinetics. Ki values were calculated
using nonlinear regression analysis fit to a one-site competition model.
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2.3 Results
2.3.1 Characterization of the anti-Fc antibody
To enable the biochemical characterization of FcC6ATP and kinase-catalyzed Fcphosphorylation, a novel anti-Fc antibody was developed. Initial studies were performed
to test the sensitivity and specificity of the anti-Fc antibody. Fc was chemically
conjugated to BSA to facilitate the detection and characterization of Fc using the anti-Fc
antibody. When analyzed by immunoblotting, the anti-Fc antibody binds to Fc-BSA and
does not bind to BSA alone, demonstrating that the anti-Fc antibody specifically
recognizes the Fc epitope and does not bind non-specifically to BSA (Figure 2-3a). To
further test the specificity of the antibody, HeLa lysate was supplemented with either
BSA or Fc-BSA and immunoblotted with the anti-Fc antibody (Figure 2-3b). The
antibody did not bind to any proteins in either the lysate only or lysate with BSA samples
and only detected a single band in the lysate with Fc-BSA sample. These results indicate
that the anti-Fc antibody does not bind non-specifically to endogenous cellular proteins or
BSA and selectively recognizes and binds the Fc epitope on Fc-BSA. To test the
sensitivity of the anti-Fc antibody, Fc-BSA was serially diluted and immunoblotted with
the anti-Fc antibody. The threshold of detection was estimated to be 100 fmol Fc and the
detection was linear over the entire range of Fc-BSA tested, up to 60 pmol Fc (Figure 24).
While the initial antibody characterization was performed using Fc-BSA, the
utility of the antibody to biochemically monitor the transfer of the Fc-phosphate from
FcATP to a substrate protein requires antibody specificity for Fc-phosphate. To test the
ability of the anti-Fc antibody to recognize and bind Fc-phosphate, phosphorylation and
Fc-phosphorylation of recombinant pro-caspase 3-His by CK2α was detected using
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Figure 2-3. Characterization of the specificity of the anti-Fc antibody. (A) Equal
amounts of BSA and Fc-BSA were separated by SDS-PAGE, transferred to PVDF
membrane, and immunoblotted with the anti-Fc antibody. (B) 30 µg of HeLa lysate
was supplemented with 100 ng BSA or Fc-BSA. Samples were separated by SDSPAGE, transferred to PVDF membrane, and immunoblotted with the anti-Fc antibody
(upper panel). The membrane (lower panel) was stained with Ponceau to show equal
loading. These assays were performed twice. IB, immunoblot.
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Figure 2-4. Characterization of the sensitivity of the anti-Fc-antibody. (A) Fc-BSA was
serially diluted in water (0-60 pmol Fc), separated by SDS-PAGE, transferred to PVDF
membrane, and immunoblotted with the anti-Fc antibody. (B) The band intensity was
measured using LiCor Odyssey v3.0 software and normalized to the highest intensity
band, 60 pmol. Results are an average of three independent experiments. Error bars
indicate the standard error. IB, immunoblot.
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phospho-specific anti-caspase 3 and anti-Fc antibodies (Figure 2-5). Only Fcphosphorylation of pro-caspase 3-His was detected by the anti-Fc antibody, again
demonstrating that the anti-Fc antibody is very specific to Fc. Notably, the phosphospecific anti-caspase 3 antibody does not recognize Fc-phosphorylated caspase-His,
suggesting that the Fc moiety interferes with the epitope recognized by that antibody.
Again, this result indicates that CK2α can use FcATP as a phosphate donor to transfer the
Fc-phosphate to caspase 3-His substrate protein.

2.3.2 Kinetic analysis of FcC6ATP
Having confirmed its specificity, the anti-Fc antibody was then used to extend our
biochemical characterization of FcC6ATP as a kinase substrate. As it was shown that
CK2α can use FcC6ATP as a phosphate donor, detailed kinetic studies with ATP and
FcC6ATP were conducted with CK2α and increasing co-substrate concentrations. To
study the kinetic parameters of nucleotide binding, kinase assays were performed with
increasing concentrations of ATP and FcC6ATP, phosphorylation of pro-caspase 3-His by
CK2α was detected by immunoblotting with phospho-specific anti-caspase 3 and anti-Fc
antibodies, and KM values were determined by nonlinear regression analysis fit to a
Michaelis-Menten model for enzyme kinetics (Figure 2-6). These results demonstrate that
CK2α has an over 10-fold lower affinity for binding FcC6ATP than ATP (KM values of
165 ± 24 µM and 12 ± 2 µM with FcC6ATP and ATP, respectively). To study the kinetic
parameters of protein substrate, kinase assays were performed with increasing
concentrations of caspase 3-His and either ATP or FcC6ATP and analyzed as above
(Figure 2-7). These results show that FcC6ATP does not affect substrate binding, as a
similar KM for pro-caspase 3-His substrate was determined for both ATP and FcC6ATP
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Figure 2-5. The anti-Fc antibody detects CK2α-catalyzed Fc-phosphorylation. Procaspase 3-His was phosphorylated by CK2α with either ATP or FcC6ATP. Reactions
were separated by SDS-PAGE, transferred to PVDF membrane, and immunoblotted
with both phospho-specific anti-caspase 3 and anti-Fc antibodies. IB, immunoblot.
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Figure 2-6. CK2α has 10-fold lower affinity for FcC6ATP than ATP. Caspase 3-His was
phosphorylated by CK2α with increasing concentrations of either ATP (A) or FcC6ATP
(C). Reactions were separated by SDS-PAGE, transferred to PVDF membrane, and
immunoblotted with anti-caspase 3, phospho-specific anti-caspase 3, and anti-Fc
antibodies. The bands were quantified using LiCor Odyssey v3.0 software and analyzed
by nonlinear regression analysis fit to a Michaelis-Menten model for enzyme kinetics
using GraphPad Prism for ATP (B) and FcC6ATP (D). Results are an average of three
independent experiments. Error bars indicate the standard error. IB, immunoblot.
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Figure 2-7. CK2α has the same affinity for caspase 3-His substrate with FcC6ATP and
ATP. Increasing concentrations of pro-caspase 3-His were phosphorylated by CK2α with
either ATP (A) or FcC6ATP (C). Reactions were separated by SDS-PAGE, transferred to
PVDF membrane, and immunoblotted with anti-caspase 3, phospho-specific anti-caspase
3, and anti-Fc antibodies. The bands were quantified using LiCor Odyssey v3.0 software
and analyzed by nonlinear regression analysis fit to a Michaelis-Menten model for
enzyme kinetics using GraphPad Prism for ATP (B) and FcC6ATP (D). Results are an
average of three independent experiments. Error bars indicate the standard error. IB,
immunoblot.
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(KM values of 1.40 ± 0.19 µM and 1.32 ± 0.15 for FcC6ATP and ATP, respectively). In
these assays with increasing pro-caspase 3-His substrate, there is a potential for nonspecific binding of the phospho-specific anti-caspase 3 and anti-Fc antibodies because of
the high levels of pro-caspase 3-His used in these assays. To address this concern, kinase
assays were performed in the absence and presence of ATP and FcC6ATP, and
phosphorylation of 50, 100, and 500 pmol pro-caspase 3-His substrate by CK2α was
evaluated by immunoblotting with phospho-specific anti-caspase 3 and anti-Fc antibodies
(Figure 2-8). Notably, phosphorylation or Fc-phosphorylation of pro-caspase 3-His was
only observed in the presence of ATP and FcC6ATP, respectively. No signal was observed
in the absence of ATP and FcC6ATP illustrating that there was no background or nonspecific binding of either antibody at large protein substrate amounts.

2.3.3 Substrate specificity of FcC6ATP
To determine if using FcC6ATP as a phosphate donor had any affect on the substrate
specificity of CK2α, known CK2 substrates α-casein, pro-caspase 3-His, and His-caspase
8 were assessed as substrates for CK2 using ATP and FcC6ATP. To monitor
phosphorylation of these substrates, [γ32P]ATP was used and [γ32P]-phosphate
incorporation was detected by phosphorimaging. To monitor Fc-phosphorylation of these
substrates, samples were immunoblotted with anti-Fc antibody. All three protein
substrates were phosphorylated by CK2α with both ATP and FcC6ATP (Figure 2-9).
Additionally, the pattern of phosphorylation between these substrates is comparable for
both ATP and FcC6ATP and follows the phosphorylation order: α-casein > pro-caspase 3His > His-caspase 8. Furthermore, when the known CK2 phosphorylation site on caspase
8, T373, was mutated to an alanine (T373A), an amino acid that lacks a hydroxyl and
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Figure 2-8
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Figure 2-8. Examination of Fc-phosphorylation with excess amounts of protein
substrate. 500 pmol pro-caspase 3-His was phosphorylated by CK2α in the presence
and absence of ATP and FcC6ATP. The reactions were serially diluted to 100 and 50
pmol caspase 3-His substrate. Samples were separated by SDS-PAGE, transferred to
PVDF membrane, and immunoblotted with anti-caspase 3, phospho-specific anticaspase 3, and anti-Fc antibodies. IB, immunoblot..
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Figure 2-9
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Figure 2-9. CK2α has similar substrate specificity with FcC6ATP and ATP. Purified
CK2 substrate proteins, namely α-casein, pro-caspase 3-His, and His-caspase 8, were
phosphorylated by CK2α with either [γ32P]ATP (A) or FcC6ATP (B). Reactions with
[γ32P]ATP were separated by SDS-PAGE, dried, and visualized by phosphorimaging.
Reactions with FcC6ATP were separated by SDS-PAGE, transferred to PVDF
membrane, and immunoblotted with anti-Fc antibody. The gels were stained with
Coomassie. IB, immunoblot.
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cannot be phosphorylated, no phosphorylation was detected with either ATP or FcC6ATP
reconfirming the specificity of the anti-Fc antibody (Figure 2-10). Collectively, these
results demonstrate that the substrate specificity of CK2α was not altered by the
utilization of FcC6ATP as a phosphate donor and that the antibody selectively recognizes
Fc-phosphorylation catalyzed by CK2α.

2.3.4 Effect of CK2 Inhibitors on Fc-phosphorylation by CK2
To further extend our characterization, the ability of CK2 inhibitors to inhibit Fcphosphorylation by CK2α was tested. Kinase assays were performed with ATP and
FcC6ATP in the presence of known CK2 inhibitors 4,5,6,7-tetrabromobenzotriazole
(TBB),

4,5,6,7-tetrabromobenzimidazole

(TBBz),

and

2-dimethylamino-4,5,6,7-

tetrabromo-1H-benzimidazole (DMAT) (Figure 2-11) (Sarno et al., 2001; Zien et al.,
2003; Pagano et al., 2004). Phosphorylation and Fc-phosphorylation of pro-caspase 3-His
by CK2α was detected by immunoblotting with phospho-specific anti-caspase 3 and antiFc antibodies. In the absence of CK2α, neither phosphorylation nor Fc-phosphorylation
were observed whereas in the presence of CK2α, phosphorylation and Fc-phosphorylation
were detected with a modest effect of DMSO. Upon the addition of increasing inhibitor
concentrations, decreasing phosphorylation and Fc-phosphorylation were observed. In the
case of both ATP and FcC6ATP, TBB and DMAT appeared to be better inhibitors than
TBBz, as stronger inhibition was observed at lower inhibitor concentrations. Using
nonlinear regression analysis fit to a one-site competition model, the Ki values were
calculated and found to be comparable between ATP and FcC6ATP (Table 2-1). Overall,
the inhibition profiles for all three inhibitors were similar between ATP and FcC6ATP
indicating that CK2 inhibitors can competitively inhibit Fc-phosphorylation as effectively
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Figure 2-10
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Figure 2-10. Substituting the phosphoacceptor site for an alanine abolishes Fcphosphorylation. Recombinant His-caspase 8 and His-caspase 8 T373A were incubated
with CK2α in the presence of either [γ32P]ATP (A) or FcC6ATP (B). Reactions with
[γ32P]ATP were separated by SDS-PAGE, stained with Coomassie, dried, and
visualized by phosphorimaging. Reactions with FcC6ATP were separated by SDSPAGE, transferred to PVDF membrane, and immunoblotted with anti-caspase 8 and
anti-Fc antibodies. IB, immunoblot.
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Figure 2-11. CK2 inhibitors inhibit Fc-phosphorylation comparable to phosphorylation.
Caspase 3-His was phosphorylated by CK2α with either ATP (A) or FcC6ATP (C) in the
presence of increasing concentrations of CK2 inhibitors TBBz, TBB, and DMAT.
Reactions were separated by SDS-PAGE, transferred to PVDF membrane, and
immunoblotted with anti-caspase 3, phospho-specific anti-caspase 3, and anti-Fc
antibodies. The bands were quantified using LiCor Odyssey v3.0 software, normalized to
the DMSO control, and graphed using GraphPad Prism for ATP (B) and FcC6ATP (D).
Results are an average of three independent experiments. Error bars indicate the standard
error. IB, immunoblot.
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Figure 2-11
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as phosphorylation.

2.3.5 Utilization of FcC6ATP by endogenous kinases in cell extract
As all our biochemical characterization has been conducted using purified components,
the ability of endogenous protein kinases to utilize FcC6ATP compared to ATP was
examined using cell extracts (Figure 2-12a). In the presence of FcC6ATP, the detection of
several bands using the anti-Fc antibody suggests that FcC6ATP is widely used by
endogenous protein kinases to phosphorylate numerous cellular proteins. Additionally,
these bands are specific to Fc-phosphorylated proteins as no background bands are
present in the cell lysate and antibody control lanes. Furthermore, these bands are specific
to kinase-catalyzed Fc-phosphorylation as treatment with EDTA, a Mg2+ chelating agent,
prevents Fc-phosphorylation. To quantify this result, a cross section of the fourth lane
was taken and the pixel intensity measured (Figure 2-12b). The intensity of bands in both
ATP and FcC6ATP are very comparable, with peaks in intensity occurring at 15, 50, 75,
90, and 145 pixels, and valleys occurring at 55-70, 110-140, and 150-200 pixels, although
a slight difference was observed in the lower molecular weight bands, under 30 kDa (>
150 pixels). Overall, these results suggest that endogenous protein kinases, including
CK2, as well as others can use FcC6ATP to phosphorylate substrates in cell lysate
conditions, as the profiles for both ATP and FcC6ATP are comparable.
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Table 2-1. Ki values (nM) determined for TBBz, TBB, and DMAT with ATP and
FcC6ATP.
Our results
Inhibitor
TBBz
TBB
DMAT

ATP
630
420
81

FcC6ATP
700
370
110

Radiolabeled
ATP data
ATP
510a
400b
40b

Ki values for our results were determined as described in 4.2.
ND, not determined.
a
Zien et al., 2008
b
Pagano et al., 2004
c
Kerman et al., 2008

Electrochemical
data
FcC6ATP
ND
450c
50c
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Figure 2-12
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Figure 2-12. FcC6ATP is used by endogenous protein kinases to phosphorylate cellular
substrates. (A) 10 µg of HeLa whole cell lysate was supplemented with either
[γ32P]ATP or FcC6ATP and incubated at 30°C for 1 hour with shaking. Control reactions
were performed in the presence of 50 mM EDTA, which blocks kinase-catalyzed
phosphorylation. Reactions were separated by SDS-PAGE, transferred to PVDF
membrane, and either phosphorimaged or immunoblotted with anti-Fc antibody. The
cross section of each lane was quantified using ImageQuant TL software to measure
the pixel intensity (B). Results are an average of three independent experiments. IB,
immunoblot.
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2.4 Discussion
Protein kinases are intricately involved in the signaling pathways that promote
oncogenesis. To realize the potential of protein kinases as therapeutic targets, effective
strategies to identify kinases that have perturbed activity are required for diagnosis and to
instruct the appropriate treatment plan. To this end, a novel electrochemical kinosensor,
using electroactive FcATP, which is robust, simple, and cost-effective, has been reported
(Figure 2-1) (Song et al., 2008; Kerman et al., 2008).
To complement these electrochemical experiments, we have developed a novel
anti-Fc antibody to biochemically detect and characterize the ability of kinases to utilize
FcC6ATP. This anti-Fc antibody displays both high specificity and sensitivity for Fc, with
a threshold limit of detection of 100 fmol Fc and linear response up to at least 60 pmol,
representing the appropriate working range to study Fc-phosphorylation (Figures 2-3 and
2-4). The development of antibodies directed towards Fc has been previously reported by
Gill and Mann (1965) however, poor specificity and sensitivity were observed. In that
study, the authors were primarily interested in developing a radiotracer, by labelling a Fcpolypeptide with a radioactive isotope of iron, and not necessarily raising an antibody
specific for Fc. In addition to binding Fc-BSA, our anti-Fc antibody also robustly detects
Fc-phosphorylation of substrate proteins (Figure 2-5). This result demonstrates two
things; one, CK2α can utilize FcC6ATP to Fc-phosphorylate a substrate protein, and two,
the presence of a 6-carbon linker and phosphate does not interfere with the recognition
and binding of the antibody to the Fc epitope. Strikingly, the anti-Fc antibody does not
display any cross reactivity with phosphorylated substrate. The synthesis of FcC6ATP
involves the synthesis of NH2(CH2)6N(H)COFc (Fc with a 6-carbon linker) which is
subsequently chemically reacted with ATP (Song et al., 2008). As a consequence, there is
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a potential for unreacted ATP to contaminate the FcC6ATP preparation. As ATP is not an
electroactive compound and electrochemical assays would be unable to directly detect
ATP-dependent substrate phosphorylation, the presence of ATP could result in reduced
Fc-phosphorylation leading to decreased electrochemical signal. In our assays, the
inability of the phospho-specific anti-caspase 3 antibody to detect any phosphorylated
pro-caspase 3-His in the reaction with FcC6ATP empirically demonstrates that the
FcC6ATP is highly pure.
The anti-Fc antibody was then used to biochemically characterize FcC6ATP in
kinase-catalyzed phosphorylation. The detection of Fc-phosphorylation of pro-caspase 3His biochemically demonstrated that CK2α efficiently uses FcC6ATP as a phosphate
donor (Figure 2-5). Further kinetic analyses of FcC6ATP and ATP revealed that while
CK2α can use FcATP, CK2 had an over 10-fold lower affinity for FcC6ATP compared to
ATP (KM values of 165 ± 24 µM and 12 ± 2 µM with FcC6ATP and ATP, respectively)
(Figure 2-6). The calculated KM for CK2 with ATP is consistent with published values
(Sarno et al., 2002). The affinity of CK2 for FcC6ATP has yet to be electrochemically
determined, however, electrochemical data with another protein kinase, atypical PKC,
suggests the affinity for FcC6ATP is also lower than ATP. The reported KM for PKC with
ATP is 13 µM, but electrochemical measurements with increasing FcC6ATP show linearly
increasing Fc-phosphorylation up to 100 µM FcC6ATP, the highest concentration tested
(Spitaler et al., 2000; Song et al., 2008). While the KM was not calculated, these data
suggest that the KM would likely be higher than that with ATP since the kinase activity
has not yet saturated. While these observations are for PKC, they suggest that PKC has a
lower affinity for FcC6ATP than ATP, which is consistent with our results for CK2α.
Overall, the lower binding affinity of FcC6ATP is likely due to steric hindrance arising
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from the 6-carbon linker and Fc group conjugated to the γ-phosphate. FcATP conjugates
with varying carbon linker sizes have been synthesized and both electrochemical and
molecular modeling data suggest that shorter linker lengths are less efficient phosphate
donors due to steric hindrance impeding the proper alignment in the active site of the
kinase required for efficient catalysis (Martic et al., 2011). On the other hand, longer
carbon linkers (6, 8, and 10-carbon) are better phosphate donors potentially because the
steric hindrance is partially reduced allowing for proper alignment in the active site and
catalysis. Molecular modeling using Src kinase also suggest, that while short linkers have
a compact and conformationally constrained geometry, the linkers with at least 6 carbons
have an elongated structure that protrudes outward from the active site. Furthermore, the
activity of CK2 with additional classes of ATP analogs modified on the γ-phosphate has
also been reported (Suwal et al., 2012). Each ATP analog displayed lower conversion
percentages with CK2 compared with ATP, and as is the case with FcATP, increasing the
length of linker in aryl analogs increased the conversion percentage. However, detailed
kinetic analyses to determine affinity with CK2 or another kinase, with these γ-modified
analogs as well as FcATP with shorter and longer linker lengths, have yet to be reported.
Based on these results, it maybe advisable to perform electrochemical kinosensor assays
using FcATP with 6, 8, and 10-carbon linkers, at concentrations higher than 100 µM,
which is routinely used. Both these modifications would increase the kinase activity with
FcATP which would increase the electrochemical signal produced.
The substrate specificity of CK2α was also compared between ATP and FcC6ATP.
CK2 is an acidophilic protein kinase with a strong preference for acid residues proximal
to the phosphate acceptor site on substrates (Sarno et al., 1999). The specificity of CK2α
towards three protein substrates was not altered by FcC6ATP and the presence of a
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phosphoacceptor site was absolutely required for Fc-phosphorylation (Figure 2-9 and 210). These data confirm that the Fc being detected by the anti-Fc antibody is solely due to
CK2α catalyzed Fc-phosphorylation at the only known CK2 site in His-caspase 8
(Duncan et al., 2011). In addition, the binding of FcC6ATP in the active site of CK2 does
not negatively affect the affinity for the substrate, as the calculated affinity for procaspase 3-His was the same with both FcC6ATP and ATP (Figure 2-7). The lack of effect
on specificity is also supported by molecular modeling studies with FcC6ATP and Src that
predicts the carbon linker and Fc extends past the kinase active site (Martic et al., 2011).
Structurally, the determinants for CK2 substrate specificity are clusters of basic amino
acids located on the protein surface, outside of the nucleotide-binding site (Sarno et al.,
1996, 1997, 1999). This suggests that the carbon linker and Fc group likely do not wrap
around the enzyme surface and make hydrophobic interactions that block substrate
binding or decrease the affinity for substrate proteins and alter substrate specificity. This
modeling only included FcC6ATP and did not include a substrate peptide. Therefore,
molecular modeling or structural methods such as X-ray crystallography or NMR studies
with FcC6ATP and a peptide substrate will be necessary to examine this further.
Broadly, substrate specificity of protein kinases has yet to be thoroughly
investigated by electrochemical methods. With respect to CK2α, kinase activity was
electrochemically measured for a single CK2 substrate peptide, RRRDDDSDDD (the
phosphoacceptor residue in each peptide is bolded), with similar studies performed with
the Abl substrate peptide, EGIYDVP (Kerman et al., 2008). Results from those studies
show that while RRRDDDSDDD is an excellent substrate for CK2α, no Fcphosphorylation was detected for EGIYDVP. This is important since CK2 is an
acidophilic kinase with a preference for S and T phosphoacceptor residues and EGIYDVP
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contains a Y phosphoacceptor and lacks the canonical CK2 consensus sequence (Pinna
and Meggio, 1997; Salvi et al., 2009). Furthermore, the affinity for RRRDDDSDDD
peptide with FcATP determined electrochemically was comparable to the affinity with
ATP using the same peptide in a radioactive assay (Kuenzel et al., 1987; Kerman et al.,
2008). These results indicate that the substrate specificity of CK2α is not significantly
changed with FcATP and are consistent with our data.
CK2 is elevated in numerous cancers and is being actively pursued as a potential
target for molecular-targeted therapy (Daya-Makin et al., 1994; Stalter et al., 1994; Faust
et al., 1996; Landesman-Bollag et al., 2001; Kim et al., 2007; Laramas et al., 2007;
Giusiano et al., 2010; Lin et al., 2010; Lin et al., 2011; Pierre et al., 2011; Piazza et al.,
2012; Chon et al., 2015; Pizzi et al., 2015). The ability of three CK2 inhibitors, TBB,
TBBz, and DMAT to block Fc-phosphorylation was determined to be very comparable to
phosphorylation (Figure 2-11). The trend in inhibitor strength and calculated Ki values are
similar between ATP and FcATP. The values are also consistent with previously reported
values for TBBz and TBB for ATP using a radioactive assay (Table 2-1) (Pagano et al.,
2004; Zien et al., 2005). More importantly, our values for TBB are also consistent with Ki
values determined for FcC6ATP using electrochemical measurements (Kerman et al.,
2008). The Ki values determined for DMAT are approximately 2-fold higher for both
ATP and FcC6ATP compared with the previously reported values (Pagano et al., 2004;
Kerman et al., 2008). These differences can possibly be assigned to different detection
methods as our Ki values for DMAT are comparable; FcC6ATP was only 35% higher than
the value with ATP (Table 2-1). Overall, the inhibitors can effectively compete with
FcC6ATP for binding to the active site of CK2α. This provides a strong foundation upon
which to further develop the electrochemical kinosensor as a high-throughput drug-
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screening platform.
Members of the protein kinase family are highly conserved with a shared active
site architecture and common utilization of ATP as a phosphate donor (Hanks et al., 1988;
Hanks and Hunter 1995; Adams, 2001). Our results have collectively shown that
recombinant CK2α can use FcC6ATP to Fc-phosphorylate recombinant protein substrates.
To extend the electrochemical kinosensor to monitor multiple kinases, it is essential that
other kinases can also use FcC6ATP. We tested the ability of endogenous protein kinases
to use FcC6ATP by supplementing HeLa cell extract with ATP and FcC6ATP and our
results demonstrate that the Fc-phosphorylation profile is very similar to the
phosphorylation profile observed (Figure 2-12). The similarity in profiles suggests that
the phosphorylated proteins are the same molecular weights are those that are Fcphosphorylated. This indicates that multiple kinases are responsible for the observed
phosphorylation and thus, Fc-phosphorylation profiles, since the ability to use ATP is
common to all kinases. The absence of phosphorylation and Fc-phosphorylation upon the
addition of EDTA further demonstrates that the signal detected is specific to an enzymecatalyzed reaction, since Mg2+ is a required cofactor for enzyme catalysis, including
kinase-catalyzed phosphorylation and EDTA is a Mg2+ chelating reagent and prevents
catalytic activity. Furthermore, as Fc, and thus Fc-phosphate, is not a molecule natively
found in our cells, the absence of background binding and cross-reactivity in the lysate
only lane is a testament to the specificity of the anti-Fc antibody. Additionally, these data
also demonstrate that kinases can efficiently use FcC6ATP in a complex cell extract in the
presence of high cellular ATP concentrations. Electrochemical data has shown that other
recombinant, purified kinases can use FcATP to Fc-phosphorylate substrates and include
Abl, Her2, Src, Cdk2/cyclinA, Erk1, PKC, Tau-tubulin kinase (TTBK), Fyn, GSK-3β,
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and PKA (Kerman et al., 2008; Song et al., 2008; Martic et al., 2011a,b, 2012; Rains et
al., 2013).
Overall, this study sought to provide a direct evaluation of the utility of FcC6ATP
in kinase-catalyzed phosphorylation using traditional biochemical assays to complement
the previously reported electrochemical data. Our results are consistent with reported
electrochemical data and provide a strong foundation for the continued development of a
robust, simple, and high-throughout platform, using FcATP, for profiling kinase activity
in patient samples.
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CHAPTER THREE: Development of an analog-sensitive CK23

3.1 Introduction
Protein kinase CK2 is a pleiotropic kinase with essential and highly regulated roles in
numerous signaling pathways including cell survival, proliferation, and apoptosis
(Litchfield, 2003; St-Denis and Litchfield, 2009). Over a decade ago, a review of the
literature identified 307 protein substrates of CK2 (Meggio and Pinna, 2003). These
substrates are as diverse as the pathways CK2 is involved in and include proteins
involved in not only signaling pathways, but transcription factors, RNA/DNA processes,
protein synthesis, cytoskeleton, structure, and metabolism as well. Since then, several
substrates have been identified and validated in low-throughput studies. More recent
unbiased studies have identified 138 phosphosites in 105 putative yet high confidence
CK2 substrates using proteome-derived peptides (Wang et al., 2013). In fact, this may
represent only a fraction of cellular CK2 substrates as bioinformatic studies predict that
an estimated 20% of the phosphoproteome can be attributed to CK2 based on matching
the consensus sequence to phosphosites present in the human phosphoElm database
(Salvi et al., 2009; Salvi et al., 2010). This indicates that the complete repertoire of CK2
substrates has yet to be identified and validated as bona fide substrates, therefore
indicating that the cellular roles of CK2 remain to be comprehensively elucidated.
The human genome encodes over 500 protein kinases and more than one-third of
the proteome can be phosphorylated (Ahn and Resing, 2001; Manning et al., 2002;
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Sharma et al., 2014). The current challenge in fully understanding of the role of protein
kinases

in

cellular

regulation

is

comprehensively

identifying

the

complete

phosphorylation landscape linked to a specific kinase in a complex cellular environment
where hundreds of distinct kinases may be present. The highly conserved structure of the
core active site, a shared catalytic mechanism to transfer the γ-phosphate from ATP to
substrates, and in many instances, overlapping specificity determinants all make it
exceptionally difficult to decipher the actions of individual kinases and kinase-substrate
relationships within cells (Hanks at el., 1988; Hanks and Hunter, 1995; Adams, 2001).
Genetic and traditional biochemical techniques currently employed to clarify the
cellular roles of CK2 include gene knockdowns (Xu et al., 1999; Lou et al., 2008), smallmolecule inhibitors (Gyenis et al., 2011), and large-scale phosphoproteomic studies
(Wang et al., 2013; Franchin et al., 2015). Although each of these approaches have
strengths that make them invaluable tools, as is the case with many techniques, each
carries its own inherent limitations regarding off-target and non-specific effects. For
example, overexpression and knockdown studies can be susceptible to compensatory
changes that mask the specific roles of CK2. Inhibitors are an excellent alternative,
however, a specific and selective CK2 inhibitor that is readily accessible to the research
community still remains elusive. Furthermore, phosphoproteomic studies can isolate
hundreds and thousands of phosphopeptides by mass spectrometry but the identification
of CK2 substrates relies extensively on consensus sequence matching.
To circumvent these limitations and provide a complementary approach to study
CK2 we have employed the chemical genetics approach pioneered by Shokat and
colleagues and applied this unbiased strategy to CK2 (Shah et al., 1997). This study is
focused on the development of an analog-sensitive CK2 (as-CK2) kinase that
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distinguishes the nucleotide specificity of CK2 from other cellular kinases allowing for
the selective phosphorylation of CK2 substrates (Figure 3-1). We hypothesize that the
expansion of the catalytic pocket of CK2 will enable utilization of ATP analogs to
phosphorylate cellular substrates. Replacement of a bulky residue in the nucleotidebinding pocket, F113, with a smaller glycine residue resulted in the efficient utilization of
an ATP analog, N6-(2-phenylethyl)ATP (2peATP) and confers increased sensitivity to
modified PP1 inhibitors. The F113G mutation does not alter peptide or protein substrate
specificity and supports viability in a yeast model. The utility of this strategy was further
demonstrated using as-CK2α and 2peATPγS to specifically phosphorylate EEF1D in cell
lysate.
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Figure 3-1

CK2$
ATP$

as+CK2$
A*TP$

-

+ CK2

-

+ as-CK2

Figure 3-1. A schematic illustrating the analog-sensitive kinase strategy. Wt-CK2 has a
binding pocket that has high affinity for ATP. When the large gatekeeper residue in
nucleotide-binding pocket is substituted with a smaller residue, the pocket becomes
enlarged to generate an analog-sensitive CK2 (as-CK2) that can bind larger N6substituted ATP analogs (A*TP). In a cell extract, cellular substrate proteins are
phosphorylated by ATP in both the presence and absence of wt-CK2. In contrast,
cellular substrate proteins are phosphorylated by A*TP only in the presence of as-CK2.
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3.2 Methods and Materials
3.2.1 Cloning and protein purification- Sequence alignments were performed using the
NCBI Constraint Based Protein Multiple Alignment Tool to compare the protein
sequence of human CK2α (NP_001886) and CK2α’ (NP_001887) with Cdk1
(NP_001777), Cdk2 (CAA43807), Cdk4 (NP_000066), Cdk6 (NP_001250), Cdk7
(NP_001790), c-Src (NP_005408), Fyn (NP_002028), Fus3 (CAA84835), MEKK1
(NP_005912), Pto (AA215368), and GRK2 (NP_001886). Site-directed mutagenesis
(Stratagene) was used to substitute CK2αF113 and CK2α’F114 to a glycine residue with
pGEX-CK2α or pGEX-CK2α’ as a template (Table 3-1). Second-site mutants, I69K,
A110V, and L111I, were made by site-directed mutagenesis using pGEX-CK2αF113G as
a template (Table 3-1). N-terminal GST-tagged CK2α, CK2α’, as-CK2α, as-CK2α’, asCK2α169K, as-CK2αA110V, and as-CK2αL111I were expressed and purified from
bacterial culture as previously described (Turowec et al., 2010). Protein concentration
was determined by BCA (Pierce) and absorbance at 565 nm, measured on a Victor3 V
1420 multilabel counter (Perkin Elmer) using BSA standards. The same primers were
used to generate the same mutation in pRC/CMV-CK2α-HA to produce pRC/CMVCK2αF113G-HA (Table 3-1).
EEF1D was amplified using pcDNA3.1-Flag-EEF1D as a template and primers to
add HindIII and NotI cut sites and cloned into pET16b-His-Trx (Dr. EH. Ball, University
of Western Ontario, Canada; Gyenis et al., 2011) (Table 3-1). EIF2β was amplified using
pCMV6-XL5-EIF2β (Origene) as a template and primers to add NcoI and BamHI cut
sites and cloned into pET28b (Novagen) (Table 3-1).
His-EEF1D, His-EIF2β, and His-CK2β recombinant proteins were expressed in
freshly transformed BL21 Escherichia coli, grown in 2xYT media supplemented with 100
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Table 3-1. Sequences of DNA primers used in this study.
Construct
CK2αF113G
CK2α’F114G

Primer
Name
Forward
Reverse
Forward
Reverse

CK2αF113G,I69K

Forward
Reverse

CK2αF113G,A110V
CK2αF113G,L111I
His-EEF1D
His-EIF2B
CKA1 promoter
CKA1
CK2α into Y70

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

CK2α’ into Y70

Forward
Reverse

Primer Sequence
5'-tgttgtttacgtgttcaccaaccaaggcgggggttcgtg-3'
5'-cacgaacccccgccttggttggtgaacacgtaaacaaca-3'
5'-ctgtattattgatatattcacctaccaaagctggtgtctttgacacgg
gg-3'
5'-ccccgtgtcaaagacaccagctttggtaggtgaatatatcaataat
acag-3'
5'-cttcttttttactggcttgagctttttaacaacaactttttcattatttgtg
atgttgatggc-3'
5'-gccatcaacatcacaaataatgaaaaagttgttgttaaaaagctca
agccagtaaaaaagaag-3'
5'-gtgttcaaaaaccaagacgggggttcgtgacac-3'
5'-gtgtcacgaacccccgtcttggtttttgaacac-3'
5'-tgtttacgtgttcaaaaactatggcgggggttcgtgacac-3'
5'-gtgtcacgaacccccgccatagtttttgaacacgtaaaca-3'
5’-aagcttgctacaaacttcctagcacatgag-3’
5’-gcggccgctcagatcttgttgaaagctgcg-3’
5'-ccatggtctggggacgagatgatttttgatcc-3'
5'-ggatccgtgttagctttggcacggagctgtgc-3'
5’-catacagcagaagcttgtggtagaaaagcgctatc-3’
5’-ctctgacgcatgcctgcatttcatatgtcgaatcaaatattc-3’
5’-gattcgacatatgaaatgcagggtatggtcagag-3’
5’-cattatttctagattatttttcaatttgttcccttattggg-3’
5’-ctgattccatatgtcgggacccgtgccaagcagggccagagttt
acacag-3’
5’-gataatctagatcactgctgagcgccagcggcagctggaacagg
catc-3’
5’-ctgattccatatgcccggcccggccgcgggc-3’
5’-tcgtgctgccgtgagaccactgggataatctagatca-3’
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µg/mL ampicillin at 37°C with shaking to an A600 of 0.6, induced with 1 mM isopropyl βD-1-thiogalactopyranoside (IPTG) and grown at 16°C overnight with shaking. Nickel2+
affinity resin was prepared by washing Chelating Sepharose Fast Flow (GE Healthcare
Life Sciences) resin with 5 bed volumes of H2O, charging with 2 bed volumes 0.1 M
NiSO4, washing with 5 bed volumes H2O, and equilibrating the resin with 5 bed volumes
of Binding Buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 20 mM imidazole). Cells
were lysed in Binding Buffer at 15 000 psi in an Emulsiflex-C3 high pressure
homogenizer (Avestin, Inc.) and centrifuged at 15 000xg for 30 min at 4°C. The
supernatant was applied to the resin and drained by gravity flow. The resin was washed
with 5 bed volumes of Wash Buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 40 mM
imidazole) and eluted with increasing concentrations of imidazole using Wash Buffer and
Elution Buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 500 mM imidazole). Fractions
were analyzed by SDS-PAGE, pooled, and the protein dialyzed into 50 mM Tris-HCl pH
7.4, 150 mM NaCl, 25% glycerol using 14 kDa MW cut off tubing (BioDesign Inc.),
overnight at 4°C with gentle stirring.
Pro-caspase 3 (C163A)-His (Addgene plasmid 11822) was expressed in E. coli
and affinity purified as previously described (Zhou et al., 1997; Denault and Salvesen,
2003).
3.2.2 In vitro kinase assays- Recombinant CK2 and as-CK2 kinases were diluted to 50
ng/µL in CK2 dilution buffer (5 mΜ MOPS pH 7.0, 200 mM NaCl, 1 mg/mL BSA)
immediately

before

use

in

kinase

assays.

Recombinant

His-p53

(1-393)

N268D/M340Q/L344R substrate (a gift from Dr. Cheryl Arrowsmith, OCI Toronto) was
phosphorylated by 100 ng CK2 in CK2 kinase assay buffer (50 mM Tris-HCl pH 7.5, 150
mM NaCl, 10 mM MgCl2, 1 mM dithiothreitol (DTT)) supplemented with 100 µM ATP
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or N6-modified ATP analogs: N6-(phenyl)ATP (phenylATP), 2peATP, N6-(1methylbutyl)ATP

(mbATP),

N6-(2-methylbutyl)ATP

(2mbATP),

and

N6-(3-

methylbenzyl)ATP (3mbATP) (BioLog). Assays were performed at 30°C for 30 min.
Reactions containing 500 ng recombinant protein substrates p53, His-EEF1D, αcasein (Dr. EH. Ball, University of Western Ontario, Canada), Caspase 3-His, His-CK2β,
or His-EIF2β, were stopped by the addition of 2x Lamelli sample buffer and boiling.
Reactions containing a synthetic CK2 peptide substrate, RRRDDDSDDD, at 100 µM
were spotted onto P81 paper (Whatman), washed 3x 5 min in 1% phosphoric acid, once
in 20% ethanol, and dried under a heat lamp. Peptide arrays were synthesized by an in
situ SPOT technology on nitrocellulose (Intavis) with the Auto-Spot Robot ASP 222
(Amimed) and processed as previously described (Duncan et al., 2011). These peptides
represent a random selection of putative CK2 substrates (Salvi et al., 2009). Two control
peptides

were

included

in

this

array;

a

standard

CK2

peptide

substrate

DDDDDDSDDDDDD as a positive control and DDDDDDADDDDDD, in which the
phosphoacceptor site serine of the CK2 peptide substrate is substituted with an alanine, as
a negative control (phosphoacceptor residue is in bold) (Table 3-2).
Phosphorylation using 100 µM ATP or 2peATP was detected by substrate specific
phospho-specific antibodies. Phosphorylation using 0.2 µCi [γ32P]ATP (specific activity
3000 Ci/mol, Perkin-Elmer) or [γ32P]2peATP was

detected by STORM 820

Phosphorimager (Molecular Dynamics). 2peATP was radiolabeled as previously
described but the reaction was scaled down to use 400 µCi [γ32P]ATP (specific activity
3000 Ci/mol, Perkin-Elmer) (Eblen et al., 2003). Scintillation counting determined the
yield to be 25% or 100 µCi [γ32P]2peATP and matrix-assisted laser desorption/ionizationtime of flight mass spectrometry (MALDI-TOF MS) analysis using a 5800 TOF/TOF
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Table 3-2. Peptides sequences contained on the peptide arrays used in this study. These
peptides were from Salvi et al., 2009.
Location

Peptide Sequence

Protein substrate

A1

DADLFDSHDDRDD

A2
A3

DKDEDSSECSDGE
DLSAACSDADLHR

A4

DRWLDESDAEMEL

A5

EAFLVLSDEEDIS

A6

EASGYISSLEYPR

A7
A8
A9
B1
B2
B3

GEETLESDDEKDE
GPCSSSSDSDSGD
KASISLTDDEVDD
KREREESEDELEE
LDEDSWSDGEQEP
LDRQSLSSIDKNP

B4
B5
B6

LENRCQSLTEDLE
LERERASQEEQIA
NDSDRYSDNEEDS

B7

NRRARDSGREDEP

B8
B9

PARVVSSTSEEEE
PDDRDASDGEDEK

C1

QGIEAASDEEDLR

C2

QQVSSLSESEESQ

C3
C4
C5

SLSRYDSDGDKSD
SNRKYESDEDSLG
SPDGASSDAEPEP

C6
C7

SVASNQSEMEFSS
TEPQEESEEEVEE

C8
C9

DDDDDDSDDDDDD
DDDDDDADDDDDD

OSBL9_HUMAN Oxysterol-binding protein-related
protein 9
PJA2_HUMAN E3 ubiquitin-protein ligase Praja2
UBP42_HUMAN Ubiquitin carboxyl-terminal
hydrolase 42
PTAD1_HUMAN Protein tyrosine phosphatase-like
protein PTPLAD1
MCAF1_HUMAN Activating transcription factor 7interacting protein 1
C1R_HUMAN Complement C1r subcomponent
precursor
CA052_HUMAN Uncharacterized protein C1orf52
IKBB_HUMAN NF-kappa-B inhibitor beta
EP400_HUMAN E1A-binding protein p400
RCOR1_HUMAN REST corepressor 1
CL041_HUMAN Uncharacterized protein C12orf41
BIG2_HUMAN Brefeldin A-inhibited guanine
nucleotide-exchange protein 2
LMNB1_HUMAN Lamin-B1
PEPL_HUMAN Periplakin
LAP2B_HUMAN Lamina-associated polypeptide 2,
isoforms beta/gamma
TUSC1_HUMAN Tumor suppressor candidate gene 1
protein
OXR1_HUMAN Oxidation resistance protein 1
SHIP2_HUMAN Phosphatidylinositol-3,4,5trisphosphate 5-phosphatase 2
PACN3_HUMAN Protein kinase C and casein kinase
substrate in neurons protein 3
ATF1_HUMAN Cyclic AMP-dependent transcription
factor ATF-1
TLE3_HUMAN Transducin-like enhancer protein 3
EF2K_HUMAN Elongation factor 2 kinase
SMC4_HUMAN Structural maintenance of
chromosomes protein 4
K1967_HUMAN Protein KIAA1967
G3BP1_HUMAN Ras GTPase-activating proteinbinding protein 1
Positive control
Negative control
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System (AB Sciex) confirmed the complete absence of ATP and generation of 2peATP
(Figure 3-2). Samples were mixed 1:1 with 2,5-dihydrobenzoic acid (DHB) matrix (20
mg/mL in 15 mM ammonium citrate, 20% ethanol, and 1% phosphoric acid) and the data
was acquired using reflectron positive mode. Data acquisition and data processing
respectively, were done using a TOF/TOF Series Explorer and Data Explorer (both from
AB Sciex). Phosphorylation reactions using 100 µM ATPγS (Sigma) or 2peATPγS
(BioLog) were alkylated by treatment with 2.5 mM p-nitrobenzylmesylate (PNBM,
Epitomics) for 2 hours at room temperature.
For inhibition assays, kinase assays were performed as described above using HisEEF1D as a substrate protein. Assays were done with either the addition of 1% DMSO,
10 µM 4,5,6,7-tetrabromobenzimidazole (TBBz, Sigma), increasing concentrations (1250

µM)

of

1-(1,1-dimethylethyl)-3-(1-naphthalenylmethyl)-1H-pyrazolo[3,4-

d]pyrimidin-4-amine (Nm-PP1, Biolog) or 1-(1,1-dimethylethyl)-3-(1-naphthalenyl)-1Hpyrazolo[3,4-d]pyrimidin-4-amine (Na-PP1, Biolog) or 0.1-50 µM staurosporine (LC
Laboratories).
3.2.3 Cell extract kinase assays- HeLa cells were cultured in Dulbecco's Modified Eagle
Medium (DMEM, Corning) supplemented with 10% fetal bovine serum (FBS,
Invitrogen) and antibiotics (0.1 mg/mL streptomycin and 100 units/ml penicillin, Life
Technologies, Inc.). HeLa cells were grown to 80% confluence and transfected with
either pRC/CMV-CK2α-HA or pRC/CMV-as-CK2α-HA and either pcDNA3.1-FlagEEF1D or a non-phosphorylatable mutant pcDNA3.1-Flag-EEF1D S162A using calcium
phosphate (Gyenis et al., 2011). After 36 hours, cells were harvested in NP-40 Lysis
Buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1 µg/mL Pepstatin A, 2
µg/mL Aprotinin, 10 µg/mL Leupeptin, 1 mM PMSF, 1 mM NaF, 1 mM Na2VO4), lysed
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Figure 3-2

2peADP

2peATP

Figure 3-2. Analysis of [γ32P]2peATP radiolabelling reaction by mass spectrometry.
The generation of 2peATP and complete loss of ATP during the radiolabelling
procedure was analyzed by spotting 1:1 in DHB matrix and performing MALDI-TOF
MS, after the sample was completely decayed. 2peATP, 612 Da; 2peADP, 532 Da;
ATP, 508 Da.
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by sonicating 3x 15 sec on ice, and centrifuged for 30 min at 55 000xg at 4°C. Kinase
assays were performed by supplementing 500 µg lysate with 5x CK2 kinase assay buffer
with 0.5 mM GTP and either 100 µM ATPγS or 100 µM 2peATPγS and incubating for 30
min at 30°C with shaking. Flag-EEF1D was then immunoprecipitated by adding 2.5 µg
Flag-M2 antibody (Sigma) and 30 µL Protein A-sepharose slurry as previously described
(Gyenis et al., 2011). The reactions were then alkylated by the addition of 2.5 mM pnitrobenzylmesylate (PNBM) (Epitomics) and incubated for 2 hours at room temperature.
Proteins were eluted by boiling the beads in 2x Laemmli Buffer.
3.3.4 Gel electrophoresis, immunoblotting, and phosphorimaging- Protein concentration
was determined by BCA (Pierce) using BSA standards and absorbance measured at 565
nm on a Victor3 V 1420 multilabel counter (Perkin Elmer). Reactions were stopped by
boiling samples in 2x Laemmli Buffer, proteins were separated by 12% SDS-PAGE, and
transferred to PVDF membrane (Millipore) by wet transfer for 1 hour at a constant 400
mA using the Mini Trans-blot Cell apparatus (Bio-Rad) (Laemmli, 1970). Gels were
stained with Coomassie Blue. Membranes were blocked in 5% BSA/TBST for 1 hour at
room temperature with rocking. Phosphorylation was analyzed by immunoblotting with
either an anti-thiophosphate ester antibody (1:2000 in 5% milk/TBST, Epitomics), antiphospho-S392 p53 antibody (1:1000 in 3% BSA/TBST, Cell Signaling Technology), antiphospho-S162 EEF1D antibody (1:20 000 in 3% BSA/TBST). Total protein levels were
analyzed by immunoblotting with either anti-Flag-M2 (1:1000 in 3% BSA/PBST, Sigma),
anti-HA 3F10 (1:500 in 3% BSA/PBST, Roche), anti-EEF1D (1:1000 in BSA/PBST,
Abcam), or anti-His (1:1000 in 3% BSA/PBST, Qiagen). Membranes were incubated
with primary antibodies at 4°C overnight with rocking. Membranes were incubated with
secondary antibody (1:10 000 GAR800 or 1:10 000 GAM680 in 5% BSA/TBST,
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Mandel) for 45 min at room temperature with rocking. The blots were scanned and
quantified using the LiCor Odyssey System (LI-COR Biosciences).
Phosphate incorporation was quantified using ImageQuant TL software
(Amersham Biosciences), using a standard curve generated by spotting serial dilutions of
a known ATP concentration, and graphed using GraphPad Prism version 4.0 for
Macintosh (GraphPad Software, San Diego California USA, www.graphpad.com). KM
values were determined by nonlinear regression analysis fit to a Michaelis-Menten model
for enzyme kinetics. Experiments were performed three times, except where noted.
3.2.5 Yeast plasmid construction- The promoter region of CKA1 was amplified from
yeast genomic DNA with primers to add HindIII, NdeI, and SphI cut sites (Table 3-1).
The promoter was cloned into both Y69 and Y70 centromeric plasmids using HindIII and
SphI. CKA1 was amplified from yeast genomic DNA with primers to add NdeI and XbaI
cut sites and cloned into Y69-CKA1promoter plasmid using NdeI and XbaI to create
Y69-CKA1 (Table 3-1). CK2α, CK2αF113G, CK2α’, and CK2α’F114G were amplified
using pGEX constructs as templates and primers to add NdeI and XbaI cut sites and
cloned into Y70-CKA1promoter plasmid using NdeI and XbaI to create Y70-CK2α, Y70CK2αF113G, Y70-CK2α’, and Y70-CK2α’F114G (Table 3-1).
3.2.6 Yeast strains and growth assays- Standard yeast genetic techniques were used.
Yeast strains were grown at 30 °C in liquid suspension or on 2% (w/v) Bactoagar plates
in YPD media (1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) glucose, 0.01% (w/v)
adenine hemisulfate), or in SD media (0.67% yeast nitrogen base without amino acids,
2% glucose, supplemented with 0.07% synthetic complete selection medium mix lacking
the appropriate amino acids).
Deletion strains (BY4741; cka1∆0 (1428) and BY4741; cka2∆0 (1837)) were
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purchased from Open Biosystems. To generate a diploid strain deleted for cka1 and cka2,
KanMX in cka2 was switched to NatMX by transformation with linearized p4339 (Tong
and Boone, 2006), creating DWL1. To create a double deletion strain complemented by
CKA1, cka1∆0 was transformed with Y69-CKA1 containing a URA3 gene and mated
with DWL1. Diploids were sporulated and Ura+ spore colonies that were G418 and
ClonNAT resistant were identified to generate DWL2. To test if human CK2 would
complement CKA1, DWL2 was transformed with Y70, Y70-CK2α, Υ70-as-CK2α, Y70CK2α’, or Y70-as-CK2α’ plasmids containing a LEU2 gene. Transformants that were
Leu+ were selected to create DWL3, DWL4, DWL5, DWL6, and DWL7, respectively.
The Y69-CKA1 plasmid was shuffled out by plating on SD Leu- plates containing 1
mg/mL 5-fluoroorotic acid (5FOA, Toronto Research Chemicals). For spotting assays,
transformants were cultured in liquid SD Leu- media overnight at 30°C with shaking.
Cultures were equalized for cell density and 5 µl aliquots of 1/5, 1/50, 1/500, and 1/5000
serial dilutions were spotted on YPD, SD Leu- and SD Leu- with 1 mg/ml of 5FOA plates
and grown at 30°C for two days. For testing inhibitors, SD Leu- 5FOA plates were
supplemented with either 1% DMSO, 50 µM and 100 µM Na-PP1 or Nm-PP1.
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3.3 Results
3.3.1 Identification of the gatekeeper residue in CK2
The chemical genetic approach pioneered by Shokat and colleagues exploits the highly
conserved structure of the nucleotide-binding pocket among protein kinases (Shah et al.,
1997). Within this site, there is a strictly conserved bulky residue, commonly a
phenylalanine, called the “gatekeeper” residue. Mutating this residue in a number of
protein kinases generates analog-sensitive kinases (as-kinases) with altered nucleotide
requirements as the gatekeeper residue acts as a natural steric barrier to bulky ATP
analogs. The underlying premise for this approach is that replacement of the large
“gatekeeper” residue with a small amino acid enlarges the nucleotide-binding pocket of
the kinase to accommodate ATP analogs with bulky side chains not accommodated
within the wild-type nucleotide-binding pocket (Figure 3-1).
To adapt the gatekeeper strategy to CK2 and engineer an as-CK2 kinase, the
protein sequences of CK2α and CK2α’ were aligned with closely related cyclindependent kinases (Cdks) Cdk1, Cdk4, Cdk6, and Cdk7 as well as c-Src (Figure 3-3a).
The sequence alignment identified a phenylalanine, F113 and F114 in CK2α and CK2α’,
respectively, that aligns with conserved bulky threonine and phenylalanine residues in cSrc and Cdks. To further confirm this phenylalanine as the “gatekeeper” residue in CK2,
available structures of c-Src and Cdks (Cdk6 and Cdk7) were aligned with CK2α (Figure
3-3b). In general, the structures aligned very closely to each other, especially in the core
active site. The conserved bulky residues identified in the sequence alignment are
highlighted and clearly demonstrate that these residues in each structure are superimposed
on one another and structurally align. Additionally, this residue is located in proximity to
the ATP bound in the nucleotide-binding pocket. Collectively, both sequence and
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Figure 3-3. Identification of the gatekeeper residue in CK2. (A) A sequence alignment of
the catalytic subunits CK2α and CK2α’ with c-Src, Cdk1, Cdk2, Cdk4, Cdk6, and Cdk7
identifies a conserved phenylalanine, F113 and F114 in CK2α and CK2α’, respectively
(the gatekeeper residue is bolded and denoted by *). (B) A structural alignment
highlighting the gatekeeper residues in CK2α (yellow) with c-Src (red), Cdk6 (blue), and
Cdk7 (green). ATP is coloured in cyan. An in silico substitution of the gatekeeper residue
in CK2α (C) with a glycine, as-CK2α (D), illustrates the enlargement of the nucleotidebinding pocket. The gatekeeper residue is coloured in magenta. The substitution was
introduced using Swiss PDB Viewer and these images were created in PyMol. PDB:
CK2α, 1JWH; c-Src, 3EL7; Cdk6, 4EZ5; Cdk7, IUA2.
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Figure 3-3
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structural alignments have resulted in the identification of the “gatekeeper” residue in
CK2 as F113 and F114 in CK2α and CK2α’, respectively. In CK2α, the conserved
phenylalanine residue is located in the back of the nucleotide-binding pocket (Figure 33c). Mutating this residue to a glycine, a smaller amino acid, visually enlarged the pocket
as illustrated by an in silico substitution (Figure 3-3d).

3.3.2 Enlarging the nucleotide-binding pocket yields an as-CK2 with catalytic activity
using 2peATP
Recombinant wt-CK2 and as-CK2 kinases were expressed and purified from E. coli and
kinase assays were performed using recombinant p53 as substrate. Five commercially
available N6-modified ATP analogs (phenylATP, 2peATP, 1mbATP, 2mbATP, and
3mbATP) were screened for activity (Figure 3-4a) and phosphorylation was detected by
immunoblotting with a phospho-specific anti-p53 antibody. In the presence of both CK2α
and CK2α’, robust phosphorylation of p53 was observed with ATP. With the ATP
analogs, wt-CK2 also had activity with 1mb and 2mb yet displayed weak phosphorylation
with phenylATP, 2peATP, and 3mbATP analogs (Figure 3-4b). In contrast, as-CK2, as
illustrated by both as-CK2α and as-CK2α’, showed marginal activity with ATP but
increased phosphorylation of p53 with 2peATP. Minimal phosphorylation was detected
using the other N6-modified ATP analogs. The screen identified efficient utilization of
one ATP analog, 2peATP, by as-CK2 that was not observed for wt-CK2.
The loss of the ability of as-CK2 to employ ATP as a substrate while exhibiting
increased utilization of 2peATP was further confirmed with a complementary approach
using radiolabeled [γ32P]ATP and [γ32P]2peATP (Figure 3-4c,d). Wt-CK2 has 11-fold
lower activity with 2peATP than ATP. Consistent with the results of our initial screen, as-
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Figure 3-4. Screening catalytic activity of CK2 with N6-substituted ATP analogs reveals
utilization of 2peATP by as-CK2. (A) The chemical structure of ATP illustrating the
addition of bulky chemical groups at the N6-position on the adenine ring as denoted by R.
The catalytic activity of wt- and as-CK2 was assessed with p53 as a protein substrate
using N6-substituted ATP analogs including ATP, N6-(phenyl)ATP (phenyl), N6-(2phenylethyl)ATP (2pe), N6-(1-methylbutyl)ATP (1mb), N6-(2-methylbutyl)ATP (2mb),
and N6-(3-methylbenzyl)ATP (3mb). Phosphorylation was detected by immunoblotting
with an anti-phospho-S392 p53 antibody (B), or phosphorimager to detect the
incorporation of 32P-phosphate from [γ32P]ATP or [γ32P]2peATP (C). The incorporation of
32

P-phosphate from (C) was quantified (D). Results are an average of three independent

experiments. Error bars indicate the standard error.

105

Figure 3-4
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CK2α and as-CK2α’ had 38- and 24-fold lower activity with ATP than wt-CK2, but most
importantly had enhanced activity with 2peATP, about 5-fold higher than wt-CK2.
Additionally, as-CK2 had approximately 10-fold higher activity with 2peATP than ATP.
These data suggest that the enlarged nucleotide-binding pocket of as-CK2 uniquely
accommodates 2peATP. Furthermore, the catalytic activity of as-CK2 with 2peATP was
3-fold lower than wt-CK2 with ATP, suggesting that the mutation of a phenylalanine may
reduce, but not abolish, the catalytic activity of CK2.
Protein kinases can be classified as either tolerant or intolerant based on their
amenability to the Shokat strategy. Tolerant as-kinases are those that display no decrease
in catalytic activity with ATP, while intolerant as-kinases show a loss of catalytic activity.
Studies with intolerant kinases have identified several mutations to suppress the reduction
in catalytic activity (Zhang et al., 2005). The sequence of CK2α was aligned with tolerant
(c-Src, Fyn, Cdk2, and Fus3) and intolerant kinases (MEKK1, Pto, and GRK2) and three
residues were identified that differed from tolerant kinases, I69, A110, and L111 (Figure
3-5a). To try to improve the catalytic activity of as-CK2, several mutations were
incorporated into as-CK2α in an attempt to stabilize the β-strands in the N-terminal lobe;
I69K, A110V, and L111I. However, none of these mutations showed any improvement in
catalytic activity with either ATP or 2peATP when phosphorylation of p53 was detected
by immunoblotting with a phospho-specific anti-p53 antibody (Figure 3-5b).

3.3.3 As-CK2 preferentially uses 2peATP
To understand the basis for this difference in catalytic activity, kinetic analyses were
conducted (Table 3-3). Wt-CK2 had an over 20-fold lower KM for ATP compared to 2pe.
The KM of CK2 with ATP is also consistent with previous studies (Dobrowolska et al.,

107

Figure 3-5
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Figure 3-5. Assessing second-site mutants of as-CK2α. (A) A sequence alignment of
CK2α with tolerant kinases (c-Src, Fyn, Cdk2, and Fus3; highlighted in green) and
intolerant kinases (MEKK1, Pto, and GRK2; highlighted in blue). Three residues were
identified in CK2α in the N-terminal β-sheets that were different than the conserved
residues present in tolerant kinases; I69, A110, and L111 (highlighted in red). These
residues were substituted with a K, V, and I, respectively. (B) The catalytic activity of
CK2α, as-CK2α, as-CK2αI69K, as-CK2αA110V, and as-CK2αL111I was assessed
with p53 as a protein substrate with ATP and 2peATP. Phosphorylation was detected by
immunoblotting with an anti-phospho-S392 p53 antibody. These assays were
performed twice. IB, immunoblot.
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Table 3-3. Kinetic analysis of CK2 and as-CK2 with ATP and 2peATP.
Kinase
CK2α
CK2α’
as-CK2α
as-CK2α’

KM (µM ± SE)
ATP
2peATP
16.0 ± 1.4
335.5 ± 80.8
14.7 ± 2.6
365.0 ± 90.9
332.7 ± 43.9
53.4 ± 7.5
339.5 ± 48.9
70.8 ± 11.4
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1999). In contrast, as-CK2 had an over 5-fold decrease in KM for 2peATP compared to
ATP. Enlarging the nucleotide-binding pocket has altered the affinity and binding of the
adenine ring of ATP and serves a dual purpose. The gatekeeper mutation both diminishes
the binding affinity for ATP and greatly improves the affinity for 2peATP.
In an effort to further investigate the observation that as-CK2 has a higher affinity
for 2peATP, competition experiments were conducted. Phosphorylation of p53 substrate
by wt-CK2 with [γ32P]ATP was unaffected by the addition of 10-fold higher
concentrations of unlabeled 2peATP as no change in the incorporation of

32

P-phosphate

was observed (Figure 3-6a,b). However, wt-CK2 phosphorylation was almost completely
diminished with [γ32P]2peATP by the addition of 10-fold more unlabeled ATP (Figure 36c,d). This is in contrast to as-CK2, where phosphorylation with [γ32P]2peATP was not
substantially affected by the addition of 10-fold more unlabeled ATP. These results
indicate that ATP cannot efficiently compete with 2peATP for binding to the active site
of as-CK2 further reinforcing the observation that as-CK2 preferentially uses 2peATP as
a phosphate donor to phosphorylate substrates.
Thus far, our results have demonstrated that both as-CK2α and as-CK2α’ have
reduced activity with and affinity for ATP while having enhanced catalytic activity and
affinity for 2peATP. Considering that CK2α and CK2α’ are highly similar in sequence
and catalytically indistinguishable from each other it can be inferred that this would
extend to as-CK2α and as-CK2α’ as well. We therefore chose to continue our study by
focusing on the detailed characterization of as-CK2α.

3.3.4 Enlarging the nucleotide-binding pocket of CK2 has no effect of substrate specificity
The gatekeeper mutation is within the core structure of the kinase, therefore an obvious

110!!
Figure 3-6. As-CK2 preferentially uses 2peATP over ATP. Kinase assays were performed
to evaluate the preferential use of 2peATP and ATP. (A) Recombinant His-EEF1D was
phosphorylated by wt-CK2 using [γ32P]ATP with and without the addition of 10-fold
excess of unlabeled 2peATP. Phosphorylation was detected by phosphorimager and the
incorporation of

32

P-phosphate was quantified (B). (C) His-EEF1D was phosphorylated

by wt- and as-CK2 using [γ32P]2peATP with and without the addition of 10-fold excess of
unlabeled ATP. Phosphorylation was detected by phosphorimager and the incorporation
of

32

P-phosphate was quantified (D). Results are an average of three independent

experiments. Error bars indicate the standard error.
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concern is whether as-CK2 are fully functional and retain the same substrate specificity as
wt-CK2. To examine this concern, we profiled both peptide and protein substrates of
CK2. First, peptides based on putative CK2 substrates were phosphorylated with either
CK2α and [γ32P]ATP or as-CK2α and [γ32P]2peATP and phosphorylation was detected by
autoradiography (Table 3-2, Figure 3-7a,b). The relative phosphate incorporation between
both arrays was very comparable (Figure 3-7c). Strong phosphorylation was observed for
a standard synthetic CK2 substrate peptide (C8; DDDDDDSDDDDDD, the
phosphoacceptor residue is in bold) and no detectable phosphorylation was observed for a
non phosphorylatable version of this peptide, lacking a phosphoacceptor residue (C9;
DDDDDDADDDDDD). The remaining substrates included in the array encompassed a
very dynamic range in the extent of phosphate incorporation by CK2. A few peptides
were not phosphorylated at detectable levels (eg. B3, B4, B5) comparable to the relative
phosphate incorporation to C9. Others were phosphorylated at low levels (eg. A4, B7, B9,
C2) and higher levels (eg. A5, A7, B1, B6), comparable to C8. The peptide with the
highest relative phosphate incorporation in both arrays was A6. Overall, the levels and
trends of phosphate incorporation on each peptide were very similar between CK2α and
as-CK2α (Figure 3-7c).
To ensure that these observations are not restricted to peptides, we also tested if
the same retention of specificity would hold true for a panel of recombinant protein
substrates of CK2. In this case, we adopted an alternative detection strategy based on
ATPγS and 2peATPγS. Phosphorylation transfers a thiophosphate to the substrate that is
then alkylated to provide a unique thiophosphate ester epitope recognized by a specific
anti-thiophosphate ester antibody. Phosphorylation of all six protein substrates analyzed
was observed for both CK2α with ATPγS and as-CK2α with 2peATPγS (Figure 3-7d).

113!
Figure 3-7. The substrate specificity of CK2 is retained by as-CK2α. Peptide arrays
containing 25 randomized putative CK2 sites, and positive control (RRRDDDSDDDDD,
denoted as S) and negative control (RRRDDDADDDDD, denoted as A) peptides (listed
in Table 3-2) were phosphorylated by CK2α with [γ32P]ATP (A) or as-CK2α with
[γ32P]2peATP (B). Phosphorylation was detected by phosphorimager and the
incorporation of

32

P-phosphate was quantified (C). Results are an average of three

independent experiments. Error bars indicate the standard error. (D) Recombinant CK2
substrate proteins were phosphorylated by either CK2α and ATPγS or as-CK2α and
2peATPγS. Samples were alkylated by treatment with PNBM and phosphorylation
detected by immunoblotting with an anti-thiophosphate ester antibody. These assays were
performed twice. IB, immunoblot.
!
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Figure 3-7
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This signal is specific to thiophosphorylation catalyzed by CK2 as no phosphorylation
was detected in the absence of ATPγS or 2peATPγS. Phosphorylation by as-CK2α with
2peATPγS was similar to that of CK2α and ATPγS. In both cases, the strongest
phosphorylation was observed with EEF1D and EIF2β substrates while the weakest
phosphorylation was observed with casein and p53 substrate. Collectively, these
experiments with both peptides and proteins demonstrate that the F113G mutation does
not have a dramatic effect on CK2 substrate specificity.
Since no difference in substrate specificity was observed with purified
recombinant as-CK2α, we were interested in determining whether as-CK2 could
functionally complement wt-CK2 in a living model system. Consequently, we tested
whether human wt- and as-CK2 were able to substitute for their yeast ortholog, since
CK2 is highly conserved. We expressed either human wt- or as-CK2 in a yeast strain with
both endogenous yeast CK2 genes, CKA1 and CKA2, disrupted and examined their
ability to support viability by plasmid shuffling (Figure 3-8a). Since a double knockout of
CKA1 and CKA2 is lethal, strain viability was maintained by expression of yeast CKA1
from a plasmid also encoding URA3 (Glover, 1998). This yeast strain was transformed
with a LEU2 plasmid encoding either human wt- or as-CK2 under the control of the yeast
CKA1 promoter. Transformant yeast cells were selected by growth on media lacking leu.
Yeast cells were then plated on media containing 5FOA, where viability requires that the
human gene functionally complement for its yeast ortholog. Yeast maintaining the yeast
CKA1 plasmid encoding URA3 convert 5FOA into a toxic compound, 5-fluorouracil, and
do not proliferate. Yeast expressing human wt- or as-CK2 that functionally complement,
will no longer maintain the yeast CKA1 plasmid encoding URA3 and be viable on 5FOA.
As a control, yeast were transformed with a LEU2 plasmid not encoding CK2 (empty
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Figure 3-8. Functional complementation of yeast cka1Δcka2Δ by human wt- and as-CK2.
(A) A schematic of the plasmid shuffling assay used to test the functional
complementation of human wt- and as-CK2 in yeast. A haploid yeast strain deleted for
both cka1 and cka2 and bearing a URA3 plasmid encoding CKA1 was transformed with
the indicated LEU2 plasmids encoding either human wt- or as-CK2. The URA3 plasmid
was shuffled out and yeast were spotted on YPD, SD, and 5FOA plates in 5-fold serial
dilutions and grown at 30° for two days (B). Refer to Section 3.2.6 and the text for more
details. These assays were performed three times.
!
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Figure 3-8
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vector) (Figure 3-8b). As expected, the empty vector did not functionally complement for
CKA1 and yeast were not viable on 5FOA. Viability on 5FOA was observed in yeast
transformed with human CK2α indicating that human CK2α does functionally
complement for yeast CKA1. Yeast expressing as-CK2α were also viable on 5FOA, with
growth comparable to that seen in yeast expressing CK2α. This suggests that both CK2α
and as-CK2α are functional in yeast and that as-CK2α can fully compensate for the
cellular roles of CK2α.
In contrast to the observations with CK2α, no growth on 5FOA was observed with
yeast expressing human CK2α’, suggesting that CK2α’ does not fully complement yeast
CKA1 (Figure 3-8b). Additionally, no growth on 5FOA was observed for yeast
expressing as-CK2α’.

3.3.5 Inhibition of wt- and as-CK2 with modified PP1 inhibitors, CK2 inhibitor TBBz,
and staurosporine
To further capitalize on the enlarged nucleotide-binding pocket of as-kinases, modified
inhibitors have also been developed to specifically inhibit as-kinases. These were first
synthesized for Src and other tyrosine kinases and use an ATP competitive Src inhibitor,
PP1, as a scaffold (Bishop et al., 1998, 1999, 2000). These inhibitors have also been
shown to inhibit not only other tyrosine as-kinases, but a number of serine/threonine askinases as well (Bishop et al., 1998; Bishop et al., 1999; Bishop et al., 2000; Weiss et al.,
2000; Carroll et al., 2001; Niswender et al., 2002; Ubersax et al., 2003; Kenski et al.,
2005; Jones et al., 2005; Frank et al., 2006; Larochelle et al., 2006; Wan et al., 2006;
Burkard et al., 2007; Oh et al., 2007; Kim et al., 2008; Shirra et al., 2008). To evaluate
whether these modified PP1 inhibitors could specifically inhibit as-CK2 we
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phosphorylated EEF1D with CK2α and as-CK2α in the presence of increasing
concentrations of two modified PP1 analogs, Na-PP1 and Nm-PP1, and phosphorylation
was detected by immunoblotting with a phospho-specific anti-EEF1D antibody (Figure 39a). With increasing inhibitor concentration there was a decrease in the phosphorylation
of EEF1D with as-CK2α but this was not observed with CK2α (Figure 3-9b). In fact,
phosphorylation with CK2α with the addition of either 250 µM Na-PP1 or Nm-PP1
inhibitor resulted in only a 20% decrease in phosphorylation of EEF1D. In contrast,
phosphorylation by as-CK2α with the addition of 250 µM Na-PP1 or Nm-PP1 resulted in
a 55% and 80% decrease in phosphorylation, respectively. These results demonstrate that
as-CK2α is more sensitive to inhibition by modified PP1 analogs than CK2α.
To determine if the difference in sensitivity to inhibition by Na-PP1 and Nm-PP1
between CK2α and as-CK2α observed in in vitro assays would translate into an in cell
phenotypic difference we spotted yeast expressing human CK2α and as-CK2α onto plates
supplemented with 50 and 100 µM Na-PP1 and Nm-PP1. Yeast expressing as-CK2α
showed reduced growth on plates containing both inhibitors, compared to CK2α (Figure
3-9c). In addition, the growth was further reduced at higher concentrations of inhibitors
(50 vs. 100 µM). While there was no observable change in growth of yeast expressing
CK2α with a high concentration of Na-PP1, there was a severe reduction in growth at
equal concentrations of Nm-PP1, indicating there may be other toxic cellular effects at
100 µM. These results mirror our in vitro assays as yeast expressing as-CK2α are more
sensitive to both Na-PP1 and Nm-PP1 inhibition than yeast expressing CK2α.
Additionally, the ability of TBBz, a well-studied inhibitor of CK2, to inhibit asCK2 was also evaluated (Zien et al., 2003). With treatment of 10µM TBBz,
phosphorylation of EEF1D with CK2α was completely abolished (Figure 3-9a, lane 3).
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Figure 3-9. Inhibition of CK2α and as-CK2α by modified PP1 inhibitors. Recombinant
His-EEF1D substrate was phosphorylated by either CK2α and ATPγS or as-CK2α with
2peATPγS with the addition of 10 µM TBBz or increasing concentrations of modified
PP1 inhibitors, Na-PP1 and Nm-PP1. Phosphorylation was detected by immunoblotting
with an anti-phospho-pS162 EEF1D antibody (A) and quantified (B). Results are an
average of three independent experiments. Error bars indicate the standard error. Samples
were also immunoblotted with anti-EEF1D and anti-His antibodies. (C) A haploid yeast
strain deleted for both cka1 and cka2 and bearing a URA3 plasmid encoding CKA1 was
transformed with the indicated LEU2 plasmids encoding either human CK2α or as-CK2α.
The URA3 plasmid was shuffled out and yeast were spotted in 5-fold serial dilutions on
YD, SD, 5FOA, plates and 5FOA plates supplemented with DMSO, Na-PP1, and NmPP1 and grown at 30° for two days. These assays were performed three times. IB,
immunoblot.

121

Figure 3-9
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Strikingly, no decrease in phosphorylation with as-CK2α was detected under the same
conditions indicating that as-CK2 is no longer sensitive to inhibition by CK2 inhibitor,
TBBz.
Staurosporine is widely considered a pan-kinase inhibitor as it broadly inhibits
numerous kinases, both serine/threonine and tyrosine, with relatively low selectivity but
with a high potency (Anastassiadis et al., 2011). Interestingly, CK2 is more resistant to
inhibition by staurosporine, requiring significantly higher inhibitor concentrations
(Meggio et al., 1995). To test if the enlarged pocket of as-CK2 could result in increased
inhibition by staurosporine, we evaluated the phosphorylation of EEF1D by CK2α and asCK2α in the presence of increasing concentrations of staurosporine and detected
phosphorylation by immunoblotting with a phospho-specific anti-EEF1D antibody
(Figure 3-10a). With increasing inhibitor concentration there was a decrease in the
phosphorylation of EEF1D with as-CK2α that was similarly observed with CK2α.
Phosphorylation by CK2α and as-CK2α with the addition of 10 µM staurosporine resulted
in a 50% decrease in phosphorylation for both kinases (Figure 3-10b). These results
demonstrate that as-CK2α is not more sensitive to inhibition by staurosporine than CK2α.

3.3.6 Assessment of the ability of as-CK2 to phosphorylate cellular substrates in cell
extract
To assess the utility of as-CK2 to identify direct substrates of CK2 within the complexity
of the cellular environment, we used EEF1D, a known cellular CK2 substrate. HeLa cells
were transfected with Flag-EEF1D and the lysates were supplemented with ATPγS or
2peATPγS.
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Figure 3-10
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Figure 3-10. Inhibition of CK2α and as-CK2α by staurosporine. Recombinant HisEEF1D substrate was phosphorylated by either CK2α and ATPγS or as-CK2α with
2peATPγS with increasing concentrations of staurosporine. Phosphorylation was
detected by immunoblotting with anti-phospho-pS162 EEF1D antibody (A) and
quantified (B). Results are an average of three independent experiments. Error bars
indicate the standard error. Samples were also immunoblotted with anti-EEF1D
antibody. IB, immunoblot.
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immunoprecipitations were detected by immunoblotting with an anti-thiophosphate ester
antibody (Figure 3-11). Phosphorylation of cellular proteins as well as Flag-EEF1D was
observed with the addition of ATPγS regardless of whether or not CK2α-HA was coexpressed (Figure 3-11a). In contrast, phosphorylation of cellular proteins and FlagEEF1D was almost undetectable with 2peATPγS in the absence of as-CK2α expression.
Phosphorylation of cellular proteins including Flag-EEF1D with 2peATPγS was only
observed when as-CK2α-HA was co-expressed. Phosphorylation of a Flag-EEF1D
S162A mutant, with the CK2 phosphorylation site serine replaced with an alanine, was
abolished when expressed indicating the only site on Flag-EEFD phosphorylated was
S162, the known CK2 site (Gyenis et al., 2011) (Figure 3-11b).
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Figure 3-11. EEF1D is phosphorylated by as-CK2α in cell extracts. HeLa cells were
transfected with either CΚ2α-HA or as-CΚ2α-HA and EEF1D-Flag (A) or a
nonphosphorylatable mutant EEF1D S162A-Flag (B). Kinase assays were performed by
supplementing the cell extracts with ATPγS or 2peATPγS. EEF1D-Flag was
immunoprecipitated by FlagM2, samples were alkylated by treatment with PNBM, and
phosphorylation was detected by immunoblotting with an anti-thiophosphate ester
antibody. Samples were also immunoblotted with anti-FlagM2 and anti-HA3F10
antibodies. These assays were performed twice. IB, immunoblot.
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Figure 3-11
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3.4 Discussion
CK2 is a pleiotropic protein kinase with essential roles in numerous signaling pathways
regulating cell growth, survival, and death (Litchfield, 2003; St-Denis and Litchfield,
2009). In order to expand our understanding of the complicated cellular roles of CK2 we
have applied a chemical genetic approach originally described by Shokat and colleagues
for v-Src (Shah et al., 1997). As outlined with this strategy, replacement of a strictly
conserved bulky “gatekeeper” residue in the nucleotide-binding pocket with a smaller
amino acid enlarges the nucleotide-binding pocket of the kinase to accommodate N6modified ATP analogs and modified ATP-site inhibitors not accommodated within the
wild-type pocket (Figure 3-1). While originally developed for Src protein tyrosine
kinases, this strategy has also been successfully applied to numerous protein
serine/threonine kinases, including PKA, Erk2, Raf-1, Cdk1, Cdk2, Cdk7, Cdk12, Plk1,
JNK, CAMKII, GRK2, ROCK2, SNF1, ATM, PKD, PKG1α, JAK2, and c-Abl, and the
lipid kinase PI3K (Shah et al., 1997; Bishop et al., 2000; Weiss et al., 2000; Carroll et al.,
2001; Habelhah et al., 2001; Chaudhary et al., 2002; Niswender et al., 2002; Eblen et al.,
2003; Ubersax et al., 2003; Hindley et al., 2004; Alaimo et al., 2005; Jones et al., 2005;
Kenski et al., 2005; Frank et al., 2006; Larochelle et al., 2006; Burkard et al., 2007; Oh et
al., 2007; Kim et al., 2008; Shirra et al., 2008; Elphick et al., 2009; Sliedrecht et al., 2010;
Cipak et al., 2014; Bartkowiak et al., 2015).
To adapt this strategy to CK2, the “gatekeeper” residue in CK2α and CK2α’ was
identified to be F113 and F114, respectively. This residue aligns with c-Src T338, the
“gatekeeper” residue previously identified for c-Src in both sequence and structural
alignments (Chaudhary et al., 2002; Witucki et al., 2002) (Figure 3-3a,b). In addition, this
residue also aligns with a conserved phenylalanine residue in Cdks, closely related family
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members to CK2. An as-c-Src was successfully generated by replacing T338 with both
and alanine and glycine residue and has been studied in great detail, along with closely
related as-v-Src. Furthermore, as-kinases have also been previously generated for Cdk1,
Cdk2, and Cdk7 with the gatekeeper residue being F88, F80 and F91, respectively
(Bishop et al., 2000; Ubersax et al., 2003; Larochelle et al., 2006). CK2 has one of the
largest “gatekeeper” residues found in protein kinases. An analysis of 420 protein kinases
determined that 63, or 15% of protein kinases have a phenylalanine “gatekeeper” residue
(Zuccotto et al., 2010).
Structurally, CK2α F113 is located between the N-terminal and C-terminal lobes
of the kinase, positioned at the end of the β5-sheet and the start of the hinge region
(Niefind et al., 2001). The hinge region forms the back of the nucleotide-binding pocket,
and F113 forms hydrophobic interactions with the adenosine rings of ATP (Figure 3-3b).
Modeling of the F113G substitution in CK2α demonstrates that replacing the
“gatekeeper” phenylalanine residue with a smaller glycine amino acid visually enlarges
the nucleotide-binding pocket. Furthermore, based on this model, the effect may possibly
be confined to the F113G mutation since large conformational changes were not observed
within the nucleotide-binding pocket (Figure 3-3c,d). This is consistent with the structure
of as-c-Src (T338G) solved with N6-(benzyl)ADP (benzylADP) (Witucki et al., 2002).
The replacement of T338 with a smaller glycine residue increased the size of the
nucleotide-binding pocket of c-Src by not only decreasing the residue size, but also
providing access to a small pocket that is adjacent to binding pocket. In addition, the wtand as-c-Src structures very closely align with an rmsd of 0.35 Å and no structural and
side chain rearrangements within the binding pocket were observed (Witucki et al., 2002).
The conclusions drawn from our as-CK2α in silico model may be limited and a more
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through evaluation could entail structural analysis of as-CK2 by X-ray crystallography.
With the “gatekeeper” residue identified, to completely exploit the full potential of
the Shokat strategy, an as-kinase should meet three criteria: 1) an as-kinase that
efficiently utilizes an N6-modified ATP analog that is not used by the wt-kinase, 2) the
gatekeeper mutation does not have a substantial functional effect, and 3) the as-kinase is
sensitive to inhibition by a modified inhibitor that the wt-kinase is resistant to.
To address the first criterion, a bio-orthogonal ATP analog to complement as-CK2
was identified by screening a panel of commercially available N6-modified ATP analogs.
As-CK2 displayed an order of magnitude increased activity with 2peATP while CK2 had
substantially reduced activity with 2peATP, compared to activity levels with ATP (Figure
3-4). This, along with the observation that both smaller (1mbATP and 2mbATP) and
larger (3mbATP) analogs display minimal activity with as-CK2 would suggest that
2peATP has the best shape and size complementarity to the enlarged nucleotide-binding
pocket present in as-CK2. In CK2, the small and hydrophobic methylbutyl groups on
1mbATP and 2mbATP may not be large enough to be sterically hindered by F113, and in
fact, F113 may have hydrophobic interactions with these small ATP analogs. In as-CK2,
F113 is substituted with a glycine and, similar to ATP, this removes any hydrophobic
interactions with F113 and 1mbATP and 2mbATP and results in the observed decreased
activity (Figure 3-4b). As for phenylATP and 2peATP, which are similar in size, as-CK2
displays much higher activity with 2peATP than phenylATP. This can likely be explained
by the increased linker length and flexibility of the longer linker in 2peATP, that is
necessary to properly position the aromatic ring in the adjacent binding pocket. The
absence of this flexibility and shorter linker size in the more rigid phenylATP analog may
prevent the aromatic ring from accessing the binding pocket. This observation is also
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consistent with previous modeling and structural studies with as-c-Src (Liu et al.,
1998a,b; Witucki et al., 2002). In addition, as-c-Src showed an increase in activity with
aromatic ring containing ATP analogs, as the size of the carbon linker increased
(phenylATP < benzylATP < 2peATP) (Liu et al., 1998b).
Other as-kinases that contain a large phenylalanine “gatekeeper” residue include
Cdk1, Cdk2, and Cdk7, however, these as-kinases have enhanced activity with cpATP
and benzylATP analogs, which are smaller in size than 2peATP (Ubersax et al., 2003;
Larochelle et al., 2006; Elphick et al., 2009). On the other hand, other as-kinases that
show robust activity with 2peATP are v-Src, c-Src, PKA, JNK, and Raf-1, which have
medium and small sized “gatekeeper” residue, either a methionine, threonine, or
isoleucine (Liu et al., 1998b; Habelhah et al., 2001; Chaudhary et al., 2002; Hindley et al.,
2004; Schauble et al., 2007). It is apparent that the size of the “gatekeeper” residue does
not necessarily predict the complementary ATP analog. While other phenylalaninesubstituted as-kinases have activity with ATP analogs containing ring structures, it is
apparent that kinases containing medium and small sized “gatekeeper” residues can not
only use ATP analogs with ring structures, but frequently use 2peATP, when this residue
is replaced by an alanine or glycine. This discrepancy in size between the substituent
added to the ATP analog and the amino acid side chain substituted in the kinase may be
attributed more to the size of the small adjacent pocket that the “gatekeeper” residue bars
access to, than to the physical size of the “gatekeeper” residue itself (Liu et al., 1998a,b;
Witucki et al., 2002). It could be possible that this could also be attributed to increased
flexibility within the interdomain hinge, as the “gatekeeper” residue is located in this
hinge region, and mutation of a large and rigid side chain with a smaller and more
flexible side chain may increase the hinge flexibility. However, this prediction was tested
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and it was demonstrated that this is not a major contributing factor. In v-Src, E339, the
residue immediately adjacent to the “gatekeeper” I338, was replaced with a glycine to
mimic the predicted flexibility introduced with an I338G mutation. This mutant kinase, vSrc E339G showed 50% less activity with ATP analogs tested compared to as-v-Src, and
only slightly higher activity levels than v-Src (Liu et al., 1998a).
The results with as-CK2 and 2peATP were further examined by determining the
kinetic parameters with wt- and as-CK2 with ATP and 2peATP, which were consistent
with the initial activity assays (Figure 3-5 and Table 3-3). The KM of CK2 with ATP is
much lower than the KM of as-CK2 with ATP. In contrast, the KM of as-CK2 with
2peATP is much higher than the KM of CK2 with 2peATP. As discussed above, this
further suggests that the substitution of the phenylalanine with a glycine reduces the
binding affinity of ATP by removing any hydrophobic interactions between ATP and the
phenylalanine. In CK2, the “gatekeeper” phenylalanine residue decreases the binding of
2peATP, and replacement with a glycine in as-CK2 results in an increase in binding
affinity by removing the steric hindrance and providing access to an adjacent pocket, thus
enlarging the nucleotide-binding pocket, as predicted by the in silico as-CK2α model
(Figure 3-3c,d). The reduced activity of either CK2 with 2peATP or as-CK2 with ATP
can be attributed to the different binding affinities, but it can also be due to poor
positioning of the γ-phosphate of ATP or 2peATP with the catalytic residues necessary
for phosphate transfer within the active site of as-CK2 and CK2, respectively. While the
majority of as-kinases have not determined the kinetic parameters with ATP and ATP
analogs, these results are consistent with those studies that have. Consistent with CK2, askinases have higher affinities for ATP analogs (N6-(cyclopentyl)ATP (cpATP),
benzylATP, and 2peATP) than wt-kinases, suggesting that enlarging the nucleotide-
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binding pocket does indeed increase the ability of as-kinases to bind and use ATP analogs
(Table 3-3) (Shah et al., 1997; Liu et al., 1998a; Kraybill et al., 2002; Ubersax et al.,
2003; Ulrich et al., 2003; Hindley et al., 2004; Schauble et al., 2007; Elphick et al., 2009).
In contrast, as-kinases had lower affinities for ATP than wt-kinases, which is consistent
with CK2. Although, this difference in affinity covers a broad range from 2- to 16-fold,
as-kinases that also had a phenylalanine to glycine substitution displayed the largest
increases. Furthermore, in every study, the KM of wt-kinase with ATP analogs is higher
than with ATP, which although not determined, is higher than 1 mM. For CK2, the
binding affinity is more than 20-fold lower with 2peATP than ATP, but the KM with
2peATP is in the 300 µM-range and 3-fold lower than other wt-kinases studied. Yet,
closely related to CK2, both Cdk1 and Cdk2 also contain a “gatekeeper” phenylalanine
residue and have substantially higher KM values with benzylATP than CK2 with 2peATP
(Kraybill et al., 2002; Ubersax et al., 2003; Elphick et al., 2009). This observation would
suggest that the phenylalanine residue in CK2 does not likely interact with the ATP
analog to increase its binding affinity, but perhaps the nucleotide-binding pockets
structurally differ slightly between CK2 and other kinases. Related to this point, CK2 is a
dual specificity kinase and can use not only ATP, but has a somewhat unique ability to
also naturally accept GTP as a phosphoacceptor, which is larger than ATP (Dobrowolska
et al., 1999; Niefind et al., 1999). By logical extension of our kinetic data, it is not
unexpected that as-CK2 preferentially uses 2peATP over ATP and CK2 preferentially
uses ATP over 2peATP (Figure 3-6). It is exciting to speculate that even in cells, as-CK2
will likely use exogenously supplied 2peATP despite the high cellular ATP
concentrations. To further investigate the basis for ATP and 2peATP binding, additional
structural studies, including X-ray crystallography and NMR, could be conducted.
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To address the second criterion, the effect of the gatekeeper mutation on substrate
selectivity was tested using in vitro kinase assays with both peptide and protein substrates
(Figure 3-7). The substrate selectivity of CK2α and ATP was determined to be very
comparable to the substrate selectivity of as-CK2α and 2peATP. Based on these results, it
can be inferred that the F113G mutation did not produce large conformational changes or
structural rearrangements. Structurally, the “gatekeeper” mutation is located in the back
of the nucleotide-binding pocket whereas the residues that confer substrate selectivity are
clustered outside the pocket and on the surface of the kinase and make specific contacts
with the individual acidic residues in the substrate. Both mutational and structural studies
have mapped the substrate-binding cleft in CK2 to the lysine-rich segment in helix αC
(K74-79, R80, K83) and the p+1 loop (R191, 195, K198) (Sarno et al., 1996, 1997, 1999;
Niefind et al., 2007). In these studies, mutations of these basic amino acids to neutral
alanine residues increased the affinity of CK2 for substrate peptide RRRADDSDDDDD
(Sarno et al., 1996, 1997). Additionally, in the absence of a structure of CK2 with a
substrate peptide, a model was generated by aligning CK2 with the structure of PKA and
a bound substrate by changing the PKA substrate to resemble a CK2 peptide substrate.
This model further implicates these basic residues as they directly interact with individual
acidic residues at the n+1, n+2, n+3, and n+4 positions on the substrate (Sarno et al.,
1999). This model was further supported by the observation of two sulfate anions bound
to the lysine-rich segment and p+1 loop in a crystal structure of CK2 (Niefind et al.,
2007). The lack of alteration in substrate specificity between wt- and as-CK2 is also
consistent with data collected for as-c-Src and as-Fyn (Witucki et al., 2002). In this very
comprehensive study, 50 625 degenerate putative peptide substrates were analyzed for
activity with wt- and as-kinases and very similar specificity profiles were observed for
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both c-Src and Fyn. Furthermore, the kinetic parameters with 11 optimal peptide
substrates were determined for both wt- and as-c-Src and no differences were observed.
Studies in yeast provide additional support that the specificity towards protein
substrates is maintained in as-CK2 (Figure 3-8b). Yeast expressing human as-CK2α
functionally replaced human wt-CK2α and supported viability of yeast containing a
double yeast CKA1 and CKA2 gene knockout. The functional complementation is
consistent with our finding that the F113G did not alter substrate specificity in vitro and
thus it can be further inferred that as-CK2α would participate in the same cellular
pathways as wt-CK2α (Figure 3-7). These results are consistent with other as-kinase yeast
models. Both wt- and as-Fus3 support viability equally in a yeast strain with a triple Fus1,
Fus2, and Fus3 gene knockout (Bishop et al., 2000). In a yeast model of PI3K, yeast
orthologs VPS34 and MEC1 were replaced with as-VPS34 and as-MEC1, and growth
was observed under conditions that absolutely required catalytic activity (Alaimo et al.,
2005). More recently, the endogenous Cdk12 gene, which is essential for cell survival,
was replaced with as-Cdk12 in HeLa HR-19 cells using CRISPR/Cas9 (Bartkowiak et al.,
2015). The as-Cdk12 expressing cells were indistinguishable in morphology and growth
from Cdk12 expressing cells, demonstrating that as-kinases can functionally complement
wt-kinases in mammalian cells as well. Perhaps just as exciting as the functional
complementation of as-CK2α, is the idea that the high cellular ATP levels in yeast must
compensate for the severely diminished catalytic activity and reduced affinity for ATP
seen with as-CK2 (Figure 3-4 and Table 3-3). This has also been observed for as-c-Src
where the minimal in vitro activity with ATP, is compensated by the cellular ATP levels
in Src/Yes/Fyn null fibroblasts (Chaudhary et al., 2002).
It is also interesting that human CK2α’, and thus as-CK2α’, does not support
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viability in yeast (Figure 3-8b). Although CK2α and CK2α’ are catalytically
indistinguishable from each other and share 90% sequence identity in the N-terminal 330
amino acids, studies with knockouts of the catalytic subunits in mice, over-expression of
catalytic-inactive mutants in mammalian cells, and temperature-sensitive mutants in yeast
all reveal a different phenotype between CK2α and CK2α’ and strongly suggest a
functional specialization (Hanna et al., 1995; Rethinaswamy et al., 1998; Vilk et al.,
1999; Xu et al., 1999; Litchfield, 2003; Lou et al., 2008). Temperature-sensitive mutants
in yeast display distinct phenotypes. Loss of CKA1 revealed a defect in cell polarity
whereas loss of CKA2 resulted in cell cycle arrest (Hanna et al., 1995; Rethinaswamy et
al., 1998). The observation that human CK2α but not CK2α’ functionally compensates for
CK2 expression in yeast, further reinforces that CK2α may have essential cellular roles,
substrates, and/or interacting proteins that CK2α’ cannot substitute for.
To address the third criterion, the sensitivity of as-CK2α and CΚ2α to modified
PP1 inhibitors, TBBz, and staurosporine was tested. Βοth in vitro and yeast studies reveal
that as-CK2α is more sensitive to modified PP1 inhibitors, Nm-PP1 and Na-PP1, than
CK2α (Figure 3-9). This suggests that the F113G substitution provides a larger binding
pocket for these inhibitors and allows them to more effectively compete for ATP and
2peATP binding than CK2α. This observation is consistent with numerous other askinases, however, higher concentrations of inhibitor were required to inhibit as-CK2α
(Bishop et al., 2000; Weiss et al., 2000; Niswender et al., 2002; Abeliovich et al., 2003;
Sreenivasan et al., 2003; Jones et al., 2005; Kenski et al., 2005; Frank et al., 2006;
Larochelle et al., 2006; Burkard et al., 2007; Hochegger et al., 2007; Oh et al., 2007; Wan
et al., 2007; Bartkowiak et al., 2015). Reported IC50 values for these as-kinases are in the
sub-micromolar range and cellular treatments largely employ 1-10 µM inhibitor.
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Unfortunately, the requirement for increased inhibitor concentrations for as-CK2 is
limited by the solubility of these inhibitors in DMSO and well as the DMSO
concentration tolerated by cells. Yeast expressing as-CK2α were more sensitive to
inhibition by Na-PP1 and Nm-PP1 than CK2α (Figure 3-9d). For Na-PP1, treatment with
100 µM showed a more pronounced phenotype between CK2α and as-CK2α than
treatment with 50 µM. However, treatment with 100 µM Nm-PP1 severely reduced
growth of both CK2α and as-CK2α expressing yeast, compared with 50 µM, suggesting
that high Nm-PP1 concentration is toxic to yeast. This toxicity has been anecdotally
described for other as-kinases in yeast. Mild toxicity has been observed with 25 µM NmPP1 for as-Pat1 and as-Elm1 in yeast. Reduced growth for wt-Pat1 was observed upon
Nm-PP1 treatment when compared to a DMSO control and wt-yeast showed G1 delay and
a decrease in budding which would result slower growth (Sreenivasan et al., 2006; Cipak
et al., 2014). A very probable explanation for cellular toxicity can be attributed to offtarget binding to other protein kinases or nucleotide-binding proteins. Although not
systematically tested in yeast, inhibition of human kinases has been profiled for several
modified PP1 inhibitors, including Nm-PP1. These studies reveal an overwhelming
number of kinases with IC50 values in the sub-micromolar range for Nm-PP1 (Bian et al.,
2007; Zhang et al., 2013). For example, the IC50 values for c-Src, RIP2, PKA, Pkd1, Ret,
and EphA1 are 0.62, 0.13, 0.5, 0.075, 0.16, and 0.065 µM, respectively.
Inhibition assays also demonstrate that as-CK2α is resistant to inhibition by
TBBz, a known CK2 inhibitor (Figure 3-9a) (Zien et al., 2003). Inhibition of as-CK2α by
staurosporine, a broad-spectrum kinase inhibitor that is not a potent CK2 inhibitor, was
similar to CK2α and required a concentration of at least 50 µM (Figure 3-10). This is
consistent with the previously determined IC50 value of 19.5 µM for CK2 and is 3 orders
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of magnitude higher than reported values for numerous protein tyrosine and
serine/threonine kinases tested, which have IC50 values in the nanomolar range (Meggio
et al., 1995). A new class of inhibitors for as-kinases have been designed based on a
staurosporine scaffold, called staralogs (Lopez et al., 2013). These inhibitors specifically
inhibit the as-kinases tested with nanomolar concentrations. In addition, these inhibitors
do not inhibit kinases that have been shown to be sensitive to PP1 analogs, including
Pkd1, EphA1, Ptk6, and Ret, and may reduce the off-target effects and toxicity associated
with higher Nm-PP1 concentrations. These staralogs may also inhibit as-CK2 and would
be a better alternative to inhibition by PP1 analogs.
The structural basis for CK2 inhibition is attributed to a considerably smaller
active site (Niefind et al 2001; Sarno et al., 2001). The binding pocket of CK2 contains
larger residues with bulky side chains that reduce the space available for inhibitors and
are not conserved among other kinases; namely V66, H160, M163, and I174 (Hanks and
Hunter, 1995). Additionally, F113 is only present in 15% of protein kinases while the
majority of kinases, 84%, contain a smaller residue in this position (Zuccotto et al., 2010).
This is supported by the fact that TBBz, a CK2 inhibitor, is much smaller in size than
modified PP1 inhibitors and staurosporine, which are not potent CK2 inhibitors. Based on
structures of CK2 and structurally related inhibitors, the selectivity of TBBz inhibition is
provided by numerous hydrophobic interactions between residues, including F113, in the
nucleotide-binding pocket and the inhibitor (Battistutta et al., 2001; Pagano et al., 2004;
Battistutta et al., 2007). It has also been shown that mutations of these residues, namely
V66 and I174, reduce the binding affinity of structurally related CK2 inhibitors TBB,
TBBz, and DMAT (Sarno et al., 2002; Pagano et al., 2004; Sarno et al., 2005a,b; Zien et
al., 2005). A double mutant, V66A/I174A, in CK2α increases the Ki with TBBz by 18-
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fold (Zien et al., 2005). Not only does replacing F113 with a glycine in as-CK2α enlarge
the pocket, but would also disrupt any hydrophobic interactions the phenylalanine has
with the inhibitor, consistent with our results (Figure 3-9a). The uniquely small binding
pocket of CK2 is also the structural basis for staurosporine resistance as a double mutant,
V66A/I174A, in CK2α decreases the Ki by 10-fold (Sarno et al., 2005b). To increase the
sensitivity of as-CK2α to Nm-PP1, Na-PP1, and staurosporine, additional mutations to
further increase the size of the binding pocket may be necessary. Consistent with this
notion, single mutants, V66A or I174A, each have a smaller effect on inhibition by TBB
and DMAT, than the double mutant, V66A/I174A (Sarno et al., 2002; Pagano et al.,
2004; Sarno et al., 2005a,b). Additional mutations may also increase the sensitivity of asCK2 to staralogs (Lopez et al., 2103).
An ultimate advantage to using an as-kinase approach to study CK2 is the ability
to specifically label direct substrates of CK2. To transition from assays with recombinant
components complex cell extracts and fully assess the utility of as-CK2 to phosphorylate
cellular substrates of CK2, we chose a known CK2 substrate, EEFID (Figure 3-11)
(Gyenis et al., 2011). Phosphorylation of cellular proteins as well as Flag-EEF1D was
observed with the addition of ATPγS regardless of whether or not CK2α-HA was coexpressed. This is perhaps not surprising, as all endogenous kinases can utilize ATP and
highlighting the challenge in assigning a distinct kinase to a specific phosphorylation
event. In contrast, phosphorylation of cellular proteins and Flag-EEF1D was almost
undetectable with 2peATPγS in the absence of as-CK2α expression. Phosphorylation of
cellular proteins including Flag-EEF1D with 2peATPγS was only observed when asCK2α-HA was co-expressed. The minimal phosphorylation of proteins in the absence of
as-CK2α-HA demonstrates the inability of other endogenous kinases, including
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endogenous CK2, to efficiently utilize 2peATPγS and really highlights the specificity of
the as-kinase approach. Additionally, as predicted by the kinetics and competition assays,
as-CK2 uses 2peATPγS to phosphorylate cellular substrates even in the presence of high
cellular ATP concentrations (Figure 3-5, Figure 3-11, and Table 3-3). Furthermore, it is
very clear that there are a multitude of other proteins specifically phosphorylated by asCK2α that remain unidentified. The specificity of as-CK2 and 2peATPγS together with
the unaltered substrate specificity of as-CK2 provides confidence that these proteins are
in fact direct substrates of CK2. Combining this assay with as-CK2 sensitive inhibitors
can be advantageous to further increase this confidence. While we assessed our strategy
by phosphorylating EEF1D in cell extracts, this strategy can be easily adapted to validate
other putative CK2 substrates.
In conclusion, we have generated an as-CK2 kinase by substituting the
“gatekeeper” phenylalanine residue with a smaller glycine residue to enlarge the
nucleotide-binding pocket. As-CK2 meets all three criteria for a useful as-kinase. A
screen of ATP analogs identified enhanced activity of as-CK2 with 2peATP, which was
not observed with CK2. As-CK2 preferentially uses 2peATP to phosphorylate substrates
and has increased sensitivity to modified PP1 inhibitors. Importantly, the effect of the
F113G substitution is confined to enlarging the nucleotide-binding pocket and does not
alter the substrate specificity of CK2. As a result, as-CK2α can functionally complement
for CK2α in yeast. Ultimately, the utility of this strategy was demonstrated using asCK2α and 2peATPγS to specifically phosphorylate EEF1D as well as many other
proteins in a cell lysate. Together, this outlines a framework to further delineate the
cellular roles of CK2 and strengthen the foundation for future drug development.
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CHAPTER

FOUR:

Systematic

investigation

of

hierarchical

phosphorylation by CK24

4.1 Introduction
Protein phosphorylation is an important regulatory mechanism with a critical role in
signal transduction pathways controlling cell growth, death, survival, and differentiation
(Litchfield, 2003; St-Denis and Litchfield, 2009). In recent years, the exponential increase
in phosphoproteomic studies to further elucidate the widespread involvement of
phosphorylation on cellular processes have contributed large datasets and identified
thousands of phosphorylation sites in the human proteome (Sharma et al., 2014). A large
amount of data has been deposited into databases, including PhosphoSite Plus which
currently has over 250 000 phosphorylation sites (Hornbeck et al., 2015). Overall, it is
apparent that the majority of the proteome is phosphorylated with many of these
phosphoproteins phosphorylated at multiple sites (Ahn and Resing, 2001; Johnson and
Hunter, 2005; Sharma et al., 2014). For example, p53 is a highly phosphorylated protein
that contains at least 20 studied phosphorylation sites, 33 identified phosphorylation sites
(PhosphoSite Plus) and is phosphorylated by multiple kinases (Gu and Zhu, 2012).
Extending this example globally, there are 10-times more phosphorylation sites than
phosphoproteins in PhosphoSite Plus and 47% of these phosphoproteins contain 3-12
phosphorylation sites, while only 15% of the known phosphoproteins are singly
phosphorylated (Sharma et al., 2014; Cesaro and Pinna, 2015). These phosphorylation
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sites are not equally distributed within the proteome and significant clustering of
phosphoserines (pS) into specific hyperphosphorylated regions throughout the proteome
show concurrent phosphorylation (Yachie et al., 2009; Schweiger and Linial, 2010;
Sharma et al., 2014; Cesaro and Pinna, 2015). In fact, a study of 70 000 phosphorylation
sites revealed that 54% of pS and phosphothreonine (pT) residues were located no further
than four amino acids from other pS or pT residues (Schweiger and Linial, 2010). This
provides an environment that is conducive to hierarchical phosphorylation.
Hierarchical phosphorylation occurs when a protein kinase phosphorylates a
substrate at its unique consensus sequence (priming kinase) and the addition of this
phosphate creates adequate sequence determinants that enable phosphorylation at a
proximal site (primed kinase). This phenomenon can involve a single kinase or more than
one distinct kinase. A few protein kinases, namely GSK3β and CK1, almost exclusively
catalyze primed phosphorylation events, as phosphorylation by these kinases usually
requires priming phosphorylation of a nearby residue to adequately fulfill their consensus
sequence determinants (Fiol et al., 1990; Flotow et al., 1990).
Classically, CK2 was demonstrated to participate in hierarchical phosphorylation
as the priming kinase for subsequent GSK3β phosphorylation of both glycogen synthase
and phosphatase inhibitor-2 to regulate glucose metabolism (DePaoli-Roach et al., 1981;
DePaoli-Roach, 1984; Woodgett and Cohen, 1984). CK2 is an acidophilic kinase and
requires one or more acidic residues C-terminal to a phosphoacceptor residue, with a
minimum canonical consensus (non-hierarchical) sequence of S/T-X-X-D/E, where X is
any amino acid (Meggio and Pinna, 2003). More importantly, CK2 has been shown to
also use pS and pY, but not pT, residues as acidic determinants for substrate
phosphorylation, which suggests that CK2 also has the ability to participate in
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hierarchical phosphorylation as the primed kinase (Kuenzel et al., 1987; Hrubey and
Roach, 1990; Litchfield et al., 1990; Perich et al., 1992; Marin et al., 1996). Several
examples where CK2 can be primed by other kinases have been recently reported in the
literature. For example, priming phosphorylation on Stem-loop binding protein (SLBP) at
T61 by Cdk1/cyclin A has been shown to be required for CK2 phosphorylation at T60
(Koseoglu et al., 2008). CK2 phosphorylation of Wee1A at S121 is dependent on
Cdk1/cyclin B priming phosphorylation at S123 (Watanabe et al., 2005). Phosphorylation
of Rad51 requires priming phosphorylation by Plk1 at S14 for subsequent
phosphorylation by CK2 at T13 (Yata et al., 2012). Phosphorylation of CFTR by Lyn at
Y512 primes CK2 phosphorylation at S511 (Cesaro et al., 2013; Venerando et al., 2014).
Together, these studies suggest that hierarchical phosphorylation by CK2 may
contribute to the regulation of cellular signaling. To this end, previous studies in our lab
have identified the optimal spacing of pS residues for CK2 hierarchical phosphorylation
(St-Denis et al., 2015). However, the precise consensus requirements for CK2
hierarchical phosphorylation have not been thoroughly investigated. In this study, we
have used a peptide-based approach to systematically outline the detailed consensus
requirements for hierarchical phosphorylation by CK2 in two contexts, multisite
phosphorylation, where CK2 or another kinase can serve as the priming kinase, and
proline-directed hierarchical phosphorylation, where a proline-directed kinase (i.e. Cdks)
can serve as the priming kinase (Figure 4-1). Using the consensus sequences that were
derived from these studies, we probed the human proteome to identify potential substrates
and then searched the PhosphoSite Plus phosphorylation database for known
phosphorylation of these candidates. The effect of CK2 hierarchical phosphorylation on a
selection of candidates was then examined using synthetic peptide substrates. Combining
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bioinformatic analysis with candidate assessment provides in vitro evidence that
hierarchical phosphorylation by CK2 may potentially contribute to the regulation of
multiple cellular processes.
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Figure 4-1
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Figure 4-1. A schematic illustrating the involvement of CK2 as the primed kinase in
hierarchical phosphorylation. (A) Multisite phosphorylation occurs when priming
phosphorylation by CK2 or another kinase generates adequate sequence determinants
for subsequent phosphorylation by CK2 at a proximal site. (B) Proline-directed
hierarchical phosphorylation occurs when priming phosphorylation by a Cdk or
another proline-directed kinase generates adequate sequences determinants for
subsequent phosphorylation by CK2 at a proximal site. P, phosphate; X, any amino
acid; S, serine; T, threonine; D, aspartic acid; E, glutamic acid.
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4.2 Methods and Materials
4.2.1 Purification of CK2- CK2 holoenzyme, consisting of GST-CK2α and His-CK2β,
was purified from bacterial culture as previously described (Turowec et al., 2010).
Briefly, GST-CK2α and His-CK2β were expressed in Escherichia coli separately. Upon
lysis, the supernatants were combined in a 1:1 ratio to allow for holoenzyme formation.
The holoenzyme complex (and uncomplexed GST-CK2α) was then affinity purified using
glutathione-agarose beads (Sigma) followed by elution with increasing glutathione.
Enzyme concentration was determined using the BCA assay (Pierce) using BSA as a
protein standard with absorbance measurements taken at 565 nm using a Victor3 V 1420
multilabel counter (Perkin Elmer). The enzyme was diluted to 50 ng/µL in CK2 Dilution
Buffer (5 mM MOPS pH 7.0, 200 mM NaCl, 1 mg/mL BSA) immediately before use in
kinase assays.
4.2.2 Peptide Synthesis- Peptides were synthesized using standard Fmoc (9fluorenylmethyloxycarbonyl) chemistry at a 2 µmol scale on a Multipep Synthesizer
(Intavis). The sequences of all peptides used in this study can be found in Table 4-1.
Peptides were cleaved from the resin using trifluoroacetic acid and precipitated with 3
tube volumes of ether. Peptides were resuspended in 200 mM HEPES pH 7.4 and the pH
was adjusted to pH 6-8 using 0.1 M NaOH.
The concentrations of peptides containing N-terminal tryptophan residues were
determined by measuring the absorbance at 280 nm using a NanoDrop 2000 (Thermo
Scientific) and NanoDrop software. The concentration of peptides lacking an N-terminal
tryptophan residue but containing an N-terminal biotin, was determined using a 4’hydroxyazobenzene-2-carboxylic acid (HABA)/Avidin (Life Technologies, Inc.) assay as
outlined in the product manual. To determine the biotinylated peptide concentration, the
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Table 4-1. Sequences of the synthesized peptides used in this study.
Peptide Sequencea
WRRRAAASpSApSAAA
WRRRDDDSpSApSAAA
WRRRDDDApSApSAAA
WRRRDAASpSApSAAA
WRRRADASpSApSAAA
WRRRAADSpSApSAAA
WRRRAAASpSDpSAAA
WRRRAAASpSApSDAA
WRRRAAASpSApSADA
WRRRAAASpSApSAAD
WRRREAASpSApSAAA
WRRRAEASpSApSAAA
WRRRAAESpSApSAAA
WRRRAAASpSEpSAAA
WRRRAAASpSApSEAA
WRRRAAASpSApSAEA
WRRRAAASpSApSAAE
WRRRFAASpSApSAAA
WRRRAFASpSApSAAA
WRRRAAFSpSApSAAA
WRRRAAASpSFpSAAA
WRRRAAASpSApSFAA
WRRRAAASpSApSAFA
WRRRAAASpSApSAAF
WRRRHAASpSApSAAA
WRRRAHASpSApSAAA
WRRRAAHSpSApSAAA
WRRRAAASpSHpSAAA
WRRRAAASpSApSHAA
WRRRAAASpSApSAHA
WRRRAAASpSApSAAH
WRRRKAASpSApSAAA
WRRRAKASpSApSAAA
WRRRAAKSpSApSAAA
WRRRAAASpSKpSAAA
WRRRAAASpSApSKAA
WRRRAAASpSApSAKA
WRRRAAASpSApSAAK
WRRRMAASpSApSAAA
WRRRAMASpSApSAAA
WRRRAAMSpSApSAAA
WRRRAAASpSMpSAAA

Purpose
Multisite oriented array parent
peptide
Positive control
Negative control
p-3 D
p-2 D
p-1 D
p+2 D
p+4 D
p+5 D
p+6 D
p-3 E
p-2 E
p-1 E
p+2 E
p+4 E
p+5 E
p+6 E
p-3 F
p-2 F
p-1 F
p+2 F
p+4 F
p+5 F
p+6 F
p-3 H
p-2 H
p-1 H
p+2 H
p+4 H
p+5 H
p+6 H
p-3 K
p-2 K
p-1 K
p+2 K
p+4 K
p+5 K
p+6 K
p-3 M
p-2 M
p-1 M
p+2 M

Figure
4-2b
4-2b
4-2b
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b, 4-3a
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b

158
WRRRAAASpSApSMAA
WRRRAAASpSApSAMA
WRRRAAASpSApSAAM
WRRRNAASpSApSAAA
WRRRANASpSApSAAA
WRRRAANSpSApSAAA
WRRRAAASpSNpSAAA
WRRRAAASpSApSNAA
WRRRAAASpSApSANA
WRRRAAASpSApSAAN
WRRRPAASpSApSAAA
WRRRAPASpSApSAAA
WRRRAAPSpSApSAAA
WRRRAAASpSPpSAAA
WRRRAAASpSApSPAA
WRRRAAASpSApSAPA
WRRRAAASpSApSAAP
WRRRQAASpSApSAAA
WRRRAQASpSApSAAA
WRRRAAQSpSApSAAA
WRRRAAASpSQpSAAA
WRRRAAASpSApSQAA
WRRRAAASpSApSAQA
WRRRAAASpSApSAAQ
WRRRRAASpSApSAAA
WRRRARASpSApSAAA
WRRRAARSpSApSAAA
WRRRAAASpSRpSAAA
WRRRAAASpSApSRAA
WRRRAAASpSApSARA
WRRRAAASpSApSAAR
WRRRpSAASpSApSAAA
WRRRApSASpSApSAAA
WRRRAApSSpSApSAAA
WRRRAAASpSpSpSAAA
WRRRAAASpSApSpSAA
WRRRAAASpSApSApSA
WRRRAAASpSApSAApS
BiSKKEDSSDSENAEP
BiRPRHRSSDSDLSPP
BiEGKQHSSDSFDDAF
BiTALLRSSGSLGHRP
BiAHSRDSSDSADGRA
BiALNRTSSDSALHTS
BiPVRLLSSESEDEEE
BiMKLHDSSGSQVGTG
BiELVELSSDSEDLGS

p+4 M
p+5 M
p+6 M
p-3 N
p-2 N
p-1 N
p+2 N
p+4 N
p+5 N
p+6 N
p-3 P
p-2 P
p-1 P
p+2 P
p+4 P
p+5 P
p+6 P
p-3 Q
p-2 Q
p-1 Q
p+2 Q
p+4 Q
p+5 Q
p+6 Q
p-3 R
p-2 R
p-1 R
p+2 R
p+4 R
p+5 R
p+6 R
p-3 pS
p-2 pS
p-1 pS
p+2 pS
p+4 pS
p+5 pS
p+6 pS
CTCF
BUD13
CMTR1
CEP170
CPSF7
CRTC2
EME1
RANBP2
TOPORS

4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-2b
4-5a, 4-6a
4-5a
4-5a
4-5a
4-5a
4-5a
4-5a, 4-6a
4-5a
4-5a, 4-6a
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BiRGRCETSASELERM
BiVQYIESSDSEEIET
BiDIQTISSGSEGDDF
BiLRRALSSDSILSPA
BiRRRHDSSGSGHSAF
BiSKKSASSESEAENL
BiRYASGSSASLGGPE
BiSDFSESSDSENSNK
BiEDKPLSSESLSESE
BiGLSGCSSGSGHSPY
BiLAELDSSESEEETL
BiPKRRGSSGSVDETL
BiTLSITSSGSAVSCS
BiELLSISSESLQARK
BiQQNMESSGSQGGRA
BiKDKRNSSDSAIDNP
BiSKKEDSpSDpSENAEP
BiRPRHRSpSDpSDLSPP
BiEGKQHSpSDpSFDDAF
BiTALLRSpSGpSLGHRP
BiAHSRDSpSDpSADGRA
BiALNRTSpSDpSALHTS
BiPVRLLSpSEpSEDEEE
BiMKLHDSpSGpSQVGTG
BiELVELSpSDpSEDLGS
BiRGRCETpSApSELERM
BiVQYIESpSDpSEEIET
BiDIQTISpSGpSEGDDF
BiLRRALSpSDpSILSPA
BiRRRHDSpSGpSGHSAF
BiSKKSASpSEpSEAENL
BiRYASGSpSApSLGGPE
BiSDFSESpSDpSENSNK
BiEDKPLSpSEpSLSESE
BiGLSGCSpSGpSGHSPY
BiLAELDSpSEpSEEETL
BiPKRRGSpSGpSVDETL
BiTLSITSpSGpSAVSCS
BiELLSISpSEpSLQARK
BiQQNMESpSGpSQGGRA
BiKDKRNSpSDpSAIDNP
BiSKKEDSpSDSENAEP
BiSKKEDSSDpSENAEP
BiPVRLLSpSESEDEEE
BiPVRLLSSEpSEDEEE
BiELVELSpSDSEDLGS
BiELVELSSDpSEDLGS

SLC19A1
HLTF
SETDB1
MISP
POM121C
PPIG
PLEC
JMJD1C
FAM133B
PRRC2B
SPIRE1
RTN4
RIOK2
SIKE1
TAF15
ATRX
CTCF p+1 p+3 pS
BUD13 p+1 p+3 pS
CMTR1 p+1 p+3 pS
CEP170 p+1 p+3 pS
CPSF7 p+1 p+3 pS
CRTC2 p+1 p+3 pS
EME1 p+1 p+3 pS
RANBP2 p+1 p+3 pS
TOPORS p+1 p+3 pS
SLC19A1 p+1 p+3 pS
HLTF p+1 p+3 pS
SETDB1 p+1 p+3 pS
MISP p+1 p+3 pS
POM121C p+1 p+3 pS
PPIG p+1 p+3 pS
PLEC p+1 p+3 pS
JMJD1C p+1 p+3 pS
FAM133B p+1 p+3 pS
PRRC2B p+1 p+3 pS
SPIRE1 p+1 p+3 pS
RTN4 p+1 p+3 pS
RIOK2 p+1 p+3 pS
SIKE1 p+1 p+3 pS
TAF15 p+1 p+3 pS
ATRX p+1 p+3 pS
CTCF p+1 pS
CTCF p+3 pS
EME1 p+1 pS
EME1 p+3 pS
TOPORS p+1 pS
TOPORS p+3 pS

4-5a
4-5a, 4-6a
4-5a, 4-6a
4-5a
4-5a
4-5a
4-5a
4-5a, 4-6a
4-5a
4-5a
4-5a, 4-6a
4-5a
4-5a
4-5a
4-5a
4-5a
4-5a, 4-6a
4-5a
4-5a
4-5a
4-5a
4-5a
4-5a, 4-6a
4-5a
4-5a, 4-6a
4-5a
4-5a, 4-6a
4-5a, 4-6a
4-5a
4-5a
4-5a
4-5a
4-5a, 4-6a
4-5a
4-5a
4-5a, 4-6a
4-5a
4-5a
4-5a
4-5a
4-5a
4-6a
4-6a
4-6a
4-6a
4-6a
4-6a
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BiVQYIESpSDSEEIET
BiVQYIESSDpSEEIET
BiDIQTISpSGSEGDDF
BiDIQTISSGpSEGDDF
BiSDFSESpSDSENSNK
BiSDFSESSDpSENSNK
BiLAELDSpSESEEETL
BiLAELDSSEpSEEETL
WSKKEDSSDSENAEP
WSKKEDSpSDSENAEP
WSKKEDSSDpSENAEP
WSKKEDSpSDpSENAEP
WRRDDDSAAEApSPVK
WRRDDDSAAEASPVK
WRRDDDAAAEApSPVK
WRRDDDSDAEApSPVK
WRRDDDSADEApSPVK
WRRDDDSAAEDpSPVK
WRRDDDSEAEApSPVK
WRRDDDSAEEApSPVK
WRRDDDSAAEEpSPVK
WRRDDDSFAEApSPVK
WRRDDDSAFEApSPVK
WRRDDDSAAEFpSPVK
WRRDDDSHAEApSPVK
WRRDDDSAHEApSPVK
WRRDDDSAAEHpSPVK
WRRDDDSKAEApSPVK
WRRDDDSAKEApSPVK
WRRDDDSAAEKpSPVK
WRRDDDSMAEApSPVK
WRRDDDSAMEApSPVK
WRRDDDSAAEMpSPVK
WRRDDDSNAEApSPVK
WRRDDDSANEApSPVK
WRRDDDSAAENpSPVK
WRRDDDSPAEApSPVK
WRRDDDSAPEApSPVK
WRRDDDSAAEPpSPVK
WRRDDDSQAEApSPVK
WRRDDDSAQEApSPVK
WRRDDDSAAEQpSPVK
WRRDDDSRAEApSPVK
WRRDDDSAREApSPVK
WRRDDDSAAERpSPVK
WRRDDDSpSAEApSPVK

HLTF p+1 pS
HLTF p+3 pS
SETDB1 p+1 pS
SETDB1 p+3 pS
JMJD1C p+1 pS
JMJD1C p+3 pS
SPIRE1 p+1 pS
SPIRE1 p+3 pS
CTCF
CTCF p+1 pS
CTCF p+3 pS
CTCF p+1 p+3 pS
Proline Directed oriented array
parent peptide
non primed negative control
alanine control
p+1 D
p+2 D
p+4 D
p+1 E
p+2 E
p+4 E
p+1 F
p+2 F
p+4 F
p+1 H
p+2 H
p+4 H
p+1 K
p+2 K
p+4 K
p+1 M
p+2 M
p+4 M
p+1 N
p+2 N
p+4 N
p+1 P
p+2 P
p+4 P
p+1 Q
p+2 Q
p+4 Q
p+1 R
p+2 R
p+4 R
p+1 pS

4-6a
4-6a
4-6a
4-6a
4-6a
4-6a
4-6a
4-6a
4-7a
4-7b
4-7c
4-7d
4-8b,c
4-8b
4-8b
4-8c, 4-9a
4-8c, 4-9a
4-8c, 4-9a
4-8c, 4-9a
4-8c, 4-9a
4-8c, 4-9a
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
4-8c
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WRRDDDSApSEApSPVK
WRRDDDSAAEpSpSPVK
WRRDDDSDAEASPVK
WRRDDDSADEASPVK
WRRDDDSAAEDSPVK
WRRDDDSEAEASPVK
WRRDDDSAEEASPVK
WRRDDDSAAEESPVK
WRRDDDSpSAEASPVK
WRRDDDSApSEASPVK
WRRDDDSAAEpSSPVK
BiWIGSVPERSPAGV
BiWEPSSMEASPEMH
BiWSITSNEDVSPDVC
BiWAASSKEGSPLHK
BiWGISSREDSPQVC
BiWDDSDEEASPEKT
BiWSFSSSEGSPLSR
BiWSASSTEPSPAGR
BiWIQSNLDFSPVNS
BiWSPSTLECSPGSQ
BiWPVSQKEVSPLSS
BiWRESSRDTSPARG
BiWRESSRDTSPVRS
BiWPGSLSEKSPSME
BiWQISTEEISPLEN
BiMSSSILDWSPILE
BiWSSSSDEGSPCPG
BiWNSSDQEQSPEDE
BiWCQSSTDCSPYAR
BiWNGSVSDISPVQA
BiWSASTQDLSPH
BiWSLSLSEESPSKE
BiWSVSQVEASPSTS
BiWSLSSTDVSPNQS
BiWDISLEEQSPVKQ
BiWDASVQEESPVTK
BiWLTSLIEKSPDAK
BiWIGSVPERpSPAGV
BiWEPSSMEApSPEMH
BiWSITSNEDVpSPDVC
BiWAASSKEGpSPLHK
BiWGISSREDpSPQVC
BiWDDSDEEApSPEKT
BiWSFSSSEGpSPLSR
BiWSASSTEPpSPAGR
BiWIQSNLDFpSPVNS

p+2 pS
p+4 pS
unprimed acidic controls p+1 D -pS
p+2 D -pS
p+4 D -pS
p+1 E -pS
p+2 E -pS
p+4 E -pS
p+1 pS -pS
p+2 pS -pS
p+4 pS -pS
AZI1
BEGAIN
BUB1B
CLIP2
CENPJ
CEP350
KIZ
CHFR
CHEK1
CROCC
CTTNBP2
CLASP1
CLASP2
DAB2IP
DOCK5
DNAH5
GAS2L1
KIF18B
KIF20A
KIF2A
KLC3
MAP1A
MAP1B
MPP
NPM2
PCNT
TRRAP
AZI1 p+5 pS
BEGAIN p+5 pS
BUB1B p+5 pS
CLIP2 p+5 pS
CENPJ p+5 pS
CEP350 p+5 pS
KIZ p+5 pS
CHFR p+5 pS
CHEK1 p+5 pS

4-8c
4-8c
4-9a
4-9a
4-9a
4-9a
4-9a
4-9a
4-9a
4-9a
4-9a
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
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BiWSPSTLECpSPGSQ
BiWPVSQKEVpSPLSS
BiWRESSRDTpSPARG
BiWRESSRDTpSPVRS
BiWPGSLSEKpSPSME
BiWQISTEEIpSPLEN
BiMSSSILDWpSPILE
BiWSSSSDEGpSPCPG
BiWNSSDQEQpSPEDE
BiWCQSSTDCpSPYAR
BiWNGSVSDpISPVQA
BiWSASTQDLpSPH
BiWSLSLSEEpSPSKE
BiWSVSQVEApSPSTS
BiWSLSSTDVpSPNQS
BiWDISLEEQpSPVKQ
BiWDASVQEEpSPVTK
BiWLTSLIEKpSPDAK
a

CROCC p+5 pS
CTTNBP2 p+5 pS
CLASP1 p+5 pS
CLASP2 p+5 pS
DAB2IP p+5 pS
DOCK5 p+5 pS
DNAH5 p+5 pS
GAS2L1 p+5 pS
KIF18B p+5 pS
KIF20A p+5 pS
KIF2A p+5 pS
KLC3 p+5 pS
MAP1A p+5 pS
MAP1B p+5 pS
MPP p+5 pS
NPM2 p+5 pS
PCNT p+5 pS
TRRAP p+5 pS

The phosphoacceptor residue is in bold. Bi, Biotin.

4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
4-11
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peptide was added to a mixture of HABA and avidin. Because of its higher affinity for
avidin, biotin displaces the HABA from avidin, the absorbance at 500 nm decreases
proportionately, and the change in absorbance can be used to calculate the peptide
concentration.
Peptide concentration was adjusted to 1 mM in distilled water. Peptide identities
were verified by mass spectrometry using a 5800 TOF/TOF System (AB Sciex). Samples
were mixed 1:1 with 2,5-dihydrobenzoic acid (DHB) matrix (20 mg/mL in 15 mM
ammonium citrate, 20% ethanol, and 1% phosphoric acid) and the data was acquired
using reflectron positive mode. Data acquisition and data processing were performed,
respectively using a TOF TOF Series Explorer and Data Explorer (both from AB Sciex).
Peptides used in the multisite and proline-directed walking arrays contained N-terminal
arginine residues for capture on P81 paper (Whatman). Biotin was added to the Nterminus of peptides used in the protein candidate peptides, instead of arginine residues,
to enable capture by streptavidin membrane.
4.2.3 Peptide Dephosphorylation- Peptides for the multisite walking array containing D
and E residues (1 mM) were dephosphorylated with 400 U lambda phosphatase (λ-PPase)
(New England Biolabs) in 50 mM HEPES pH 7.5, 10 mM NaCl, 2 mM DTT, 1 mM
MnCl2, for one hour at 30°C, followed by heat inactivation for one hour at 95°C.
Complete dephosphorylation of peptides was determined by mass spectrometry as
described in 4.2.2. Control reactions were performed in the absence of λ-PPase.
4.2.4 Peptide Kinase Assays- Kinase assays were performed for 10 minutes at 30°C in a
final reaction volume of 10 µl containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10
mM MgCl2, 100 µM ATP, supplemented with 0.2 µCi [γ32P]ATP (specific activity 3000
Ci/mol, Perkin Elmer). Substrate peptides were used at 100 µM. Reactions were initiated
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by the addition of 100 ng CK2, incubated at 30°C with shaking for 20 min, and stopped
by the addition of 500 mM EDTA pH 8.0 to a final concentration of 25 mM, followed by
spotting 1.5 µL aliquots twice from each reaction onto either SAM2 streptavidin
membrane (Promega) or P81 paper (Whatman). The SAM2 membrane was washed twice
in 0.1% SDS in TBS, twice in 2 M NaCl, twice in 2 M NaCl and 1% H3PO4, and twice in
distilled water, once in ethanol, and then dried under a heat lamp. The P81 paper was
washed 3 times in 1% phosphoric acid, once in ethanol, and then dried under a heat lamp.
Following exposure to a phosphor storage screen, CK2 phosphorylation was visualized
using a STORM Phosphorimager (Molecular Dynamics) and [γ32P]-phosphate
incorporation for each peptide was determined using ImageQuant TL software
(Amersham Biosciences), using a standard curve generated by spotting serial dilutions of
a known ATP concentration. All phosphorylation and dephosphorylation assays were
performed in triplicate.
4.2.5 Bioinformatics- A peptide match program was designed to search the NCBI nonredundant human proteome (accessed May 15, 2014) for human proteins containing
potential hierarchical phosphorylation events. The program was engineered to search for
peptides

matching

the

multisite

phosphorylation

sequence

[ST]S[ADEG]S[ADEGLIVFHNQ][ADEGLIVFHNQS][ADEGLIVHS] or the prolinedirected sequence [ST][ACDEFGHILMNQSTVWY]X[DE]XSP, where X is any amino
acid. For protein candidates with a matching motif, the program returned the GI number,
protein name, peptide sequence, and position of the phosphoacceptor residue within the
protein. The PhosphoSite Plus phosphorylation database (accessed June 10, 2014) was
searched to determine if the resultant peptide sequences were previously reported to be
phosphorylated (Hornbeck et al., 2015).
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4.3 Results
Hierarchical phosphorylation by CK2 was investigated in two separate cellular contexts,
multisite and proline-directed CK2 hierarchical phosphorylation (Figure 4-1).
Hierarchical multisite phosphorylation occurs when CK2 or another kinase primes CK2
phosphorylation at a proximal site (Figure 4-1a). If a single kinase is responsible for all
phosphorylation events, multisite phosphorylation could be considered processive.
Proline-directed hierarchical phosphorylation occurs when a proline-directed kinase (i.e.
Cdks) primes CK2 phosphorylation at a proximal site (Figure 4-1b). To this end, previous
studies conducted in our lab have determined the optimal spacing of pS residues in
multisite hierarchical phosphorylation to be at the p+1 and p+3 positions, S/T-pS-X-pS,
and the optimal spacing of pS-P in proline-directed hierarchical phosphorylation to be at
the p+5 position, S/T-X-X-D/E-X-pS-P, where X is any amino acid (the phosphoacceptor
serine is in bold) (St-Denis et al., 2015).

4.3.1 Determination of the optimal consensus sequence for hierarchical multisite CK2
phosphorylation
To further characterize the optimal consensus sequence for hierarchical multisite CK2
phosphorylation, we used an oriented peptide array to test what effect the addition of
other amino acids might have on CK2 phosphorylation. Peptides were synthesized based
on a parent peptide with the optimal pS spacing fixed and alanines at all other positions,
WRRRAAASpSApSAAA (Figure 4-2a). The priming pS were fixed at the p+1 and p+3
positions, relative to the phosphoacceptor serine residue. The alanine residues at the p-3,
p-2, p-1, p+2, p+4, p+5, and p+6 positions were then systematically changed to other
selected amino acids (D, E, F, H, K, M, N, P, Q, R, and pS). Serine, threonine, and
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Figure 4-2
A

WRRRAAASpSApSAAA
-3 -2 -1

B

A

D E

+2

+4+5+6

F H K M N P Q R pS

-3
-2
-1
+2
+4
+5
+6

Figure 4-2. Determination of the optimal consensus sequence for multisite CK2
phosphorylation. (A) Peptides were synthesized based on the parent sequence
WRRRAAASpSApSAAA, with alanines systematically changed to various amino acid
residues at the p-3, -2, p-1, p+2, p+4, p+5, and p+6, where p is the phosphoacceptor
serine (in bold). (B) Peptides were incubated with CK2 and [γ32P]ATP, reactions
spotted onto P81 paper, and washed. Phosphorylation was detected by phosphorimager
and the average [γ32P]-phosphate incorporation into each peptide was calculated for (C)
p-3, (D) p-2, (E) p-1, (F) p+2, (G) p+4, (H) p+5, and (I) p+6. All values are the average
from three independent experiments. Error bars indicate one standard error from the
mean. pS, phosphoserine.
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Figure 4-2 continued
p-3
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p+2

D

p-2

G

p+4
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p-1

H

p+5

I

p+6
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tyrosine were excluded to avoid the formation of additional phosphorylation sites that
could confound the analysis and interpretation. Small hydrophobic residues (G, I, L, and
V) were excluded as they are redundant with alanine. Tryptophan was excluded because it
was used to measure peptide concentrations and cysteine was excluded to prevent the
formation of disulfide bonds between peptides. The N-terminal RRR was included in the
peptide sequence because it provides a positively charged tag that has affinity for the
negatively charged P81 paper. Peptides were phosphorylated by CK2 with [γ32P]ATP,
reactions spotted onto P81 paper, washed, and [γ32P]-phosphate incorporation detected by
phosphorimaging (Figure 4-2).
Overall, substituting alanine with any other amino acid had a larger effect on
phosphorylation when positioned C-terminal to the phosphoacceptor serine residue (p+2,
p+4, p+5, and p+6), than when positioned at the N-terminal (p-3, p-2, and p-1). In
general, replacing an alanine with a basic amino acid (K and R) was unfavourable at
every position, and reduced phosphate incorporation. By comparison, replacing an
alanine with an acidic amino acid (D and E) was favourable at every position, and
increased phosphate incorporation. Phosphate incorporation was increased by the greatest
extent with aspartic acid and glutamic acid at p-1 and p+4, positions closest to the
phosphoacceptor serine. The substitution of alanine with pS was favourable and increased
phosphorylation at p-3, p-2, p+5, and p+6, positions that are the furthest away from the
phosphoacceptor serine. Closest to the phosphoacceptor serine, the replacement of alanine
with pS was actually unfavourable and displayed decreased phosphorylation.
Interestingly, substituting alanine with histidine at p+4 was also favourable and increased
phosphate incorporation. Replacing alanine with either a phenylalanine or histidine, both
large hydrophobic residues, slightly increased phosphorylation when positioned N-
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terminal to the phosphoacceptor serine, at p-3, p-2, and p-1. Replacing alanine with
asparagine or glutamine amino acids at every position other than p+2 and p+6 was not
unfavourable and showed similar phosphate incorporation compared with alanine.
Overall, the most critical position for phosphorylation appeared to be position p+2, as
only an alanine, aspartic acidic, or glutamic acid showed any appreciable phosphate
incorporation.
Canonical phosphorylation by CK2 occurs in acidic sequences with aspartic acid
and glutamic acid and substituting alanine with both aspartic acid and glutamic acid
increased hierarchical phosphorylation by CK2 (Figure 4-2). To test whether this
observed phosphorylation was truly hierarchical and due to the presence of priming pS at
p+1 and p+3, or solely due to the formation of a canonical consensus sequence, the
peptides containing aspartic acid and glutamic acid were dephosphorylated with λ-PPase.
The λ-PPase was heat inactivated and peptides were then phosphorylated by CK2 with
[γ32P]ATP, reactions spotted onto P81 paper, washed, and [γ32P]-phosphate incorporation
detected by phosphorimaging (Figure 4-3a,b). Phosphorylation of the dephosphorylated
peptides lacking priming pS by CK2 was completely abolished at every position and with
both aspartic acid and glutamic acid (Figure 4-3b). As a further control to test that this
decreased phosphorylation was not due to incomplete heat inactivation of the λ-PPase,
assays were performed with CK2 and a synthetic substrate RRRDDDSDDDDD (Figure
4-3c,d). As expected, phosphorylation was completely abolished upon the addition of λPPase. Importantly, the addition of heat inactivated λ-PPase only very slightly decreased
phosphorylation

suggesting

that

the

lack

of

observed

phosphorylation

of

dephosphorylated acidic peptides was due the removal of the priming pS and not due to
residual λ-PPase activity. Taken together, the results indicate that the ideal substrate
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Figure 4-3. Multisite CK2 phosphorylation is dependent on priming phosphorylation, not
a canonical CK2 motif. (A) Peptides containing D/E at each position in the parent
WRRRAAASpSApSAAA peptide were dephosphorylated by treatment with λphosphatase (λ-PPase) before incubation with CK2 and [γ32P]ATP, reactions spotted onto
P81 paper, and washed. Phosphorylation was detected by phosphorimager and the
average [γ32P]-phosphate incorporation into each peptide was calculated (B). (C) Control
reactions with λ-PPase were performed with CK2 and [γ32P]ATP using a
RRRDDDSDDDDD peptide substrate, reactions spotted onto P81 paper, and washed.
Phosphorylation was detected by phosphorimager and the average [γ32P]-phosphate
incorporation into each peptide was calculated (D). All values are the average from three
independent experiments. Error bars indicate one standard error from the mean. pS,
phosphoserine.
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consensus sequence for CK2 hierarchical multisite phosphorylation does not only include
multiple priming pS, but also contains additional acidic residues; [ST]-pS-[ADE]-pS[ADEFHNQ]-[ADEFHNQpS]-[ADEHpS].

4.3.2 Bioinformatic analysis of hierarchical multisite CK2 phosphorylation
The optimal consensus sequence of CK2 hierarchical multisite phosphorylation described
above was generalized to include other similar amino acids that were initially excluded
(G, I, L, and V). This consensus sequence, [ST]-S-[ADEG]-S-[ADEGLIVFHNQ][ADEGLIVFHNQS]-[ADEGLIVHS], was used to search the NCBI human nonredundant proteome to identify candidate proteins that contain sequences that match the
optimal pS spacing and sequence determinants for CK2 hierarchical multisite
phosphorylation. This search revealed 1319 sequences within 1123 proteins matching the
CK2 multisite hierarchical phosphorylation consensus sequence (Appendix A). Almost
15% of candidate proteins contained more than one matched sequence. The dentin
sialophosphoprotein preproprotein contained 14 matched sequences, the largest number
of all candidate proteins identified. The majority of matched sequences contained a
phosphoacceptor serine residue and only 347 or 26% of matched sequences contained a
phosphoacceptor threonine residue.
These candidate sequences were then used to search the PhosphoSite Plus
database to identify known phosphorylation at the phosphoacceptor serine/threonine as
well as the priming serines at positions p+1 and p+3 (Figure 4-4 and Appendix B). This
search revealed the 187 or 14% of matched sequences had at least one serine
phosphorylated in 180 candidate proteins. Seven candidate proteins had known
phosphorylation at more than one matched sequence. Additionally, 109 peptides had
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known phosphorylation at the phosphoacceptor serine/threonine residue (p) and 61
peptides had known phosphorylation at all three sites (p, p+1, and p+3).
To further evaluate the multisite hierarchical phosphorylation of the candidate
proteins, we wanted to know if the phosphoacceptor site (p), and/or the priming
phosphorylation sites (p+1 and p+3) were phosphorylated together on a single physical
peptide, or present in a population of separate peptides that are differentially
phosphorylated. To investigate this we searched a dataset of phosphopeptides enriched
from the HeLa proteome (obtained from Adam Rabalski) with our candidate sequences
and matched 18 of our candidate sequences to phosphopeptides found in the dataset
(Table 4-2). Most importantly, eight of these candidates, highlighted in red, are sequences
where phosphorylation at the p position is only present with priming phosphorylation at
the p+1, p+3, or both positions on a single peptide. This provides further evidence that
hierarchical phosphorylation of these candidate sequences could indeed occur in cells.
Some candidate sequences were only present when triply phosphorylated at the p, p+1,
and p+3 positions. These candidates include the death-inducer obliterator 1 isoform 1 and
GC-rich sequence DNA-binding factor 2 isoform 1. Other candidate sequences such as
Cytosolic phospholipase A2, RNA polymerase-associated protein LEO1 isoform 1, and
U3 small nucleolar RNA-interacting protein 2 had phosphopeptides identified with
phosphorylation at the priming sites only as well as phosphorylation at the p position
together with the priming sites, p+1 and/or p+3. If phosphorylation did not require
priming phosphorylation, phosphorylation at the p position would be expected to be
found on a single peptide without priming phosphorylation at the p+1 and p+3 positions,
as seen with Nuclear receptor co-repressor 2 isoform 1.
Taken together, our results

demonstrate that multisite CK2 hierarchical
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Figure 4-4

No known phosphorylation
1132
Known
phosphorylation
187

All 3 sites

61

p and p+1
p and p+3

10
16

p+1 and p+3 23
p only

22

p+1 only

24

p+3 only

31

Figure 4-4. A summary of the phosphorylation status of multisite CK2 hierarchical
phosphorylation candidate sequences. The candidate sequences for multisite CK2
hierarchical phosphorylation identified in the human proteome were searched in the
PhosphoSite Plus database. The number of sequences with no known phosphorylation,
and known in cell phosphorylation at the p, p+1, and p+3 positions are displayed.

175
Table 4-2. Phosphorylation of multisite CK2 hierarchical candidate sequences at the p,
p+1, and p+3 positions on a single peptide level enriched from the HeLa proteome.
GI
260763969
18375617
44890065
27735067
48255924
190014586

145580615

31377798
331284178
20373175
203098629
23943920
548923888
20270337
4759276
332164768
226371764
21450814

Protein Name
Crossover junction endonuclease
EME1 isoform 1
death-inducer obliterator 1 isoforma
GC-rich sequence DNA-binding
factor 2 isoform 1
Mitotic interactor and substrate of
PLK1

Protein Sequencea
qtqpvRLLSSESEDEeefip

NADH dehydrogenase
[ubiquinone] flavoprotein 3,
mitochondrial isoform a precursor
PC4 and SFRS1-interacting protein
isoform 1

pssssSSSSSDSESDdeadv

Protein KRI1 homolog

tfynrTASSSDSEEDpeale

Rab GTPase-binding effector
protein 1 isoform 1
Nuclear receptor corepressor 2
isoform 1
RNA-binding protein Musashi
homolog 2 isoform a
acyl-CoA-binding domaincontaining protein 5 isoform 1
Cytosolic phospholipase A2

aqstdSLGTSGSLQSkalgy

Nucleolar and coiled-body
phosphoprotein 1 isoform 1
RNA polymerase-associated protein
LEO1 isoform 1

kkakkKASSSDSEDSseeee

U3 small nucleolar RNAinteracting protein 2

ggkmnEEISSDSESEslapr

AT-rich interactive domaincontaining protein 4B isoform 1
Transcription factor 7-like 2
isoform 1
Uncharacterized protein C18orf25
isoform a

p
✗
✓
✓
✓

p+1
✓
✗
✓
✓

p+3
✗
✗
✓
✓

✗
✗
✓
✗
✗

✗
✓
✓
✗
✓

✓
✗
✗
✓
✗

egrvgRAISSASIEGlmgra

✗
✗
✓
✓
✗
✗
✓
✗
✓
✓
✓

✗
✓
✓
✗
✗
✓
✗
✓
✗
✗
✗

✓
✓
✗
✓
✓
✗
✓
✓
✗
✓
✗

meangSQGTSGSANDsqhdp

✗

✗

✓

ktvngKAESSDSGAEseeee

✓

✗

✗

tkhivSNDSSDSDDEshepk

ndrkaEFPSSGSNSVlntpp

✗
✗
✓
✗
✗
✗
✗
✓
✗
✓
✓
✗

✗
✓
✓
✗
✓
✗
✓
✓
✓
✗
✓
✓

✓
✗
✓
✓
✓
✓
✓
✓
✓
✓
✓
✗

esetnQNSSSDSEAErrppp

✗

✓

✗

llmelRRDSSESQLAstesd

✓
✗
✗
✓
✓
✗

✗
✓
✗
✓
✗
✓

✗
✗
✓
✗
✓
✓

kggddHDDTSDSDSDgltlk
tfrqrAADSSDSDGAeespa
qpglrRALSSDSILSpapda

laktgVTSTSDSEEEgddqe

reeraRIYSSDSDEGseedk

Each row within a candidate sequence represents a single identified peptide that is phosphorylated (✓) or nonphosphorylated (✗) at the p, p+1, and p+3 sites. Highlighted in red are those sequences where phosphorylation at the p
position is only present with priming phosphorylation at the p+1, p+3, or both positions on a single peptide.
a

Amino acids in capitals represent the sequence that matches the searched consensus sequence for CK2 hierarchical
multisite phosphorylation. Amino acids in lower case are the surrounding sequence within the candidate protein.
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phosphorylation may occur on a global level with over a thousand substrates involved in
many different cellular processes. Several of these sites have been shown to be
phosphorylated in cells and a handful are found phosphorylated only in the presence of
priming phosphorylation.

4.3.3 Assessment of candidate peptides for hierarchical multisite CK2 phosphorylation
A random selection of 25 candidate sequences was chosen for further examination
(summarized in Table 4-3). To test the effect of priming phosphorylation on CK2
hierarchical phosphorylation, candidate peptides were synthesized as non-phosphorylated
peptides lacking pS at both the p+1 and p+3 positions (SSXS), as well as doubly
phosphorylated with priming pS at both the p+1 and p+3 positions (SpSXpS). These
peptides were synthesized with an N-terminal biotin to enable capture using a streptavidin
membrane. Peptides were phosphorylated by CK2 with [γ32P]ATP, reactions spotted onto
SAM2

membrane,

washed,

and

[γ32P]-phosphate

incorporation

detected

by

phosphorimaging (Figure 4-5). Some candidate peptides showed no CK2 phosphorylation
on either the primed or unprimed substrate including BUD13, CEP170, SLC19A1, PPIG,
RTN4, and SIKE1. A handful more peptides showed minimal CK2 phosphorylation, but
only on the primed substrate, including CMTR1, CRTC2, RANBP2, MISP, POM121C,
TAF15, and ATRX. The remaining peptides showed robust CK2 phosphorylation and can
be classified into three categories; higher phosphate incorporation into the primed
substrate than the unprimed substrate (SSXS < SpSXpS), equivalent phosphate
incorporation into both the primed and unprimed substrate (SSXS

SpSXpS), and higher

phosphate incorporation into the unprimed substrate than the primed substrate (SSXS >
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Table 4-3. Candidate proteins and resulting sequences for multisite CK2 hierarchical
phosphorylation that were selected for assessment.
GI
5729790
14249338
24307983
109255228
217035102
32171215
260763969
150418007
40805104
34808710
21071052
224177467
27735067
526479837
42560244
217416392
118600981
91206456
115298682
191250773
24431935
229331967
156151379
21327701
530788276
a

Protein Name
CTCF
BUD13
CMTR1
CEP170
CPSF7
CRTC2
EME1
RANBP2
TOPORS
SLC19A1
HLTF
SETDB1
MISP
POM121C
PPIG
PLEC
JMJD1C
FAM133B
PRRC2B
SPIRE1
RTN4
RIOK2
SIKE1
TAF15
ATRX

The phosphoacceptor residue is in bold.

Peptide Sequencea
SKKEDSSDSENAEP
RPRHRSSDSDLSPP
EGKQHSSDSFDDAF
TALLRSSGSLGHRP
AHSRDSSDSADGRA
ALNRTSSDSALHTS
PVRLLSSESEDEEE
MKLHDSSGSQVGTG
ELVELSSDSEDLGS
RGRCETSASELERM
VQYIESSDSEEIET
DIQTISSGSEGDDF
LRRALSSDSILSPA
RRRHDSSGSGHSAF
SKKSASSESEAENL
RYASGSSASLGGPE
SDFSESSDSENSNK
EDKPLSSESLSESE
GLSGCSSGSGHSPY
LAELDSSESEEETL
PKRRGSSGSVDETL
TLSITSSGSAVSCS
ELLSISSESLQARK
QQNMESSGSQGGRA
KDKRNSSDSAIDNP
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Figure 4-5. Assessment of CK2 phosphorylation of multisite hierarchical candidates
identified by bioinformatics. (A) Candidate peptides were synthesized with and without
priming phosphoserine at the +1 and +3 positions and with an N-terminal biotin. Peptides
were incubated with CK2 and [γ32P]ATP, reactions spotted onto SAM2 membrane, and
washed. Phosphorylation was detected by phosphorimager and the average [γ32P]phosphate incorporation into each peptide was calculated (B). All values are the average
from three independent experiments. Error bars indicate one standard error from the
mean. pS, phosphoserine.
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SpSXpS). Higher phosphate incorporation with the primed substrate was observed for
CTCF, CPSF7, SETDB1, PLEC, JMJD1C, FAM133B, PRRC2B, and RIOK2. This
would suggest that for these candidate sequences, CK2 phosphorylation might be
dependent on priming phosphorylation by a different kinase, and thus hierarchical. Equal
phosphorylation of both primed and unprimed substrates was observed for HLTF and
SPIRE1. This would suggest that for these candidate sequences, CK2 phosphorylation
may not be dependent on priming phosphorylation, and thus not considered hierarchical.
Interestingly, higher phosphate incorporation with the unprimed substrate was observed
for a single candidate, EME1. This observation could have many plausible explanations
and would require additional experiments.
Seven candidate sequences (CTCF, EME1, TOPORS, HLTF, SETDB1, JMJD1C,
and SPIRE1) were selected for further analysis and singly phosphorylated peptides were
synthesized to evaluate the effect of CK2 phosphorylation with priming phosphorylation
at either p+1 (SpSXS) or p+3 (SSXpS) separately (Figure 4-6). For SPIRE1, no
difference in phosphorylation was detected with either the singly or doubly
phosphorylated peptides (SpSXS, SSXpS, and SpSXpS), compared with the nonphosphorylated peptide (SSXS), indicating that CK2 phosphorylation is not dependent on
priming phosphorylation and would not be considered hierarchical. Another potential
explanation could be that CK2 primes its own hierarchical phosphorylation. However, the
phosphate incorporation by CK2 of the non-phosphorylated and doubly phosphorylated
peptides was comparable, suggesting this may not be the case. If CK2 were
phosphorylating more than one site, a decrease in phosphate incorporation on the doubly
phosphorylated peptide would be expected since only one site is available to be
phosphorylated because the other two sites were synthesized with a pS. For SETDB1, the
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Figure 4-6. Assessing the effect of priming phosphorylation at each site on CK2
phosphorylation of multisite hierarchical candidates. (A) Candidate peptides were
synthesized without priming phosphoserine (SSXS), with priming phosphosrine at a
single site, either +1 or +3 (SpSXS or SSXpS), and priming phosphoserine at both the +1
and +3 positions (SpSXpS), and with an N-terminal biotin. Peptides were incubated with
CK2 and [γ32P]ATP, reactions spotted onto SAM2 membrane, and washed..
Phosphorylation was detected by phosphorimager and the average [γ32P]-phosphate
incorporation into each peptide was calculated (B). All values are the average from three
independent experiments. Error bars indicate one standard error from the mean. pS,
phosphoserine.
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doubly phosphorylated peptide primes CK2 phosphorylation as determined by an increase
in phosphate incorporation into the doubly phosphorylated primed substrate (SpSXpS)
compared with the non-phosphorylated unprimed substrate (SSXS). Yet, each of the
singly phosphorylated peptides (SpSXS and SSXpS) results in the same phosphate
incorporation by CK2 as the doubly phosphorylated peptide substrate (SpSXpS). This
suggests that CK2 phosphorylation of SETDB1 may be dependent on priming
phosphorylation, but potentially only a single phosphorylation at either the p+1 or p+3
position is sufficient to result in hierarchical CK2 phosphorylation. For EME1, CK2
phosphorylation was higher with the unprimed non-phosphorylated peptide (SSXS) than
the primed doubly phosphorylated peptide (SpSXpS). CK2 phosphorylation of the singly
phosphorylated peptide with pS at p+1 (SpSXS) was similar to the level of the nonphosphorylated peptide. In contrast, CK2 phosphorylation of the singly phosphorylated
peptide with pS at p+3 (SSXpS) was similar to the level of the doubly phosphorylated
peptide. In this case, CK2 potentially phosphorylates two sites, p and p+3, because lower
levels of phosphorylation, about 2-fold, were detected when the p+3 was synthesized with
a pS. Another explanation could be that phosphorylation at p+3 was unfavourable for
subsequent CK2 phosphorylation and therefore reduces phosphate incorporation.
Additionally, priming pS at p+1 (SpSXS) appears to block or completely abolish CK2
phosphorylation of other substrates CTCF, TOPORS, and JMJD1C. For CTCF and
JMJD1C, CK2 phosphorylation of the doubly phosphorylated primed substrate (SpSXpS)
was higher than the non-phosphorylated unprimed substrate (SSXS). This suggests that
CK2 phosphorylation of both CTCF and JMJD1C was dependent on priming
phosphorylation and is thus hierarchical. The presence of pS at the p+3 position appears
to be the initial priming phosphorylation site because the highest levels of CK2
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phosphorylation were only observed when the p+3 position was synthesized with a pS
(SSXpS and SpSXpS). In the absence of priming pS at p+3, the non-phosphorylated
peptide may represent a weak CK2 consensus sequence and low levels of phosphate were
incorporated. Furthermore, CK2 may phosphorylate more than one site, and may even
prime its own phosphorylation, because phosphorylation of the doubly phosphorylated
peptide (SpSXpS) was lower (half for CTCF and one-third for JMJD1C) than the singly
phosphorylated peptide with pS at p+3 (SSXpS) suggesting that sites phosphorylated by
CK2 have been removed when they were synthesized with a pS.
While these kinase assays were all performed with equimolar substrate to ATP at
100 µM, technically on the unprimed peptide there are three potential phosphoacceptor
residues. The ATP concentration was adjusted to 300 µM in additional kinase assays,
however, no differences in the phosphorylation trends were observed (data not shown).
These assays provide quantitative analysis of total phosphate incorporation by
CK2, but are limited in their ability to distinguish how many sites are being
phosphorylated. In an attempt to further investigate the multisite CK2 hierarchical
phosphorylation of one candidate, CTCF, non-phosphorylated unprimed (SSDS), singly
phosphorylated primed (SpSDS and SSDpS), and doubly phosphorylated primed
(SpSDpS) substrate peptides were phosphorylated by CK2 and ATP and the reactions
were then analyzed by mass spectrometry (Figure 4-7). Phosphorylation by CK2 of the
non-phosphorylated

substrate

peptide

yielded

non-phosphorylated

and

singly

phosphorylated peptides in approximately a 1:1 ratio (Figure 4-7a). Phosphorylation by
CK2 of the singly phosphorylated p+1 pS substrate peptide (SpSDS) generated mostly
singly phosphorylated peptides, with low levels of doubly and triply phosphorylated
peptides (Figure 4-7b). Phosphorylation by CK2 of the singly phosphorylated p+3 pS
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Figure 4-7. Analysis of phosphorylation of CTCF candidate peptides by mass
spectrometry. Nonphosphorylated (A; WSKKEDSSDSENAEP), singly phosphorylated
(B;

WSKKEDSpSDSENAEP

phosphorylated

(D;

and

C;

WSKKEDSSDpSENAEP)

WSKKEDSpSDpSENAEP)

peptides

were

and

doubly

synthesized

and

phosphorylated by CK2 with ATP. Samples were diluted 1:100 in H2O, spotted 1:1 with
DHB matrix, and phosphorylation was then analyzed by MALDI TOF/TOF mass
spectrometry. Non phosphorylated, 1707 Da; 1 x phosphorylated, 1787 Da; 2 x
phosphorylated, 1867 Da; 3 x phosphorylated, 1947 Da; Ac, acetylated +42 Da.
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Figure 4-7
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C

3 x phos

Substrate:
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2 x phos

D
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WSKKEDSpSDpSENAEP
2 x phos
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substrate peptide (SSDpS) generated high levels of triply phosphorylated peptides, with
lower levels of doubly phosphorylated peptides (Figure 4-7c). No singly phosphorylated
substrate peptide was detectable in this reaction. Phosphorylation by CK2 of the doubly
phosphorylated substrate peptide (SpSDpS) yielded mostly triply phosphorylated
peptides, with very low levels of doubly phosphorylated peptides (Figure 4-7d). These
results suggest that CK2 has the ability to prime its own phosphorylation of CTCF and
initiate processive multisite hierarchical phosphorylation, as evidenced by the generation
of triply phosphorylated peptides. Phosphorylation at the p+1 site appears to be the ratelimiting step in this cascade, as CK2 phosphorylation of the primed SSDpS substrate
peptide yielded predominately triply phosphorylated peptides whereas as CK2
phosphorylation of the unprimed SSDS substrate peptide yielded singly phosphorylated
peptides (Figure 4-7a,c). MS/MS analysis of these peptides was attempted, but
unfortunately the entire SSDS sequence fragmented together and we were unable to
assign phosphorylation to a specific site (data not shown).
Collectively, our results with these candidates for multisite hierarchical CK2
phosphorylation demonstrate that for at least a subset of peptide sequences, priming
phosphorylation is required to increase phosphorylation by CK2.

4.3.4 Determination of the optimal consensus sequence for hierarchical proline-directed
CK2 phosphorylation
Previous studies in our laboratory had already determined that proline-directed CK2
hierarchical phosphorylation occurred when the priming pS-P motif was fixed at the p+5
position and a glutamic acid was fixed at p+3 (Figure 4-1b). The parent peptide for
proline-directed CK2 hierarchical phosphorylation was WRRDDDSAAEApSPVK
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(Figure 4-8a), where SPVK represents a generic Cdk consensus sequence. Since a
glutamic acid at the p+3 position forms a weak canonical (not hierarchical) CK2
consensus sequence, two control peptides were synthesized, one lacking priming pS
(WRRDDDSAAEASPVK) and another with the phosphoacceptor serine replaced with an
alanine (WRRDDDAAAEApSPVK), to ensure that observed phosphorylation was due to
the presence of priming pS. Peptides were phosphorylated by CK2 with [γ32P]ATP,
reactions spotted onto P81 paper, washed, and [γ32P]-phosphate incorporation detected by
phosphorimaging (Figure 4-8b). Phosphate incorporation by CK2 onto the primed parent
peptide was 5-fold higher than the minimal phosphorylation of the unprimed peptide
indicating that CK2 phosphorylation is largely dependent on the presence of priming pS
at the p+5 position. No CK2 phosphorylation was detected with the non-phosphorylatable
alanine-substituted peptide.
To further optimize the consensus sequence for proline-directed hierarchical CK2
phosphorylation, we used an oriented peptide array to test what effect the addition of
other amino acids might have on phosphorylation by CK2. Peptides were synthesized
using a parent peptide with the optimal pS-P spacing, a glutamic acid at p+3, and alanines
at all other positions, WRRDDDSAAEApSPVK. The alanine residues at the p+1, p+2,
and p+4 positions were systematically changed to other selected amino acids (D, E, F, H,
K, M, N, P, Q, R, and pS). Peptides were phosphorylated by CK2 with [γ32P]ATP,
reactions spotted onto P81 paper, washed, and [γ32P]-phosphate incorporation detected by
phosphorimaging (Figure 4-8c,d,e,f). Overall, the substitution of alanine with an acidic
amino acid (D and E) or pS was favourable and showed an increase in phosphorylation.
The substitution of alanine with pS displayed the higher level of phosphate incorporation
immediately after the phosphoacceptor serine, at position p+1, and decreased as it was
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Figure 4-8. Determination of the optimal consensus sequence for proline-directed
hierarchical CK2 phosphorylation. (A) Peptides were synthesized based on the parent
sequence WRRDDDSAAEApSPVK, with alanines at p+1, p+2, and p+4, where p is the
phosphoacceptor serine (in bold). (B) Parent and control peptides were phosphorylated by
CK2

and

[γ32P]ATP

and

[γ32P]-phosphate

incorporation

was

detected

by

phosphorimaging. (C) The alanines were systematically changed to various amino acid
residues and the p+1, p+2, and p+4 positions. Peptides were incubated with CK2 and
[γ32P]ATP, reactions spotted onto P81 paper, and washed. Phosphorylation was detected
by phosphorimager and the average [γ32P]-phosphate incorporation into each peptide was
calculated for (D) p+1, (E) p+2, and (F) p+4. All values are the average from three
independent experiments. Error bars indicate one standard error from the mean. pS,
phosphoserine.
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positioned further away in p+2 and then p+4. Generally, the substitution of alanine with
basic amino acids (K and R) was unfavourable and resulted in decreased phosphorylation.
This effect was most pronounced at position p+1 and was least at p+4, furthest away from
the phosphoacceptor serine. Additionally, the presence of a proline in proximity to the
phosphoacceptor serine was unfavourable and resulted in reduced CK2 phosphorylation.
The most critical position for proline-directed CK2 hierarchical phosphorylation was
position p+1, where phosphorylation was favourable only in the presence of alanine,
aspartic acid, glutamic acid, and pS (Figure 4-8d). Replacement of the alanine with any
other amino acid almost completely abolished phosphorylation.
Canonical phosphorylation by CK2 occurs in acidic sequences with aspartic acid
and glutamic acid. Our results indicate that substituting alanine with both aspartic acid
and glutamic acid increased proline-directed hierarchical phosphorylation by CK2 (Figure
4-8). Therefore, to test whether this observed phosphorylation was truly hierarchical and
due to the presence of priming pS at p+5, or solely due to the formation of a canonical
consensus sequence, peptides containing aspartic acid, glutamic acid, and pS were
synthesized without a pS at the p+5 position. Peptides were phosphorylated by CK2 with
[γ32P]ATP, reactions spotted onto P81 paper, washed, and [γ32P]-phosphate incorporation
detected by phosphorimaging (Figure 4-9). Phosphorylation by CK2 of the peptides
lacking priming pS at position p+5 was substantially reduced at every position with
aspartic acid, glutamic acid, and pS compared to the same peptide but with priming pS at
position p+5 (Figure 4-9b). This indicates that robust phosphorylation by CK2 is
dependent on priming phosphorylation, even when additional acidic amino acids produce
a canonical consensus sequence.
Taken together, the results indicate that the ideal substrate consensus sequence for
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Figure 4-9
A

Determinant:

D

E

pS

Priming Sites: pS S pS S pS S
+1
+2
+4

B

Figure 4-9. Proline-directed CK2 hierarchical phosphorylation is dependent on priming
phosphorylation, not a canonical CK2 motif. (A) Peptides containing D/E/pS at each
position were synthesized with or without priming phosphorylation (pS or S). Peptides
were incubated with CK2 and [γ32P]ATP, reactions spotted onto P81 paper, and
washed. Phosphorylation was detected by phosphorimager and the average [γ32P]phosphate incorporation into each peptide is shown (B). All values are the average
from three independent experiments. Error bars indicate one standard error from the
mean. pS, phosphoserine.
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proline-directed CK2 hierarchical phosphorylation not only requires priming pS, but also
contains

additional

acidic

residues;

[ST]-[ADEpS]-[ADEFHNpS]-[DE]-

[ADEFHKMNPQRpS]-pS-P.

4.3.5 Bioinformatic analysis of hierarchical proline-directed CK2 phosphorylation
The outlined optimal consensus sequence of proline-directed CK2 hierarchical
phosphorylation was generalized to include other similar amino acids that were initially
excluded (C, G, I, L, T, V, W, and Y). This consensus sequence, [ST][ACDEFGHILMNQSTVWY]-X-[DE]-X-S-P, where X is any amino acid, was used to
search the NCBI human non-redundant proteome to identify candidate proteins that
contain sequences that match the optimal pS spacing and sequence determinants for
proline-directed CK2 hierarchical phosphorylation. This search revealed 837 sequences
within 796 proteins matching the proline-directed CK2 hierarchical phosphorylation
consensus sequence (Appendix C). Many candidate proteins contained two matched
sequences, including A-kinase anchor protein 12, dual specificity protein phosphatase 16,
and Rho guanine nucleotide exchange factor 17. Notably, serine/arginine repetitive matrix
protein 2 contained eight matched sequences, TFIIIB component B” homolog had seven,
mucin-16 had five, and BUD13 homolog contained three matched sequences. The
majority of matched sequences contained a phosphoacceptor serine residue and only 285
or 34% of matched sequences contained a phosphoacceptor threonine residue. Applying a
more stringent search criteria, and searching with [ST]-[DE]-X-[DE]-X-S-P, to more
closely resemble the optimal consensus sequence expectedly reduced the number of
candidates and identified 175 matching sequences in 127 candidate proteins.
Candidate sequences were then used to search the PhosphoSite Plus database to
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identify known phosphorylation at the phosphoacceptor serine as well as the priming
serine at position p+5 (Figure 4-10 and Appendix D). This search revealed that 221 or
26% of matched sequences had at least one phosphorylated residue in 206 candidate
proteins. Eight candidate proteins had known phosphorylation at more than one matched
sequence. Both sites (p and p+5) were known to be phosphorylated in 71 matched
sequences and the phosphoacceptor (p) only was found to be phosphorylated in an
additional 32 matched sequences.
To further evaluate the proline-directed CK2 hierarchical phosphorylation of the
candidate proteins, we wanted to know if the phosphoacceptor site (p), and/or the priming
phosphorylation site (p+5) were phosphorylated together on a single physical peptide, or
present in a population of separate peptides that are differentially phosphorylated. To
investigate this we searched a dataset of phosphopeptides enriched from the HeLa
proteome (obtained from Adam Rabalski) with our candidate sequences and matched 16
of our candidate sequences to phosphopeptides found in the dataset (Table 4-4). Most
importantly, a single candidate, Transforming growth factor beta-1-induced transcript 1
protein isoform 1, had phosphorylation at the p position only with priming
phosphorylation at the p+5 position on a single peptide. This provides further evidence
that hierarchical phosphorylation of these candidate sequences could occur in cells.
Our results collectively demonstrate that proline-directed CK2 hierarchical
phosphorylation may occur on a global level with over 800 substrates involved in many
different cellular processes. Many of these sites have been shown to be phosphorylated in
cells and one was found phosphorylated only in the presence of priming phosphorylation.
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Figure 4-10

No known phosphorylation
612

Known
Phosphorylation
221

Both sites

71

p only

32

p+5 only

118

Figure 4-10. A summary of the phosphorylation status of proline-directed CK2
hierarchical phosphorylation candidate sequences. The candidate sequences for
proline-directed CK2 hierarchical phosphorylation identified in the human proteome
were searched in the PhosphoSite Plus database. The number of sequences with no
known phosphorylation, and known in cell phosphorylation at the p and p+5 positions
are displayed.
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Table 4-4. Phosphorylation of proline-directed CK2 hierarchical candidate sequences at
the p and p+5 positions on a single peptide level enriched from the HeLa proteome.
GI
41349439
32171241
213972636
5803145
7661858
30089916
50659095
7661958
50962882
118572613
118572613
5901962
118572613
109638745
33469966
208022661

Protein Name
Protein transport protein Sec31A
isoform 1
cAMP-specific 3',5'cyclicphosphodiesterase 4B isoform 1
Tumor suppressor p53-binding protein
1 isoform 1
ralA-binding protein 1
Rho GTPase-activating protein 11A
isoform 1
Phosphofurinacidic cluster sorting
protein 1
Nucleolar RNA helicase 2 isoform 1
bcl-2-associated transcription factor 1
isoform 1
G patch domain-containing protein 8
serine/arginine repetitive matrix protein
2
serine/arginine repetitive matrix protein
2
Histone acetyltransferase KAT7
isoform 1
serine/arginine repetitive matrix protein
2
Transforming growth factor beta-1induced transcript 1 protein isoform 1
sec1 family domain-containing protein
1 isoform a
nck-associated protein 5-like

Protein Sequencea
kdsdqvaqSDGEESPaaeeqllg

p
✗

p+5
✓

esflyrsdSDYDLSPkamsrn

✗

✓

sgkrklitSEEERSPakrgrksa
gsgltrtpSSEEISPtkfpglyr
tgkgekcfSERDFSPlqtqtfnr

✗
✓
✗
✗

✓
✗
✓
✓

plsertnsSDSERSPdlghstqi

✗

✓

kakkkeepSQNDISPktkslrkk
sgdiwpglSAYDNSPrsphspsp
snigtgrgSEGDCSPedknsvta
qstrssghSSSELSPdavekagm

✗
✗
✓
✗
✗

✓
✓
✗
✓
✓

praapraqSGSDSSPepkapapr

✗

✓

rssarlsqSSQDSSPvrnlqsfg

✗

✓

qsvtpqrrSCFESSPdpelksrt

✗

✓

ptqppvvsSTNEGSPsppeptgk
nrvnleesSGVENSPagarpkrk

✗
✓
✗

✓
✓
✓

nsripcrnSGSDGSPspllarrg

✗

✓

Each row within a candidate sequence represents a single identified peptide that is phosphorylated (✓) or nonphosphorylated (✗) at the p, p+1, and p+3 sites. Highlighted in red are those sequences where phosphorylation at the p
position is only present with priming phosphorylation at the p+5 position on a single peptide.
a

Amino acids in capitals represent the sequence that matches the searched consensus sequence for CK2 hierarchical
multisite phosphorylation. Amino acids in lower case are the surrounding sequence within the candidate protein.
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4.3.6 Assessment of candidate peptides for hierarchical proline-directed CK2
phosphorylation
A random selection of 27 candidate sequences was chosen for further examination
(summarized in Table 4-5). To test the effect of priming phosphorylation on CK2
hierarchical phosphorylation, candidate peptides were synthesized as non-phosphorylated
peptides lacking pS at the p+5 position (SXXXXSP), as well as phosphorylated with
priming pS at the p+5 position (SXXXXpSP). These peptides were synthesized with an
N-terminal biotin to enable capture using a streptavidin membrane. Peptides were
phosphorylated by CK2 with [γ32P]ATP, reactions spotted onto SAM2 membrane,
washed, and [γ32P]-phosphate incorporation detected by phosphorimaging (Figure 4-11).
For many candidate peptides, CK2 phosphorylation was higher with the primed peptide
compared to the unprimed peptide. The candidate peptide with that largest pS/S ratio was
GAS2L1, with a pS/S ration of 7.5. Both CENPJ and CHFR have the second largest pS/S
ratio, and phosphate incorporation of the primed peptide was 5-fold higher than the
unprimed substrate. Ten other substrates also had pS/S ratios larger than two, including
BEGAIN, KIZ, CROCC, DOCK5, DNAH5, KIF18B, KIF20A, KIF2A, MAP1A, and
MPP. Interestingly, one candidate substrate, CEP350, displayed the opposite effect. In
this case, CK2 phosphorylation of the unprimed peptide was 5-fold higher than the
primed peptide. On the other hand, half of the candidate peptides displayed no or very
minimal phosphorylation by CK2 and there was no difference in phosphorylation
between the primed and unprimed substrate (AZI1, CLIP2, CHEK1, CTTNBP2,
CLASP1, CLASP2, DAB2IP, KLC3, MAP1B, NPM2, PCNT, and TRRAP). Therefore,
these candidate sequences had a pS/S ratio around 1 and clustered together.
Taken together, these results with our proline-directed candidates demonstrate that
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for at least a subset of peptide sequences, priming phosphorylation by a proline-directed
kinase is required to increase phosphorylation by CK2.
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Table 4-5. Candidate proteins and resulting sequences for proline-directed CK2
hierarchical phosphorylation that were selected for assessment.
GI
111955084
13124765
59814247
116008447
130980075
171184451
118150654
239048792
166295194
612407805
16975496
31563537
187954509
94967023
117553586
19115954
19923777
387942373
5032013
148612877
91825557
95147555
153945728
508083049
33391150
81295809
347360922
a

Protein Name
AZI1
BEGAIN
BUB1B
CLIP2
CENPJ
CEP350
KIZ
CHFR
CHEK1
CROCC
CTTNBP2
CLASP1
CLASP2
DAB2IP
DOCK5
DNAH5
GAS2L1
KIF18B
KIF20A
KIF2A
KLC3
MAP1A
MAP1B
MPP
NPM2
PCNT
TRRAP

The phosphoacceptor residue is in bold.

Peptide Sequencea
IGSVPERSPAGV
EPSSMEASPEMH
ITSNEDVSPDVC
AASSKEGSPLHK
GISSREDSPQVC
DDSDEEASPEKT
SFSSSEGSPLSR
SASSTEPSPAGR
IQSNLDFSPVNS
SPSTLECSPGSQ
PVSQKEVSPLSS
RESSRDTSPARG
RESSRDTSPVRS
PGSLSEKSPSME
QISTEEISPLEN
MSSILDWSPILE
SSSSDEGSPCPG
NSSDQEQSPEDE
CQSSTDCSPYAR
NGSVSDISPVQA
SASTQDLSPH
SLSLSEESPSKE
SVSQVEASPSTS
SLSSTDVSPNQS
DISLEEQSPVKQ
DASVQEESPVTK
LTSLIEKSPDAK
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Figure 4-11. Assessment of CK2 phosphorylation of proline-directed hierarchical
candidates identified by bioinformatics. (A) Candidate peptides were synthesized with
and without priming phosphoserine and an N-terminal biotin. Peptides were incubated
with CK2 and [γ32P]ATP, reactions spotted onto SAM2 membrane, and washed.
Phosphorylation was detected by phosphorimager and the average [γ32P]-phosphate
incorporation into each peptide was calculated the ratio of primed/unprimed
phosphorylation (pS/S) was plotted (B). All values are the average from three
independent experiments. Error bars indicate one standard error from the mean. S, serine;
pS, phosphoserine.
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4.4 Discussion
In this study, we have used an oriented peptide array approach and bioinformatics to
systematically investigate hierarchical phosphorylation involving CK2 as the primed
kinase. We have studied CK2 hierarchical phosphorylation in two contexts, multisite and
proline-directed CK2 hierarchical phosphorylation (Figure 4-1). In each case, our results
have defined the optimal consensus sequence for primed CK2 phosphorylation, identified
candidate sequences within the human proteome, and analyzed the known
phosphorylation of these sequences using the PhosphoSite Plus database. Finally, we
have assessed a selection of matched sequences for CK2 hierarchical phosphorylation
using primed and unprimed peptide substrates in kinase assays.

4.4.1 Hierarchical phosphorylation combines canonical and non-canonical sequence
determinants
Initial assays were conducted using an oriented peptide array approach to further
delineate the optimal sequences for multisite and proline-directed CK2 hierarchical
phosphorylation (Figure 4-2 and Figure 4-8). Specifically for multisite CK2 hierarchical
phosphorylation, the substitution of alanine with any other amino acid N-terminal to the
phosphoacceptor serine largely had no effect on multisite CK2 hierarchical
phosphorylation and is consistent with weblogo analysis of CK2 phosphorylation sites in
the PhosphoElm database (Figure 4-2c,d,e) (Salvi et al., 2009). This observation
prompted us to fix these residues with aspartic acids in the proline-directed hierarchical
peptide array in an attempt to boost relatively low levels of CK2 phosphorylation, since
this would have little effect on defining the optimal proline-directed CK2 hierarchical
consensus sequence (Figure 4-8).
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There are several similarities between these two hierarchical consensus sequences
(Figure 4-2 and Figure 4-8). Consistent with the canonical CK2 consensus sequence, S/TX-X-D/E, in our hierarchical CK2 consensus sequence the addition of acidic residues was
also favourable and increased phosphorylation while the addition of basic residues was
generally unfavourable and decreased phosphorylation (Figure 4-2 and Figure 4-8)
(Meggio and Pinna, 2003). The presence of acidic residues at the p+1 and p+3 positions is
strongly favoured in canonical sites. In multisite CK2 phosphorylation, these positions are
fixed with acidic pS residues, whereas in proline-directed phosphorylation, the p+3
position is fixed with an acidic residue but the addition of acidic residues (D, E, and pS)
at the p+1 position greatly increases CK2 phosphorylation (Figure 4-2). All other amino
acids at the p+1 position in proline-directed CK2 phosphorylation severely diminished
CK2 phosphorylation (Figure 4-8c,d). This is perhaps not surprising, as the structural
elements that dictate substrate selectivity specifically interact with the substrate and the
p+1 and p+3 positions in a specific conformational geometry (Sarno et al., 1999). Both
mutational and structural studies have mapped this substrate-binding cleft in CK2 to
clusters of basic residues in helix αC (K74-79, R80, K83) and the p+1 loop (R191, 195,
K198) (Sarno et al., 1996, 1997, 1999; Niefind et al., 2007). In these studies, mutations of
these basic amino acids to neutral alanine residues increased the affinity of CK2 for
substrate peptide RRRADDSDDDDD (Sarno et al., 1996, 1997).
The inclusion of additional pS residues in multisite hierarchical phosphorylation
increases CK2 phosphorylation when placed furthest away from the phosphoacceptor
serine but blocks CK2 phosphorylation when placed closer, especially in the p+2 position
(Figure 4-2f). In contrast, the addition of pS residues in the proline-directed hierarchical
phosphorylation consensus has the opposite effect and increases CK2 phosphorylation
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when positioned immediately adjacent to the phosphoacceptor serine, but results in
decreased CK2 phosphorylation as moved further away in position (Figure 4-8). The
parent peptide for multisite hierarchical phosphorylation contains two priming pS in close
proximity while the proline-directed parent peptide only contains a single priming pS
which is positioned further away (Figure 4-2a and Figure 4-8a). This observation suggests
that while strings of acidic residues have an additive effect on CK2 phosphorylation, too
many pS residues may actually be detrimental to CK2 phosphorylation (Meggio and
Pinna, 2003; St-Denis et al., 2015). This effect may relate back to the structural
determinants for substrate binding and can be explained by the difference in charge
between acidic residues and pS at physiological pH. While the pKa values of aspartic acid
and glutamic acid are 3.9 and 4.07, respectively, the pKa value of pS is ~6.7 (Johnson,
2009). Therefore, acidic residues will each have a net charge of -1, but the phosphate on
pS will have a net charge of -2, double the charge of aspartic acid and glutamic acid.
Structurally, substrate binding is coordinated by numerous basic residues in CK2 and is
largely charge dependent (Sarno et al., 1996, 1997, 1999; Niefind et al., 2007). Too many
pS in close proximity may produce an overwhelming negative charge that cannot be
properly coordinated by the basic residues in the substrate-binding cleft of CK2 and
results in reduced binding affinity. Furthermore, the additional negative charge coupled
with the difference in size between acidic residues and pS may not be as compatible with
the binding site and could result in small conformational changes that reduce substrate
binding or incorrectly position the phosphoacceptor for catalysis.
Interestingly, the presence of histidine and asparagine increases CK2
phosphorylation in both multisite and proline-directed hierarchical phosphorylation that is
not observed in the canonical CK2 consensus sequence (Figure 4-2b and Figure 4-8c)
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(Meggio and Pinna, 2003).
It is intriguing to speculate that while phosphorylation at the p+1 and p+3
positions can prime CK2 phosphorylation, additional phosphorylation at the p+2 position
by another distinct kinase can actually block CK2 phosphorylation. Furthermore, the
optimal consensus sequence for both multisite and proline-directed CK2 hierarchical
reveals that not only does CK2 phosphorylation require priming phosphorylation, but
includes additional acidic residues. This indicates that the combination of hierarchical and
canonical sequences exist to create the necessary determinants for either a new CK2
consensus or to strengthen an existing CK2 consensus sequence. Together, these
combinations may serve as a higher-order signaling modules that can fine-tune CK2
activity towards select substrates.

4.4.2 Candidates of hierarchical CK2 phosphorylation may have a global impact on
signaling networks
To evaluate the global occurrence of both multisite and proline-directed CK2 hierarchical
phosphorylation, our defined consensus sequences were used to search the human
proteome for candidate protein sequences (Appendix A and C). Notably, the consensus
sequences are distinct and do not match those of other primed kinases CK1 (pS/pT-X-XS) and GSK3β (S-X-X-X-pS) (Fiol et al., 1990; Flotow et al., 1990). These sequences
were then used to search the PhosphoSite Plus database for known phosphorylation
(Appendix B and C) and the results are summarized in Table 4-6. A larger number of
sequences were identified for multisite hierarchical phosphorylation than proline-directed
hierarchical phosphorylation. Additionally, a higher percentage of proteins contained
multiple sequences matching the multisite hierarchical consensus, nearly three times more
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Table 4-6. A side-by-side summary of the sequences in the human proteome matching
CK2 hierarchical phosphorylation consensus requirements and known phosphorylation
for multisite and proline-directed CK2 hierarchical phosphorylation.

Matching Consensus Sequences in Proteome
Proteins Containing Matching Sequence(s)
% Proteins Containing Multiple Sequences
Consensus Sequences with Known
Phosphorylation Sites
% Consensus Sequences with Known
Phosphorylation Sites
Consensus Sequences with All Sites
Phosphorylated
% Consensus Sequences with All Sites
Phosphorylated

Multisite
1319
1123
14.86

Proline-Directed
837
796
4.90

187

221

14.18

26.41

61

71

4.6

8.5
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than the proline-directed hierarchical consensus. However, a higher percentage of prolinedirected hierarchical candidate sequences were known to be phosphorylated in cell than
multisite hierarchical candidates. Additionally, a higher percentage, almost double, of
proline-directed hierarchical candidate sequences were known to be phosphorylated at
both the priming (p+5) and the CK2 (p) site, than multisite hierarchical candidates at both
the priming (p+1 and p+3) and the CK2 (p) site. The percentage of candidate sequences
known to be phosphorylated may actually be an underestimate since phosphopeptides can
be challenging to identify using mass spectrometry for several reasons. These can include
low protein abundance and/or low stoichiometry of phosphorylation, specific stimulus
required for phosphorylation, and the amenability of the phosphopeptides sequence to
mass spectrometry analysis can all reduce the detectable signal.
Interestingly, there is very little overlap between the two candidate protein lists.
Only 102 candidate proteins are shared between both sets and include sequences that
match

both

the

multisite

hierarchical

and

proline-directed

CK2

hierarchical

phosphorylation consensus sequences. This roughly accounts for 10% of the candidates
identified in each data set. While there is little overlap between the two sets, there is
considerable overlap in the cellular functions in which the candidate proteins are
involved. Both multisite and proline-directed CK2 hierarchical candidates contain
multiple proteins within the same family or function, including cytoskeletal and
centrosomal proteins, transcription-related and DNA-binding proteins, epigenetic
modifiers, and ubiquitin-related proteins (Appendix A and C). Canonical CK2
phosphorylation has also previously been implicated in these processes.
CK2 regulates cell morphology, through modulation of the actin and tubulin
cytoskeletons. CK2 has been shown to localize to centrosomes, actin stress fibers, and
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microtubule mitotic spindles and can directly bind to tubulin (Faust et al., 2002; Lim et
al., 2004; Kramerov et al., 2011; St-Denis et al., 2011). CK2 interacts with CKIP-1, and
has numerous canonical substrates that regulate both actin and tubulin polymerization
including WASP, CPα, RP1, CRN2, MAP1B, myosin 2A, KIF5C, and CLIP-170 (Avila
et al., 1994; Cory et al., 2003; Canton et al., 2005; Dulyaninova et al., 2005; Schafer et
al., 2008; Li et al., 2010; Xavier et al., 2012; Stenner et al., 2013). Our search for CK2
hierarchical candidates revealed multiple cytoskeleton-associated proteins in both
multisite and proline-directed datasets and contained more than one candidate in the
actin-binding, dynamin, kinesin, centrosomal, and microtubule-associated protein
families (Appendix A and C). Notably, centrosomal protein Kizuna and microtubuleassociated serine/threonine protein kinase 1 contain sequences that match both multisite
and proline-directed CK2 hierarchical phosphorylation consensuses.
Canonical CK2 phosphorylation is also a well-known regulator of transcription
through direct phosphorylation of RNA polymerase II, several general transcription
factors, including TFIIA, TFIIE, and TFIIF as well as a variety of other transcription
factors such as C/EPBδ, STAT1, YY1, and Pax3 (Trembley et al., 2003; Cabrejos et al.,
2004; Timofeeva et al., 2006; Dietz et al., 2009; Riman et al., 2012; Schwind et al.,
2015). Although not a transcriptions factor, CK2 phosphorylation of H2A has been shown
to be required for transcriptional elongation (Basnet et al., 2014). In our datasets, 86 and
51 transcriptions factors were identified for multisite and proline-directed CK2
hierarchical phosphorylation, respectively (Appendix A and C). Only one transcription
factor, HMG box transcription factor BBX isoform 1, was shared between sets.
With regards to histone modifying enzymes, CK2 has been shown to
phosphorylate LSD1, HDAC1, and HDAC2 proteins at canonical CK2 sites to modulate
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their demethylase/deacetylase activity or protein interactions, suggesting that CK2 plays
an important role in epigenetic regulation (Tsai and Seto, 2002; Costa et al., 2014).
Additionally, CK2 has been shown to phosphorylate DNA methyltransferase Dnmt3a that
decreases the ability of Dnmt3a to methylate DNA and CpG islands (Deplus et al., 2014).
Our datasets identified 18 and 10 histone modifying proteins that contain multisite and
proline-directed CK2 hierarchical sequences, respectively (Appendix A and C). Most
notably, 11 members of the lysine-N-methyltransferase family were identified, but only
two members, SETD2 and KMT2A, were shared between the two candidate sets.
Evidence supporting a role for CK2 in regulating protein ubiquitination has also
been increasing in recent years. CK2 has been shown to phosphorylate deubiquitinase
OTUB1 and USP48, E2-ubiquitin conjugating enzymes UBC3B and CDC34, and E3ubiquitin ligase SAG-SCF at canonical CK2 sites (Block et al., 2001; Semplici et al.,
2002; He et al., 2007; Herhaus et al., 2015; Schweitzer and Naumann, 2015). Our datasets
identified 29 and 17 ubiquitin-related proteins that contain multisite and proline-directed
CK2 hierarchical sequences, respectively (Appendix A and C). Most notably, 26
members of the E3-ubiquitin ligase family were identified, but only three members,
HUWE1, NEURL1B, and TRIM37, were shared between the two candidate sets.
Collectively, it can be concluded from this bioinformatic analysis of CK2
hierarchical phosphorylation that processes represented by our candidates are also
processes that canonical CK2 phosphorylation intricately regulates. This indicates that
our understanding of the roles that CK2 plays in these outlined processes as well as
potentially others are likely underappreciated and not yet complete. It is also interesting
that CK2 hierarchical sequences are present in multiple members of a single protein
family. This might suggest that the sequence is conserved between members possibly due

210
to the importance of its biological function.

4.4.3 Complexity of hierarchical CK2 phosphorylation requires a precise order in
phosphorylation
The majority of known phosphorylation sites matching both hierarchical consensus
sequences were identified in large-scale phosphoproteomic studies and have not largely
been characterized for biological function or even associated with a specific kinase.
CTCF is a multi zinc finger-containing transcription factors that can influence
transcription by either binding insulator elements to reduce transcription or binding
promoter-proximal sites to stimulate transcription. CTCF phosphorylation by CK2 in
vitro and in vivo at serines 609 (p), 610 (p+1), and 612 (p+3) has been well-documented,
at the exact sites that match our multisite CK2 hierarchical consensus sequence
(corresponding positions in brackets) (Klenova et al., 2001; El-Kady et al., 2005).
Phosphorylation of these three sites is absolutely required for transcriptional stimulation
of c-myc and cell proliferation (Klenova et al., 2001; El-Kady et al., 2005). Our data with
the CTCF peptide, WSKKEDSSDSENAEP, analyzed by both [γ32P]-phosphate
incorporation and mass spectrometry indicate that priming phosphorylation at p+1 and
p+3 increase CK2 phosphorylation (Figure 4-5, Figure 4-6, and Figure 4-7). While low
levels of phosphorylation by CK2 results in a singly phosphorylated peptide with a nonphosphorylated, unprimed peptide substrate (SSDS), high levels of CK2 phosphorylation
and a triply phosphorylated peptide is observed with peptide substrates containing
priming phosphorylation at p+3 as well as p+1 and p+3 (SSDpS and SpSDpS). In
contrast, priming phosphorylation at p+1 abolishes CK2 phosphorylation, suggesting that
phosphorylation at p+3 may be the initial priming phosphorylation event. This is
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consistent with in vitro and in vivo studies with CTCF (El-Kady et al, 2005). Replacing
S612 with an alanine resulted in strong repression of c-myc reporter expression similar to
the repression observed with the S604,609,610,612A mutant. Overexpression of ectopic
CK2 was unable to relieve the repression observed with the S612A mutant provided
further evidence that S612 is the critical residue and the initial priming phosphorylation
event in this phosphorylation cascade (El-Kady et al., 2005). Importantly, this example
illustrates that hierarchical phosphorylation by CK2 can have a significant contribution to
cellular signaling. Interestingly, based solely on sequence determinants for CK2
phosphorylation, S610, which is at the p+1 position in our consensus sequence, has the
strongest canonical determinants with an aspartic acid and glutamic acid at the +1 and +3
positions (SSDSE), respectively (Table 4-3). Not only is CTCF a published example of
multisite CK2 hierarchical phosphorylation, it is also considered an example of
processive CK2 phosphorylation since CK2 primes its own phosphorylation as all three
sites are phosphorylated by CK2.
The assessment of additional candidates for both multisite and proline-directed
CK2 hierarchical phosphorylation further reveals the complexity of CK2 hierarchical
phosphorylation. Hierarchical CK2 phosphorylation was observed for multiple prolinedirected and multisite candidates, where priming phosphorylation was either absolutely
required for or increased CK2 phosphorylation (Figure 4-5 and Figure 4-11). This
spectrum of activity further supports the observation that priming phosphorylation can
provide adequate sequence determinants to produce a novel CK2 site or combine with an
existing canonical CK2 site to strengthen it. The added complexity of hierarchical
phosphorylation is also observed with CEP350, CTCF, TOPORS, JMJD1C. Surprisingly,
priming phosphorylation of CEP350 resulted in a substantial decrease in CK2
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phosphorylation (Figure 4-11). This was unexpected, however the CEP350 peptide
sequence contained more acidic residues proximal to the phosphoacceptor than the other
candidate sequences tested (Table 4-5). A possible explanation is that the acidic residues
conformed to a strong canonical CK2 site and the addition of a phosphate on the priming
serine further increases the negative charge of the peptide which interferes with the
coordination of the substrate in the binding cleft and either reduces binding affinity and/or
improperly positions the phosphoacceptor for catalysis. For CTCF, TOPORS, and
JMJD1C, priming phosphorylation at p+3 or p+1 and p+3 increased CK2 phosphorylation
(Figure 4-5 and Figure 4-6). However, a single priming phosphorylation at the p+1
position was shown to abolish CK2 phosphorylation, to levels even lower than the
unprimed substrate (Figure 4-6). This suggests that the same sequence can be
differentially phosphorylated to elicit distinct signaling modules and thus cellular
function, adding yet another layer of complexity. Although the candidate sequences
assessed matched the optimal consensus sequences for CK2 hierarchical phosphorylation,
it was not able to consistently predict CK2 phosphorylation since half of the prolinedirected and a few of the multisite candidate peptides were not phosphorylated by CK2,
even in the presence of priming phosphorylation. These results also highlight the
importance of studying the cellular functions of hierarchical phosphorylation as
combinatorial higher-order signaling modules. Further studies will be required to
delineate these cellular roles on candidate CK2 hierarchical proteins.

4.4.4 Summary
In summary, we have performed a systematic investigation of hierarchical CK2
phosphorylation

for

both

multisite

and

proline-directed

CK2

hierarchical
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phosphorylation. Bioinformatic analysis revealed that hierarchical phosphorylation by
CK2 may potentially have a global effect on signaling pathways and contribute to the
regulation of multiple cellular processes. The results also suggest a mechanism by which
CK2, a constitutively active kinase, can have critical roles in highly regulated cellular
processes. Ultimately, hierarchical phosphorylation is a very complex system to study and
individual phosphorylation sites should not be studied alone in isolation. Additional
studies are needed to further delineate the functional consequences of CK2 hierarchical
phosphorylation.
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CHAPTER FIVE: DISCUSSION

5.1 Overview
As highlighted in this thesis, CK2 is a constitutively active protein serine/threonine kinase
that displays elevated levels in several cancers and higher levels correlate with a
significantly unfavorable prognosis and poor overall survival (Litchfield, 2003; Kim et
al., 2007; Laramas et al., 2007; Giusiano et al., 2010; Lin et al., 2010; Lin et al., 2011;
Piazza et al., 2012). CK2 is intricately involved in numerous highly regulated processes
that include cell death and proliferation where it has a plethora of substrate proteins
(Litchfield, 2003; Meggio and Pinna, 2003). Many of these substrates are potentially
unidentified, as an estimated 20% of the phosphoproteome may be attributed to CK2, and
many others have not been validated as bona fide cellular substrates (Salvi et al., 2009;
Salvi et al., 2010). Consequently, CK2 has emerged as an attractive target for drug
development and one inhibitor, CX-4945 (Silmitasetib), is currently in clinical trials
(Pierre et al., 2011; Chon et al., 2015; www.clinicaltrials.gov). However, in order to
realize the full potential of molecular therapeutics targeting CK2, it is essential to have
robust methods to monitor CK2 activity as well as interrogate the cellular specificity and
substrates of CK2 to further understand the cellular role of CK2 and identify potential
biomarkers for CK2 activity. With this in mind, the goal of this thesis was to monitor the
activity and evaluate the substrate specificity of CK2 by utilizing chemical biology
approaches.
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5.2 Summary of findings and significance
5.2.1 Monitoring CK2 activity with FcATP: a biochemical characterization
The rapid development of molecular therapies targeting protein kinases, including CK2,
has spurred great interest into developing strategies to monitor protein kinase activity to
increase the clinical potential for personalized treatment. To overcome the limitations
associated with traditional strategies that have been developed, an electrochemical
kinosensor has been proposed by Kraatz and colleagues as a direct and robust method
(Kerman et al., 2008; Song et al., 2008). The kinosensor utilizes an electroactive 5’-γferrocenyl-ATP (FcATP) analog to directly monitor the transfer of ferrocene (Fc) to
substrate peptides catalyzed by protein kinases. While Fc-phosphorylation has been
demonstrated for a few kinases, including CK2, a thorough biochemical characterization
of the utility of FcATP in kinase-catalyzed phosphorylation had not been performed
(Kerman et al., 2008; Song et al., 2008).
In chapter 2, we performed a detailed biochemical assessment of the ability of
CK2 to utilize FcATP to monitor CK2 kinase activity. To do so, we developed a novel
anti-Fc antibody to facilitate the direct detection of Fc-phosphorylation, the kinasecatalyzed transfer of a Fc-phosphate from FcATP to a substrate using traditional
biochemical assays to complement previously reported electrochemical measurements.
Our initial characterization of the antibody demonstrated that the anti-Fc antibody was
both specific and highly sensitive for the Fc epitope. Subsequent use of this anti-Fc
antibody enabled an extensive detailed analysis of the effective use of FcATP by CK2 to
Fc-phosphorylate substrate proteins. Our results offer the first direct comparison of
FcATP with ATP in CK2-catalyzed phosphorylation to benchmark the utility of FcATP
against traditional assays using ATP. Importantly, these results were largely consistent
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with published electrochemical measurements collected for CK2 and other kinases.
Furthermore, this biochemical characterization of FcATP provides confidence and a
strong foundation upon which to continue developing an electrochemical biosensor to
monitor CK2 activity. This kinosensor may improve the diagnosis and identification of
patients that would benefit the most from treatment with targeted-CK2 therapies and
ensure the clinical success of CK2 inhibitors.
Perhaps even more exciting, is our observation that FcATP is used by endogenous
kinases present within the complex mixture of an extract from HeLa cells, suggesting that
FcATP is broadly used by the kinome. There are over 500 protein kinases in the human
genome and numerous alterations have been identified in many kinases that result in
deregulated activity and are associated with cancer (Manning et al., 2002; Lahiry et al.,
2010). The success of Gleevec, a kinase inhibitor targeting Bcr-Abl, demonstrated that
protein kinases are “druggable” and to date there are thousands of patents filed and 20
licensed protein kinase inhibitors in the clinic (Capdeville et al., 2002; Cohen, 2002;
Fabbro, 2015; Savage and Mahmoud, 2015). Ultimately, the results in this chapter
support the development of a kinosensor chip that has the ability to monitor the activities
of multiple proteins kinases in patient samples simultaneously (Figure 5-1; see section
5.3.1). The advantages in sensitivity, safety, affordability, and throughput potentially
offered by a multiplexed kinosensor may be essential in realizing the promise of protein
kinases as therapeutic targets in personalized medicine, as monitoring kinase activity can
facilitate the accurate selection of the correct drugs for treatment on an individual basis.

5.2.2 Approaches to study the cellular roles and substrate specificity of CK2
While it is important to have strategies to monitor CK2 activity, it is equally important
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Figure 5-1
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Figure 5-1. A schematic illustration of the electrochemical kinosensor. Peptide
substrates and controls (non-phosphorylatable peptides) are immobilized onto Au
microelectrodes in quadruplicates at specific locations on a microchip. The chip is
incubated with patient sample and FcATP and the kinase-catalyzed transfer of Fc to
peptide substrate is detected electrochemically by cyclic voltammetry, where an
electric potential is applied and the current is measured. Peptides with Fcphosphorylation will generate a larger current than controls.
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to have effective strategies to further examine the cellular roles and substrate specificity
of CK2. We have developed two approaches to evaluate the cellular roles of CK2 to
further discern substrate-kinase relationships.
In chapter 3, we took advantage of a chemical biology approach pioneered by
Shokat and colleagues that has been successfully applied to numerous protein kinases and
adapted it to study CK2 (Shah et al., 1997). This chemical biology strategy was chosen to
provide a different perspective to currently used approaches, which include adding or
inhibiting CK2 activity followed by mass spectrometry analysis of phosphopeptides (Bian
et al., 2013; Wang et al., 2013; Franchin et al., 2015). While these studies produce useful
datasets they are inherently limited in their ability to separate direct and indirect CK2
substrates since all protein kinases use ATP as a cofactor to phosphorylate substrate
proteins. This is due to the highly conserved sequence and structure in the active sites of
protein kinases (Hanks et al., 1988; Hanks and Hunter, 1995; Manning et al., 2002). For
example, CK2 could phosphorylate another kinase, which could result in either activation
or inactivation of that kinase leading to changes in phosphorylation of substrates specific
to that kinase. The indirect effects of CK2 inhibitors are highlighted by the abundance of
phosphopeptides identified in these studies that do not conform to the consensus sequence
for CK2 phosphorylation (Bian et al., 2013; Wang et al., 2013; Franchin et al., 2015). For
example, phosphopeptides containing an S-P motif, which is incompatible with CK2
phosphorylation can likely be attributed to Cdks (Meggio and Pinna, 2003; Section 4.3.1
and 4.3.4).
Using the Shokat strategy, we engineered an analog-sensitive-CK2 (as-CK2) with
an expanded nucleotide-binding pocket by substituting a large phenylalanine residue with
a smaller glycine residue. As-CK2 preferentially uses an ATP analog, 2peATP that is not

228
used by wild-type kinases and is sensitive to inhibition by modified inhibitors that do not
inhibit wild-type kinases. These changes differentiate as-CK2 from the other hundreds of
cellular proteins kinases and provides a new approach to identify substrates of CK2 where
only substrates that are directly phosphorylated by as-CK2 using 2peATP can be
specifically labeled (Manning et al., 2002). Indeed, we observed specific phosphorylation
of Flag-EEF1D, a known CK2 substrate, in cell extracts only in the presence of as-CK2.
In chapter 4, we used a synthetic phosphoserine oriented peptide array to
systematically investigate the determinants for the role of CK2 in hierarchical
phosphorylation and subsequently assessed candidate substrates identified by
bioinformatic analysis of the human proteome. These studies were performed on the basis
of several lines of evidence that support a role for CK2 in hierarchical phosphorylation.
First, the majority of phosphoproteins are phosphorylated at multiple sites and
phosphorylated residues are frequently found clustered together (Yachie et al., 2009;
Sharma et al., 2014; Cesaro and Pinna, 2015). Second, CK2 has been shown to use pS
and pY, but not pT, residues as acidic determinants for substrate phosphorylation
(Kuenzel et al., 1987; Hrubey and Roach, 1990; Litchfield et al., 1990; Perich et al., 1992;
Marin et al., 1996). Finally, several examples where CK2 can be primed by other kinases
have been recently reported in the literature (Watanabe et al., 2005; Koseoglu et al., 2008;
Yata et al., 2012; Cesaro et al., 2013; Venerando et al., 2014). The results presented in
this chapter are the first to outline an optimal consensus sequence for hierarchical CK2
phosphorylation in the context of multisite and proline-directed primed phosphorylation.
Our results demonstrate that hierarchical phosphorylation was dependent on combining
priming phosphorylation at precise positions with additional acidic determinants, similar
to the canonical CK2 consensus sequence. This indicates that hierarchical consensus
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sequences exist to create the necessary determinants to either create a new CK2
consensus or to strengthen an existing weak CK2 consensus sequence and may serve to
fine-tune CK2 activity towards select substrates over a broad continuum.
Performing a bioinformatic search of the human proteome to match sequences that
conform to the consensus for hierarchical CK2 phosphorylation identified over 2000
candidate sequences, a fraction of which are known to be phosphorylated in cell, and
suggests that the number of CK2 substrates may currently be greatly underappreciated.
Strikingly, cellular processes that may be regulated by CK2 hierarchical phosphorylation
are also processes that canonical CK2 phosphorylation intricately regulates. The majority
of known phosphorylation sites matching CK2 hierarchical consensus sequences were
identified in large-scale phosphoproteomic studies and have not largely been
characterized for biological function or even associated with a specific kinase. Yet, our
systematic approach to study hierarchical CK2 phosphorylation by combining in vitro
kinase assays and bioinformatic analysis provides compelling in vitro evidence that
hierarchical phosphorylation by CK2 may potentially contribute to the regulation of
multiple cellular processes.

5.2.3 Regulation of CK2 through hierarchical phosphorylation
CK2 is largely regarded as constitutively active, and unlike many other protein
serine/threonine kinases, it is not susceptible to second messenger regulation or activating
or inhibitory phosphorylation (Litchfield, 2003; St-Denis and Litchfield, 2009). Although
the mechanisms of CK2 regulation are not completely understood, it appears to involve a
number of more subtle means including localization, phosphorylation, and protein-protein
interactions (Litchfield, 2003; St-Denis and Litchfield, 2009; St-Denis et al., 2009; St-
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Denis et al., 2011). Despite the uncertainty regarding its mechanisms of regulation, it is
important to note that CK2 has essential roles in several highly regulated cellular
processes including cell cycle progression. Furthermore, some substrates show evidence
of regulated phosphorylation suggesting that CK2 activity is in fact regulated (Ford et al.,
2000; Keller et al., 2001; Li et al., 2012). For example, mitosis is a highly regulated
cellular process that is driven by the mitotic master kinase Cdk1. Both CK2 and Cdk1
have numerous protein substrates in mitosis and both genetic and biochemical
experiments in yeast and mammalian cells provide evidence for the requirement of CK2
at the G2/M transition for proper mitotic progression (Lorenz et al., 1993; Hanna et al.,
1995; St-Denis et al., 2009). For example, priming phosphorylation by Cdk1 on mitotic
regulator Wee1A resulted in subsequent phosphorylation by CK2 at a proximal site that
promoted degradation of Wee1A and ultimately the onset of mitosis (Watanabe et al.,
2005). In the context of regulation, CK2 hierarchical phosphorylation would be
dependent on previous priming phosphorylation by another kinase, implying that CK2
activity would be placed under the same regulation as the priming kinase. This
involvement in hierarchal phosphorylation could thus provide a mechanism for the
regulated phosphorylation of CK2 substrates despite the fact that CK2 is ubiquitously
expressed and constitutively active. Specifically for proline-directed CK2 hierarchical
phosphorylation, the activity of CK2 could be stringently regulated by the activation of
Cdks, which are highly regulated and cell cycle dependent, required for priming
phosphorylation. The demonstration of Cdk-primed phosphorylation of Wee1A by CK2,
prompted us to perform a detailed analysis of proline-directed hierarchical CK2
phosphorylation, which identified almost 800 potential candidate proteins suggesting this
may be a widespread phenomenon. Strikingly, nearly 25% of these candidate proteins are
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involved in cell-cycle dependent pathways regulated by Cdks. While we specifically
addressed priming phosphorylation by Cdks, there is great potential for other kinases to
globally regulate the activity of CK2 in the same manner, such as Plks or tyrosine kinases
as has been previously reported for Rad51 and CFTR (Yata et al., 2012; Cesaro et al.,
2013; Venerando et al., 2014).

5.2.4 Cross-talk between post translational modifications as hierarchical signaling
modules
Collectively, our work on hierarchical phosphorylation has shed light on the complexity
of intracellular signaling pathways. Not only does hierarchical CK2 phosphorylation
require the precise spacing of priming phosphorylation and acidic determinants, but also
the exact order of phosphorylation is critical (Figure 5-2a). As was observed with CTCF,
robust CK2 phosphorylation at S609 was dependent on priming phosphorylation at S612,
whereas priming phosphorylation at S610 completely abolished CK2 phosphorylation.
This effect was also observed with peptide substrates derived from TOPORS and
JMJD1C. These observations highlight the notion that phosphorylation sites should not be
studied in isolation especially when considering that the majority of phosphoproteins are
phosphorylated at multiple sites and often with clustering of phosphorylation sites.
Overall, it is evident that a complete understanding of the impact of phosphorylation
events and their biological effects will require analysis of the interplay between multiple
kinases.
Protein phosphorylation is a reversible modification, and protein phosphatases are
the enzymes that catalyze the removal of the phosphate. As both kinases and
phosphatases are critical to maintaining the balance of protein phosphorylation, this adds
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Figure 5-2. An illustration of potential cross-talk between post-translational
modifications. (A) The precise order of hierarchical phosphorylation is essential.
Phosphorylation at the C-terminal serine primes phosphorylation at proximal serines and
initiates a phosphorylation cascade. However, initial phosphorylation at the middle serine
prevents phosphorylation at proximal serines. Dephosphorylation of individual
phosphorylated serines by protein phosphatase can result in additional combinations of
phosphoserines on the same peptide. (B) The effect of acetylation, methylation, and
oxidation on phosphorylation by CK2. Acetylation and oxidation may increase CK2
phosphorylation whereas methylation could either increase or decrease phosphorylation.
(C) Phosphorylation by CK2 is required for subsequent SUMOylation by UBC9 on
NOP58. (D) Phosphorylation by CK2 at serine or threonine residues proximal to the
cleavage site (aspartic acid) protects against caspase cleavage. In the absence of CK2,
these proximal sites are not phosphorylated, and caspase cleavage occurs.

A, acetylation; M, methylation; O, oxidation; P, phosphorylation; S, SUMOylation; X,
any amino acid; !, the scissile bond cleaved by caspase.
!
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yet another layer of complexity. The selective removal of specific phosphorylated
residues within these hierarchical clusters may result in alternative patterns of
phosphorylation (Figure 5-2a). Theoretically, a peptide with three phosphorylation sites
could exist in eight different phosphorylated states, each with its own biological function.
Phosphorylation is just one example of post-translational modification that occurs
on proteins. The interplay between phosphorylation and other post-translational
modifications adds yet another level of complexity, such as oxidation, acetylation,
methylation, and SUMOylation; much like the “histone code”. This cross-talk has not yet
been systematically investigated, but it is entirely conceivable that these modifications
can change the local charge, size, and structure of substrate proteins. Logically extending
our work on CK2, these modifications may provide favourable and/or unfavourable
determinants for subsequent CK2 phosphorylation (Figure 5-2b). For example,
acetylation of the N-terminus can remove the positive charge of the amino group and thus
make phosphorylation by CK2 at a proximal phosphoacceptor residue more favourable.
Protein oxidation of thiol containing residues may increase the acidic properties of these
residues, which is favourable for proximal CK2 phosphorylation. In contrast, methylation
of lysine and arginine residues reduces the positive charge and increases the size of the
residue, which could result in increased or decreased CK2 phosphorylation, respectively.
Protein methylation can exist in mono-, di-, and trimethylation and each of these can
potentially have a different impact on subsequent phosphorylation. Additionally, CK2
phosphorylation-dependent SUMOylation has been demonstrated with NOP58 (Figure 52c) (Westman and Lamond, 2011; Eifler and Vertegaal, 2015). While this has been
documented for one substrate, this phosphorylation-dependent SUMOylation motif has
been identified in many other proteins (Hietakangas et al., 2006). Furthermore,
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phosphorylation proximal to caspase cleavage sites has been demonstrated to promote or
block peptide cleavage (Dix et al., 2012; Turowec et al., 2014). Specifically, the
consensus sequences of CK2 and caspases overlap and phosphorylation by CK2 has been
shown to block caspase cleavage in cell (Figure 5-2d) (Walter et al., 1999; Desagher et
al., 2001; Krippner-Heidenreich et al., 2001; Yin et al., 2001; Ruzzene et al., 2002; Riman
et al., 2012; Duncan et al., 2011; Turowec et al., 2011).
Collectively, the combination of post-translational modifications may impact CK2
phosphorylation and serve as higher-order signalling modules, each eliciting a specific
biological effect. Ultimately, increasing the sensitivity of mass spectrometers, increasing
the number of global phosphorylation/methylation/acetylation/oxidation/SUMOylation
studies, and the compilation of these datasets into accessible databases will lead to the full
complement of the post-translational modification landscape and increased understanding
of the cross-talk between intracellular signaling pathways. It will also be important to
delineate the protein-protein interactions resulting these modification combinations. A
detailed understanding of CK2 and its relationships with other signaling pathways offers
the promise of new insights for targeting CK2 for therapy.

5.3 Future Directions
5.3.1 Developing an electrochemical kinosensor to monitor the activities of multiple
protein kinases simultaneously
The ultimate goal of the multiplexed kinosensor is the ability to monitor the activities of
several protein kinases simultaneously on a gold “chip” (Figure 5-1). Distinct peptide
substrates for numerous kinases can be immobilized in quadruplicate at specific locations
on a micro-sized gold “chip” and incubated with FcATP and cell extract. Control peptides
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where the phosphoacceptor residue is replaced with a non-phosphorylatable alanine
residue could also be immobilized. Electrochemical redox signals generated by Fcphosphorylation in close proximity to the gold surface can be detected directly by cyclic
voltammetry, using a simple potentiostat to measure current changes in response to
varying potential. Ongoing and future development of the kinosensor can involve the
logical transition from purified components to simple mixtures of kinases, extracts from
cultured cells, and finally patient samples.
Initial assays could include proof of principle studies using purified recombinant
kinases with different consensus sequence determinants (ie. basic, acidic, prolinedirected, and tyrosine) to enable an assessment of the multiplex kinosensor format.
Kinase assays can be performed on-chip with individual kinases and their respective
immobilized peptide substrates with FcATP in parallel with [γ32P]ATP. Phosphorylation
in reactions using [γ32P]ATP could be detected by phosphorimaging. While Fcphosphorylation using FcATP could be detected both electrochemically by cyclic
voltammetry as well as immunologically with our anti-Fc antibody. Once assay reliability
has been established with single kinases, the complexity of assays can be increased by the
combinatorial inclusion of more kinases in reaction mixtures. Moving stepwise from
recombinant kinases to more complex mixtures, we could perform on-chip kinases assays
using endogenous kinases in extracts prepared from cultured cells. Ultimately, once the
multiplexed on-chip assays can reliably monitor multiple kinases simultaneously, the
clinical utility of the kinosensor could be tested with patient samples. A good starting
point might be hematological malignancies such as CML for two reasons: they express
constitutively active Bcr-Abl fusion kinase and extracts can be easily acquired from blood
samples.
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In addition, these assays can be performed in the presence of protein kinase
inhibitors as a prelude to using the kinosensor as a drug screening platform. The
kinosensor “chip” could potentially be useful in profiling the activity of multiple kinases
simultaneously upon treatment with an inhibitor to identify targets and/or off-target
effects. Furthermore, the kinosensor could be used to monitor patients undergoing kinasetargeted therapies.

5.3.2 Identification of CK2 substrates
The work in this thesis has developed strategies to study the cellular roles and substrate
specificity of CK2. We developed an as-CK2 and the logical extension of this work can
enable the global identification of direct CK2 substrates in cell (Figure 5-3). HeLa cells
can be transfected with CK2α-HA or as-CK2α-HA. Cells can then be treated with
digitonin, a detergent that permeablizes the cell membrane, to allow negatively charged
2peATPγS to enter the cell. Thus, the kinase assay can be performed in cell so as not to
disrupt localization and complex formation. Cells that express as-CK2α-HA can use
2peATPγS to transfer a thiophosphate to substrate peptides. The cells can then be lysed
and the proteins digested with trypsin. The thiophosphorylated peptides can be selectively
enriched by capture on iodoacetyl-coupled beads, removing all non-phospho and
phosphopeptides. Oxidation of the beads specifically elutes the immobilized
thiophosphorylated peptides as phosphopeptides, which can be analyzed by LC-MS/MS.
This strategy has been successfully used to identify substrates of other analog-sensitive
kinases including Cdk1/cyclin B, Cdk2/cyclin A, Erk2, and Aurora B (Blethrow et al.,
2008; Chi et al., 2008; Hertz et al., 2010; Carlson et al., 2011; Hengeveld et al., 2012).
This process can be quantitative by the differential labeling of as-CK2α-HA sample and
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Figure 5-3. An enrichment strategy to identify direct substrates of as-CK2. HeLa cells are
transfected with CK2α-HA or as-CK2α-HA. Cells are treated with digitonin to
permeablize the cell membrane and incubated with 2peATPγS. The cells will then be
lysed and the proteins digested with trypsin. The thiophosphorylated peptides will be
selectively enriched by capture on iodoacetyl-coupled beads, removing all nonphosphopeptides and phosphopeptides. Oxidation of the beads specifically elutes the
immobilized thiophosphorylated peptides as phosphopeptides, which are then analyzed by
mass spectrometry. Labeling the as-CK2α sample (red) with a heavy isotope shifts the
peptides in mass to separate identical peptides in the CK2α sample (blue) labeled with a
light isotope. Direct substrates of CK2 will be more abundant in the as-CK2α-HA
expressing sample than the CK2α-HA expressing control. Modified from Hertz et al.,
2010.
!
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CK2α-HA control, by either SILAC or dimethyl heavy and light isotope labeling. Direct
substrates of CK2 would be more abundant in the as-CK2α-HA expressing sample than
the CK2α-HA expressing control. To further increase the confidence in the results, HeLa
cells expressing as-CK2α could also be treated with modified inhibitors identified by our
work. Results could be analyzed to confirm representation of the CK2 motif, GO analysis
to investigate pathways, and substrates can be validated by traditional biochemical
techniques such as immunoblotting, in vitro kinase assays, and manipulating CK2 activity
using CK2 inhibitors and RNA interference (RNAi).
Since CK2 participates in several temporally regulated processes such as cell
cycle progression, many substrates may not be phosphorylated by CK2 at appreciable
levels in unstimulated or asynchronous cells. Therefore, cells could be treated with
different stimuli, or arrested during the cell cycle to enrich for and identify CK2
substrates at specific times or in response to stimuli. Also, cells could be fractionated to
further enrich for substrates. For example, mitotic spindles or the actin cytoskeleton and
their respective associated proteins could be isolated to identify CK2 substrates that
localize to these structures. These studies could be helpful in elucidating specific roles for
CK2 in dynamic cellular processes.
Interestingly, this approach can also be modified to globally delineate the
interplay between CK2 and other kinases. Using Cdk1 as an example, HeLa cells can be
transfected with as-CK2α-HA and the activity of Cdk1 modulated by either RNAi or
pharmacological inhibition by a Cdk1 specific inhibitor, RO-3306 (Vassilev et al., 2006).
Thiophosphopeptide enrichment could be performed as described above. If CK2
phosphorylation of a substrate was dependent on Cdk1 phosphorylation, a decrease in
thiophosphorylation by as-CK2α-HA might be expected when Cdk1 activity was
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downregulated. In contrast, substrates where Cdk1 phosphorylation blocks as-CK2α-HA
phosphorylation might show an increase in thiophosphorylation when Cdk1 activity was
downregulated. To study the interplay of Cdk1 and CK2 specifically in mitosis, cells
could be arrested in mitosis by treatment with nocodazole. As a positive control for this
assay, phosphorylation of Wee1A by CK2 is dependent on priming phosphorylation by
Cdk1 and should not be detected with downregulated Cdk1 (Watanabe et al., 2005).
In sum, using these approaches will increase the number of bona fide CK2
substrates and further decipher the kinase-substrate relationships of CK2.

5.3.3 Analysis of CK2 hierarchical phosphorylation substrates
Our systematic study defined the optimal consensus sequence for hierarchical CK2
phosphorylation and subsequent bioinformatic analysis identified over 2000 potential
candidates. These advances can be extended to enable the functional effects of
hierarchical CK2 phosphorylation. Peptides of several candidates tested showed primed
CK2 phosphorylation when tested in in vitro kinase assays. To screen for additional
candidates, peptide arrays can be synthesized with and without priming phosphoserine.
As described in chapter 4, priming phosphorylation largely resulted in an increase in CK2
phosphorylation, but one candidate showed the opposite, a decrease in CK2
phosphorylation. It could be interesting to identify other candidates where this is true to
further study this effect. While these in vitro assays provide evidence that these
candidates may be potential physiological substrates, they may not reflect the natural
environment of the site within the entire protein, or represent in cell phosphorylation. To
determine if the in vitro results can be recapitulated in cell, we could confirm the
phosphorylation of these candidates using a targeted mass spectrometry approach called
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selected reaction monitoring (SRM). In SRM, a triple quadrupole mass spectrometer is
employed for increased specificity and sensitivity over traditional mass spectrometry. The
first and third quadrupoles act as filters to select for specific peptide ions by predefined
mass-to-charge ratios. The second quadrupole acts as a collision cell to fragment peptides.
The phosphorylation status of each phosphorylation site will be analyzed by selecting for
peptides that have mass-to-charge ratios specific to phosphorylated and unphosphorylated
sites. Importantly, absolute quantification is possible by spiking isotopically labeled,
synthetic phosphopeptides into the sample being analyzed (Lange et al., 2008). To
specifically address the issue of hierarchical phosphorylation, phosphorylation site
mutants could be used to uncouple the individual sites to validate selected candidates.
Mutations to alanines remove the hydroxyl group on serine, threonine, and tyrosine
residues required for the addition of phosphate therefore abolishing phosphorylation. In
contrast, mutations to glutamic acids may mimic phosphorylation based on structure
similarity to a phosphorylated amino acid. Affinity-tagged constructs containing these
substitutions can be transfected into cells, immunoprecipitated from lysate, and analyzed
by SRM. In addition, these substitutions could also be useful in delineating the precise
order of phosphorylation.
Once candidates have been validated in cell, the functional effects of this
regulation could be investigated. To test the effect of loss of hierarchical phosphorylation
on these mitotic substrates, the expression of candidates can be knocked down using
RNAi. To rescue any defects and reconfirm the importance of hierarchical
phosphorylation, site mutants that are resistant to RNAi can be transfected in parallel to
endogenous protein knockdown. Expression of different combinations of alanine and
glutamic acid substitutions may uncouple the functional effects of hierarchical CK2
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phosphorylation from priming phosphorylation. For example, phosphorylation of only the
priming sites may produce one effect while CK2 phosphorylation may produce a second
distinct effect. The functional assays used would be entirely dependent on the selected
candidate, and may include cell viability, cell cycle analysis, cell mobility, enzyme
activity, localization, and protein binding interactions/complex formation assays.
Together, these experiments could provide a comprehensive knowledge of the
functional roles of hierarchical CK2 phosphorylation and insight into how CK2 may be
regulated in various cellular processes.

5.4 Perspectives and conclusions
The highly conserved features of protein kinases that regulate large networks of
intracellular signaling pathways highlights the challenge in studying the roles of a single
kinase. Collectively, the work in this thesis highlights the complexity of the pathways in
which CK2 is intricately involved in and reinforces that notion that the cellular roles of
CK2 are currently underappreciated. Importantly, by using chemistry to probe biological
systems, we have developed three strategies to monitor the activity and elucidate the
substrate specificity of CK2.
Due to the elevated levels of activity in numerous cancers, and essential roles in
cell proliferation and death, CK2 is currently being developed as a therapeutic target.
Ultimately, this work will contribute to increasing our knowledge and understanding of
CK2, which will aid in the continued development and future clinical usage of
therapeutics targeting CK2.
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Appendix A. Candidate sequences in the human proteome that match the multisite CK2
hierarchical consensus sequence.
GI

Protein Name

514052656
5803227
110556636
13375891
11559927
186928854

Position

Sequencea

[Pyruvate dehydrogenase (acetyl-transferring)] kinase
isozyme 1, mitochondrial isoform 1 precursor
14-3-3 protein theta

28

aagfsRSFSSDSGSSpaser

228

lrdnlTLWTSDSAGEecdaa

82 kDa tankyrase-1-binding protein

1707

tlppkPEKSSGSEGSspnwl

2-oxoglutarate and iron-dependent oxygenase domaincontaining protein 3 isoform 1
28S ribosomal protein S14, mitochondrial

280

ragrvSFFTSGSENLhrvek

18

rtfkqMVPSSASGQVrshyv

28S ribosomal protein S31, mitochondrial

83

rteetSKETSESQDSekent

31543184

3'-5' exoribonuclease 1

55

tkgskFITSSASDFSdpvyk

21265040

39S ribosomal protein L22, mitochondrial isoform a

34

vlpqsYIHTSASLDIsrkwe

51558724

A disintegrin and metalloproteinase with
thrombospondin motifs 12 preproprotein
A-kinase anchor protein 10, mitochondrial precursor

1123

egglvATTTSGSGLSssrnp

542

eshpgSSDSSASQSSvkkas

21493033

A-kinase anchor protein 11

1175

rslseEVESSESGELpevdv

21493022

7706457

A-kinase anchor protein 12 isoform 1

150

peiieQIPSSESNLEeltqp

31563330

A-kinase anchor protein 13 isoform 1

255

reldiYTLTSESDSHhehpf

21493045

A-kinase anchor protein 6

1620

hssgdISVSSGSVGElskrt

612407827
22538387
126116596
301069394
55742689

A-kinase anchor protein 8-like isoform 1

79

pssdtNANTSASGSAsadsv

A-kinase anchor protein 9 isoform 2

2901

ayqtrEICSSDSGSDwgqgi

abnormal spindle-like microcephaly-associated protein
isoform 1
absent in melanoma 1-like protein

1181

tgsvvLNSSSESDDSsldms

483

trkevVQGSSASAASsptwk

actin filament-associated protein 1-like 1 isoform 1

347

krlsqEKQTSDSDSVgvgdn

194272196

actin-binding LIM protein 2 isoform 1

278

drnkeTRTSSESIISvpass

31657094

actin-binding protein anillin isoform 1

238

gtaclSKFSSASGASarins

530788283

actin-like protein 9

7

yRPKSSESQSSleapr

217330646

activated RNA polymerase II transcriptional
coactivator p15
activating molecule in BECN1-regulated autophagy
protein 1 isoform 1
activin receptor type-1 precursor

11

skelvSSSSSGSDSDsevdk

676

lltsgDLPTSASQSAgitgv

188

adlldHSCTSGSGSGlpflv

activin receptor type-1B isoform a precursor

187

qdlvyDLSTSGSGSGlplfv

54

ggrgcRALSSGSGSEykthf

183

ktvngKAESSDSGAEseeee

292

dvtgiQHLTSDSDSEvycds

5031587

acyl-CoA synthetase short-chain family member 3,
mitochondrial precursor
acyl-CoA-binding domain-containing protein 5
isoform 1
acyl-CoA-binding domain-containing protein 5
isoform 1
adenomatous polyposis coli protein 2

1710

aaaatREASSESDSIlsfvs

5031587

adenomatous polyposis coli protein 2

1979

lvrvaSALSSGSESSdrsgf

306922386

adenomatous polyposis coli protein isoform a

2110

aaclsRQASSDSDSIlslks

306922386

adenomatous polyposis coli protein isoform a

2405

lsrmsSTKSSGSESDrserp

157649073

adenylyl cyclase-associated protein 1

244

pppppVSTSSGSDESasrsa

5453595

adenylyl cyclase-associated protein 1

244

pppppVSTSSGSDESasrsa

6912268

ADP-ribosylation factor-like protein 2-binding protein

13

gesfaLSFSSASDAEfdavv

392306969
166235898
4757720
13375727
203098629
203098629

254
507834119

ADP-ribosylation factor-like protein 6-interacting
protein 4 isoform 1
adrenodoxin-like protein, mitochondrial precursor

39

gpyghEFATSESLGGrvgkt

29

twwnrPGGTSGSGEGvalgt

262359911

AF4/FMR2 family member 1 isoform 1

480

sssaeSESTSDSDSSsdses

87162461

AF4/FMR2 family member 2 isoform 1

486

qasggSGSSSESESSsesds

68348714

AF4/FMR2 family member 3 isoform 1

424

sssgsSSSSSDSESSsgsds

68348714

72534754

AF4/FMR2 family member 3 isoform 1

675

tesssSSSSSDSDLEseqee

7656879

AF4/FMR2 family member 4

649

eiietDTSSSDSDESeslpp

7656879

AF4/FMR2 family member 4

436

sshsgSESSSGSDSEsesss

7656879

AF4/FMR2 family member 4

1073

sgnysSGASSASASGssvti

256017259

aggrecan core protein isoform 1 precursor

1556

psggeGLETSASEVGtdlsg

256017259

aggrecan core protein isoform 1 precursor

1497

lpsgeVVETSASGIEdvsel

256017259

aggrecan core protein isoform 1 precursor

1516

lpsgeGLETSASGVEdlsrl

256017259

aggrecan core protein isoform 1 precursor

1577

psgreGLETSASGAEdlsgl

256017259

aggrecan core protein isoform 1 precursor

964

lpsgeVLETSASGVGdlsgl

256017259

aggrecan core protein isoform 1 precursor

1819

vpdlvSGTTSGSGESsgitf

aldehyde dehydrogenase family 3 member B2

300

vnqmlERTSSGSFGGnegft

115511036

73695879

alpha-protein kinase 3

779

dvasiGVSTSGSQGIiepmd

110349786

Alstrom syndrome protein 1

3856

iqvanHVISSDSISSsassf

300934738

aminopeptidase O isoform 1

562

pskdkTGHTSDSGASvikhg

amphiregulin preproprotein

57

evtsrSEMSSGSEISpvsem

242

mslsmTSITSASEASpehgp

156231049

amyloid beta A4 precursor protein-binding family A
member 2 isoform a
AN1-type zinc finger protein 5

59

tasgsNSPTSDSASVqradt

168823435

androglobin

1488

lrdvaKSTSSESGGVsspgk

522838240

angiomotin-like protein 2 isoform 1

591

rqagaPGGSSGSGGSpelsa

522838240

angiomotin-like protein 2 isoform 1

362

vsaqaSSATSGSAHLaqmea

385862235

anion exchange protein 4 isoform 1

4502199
22035550

37620163
284413734
65786661
110815813
46519147
148664230

77

lewreTGSSSASLLLdmgem

ANKHD1-EIF4EBP3 protein

2336

qhfspHPWTSASNSStsapp

ankyrin and armadillo repeat-containing protein

874

lpyliRFLSSDSDVLkavss

ankyrin repeat and BTB/POZ domain-containing
protein BTBD11 isoform a
ankyrin repeat and FYVE domain-containing protein 1
isoform 1
ankyrin repeat and KH domain-containing protein 1
isoform 1
ankyrin repeat and LEM domain-containing protein 2

304

sggacSAASSASGGSsccap

45

aaqanKESSSESFISrllai

2336

qhfspHPWTSASNSStsapp

628

ascrdKATTSGSNSIsvraf

477

gkrsdKFCSSESESEssesg

56676397

ankyrin repeat domain-containing protein 11

38683807

ankyrin repeat domain-containing protein 17 isoform a

88

rppssSESSSDSDNSggggg

38683807

ankyrin repeat domain-containing protein 17 isoform a

2381

plsllTPCSSASNDSsaqsv

38683807

ankyrin repeat domain-containing protein 17 isoform a

1607

ngeskSSSTSESGDSdnmri

222537750

ankyrin repeat domain-containing protein 30B

872

grkedTKSTSDSEIIsvsdt

188219549

ankyrin repeat domain-containing protein 32

692

vfkklCLQSSGSVSSeplsl

257467559

ankyrin repeat domain-containing protein 34B

369

rnlgaNHYSSDSQLSagltp

ankyrin repeat, SAM and basic leucine zipper domaincontaining protein 1
annexin A4

16

lpvagGGESSESEDDgweig

229

ieqsiKSETSGSFEDallai

103472005

antigen KI-67 isoform 1

800

sgeepLLPTSESFGGnvffs

260436862

AP-1 complex subunit beta-1 isoform a

598

kslppRTASSESAESpetap

18640738
4502105

255
190358499

AP-1 complex-associated regulatory protein isoform a

248

nkktgSNPTSASDDSnglew

32484979

AP-3 complex subunit beta-1 isoform 1

688

eeedsSDSSSDSESEsgses

32484979

AP-3 complex subunit beta-1 isoform 1

778

esssiEDSSSDSESEsepes

511772996

AP-3 complex subunit beta-2 isoform 1

794

sssseSEMTSESEEEqlepa

511772996

AP-3 complex subunit beta-2 isoform 1

724

esesdSKSSSESGSGessse

AP-3 complex subunit sigma-1

78

lyfvfCVDSSESELGildli

4502861
124244056

APC membrane recruitment protein 1

788

nlfssMSCSSDSDSSftqnl

105990532

apolipoprotein B-100 precursor

2500

inwlqEALSSASLAHmkakf

218563749

606

agagpRSLSSDSGLGgssdg

504

gtgapHSASSASLHSerpls

485

pssefLDLSSASEDDfdsed

585866234

arf-GAP with coiled-coil, ANK repeat and PH
domain-containing protein 3
arf-GAP with GTPase, ANK repeat and PH domaincontaining protein 3 isoform a
arginine-glutamic acid dipeptide repeats protein
isoform a
armadillo repeat-containing protein 4 isoform 1

426

ieetvSDSSSESEEDeeppd

609876456

armadillo repeat-containing X-linked protein 4

1072

kpeaeAMPTSESEGGsgtqa

122937478

arrestin domain-containing protein 5

316

kakvpIIITSASVDSaicql

68303555

aryl hydrocarbon receptor nuclear translocator 2

510

sasekKMMSSASAAGtqqiy

14589866

aspartyl/asparaginyl beta-hydroxylase isoform a

14

akssgNSSSSGSGSGstsag

46488915

astrotactin-2 isoform a precursor

348

isfgrAKGTSGSEADdetql

71274144

AT-hook DNA-binding motif-containing protein 1

1250

eashlGFPTSASAAAsgyps

21264565

AT-rich interactive domain-containing protein 1A
isoform a
AT-rich interactive domain-containing protein 2

254

agskpPPSSSASASSssssf

855

iappqYVTTSASNIVsatsv

AT-rich interactive domain-containing protein 4A
isoform I
AT-rich interactive domain-containing protein 4A
isoform I
AT-rich interactive domain-containing protein 4B
isoform 1
AT-rich interactive domain-containing protein 4B
isoform 1
AT-rich interactive domain-containing protein 4B
isoform 1
ataxin-7-like protein 2

981

siedvAVESSESNSLvsipp

1107

nekngTGQSSDSEDLpvldn

1151

kkkgkGTNSSDSEELsages

1012

ndrkaEFPSSGSNSVlntpp

1299

ltlaePSMSSASQNGmsvec

349

calprSRASSESELDdegpc

110227613
112382224

56549668
115334677
115334677
332164768
332164768
332164768
93277115
4502297

ATP synthase subunit delta, mitochondrial precursor

99

gttskYFVSSGSIAVnadss

50345991

ATP synthase subunit delta, mitochondrial precursor

99

gttskYFVSSGSIAVnadss

45446740

136

ealsaGPGTSGSHLDrstvs

1777

vtnhpMNKTSASLSLdyllq

489

kyqglEWKSSASLVLlnqtq

11967971

ATP-binding cassette sub-family A member 2 isoform
a
ATP-binding cassette sub-family A member 2 isoform
a
ATP-binding cassette sub-family B member 6,
mitochondrial
ATP-binding cassette sub-family G member 8

28

sglqdRLFSSESDNSlyfty

45446747

ATP-dependent RNA helicase DDX42

496

trrlvEFTSSGSVLLfvtkk

154759257

ATP-dependent RNA helicase DDX51

136

eeapgERSTSASAEAapdgp

49

vsvlaTASSSASGGSkipnt

31083344

ATP-dependent RNA helicase SUPV3L1,
mitochondrial precursor
atypical chemokine receptor 3

186

dtyylKTVTSASNNEtycrs

17864090

autism susceptibility gene 2 protein isoform 1

472

alpppPPLTSGSLQVaghpa

187829452

autism susceptibility gene 2 protein isoform 2

472

alpppPPLTSGSLQVaghpa

119393878

baculoviral IAP repeat-containing protein 1 isoform 1

370

elcelLETTSESNLEdsiav

153792694

baculoviral IAP repeat-containing protein 6

3724

fllchSGSTSGSHNLgaqqt

45446740
9955963

31543667

256
4503579
87042275

band 4.1-like protein 2 isoform a

744

lssesSSSSSESEEEdvgey

band 4.1-like protein 4A

482

rsrsrCNTSSGSESEnsnre

100816407

Bardet-Biedl syndrome 10 protein

269

etiqpLFSTSGSEFIlnsea

629266065

basement membrane-specific heparan sulfate
proteoglycan core protein isoform a precursor
basic helix-loop-helix domain-containing protein
KIAA2018
basic helix-loop-helix domain-containing protein
KIAA2018
beclin 1-associated autophagy-related key regulator

169

qemllRVISSGSVASyvtsp

2215

splltIANSSASDSSkqssn

251

sesnvLGATSGSLIAvsies

613410205
613410205

221

gvrdpADVSSESDSAmtsst

148762950

50540545

BEN domain-containing protein 4 isoform a

297

lggwtSPATSESHGHpssst

390979647

beta/gamma crystallin domain-containing protein 3

1019

sdsslEKNSSASEDSsflkv

125988395

bifunctional arginine demethylase and lysylhydroxylase JMJD6 isoform 1
bifunctional glutamate/proline--tRNA ligase

353

sssssSSSSSDSDSEcesgs

815

igqniSSNSSASILEsksly

biorientation of chromosomes in cell division protein
1-like 1
BIVM-ERCC5 protein

1770

gdndaPPGTSASQEGdgsvn

1601

nggatTSSSSDSDDDggkek

blood vessel epicardial substance

298

emrnsIASSSDSDDGlhqfl

Bloom syndrome protein isoform 1

211

vktdlPPPSSESEQIdltee

bone morphogenetic protein receptor type-1A
precursor
bone morphogenetic protein receptor type-1B isoform
a precursor
bone morphogenetic protein receptor type-1B isoform
b precursor
BPI fold-containing family A member 2 precursor

214

kdlidQSQSSGSGSGlpllv

214

rdlieQSQSSGSGSGlpllv

184

rdlieQSQSSGSGSGlpllv

16

llcgvLTGTSESLLDnlgnd

261

dtsseGISSSDSDDLeedee

1504

ssgvtSGDSSDSAESserrk

1903

kisrkRVCSSDSDSSlqvvk

296011086

bromodomain adjacent to zinc finger domain protein
2B isoform a
bromodomain and WD repeat-containing protein 1
isoform A
bromodomain and WD repeat-containing protein 1
isoform A
bromodomain and WD repeat-containing protein 3

1602

tkeksHLSTSESGELgssls

338797757

bromodomain testis-specific protein isoform a

665

ssdlsSSDSSDSESEmfpkf

338797757

bromodomain testis-specific protein isoform a

650

essssSSSSSESESSssdls

164419758

bromodomain-containing protein 2 isoform 1

794

sssssSSDTSDSDSG

164419758

bromodomain-containing protein 2 isoform 1

508

deeeeESESSDSEEErahrl

11067749

bromodomain-containing protein 3

706

psrlsSSSSSESGSSsssgs

11067749

bromodomain-containing protein 3

446

ssrssEESSSDSGSSdseee

19718731

bromodomain-containing protein 4 isoform long

492

ssdssSDSSSDSDSStddse

19718731

bromodomain-containing protein 4 isoform long

710

sesssESSSSDSEDSetema

19718731

bromodomain-containing protein 4 isoform long

699

sskmkGFSSSESESSsesss

34452705

bromodomain-containing protein 8 isoform 1

892

latqlIMQTSESGISakslr

221316581

62241042
87299628
324715041
22202606
4557365
41349437
377823725
377823731
45592961
94681063
16445436
16445436

BSD domain-containing protein 1 isoform a

295

paevtPSESSESISLvtqia

58532587

BTB/POZ domain-containing protein 7 isoform 1

253

yydvvLSFSSDSELVeafgg

14249338

BUD13 homolog isoform 1

400

prrrqRTKSSDSDLSpprrs

14249338

BUD13 homolog isoform 1

384

prnrpRHRSSDSDLSpprrr

221307568

C-myc promoter-binding protein isoform 1

1449

dlsriSLESSASLEGslskf

221307568

C-myc promoter-binding protein isoform 1

1574

qtrqsCISTSASGLDtsals

557357745

C-type lectin domain family 4 member K

233

rnshlTSVTSESEQEflykt

312261267

C15orf38-AP3S2 fusion protein

279

lyfvfCVDSSESELGildli

257
7656967

2824

sssyaSSHSSDSEDDgvgae

2910

kagtvDEDSSGSEFLffnfl

16306537

cadherin EGF LAG seven-pass G-type receptor 1
precursor
cadherin EGF LAG seven-pass G-type receptor 2
precursor
cadherin-20 preproprotein

766

slsslQSATSDSEQSfdflt

16753221

cadherin-22 precursor

791

slsslHSGSSGSEQDfayls

13325064

189571674

cadherin-23 isoform 1 precursor

1420

dnsprFDFTSDSAVSipedc

14589891

cadherin-3 preproprotein

796

aaslsSLTSSASDQDqdydy

166362713

cadherin-5 preproprotein

749

slsslGTDSSDSDVDydfln

calcium-binding and coiled-coil domain-containing
protein 1 isoform 1
calcium/calmodulin-dependent 3',5'-cyclic nucleotide
phosphodiesterase 1C isoform 1
calmodulin-regulated spectrin-associated protein 2

593

lsgpaEDSSSDSEAEdeksv

484

dakrsGVKTSGSEGSapinn

393

rysrpQAHSSASGGIrrsss

215490104

calpain-11

278

lmgcsIEVTSDSELEsmtdk

5032105

calpain-15

315

srveaGSSTSGSDIIdlagd

7305199

calsenilin isoform 1

61

stapqGSDSSDSELElstvr

14149742
300796827
44955929

calsenilin isoform 2 precursor

35

lepisMEDSSDSELElstvr

209364544

78190495

calsyntenin-2 precursor

915

eaeeeMSSSSGSDDSeeeee

42475534

calsyntenin-3 precursor

931

ggqqeDEDSSDSEVAdspss

32483386

cAMP-dependent protein kinase inhibitor alpha

28

naihdILVSSASGNSnelal

24307983

62

setegKQHSSDSFDDafkad

42558250

cap-specific mRNA (nucleoside-2'-O-)methyltransferase 1
caprin-1 isoform 1

22

sgpppPSGSSGSEAAagaga

27369497

carbohydrate sulfotransferase 2

458

meqfaLNMTSGSGSSskpfv

62241003

cardiomyopathy-associated protein 5

897

lerytPSSTSASEFSvppya

62241003

cardiomyopathy-associated protein 5

2898

nyaqfISNTSASNADkmvsn

62241003

cardiomyopathy-associated protein 5

170

tnkkgSPLTSASQVLtteke

cathepsin D preproprotein

163

vsvpcQSASSASALGgvkve

CCDC169-SOHLH2 protein

413

deavrVPSSSASENAigdpy

5901910

CD160 antigen precursor

30

sggciNITSSASQEGtrlnl

4505183

CD99 antigen isoform a precursor

85

npnpnHPSSSGSFSDadlad

8923040

CDKN2A-interacting protein

378

lasksSSQTSGSLVSkstsl

4

ysslSENSSDSDSScgwtv

4503143
312032455

75677574
281427267

cell cycle progression protein 1 isoform 1
cell division cycle protein 20 homolog B isoform 1

85

qqsqtRALSSDSFGEeqstt

31542537

cell division cycle-associated 7-like protein isoform 1

195

qviqrEDSTSESEDDsrdes

56118234

centromere protein V

100

pptpaTPTSSASNLDlgeqr

160420295

centrosomal protein KIAA1731

2373

lgeseLFASSGSFSLqssip

118150654

centrosomal protein kizuna isoform 1

295

ttdlkCDSSSGSEGEiltre

109255228

centrosomal protein of 170 kDa isoform alpha

124

iqlqlSQKSSESELSksasa

109255228

centrosomal protein of 170 kDa isoform alpha

462

flqtaLLRSSGSLGHrpsqe

centrosomal protein of 72 kDa

636

ktmalFPHSSASHGGcqac

149274621

centrosomal protein of 78 kDa isoform a

441

seveeVDDSSESVHEvpekt

217035093

cGMP-gated cation channel alpha-1 isoform 1

58

llissDLPTSASQSAgitdm

784

tvindHGSTSDSDSDsgfth

166295200

cGMP-inhibited 3',5'-cyclic phosphodiesterase A
isoform 1
cholesterol 7-alpha-monooxygenase

356

iikesLRLSSASLNIrtake

169636439

cholesteryl ester transfer protein isoform 1 precursor

417

tvsnlTESSSESVQSflqsm

24429592

chondroitin sulfate N-acetylgalactosaminyltransferase

325

vksilESVTSESNFHnytlv

62899065

70608155

258
2
40255020
68299795
118421089
118421089
118421089
282165704
95147342
31563396

chromatin modification-related protein MEAF6
isoform 1
chromodomain-helicase-DNA-binding protein 1

159

pqkaaSSTSSGSHHSshkkr

48

dgsssQSGSSDSDSGsesgs

chromodomain-helicase-DNA-binding protein 2
isoform 1
chromodomain-helicase-DNA-binding protein 2
isoform 1
chromodomain-helicase-DNA-binding protein 2
isoform 1
chromodomain-helicase-DNA-binding protein 8
isoform 1
chromodomain-helicase-DNA-binding protein 9

58

sesnsSSESSESQSEseses

128

rfnikEEASSGSESGspkrr

1097

eskrqAQRSSASESEtedsd

60

ggggdVGNSSASELVpppee

2130

vhkrgSESSSDSDSDserss

28

petaaALASSGSVDLtnsii

61

itficYVASSASAFLtapll

12

aglvrTTCSSGSALGpgaga

338753419

CKLF-like MARVEL transmembrane domaincontaining protein 1 isoform 3
CKLF-like MARVEL transmembrane domaincontaining protein 3
CKLF-like MARVEL transmembrane domaincontaining protein 7 isoform a
clathrin coat assembly protein AP180 isoform a

662

pasqaASSSSASADLlagfg

307078123

clathrin interactor 1 isoform 1

162

nkdkyVGVSSDSVGGfryse

217035102

cleavage and polyadenylation specificity factor
subunit 7 isoform 1
CLIP-associating protein 2 isoform 1

236

pprahSRDSSDSADGratps

543

kslqtYLKSSGSVASlpqsd

87162455

clustered mitochondria protein homolog

668

eagseEEGSSASGLAkvkel

38455398

CMRF35-like molecule 1 isoform 1 precursor

32130526
19923929

333440449

67

rdckiLVKTSGSEQEvkrdr

319655556

coiled-coil domain-containing protein 136 isoform 1

1005

kvtkpCSDTSESDLEtrksl

407892483

coiled-coil domain-containing protein 177

244

srrreGALSSESGASsssys

407892483

coiled-coil domain-containing protein 177

39

qgaqePAASSASASAsaavp

375298727

239

nmivpIKLSSDSEIVqqsmq

87196339

coiled-coil domain-containing protein R3HCC1L
isoform 1
collagen alpha-1(VI) chain precursor

621

idllfVLDSSESIGLqnfei

87196339

collagen alpha-1(VI) chain precursor

43

vdlffVLDTSESVALrlkpy

8

msdnqSWNSSGSEEDpetes

5031717

collagen type IV alpha-3-binding protein isoform 1

169636415

complement component C6 precursor

4502511

366

ddfgtHYFTSGSLGGvydll

complement component C9 precursor

33

sydpeLTESSGSASHidcrm

45356151

condensin-2 complex subunit D3

476

ahcleLTVTSASESIlelli

39652628

constitutive coactivator of PPAR-gamma-like protein
1 isoform a
contactin-1 isoform 1 precursor

509

kaegsSTASSGSQLAegkgs

591

taqtiVDNSSASADLvvrgp

28373117

contactin-associated protein-like 2 precursor

217

dvialNFKTSESEGVilhge

67782356

7662350

corneodesmosin precursor

142

gssssHSGSSGSHSGssssh

67782356

corneodesmosin precursor

117

tgysqVSYSSGSGSSlqgas

CREB-regulated transcription coactivator 1 isoform 1

168

tptqpESFSSGSQDVhqkrv

32171215

CREB-regulated transcription coactivator 2

169

lpsalNRTSSDSALHtsvmn

88900495

CREB/ATF bZIP transcription factor

175

ngiggCSSSSDSGSAekrrr

148596965

260763969

crossover junction endonuclease EME1 isoform 1

83

qtqpvRLLSSESEDEeefip

259013213

CUB and sushi domain-containing protein 1 precursor

3483

ssshyHGTSSGSVAAailvp

428755338

CUE domain-containing protein 1

101

ssggvYEDSSDSEDSippei

428755338

CUE domain-containing protein 1

8

mtslfRRSSSGSGGGgtaga

121114298

cullin-4B isoform 1

4

nyiaMSQSSGSGDGnddea

24307991

cullin-9

1047

clnclSGPSSDSEIVqeltc

259
21361794

cullin-associated NEDD8-dissociated protein 1

120

vigelPPASSGSALAanvck

21361794

cullin-associated NEDD8-dissociated protein 1

917

lhslkEIISSASVVGlkpyv

cyclic AMP-dependent transcription factor ATF-1

43

seseeSQDSSDSIGSsqkah

cyclic AMP-responsive element-binding protein 3-like
protein 2 isoform 1
cyclin-O

99

qspftHITTSDSFNDdeves

64

icdlfESPSSGSDGAespsa

4885073
56550067
153791755
13540602

cysteine/serine-rich nuclear protein 2

30

snsddEISSSDSADScdsln

13540602

cysteine/serine-rich nuclear protein 2

344

kaeedSSGSSASLDSsiesl

288557242

cysteine/serine-rich nuclear protein 3

29

resddEVSSSESADSgdsvn

193083180

cytochrome P450 4F11 precursor

110

hpdiiRPITSASAAVapkdm

cytoplasmic dynein 1 light intermediate chain 2
isoform 1
cytoplasmic polyadenylation element-binding protein
1 isoform 1
cytoskeleton-associated protein 2-like

201

spqrrGPLTSGSDEEnvalp

191

sdsdtSGFSSGSDHLsdlis

609

snrttEGITSDSLVAetsit

5453634
119395725
167466272
19920317

cytoskeleton-associated protein 4

82

gggksSSSSSASAAAaaaaa

31657119

cytosolic carboxypeptidase 2

716

slsdiESSTSGSDSSlsdgl

222352158

cytosolic carboxypeptidase 3

619

esssrGSDSSESIDSltyll

23943920

cytosolic phospholipase A2

433

tkhivSNDSSDSDDEshepk

513788259

cytospin-A isoform 1

367

ddaldAPSSSESEGIpsier

119964728

D-2-hydroxyglutarate dehydrogenase, mitochondrial
isoform 1 precursor
dapper homolog 1 isoform 1

341

spfyvLIETSGSNAGhdaek

772

efvgeSTTTSDSEESggliw

182507165

dapper homolog 3

549

gggygESESSASEGEspafs

182507165

dapper homolog 3

563

espafSSASSDSDGSgglvw

151301098

DBF4-type zinc finger-containing protein 2 isoform 1

1366

snsysPEESSDSNDSfqaaa

151301098

DBF4-type zinc finger-containing protein 2 isoform 1

1704

glkgkSCQSSASAVDfgass

24158478

DCC-interacting protein 13-alpha

426

rpptaRTSSSGSLGSestnl

55741849

6912242

DDB1- and CUL4-associated factor 5 isoform 1

430

vrreiEGWSSDSDSDlsest

18375617

death-inducer obliterator 1 isoform a

150

kggddHDDTSDSDSDgltlk

31377468

dedicator of cytokinesis protein 2

1661

dcstpSKPTSESFDLelasp

238231392

dedicator of cytokinesis protein 8 isoform 1

1241

vadtrRYRTSGSDEEqegag

299473744

dedicator of cytokinesis protein 8 isoform 2

1141

vadtrRYRTSGSDEEqegag

302129691

dedicator of cytokinesis protein 8 isoform 3

1173

vadtrRYRTSGSDEEqegag

148922920

DENN domain-containing protein 4B

1110

rpgstASESSASLGSewdls

122891862

DENN domain-containing protein 5B

1048

riligELMTSASDEDlvkqc

351

anlssQENSSESQEEvvses

335

anlssQENSSESQEEvvses

89001107

dentin matrix acidic phosphoprotein 1 isoform 1
precursor
dentin matrix acidic phosphoprotein 1 isoform 2
precursor
dentin sialophosphoprotein preproprotein

548

dsgkgKSDSSDSDSSdssns

89001107

dentin sialophosphoprotein preproprotein

565

snssdSSDSSDSDSSdsnss

89001107

dentin sialophosphoprotein preproprotein

589

ssdsdSSDSSDSDSSdssns

89001107

dentin sialophosphoprotein preproprotein

706

sessdSSDSSDSDSSdssds

89001107

dentin sialophosphoprotein preproprotein

814

sdssdSSDSSDSDSSnssds

89001107

dentin sialophosphoprotein preproprotein

641

sdsdsKSDSSDSNSSdssdn

89001107

dentin sialophosphoprotein preproprotein

967

sdssnSSDSSDSNSSdssds

89001107

dentin sialophosphoprotein preproprotein

881

snssdSSDSSDSNESsnssd

89001107

dentin sialophosphoprotein preproprotein

1227

sdssdSSDSSDSNESsdssd

4758172
121256621

260
89001107

dentin sialophosphoprotein preproprotein

576

sdssdSNSSSDSDSSdsdss

89001107

dentin sialophosphoprotein preproprotein

722

ssdssNSNSSDSDSSnssds

89001107

dentin sialophosphoprotein preproprotein

899

sdssdSSNSSDSDSSdssns

89001107

dentin sialophosphoprotein preproprotein

781

sdssdSSNSSDSNDSsnssd

89001107

dentin sialophosphoprotein preproprotein

1261

dssdsSDSTSDSNDEsdsqs

189571664

DEP domain-containing mTOR-interacting protein
isoform 1
diacylglycerol kinase alpha

15

gsagsDSSTSGSGGAqqrel

562

klwyfEFATSESIFStckkl

diacylglycerol kinase eta isoform 1

37

asagpGEDSSDSEAEqegpq

diacylglycerol kinase iota

70

kgatgGSSSSGSGAGscclg

diacylglycerol kinase zeta isoform 2

11

rdgspEARSSDSESAsasss

diacylglycerol O-acyltransferase 1

76

hrlqdSLFSSDSGFSnyrgi

digestive organ expansion factor homolog

54

cqlseSSDSSDSESDsesep

diphthine synthase isoform a

275

slfsiPENSSESQSIngl

33350928

disabled homolog 1

494

prqssPSKSSASHASdpttd

45827692

disco-interacting protein 2 homolog A isoform a

136

etytpPDTSSASEDEgslrr

55749758

disco-interacting protein 2 homolog B

144

dactpPDTSSASEDEgslrr

55749758

disco-interacting protein 2 homolog B

199

lshgeVKGTSGSLADvfant

44888818

41872494
325197213
4758156
41872507
145864459
75677335
117190262

disco-interacting protein 2 homolog C

133

daytpPDTSSGSEDEgsvqg

148539628

disks large homolog 1 isoform 1

569

eqmmnSSISSGSGSLrtsqk

218156338

disks large homolog 2 isoform 1

629

119943106

disks large homolog 3 isoform a

489

eqmmnHSMSSGSGSLrtnq
k
eqmmnSSMSSGSGSLrtsek

disks large-associated protein 4 isoform a

607

tsqsgLSNSSDSLDSstrpp

257153463

34335253

disrupted in schizophrenia 1 protein isoform c

316

lagcgGDGSSGSGDAhswdt

257153463

disrupted in schizophrenia 1 protein isoform c

735

lltssDPPSSASQSAgitdm

291621657

dmX-like protein 2 isoform 1

928

lakasEGASSESLLSvpgqk

91992162

DNA mismatch repair protein Mlh3 isoform 1

1293

glefvFPDTSDSLVLvgkvp

91992162

DNA mismatch repair protein Mlh3 isoform 1

1133

rdtvdDTVSSESLQSlfsew

91992162

DNA mismatch repair protein Mlh3 isoform 1

868

rkpldLEKSSESLASklsrl

4504191

DNA mismatch repair protein Msh6 isoform 1

662

lpqvlKGMTSESDSIgltpg

DNA polymerase alpha subunit B

414

rtiieGTRSSGSHLVfvpsl

139394648

20127448

DNA polymerase theta

1820

lqltpASSSSESLSIidvas

139394648

DNA polymerase theta

1400

ktvgtMKQSSDSHGVdiltp

DNA repair protein complementing XP-G cells

1147

nggatTSSSSDSDDDggkek

DNA repair-scaffolding protein isoform 1

102

gltdiTWSSSGSDLSdedkt

555

eaffsVNSSSESLNHllyde

72534740

DNA-dependent protein kinase catalytic subunit
isoform 1
dnaJ homolog subfamily B member 14 isoform 1

81

kpnctKDSTSGSGEGgkgyt

61969662

51988900
145301598
13654237

double homeobox protein A

192

dtqngTNFTSDSHFSgartw

324120908

doublecortin domain-containing protein 5

623

nrlfaKSVTSDSLDGidksl

157779137

dymeclin

140

eekspGNYSSDSEDLleell

dynamin-3 isoform a

817

gplppFPSSSDSFGAppqvp

42544243
224831243

dynamin-like 120 kDa protein, mitochondrial isoform1

507

avvtgKGNSSESIEAireye

75677365

dynein heavy chain 2, axonemal

2869

arveqVPESSDSLFAylier

33359221

dyslexia-associated protein KIAA0319-like protein

216

snelgGLTTSGSAEVhkait

9

hsssySYRSSDSVFSnttst

4502443

dystonin isoform 1e precursor

261
34577049

dystonin isoform 1eA precursor

7706637
150418007
52426745
209180481

9

hsssySYRSSDSVFSnttst

E3 SUMO-protein ligase PIAS1

607

slpttNGSSSGSNSSlvssn

E3 SUMO-protein ligase RanBP2

1831

gsemkLHDSSGSQVGtgfks

E3 ubiquitin-protein ligase CBL

510

lpqrvCVPSSASALGtaska

12

dnelqGTNSSGSLGGldvrr

E3 ubiquitin-protein ligase HUWE1

2420

eehtqEEDSSGSNEDeddsq

380420335

E3 ubiquitin-protein ligase Itchy homolog isoform 1

276

svngsPSATSESDGSstgsl

231573214

E3 ubiquitin-protein ligase listerin

807

nedleSRVSSESHFSerwtl

12383066

E3 ubiquitin-protein ligase MARCH7 isoform a

364

lsslsHNHSSESDSEnfnqe

12383066

E3 ubiquitin-protein ligase MARCH7 isoform a

52

rldseYQSTSASASAspfqs

12383066

61676188

E3 ubiquitin-protein ligase Hakai isoform 1

E3 ubiquitin-protein ligase MARCH7 isoform a

462

ssattGGSTSDSAQGgrntg

114520609

E3 ubiquitin-protein ligase NEDD4 isoform 1

153

lkmtyLPKTSGSEDDnaeqa

217416388

E3 ubiquitin-protein ligase NEURL1B

466

mtfsvNQSSSASESSlvtap

33620769

E3 ubiquitin-protein ligase RBBP6 isoform 1

104

attkaIDDSSASISLaqltk

71143112

E3 ubiquitin-protein ligase RFWD3

212

seelqVSSSSDSDSDssaey

37588869

E3 ubiquitin-protein ligase RNF123

1234

veqmlAHLTSASAQAaaasl

338827720

E3 ubiquitin-protein ligase RNF146 isoform a

291

ieeteSDASSDSEDVsavva

56711322

E3 ubiquitin-protein ligase RNF43 precursor

442

lrrarPPDSSGSGESycter

51988887

E3 ubiquitin-protein ligase SH3RF1

669

apltsPSITSASLEAepsgr

40805104

E3 ubiquitin-protein ligase Topors isoform 1

497

rtpelVELSSDSEDLgsyek

74027249

E3 ubiquitin-protein ligase TRIM33 isoform alpha

70

ddggvAAASSGSAQAasspa

15147333

E3 ubiquitin-protein ligase TRIM37

900

saapeEGMSSDSDIEcdten

28372497

E3 ubiquitin-protein ligase UBR1

998

kscliVATTSGSESIkndei

82659109

E3 ubiquitin-protein ligase UBR4

3382

kekekDGETSGSQEDqlcta

82659109

E3 ubiquitin-protein ligase UBR4

1981

dchvlTFSSSGSVSDhlvlh

15147337

E3 ubiquitin-protein ligase UBR5 isoform 1

1670

eddsqSNDSSDSDSSssqsd

332801080

E3 ubiquitin-protein ligase ZNRF3 isoform 1
precursor
early growth response protein 3 isoform 1

563

ssgqcHCSSSDSVVDctevs

38

salnlFSGSSDSVVHynqma

ectoderm-neural cortex protein 1 isoform 1

13

henrkSRASSGSINIylfhk

16604260

egl nine homolog 2

154

eggmsCSCSSGSGEAsaglm

38569495

ELL-associated factor 1

194

mssssGSSSSDSESSsgsdd

21361796

ELL-associated factor 2

193

sssssEDSSSDSEDEdckss

24497531

ellis-van Creveld syndrome protein

959

edlasGDQTSGSLSSkrlsq

45827771

enhancer of mRNA-decapping protein 4

668

ldgslTMSSSGSLQAsprgl

10864017

enolase-phosphatase E1

152

agmkvYIYSSGSVEAqkllf

enteropeptidase precursor

233

dgrflLTGSSGSFQAthypk

32967311

ephrin type-A receptor 2 precursor

897

rvsirLPSTSGSEGVpfrtv

56682953

epidermal growth factor receptor kinase substrate 8

660

nitrqNSSSSDSGGSivrds

385428859

370

ergtpGPDSSGSLGSgeftg

13449287

epidermal growth factor receptor substrate 15-like 1
isoform 1
epidermal growth factor-like protein 8 precursor

191

megspEPPTSASILSvavre

56790297

epithelial splicing regulatory protein 1 isoform 1

75

tkidvESLSSASQLDqalrq

166362730

ETS domain-containing protein Elk-1 isoform a

398

aklsfQFPSSGSAQVhipsi

166851840

ETS-related transcription factor Elf-3

208

tgasrSSHSSDSGGSdvdld

187608767

ETS-related transcription factor Elf-4

617

tpvaeLELSSGSGSLlmaep

eukaryotic translation initiation factor 2 subunit 2

245

afllaELGTSGSIDGnnqlv

31317228
375268724

223942069

29826335

262
134304838

732

giscdQTSSSESQFSplefs

236

edwdtGSTSSDSDSEeeegk

229577000

eukaryotic translation initiation factor 2-alpha kinase 3
precursor
eukaryotic translation initiation factor 3 subunit C
isoform a
EVI5-like protein isoform 1

786

rpakdSEGSSDSDADelaap

229577000

EVI5-like protein isoform 1

23

lsaptCSPTSDSENLspdel

66773030

excitatory amino acid transporter 3

401

iitisITATSASIGAagvpq

26667227

eyes absent homolog 2 isoform a

214

ashnvPNQSSESLAGeynth
vrakrMASSSDSEDDsfmav

312433975

62955044

F-box only protein 42

3

117606351

F-box only protein 43

191

inlekNIPSSASGFSrannf

157168349

F-box/LRR-repeat protein 19 isoform 1

326

rvpdtSSSSSDSDSDsdssg

164607124

Fanconi anemia group I protein isoform 1

799

aktkmANKTSDSLLSmkfvs

17402900

far upstream element-binding protein 1

10

dystvPPPSSGSAGGggggg

14550416

Fc receptor-like protein 4 precursor

100

snpvrLLFSSDSLILqapys

157694526

Fc receptor-like protein 5 isoform 1 precursor

100

sspvhLDFSSASLILqapls

239049440

FCH domain only protein 1 isoform a

343

taepsRFSSSDSDFDdeepr

226371723

FCH domain only protein 2 isoform a

341

tkenhFYSSSDSDSEdeepk

226371723

FCH domain only protein 2 isoform a

513

aesssSISSSASLSAantpt

281604114

FERM and PDZ domain-containing protein 2 isoform3

279

dqqagRRLSSGSVHSaadss

211971072

FERM and PDZ domain-containing protein 4

903

lraysPESSSDSGNEtnsse

116063562

FERM domain-containing protein 4A

364

skgkiISGSSGSLLSsgsqe

150010540

FERM domain-containing protein 4B

409

masngSLISSGSQDSevsee

34916000

FERM domain-containing protein 7

649

aeryvASESSDSESEilkpd

34916000

FERM domain-containing protein 7

679

spmarIRLSSGSLQLdeede

528524524

FH1/FH2 domain-containing protein 3 isoform 3

549

aesqkENSSSDSFSLstysa

528524524

FH1/FH2 domain-containing protein 3 isoform 3

723

aplshSPSSSDSQEAltvsa

fibroblast growth factor receptor 4 isoform 1 precursor

776

gdassTCSSSDSVFShdplp

fibrocystin-L precursor

1838

ppvasLSPTSGSIGGgttlv

fibronectin isoform 1 preproprotein

1131

ggeapREVTSDSGSIvvsgl

fibronectin type III domain-containing protein 7
precursor
fibrous sheath-interacting protein 2

124

pilevSSPSSDSILVqweav

4642

svfanVVQTSGSQESavqni

60097902

filaggrin

1065

vrdsgHWGSSGSQASdsegh

60097902

filaggrin

3334

vrdsrHWGSSGSQASdsegh

60097902

filaggrin

416

vsdrgHRGSSGSQASdsegh

60097902

filaggrin

1713

vgdsgNRGSSGSQASdsegh

60097902

filaggrin

2362

vrdsgHRGSSGSQASdsegh

60097902

filaggrin

3658

vrdsgHRGSSGSQASdsegh

62122917

filaggrin-2

1426

rrgsgHSESSDSEVHsggsh

62122917

filaggrin-2

1503

rrgsgHSESSDSEVHsggsh

62122917

filaggrin-2

1655

rqrssHSESSDSEVHsgvsh

62122917

filaggrin-2

1882

rrrsgHSESSDSEVHsggsh

62122917

filaggrin-2

2107

rrgsgHSESSDSEVHsgvsh

62122917

filaggrin-2

2182

rqrssHSESSDSEVHseasp

62122917

filaggrin-2

2257

rrgsgHSESSDSEVHswgsh

614458185

focadhesin

978

vsrheASLSSDSDGLlevqp

folate transporter 1 isoform 1

221

rddrgRCETSASELErmnpg

47524173
126116589
47132557
222144290
297206791

34808710

263
120953291

folliculin-interacting protein 1 isoform 1

937

ewdipRNESSDSALGdsese

154689769

folliculin-interacting protein 2

891

egdipRNESSDSALGdsdde

146232000

forkhead box protein N3 isoform 1

350

snarsTSPTSDSISSssssa

forkhead box protein O3

474

nqtlqDLLTSDSLSHsdvmm

formin-1 isoform b

144

vrgtlVHTTSDSDSDdggqe

fos-related antigen 2

313

rssssGDQSSDSLNSptlla

fragile X mental retardation syndrome-related protein
1 isoform a
FRAS1-related extracellular matrix protein 1 isoform
1 precursor
G patch domain-containing protein 1

583

sekaiNGPTSASGDDisklq

1885

ppgssSSTTSGSFHLerrpl

901

sssseSSDSSDSQSDeetad

G-protein coupled receptor 124 precursor

1215

aagalELLSSESGSLhnspt

640

nifsnILSSSDSDLLessse

113722120

G-protein coupled receptor 126 isoform alpha 1
precursor
G-protein coupled receptor 98 precursor

1954

fsvsvLSVSSGSLGAhinat

103472136

G-protein coupled receptor-associated sorting protein1

249

nqelyIASSSGSEDEsvktp

103472136

G-protein coupled receptor-associated sorting protein1

295

kkevyVESSSGSEHEdhles

103472136

G-protein coupled receptor-associated sorting protein1

483

smktgAEATSESILAaddeq

galactokinase

140

vplggGLSSSASLEVatytf

gamma-aminobutyric acid receptor subunit beta-1
precursor
gamma-aminobutyric acid receptor subunit theta
precursor
gamma-glutamyltransferase 6 isoform a

377

stleiRNETSGSEVLtsvsd

574

ahgqeKDSSSESEDScppsp

357

ssalaAVDSSGSVLLltssl

5453660

gamma-tubulin complex component 3 isoform 1

152

drsaqSAQSSGSVGSsgiss

156616297

gamma-tubulin complex component 5 isoform a

533

kmsdnASASSGSDQGpssrq

222831645

GATS-like protein 2

256

rfpsnLLFTSASGELwkmvr

44890065

GC-rich sequence DNA-binding factor 2 isoform 1

15

tfrqrAADSSDSDGAeespa

11968150

4503739
157168329
4885245
61835148
122056683
21361684
300934750
74048357

4503895
194097327
527122097
171543825

GDNF-inducible zinc finger protein 1

151

sesqeVEVSSGSQVSaapap

144922725

general transcription factor IIE subunit 1

357

ngsdsESETSESDDDspprp

282721063

glutamate-rich protein 3

590

tssrsHPYSSDSEDEsavgd

119964690

glycogenin-2 isoform b

23

llrssNSPTSASQSAgmtvt

glypican-6 precursor

491

nfqdtSDESSGSGSGsgcmd

Golgi pH regulator A isoform 1

235

wgmikSVTTSASGSEnltli

5031719
148228819

Golgi pH regulator B

235

wgmikSVTTSASGSEnltli

58219040

7706704

Golgin subfamily A member 7B

150

sgsssSGSSSGSGSSsgggg

68509940

Golli-MBP isoform 1

126

tiqedSAATSESLDVmasqk

GON-4-like protein isoform a

1476

tqdeeDEMSSASEESvlsvp

GPALPP motifs-containing protein 1

45

nykssSSDSSDSDEDsssly

GPI mannosyltransferase 3

428

vcynnPNKSSASIFImmpch

15088795

GPI transamidase component PIG-S

119

ldheeEALSSGSVQEaeaml

92110010

GRAM domain-containing protein 1A isoform 1

582

pcaraGIHTSGSLSSrfsep

187936935

544583541
33354279
110224465

GRAM domain-containing protein 1C isoform 1

310

ylsldKSSTSDSVDEenvpe

46370071

GRB2-associated-binding protein 1 isoform a

608

dsvhsTTSSSDSHDSeenyv

46370071

GRB2-associated-binding protein 1 isoform a

674

stpprKQKSSGSGSSvader

83716021

GRB2-associated-binding protein 4

165

stgflGNISSASHGLcsspa

growth arrest-specific protein 1 precursor

253

aelgnGPGSSGSDGGlddyy

growth hormone-releasing hormone receptor precursor

85

cpdffSHFSSESGAVkrdct

167466169
58530851

264
20070266

GTP-binding protein REM 1

69

apddwSSESSDSEGSwealy

124248562

GTP-binding protein REM 2

96

ppqasSSGSSDSLGSgeaap

374093198

guanylate cyclase soluble subunit alpha-2 isoform 1

6

slRKISSESFSSlgsdy

116812606

gypsy retrotransposon integrase-like protein 1

297

srnpyMPETSDSLHEvdgdn

193083157

H/ACA ribonucleoprotein complex non-core subunit
NAF1 isoform a
H/ACA ribonucleoprotein complex non-core subunit
NAF1 isoform a
H2.0-like homeobox protein

112

arapdSLETSDSDSDsdset

358

vhqnwNAHSSASEHAkgyr
n
segeaESESSDSESLdmaps

193083157
11386181
105990528

377
9

krahpEYSSSDSELDetiev

333805659

hairy/enhancer-of-split related with YRPW motif
protein 1 isoform a
HEAT repeat-containing protein 4

250

wshirDELTSASDLEllkql

109715835

HEAT repeat-containing protein 6

1167

eilavCFDSSGSQGAlpglt

109715835

HEAT repeat-containing protein 6

395

ssswkRVSSSESDFSdaegg

heat shock 70 kDa protein 4

492

nvhgiFSVSSASLVEvhkse

38327039

heat shock factor protein 2 isoform a

312

neparESLSSGSDGSsplms

153792590

4758568

heat shock protein HSP 90-alpha isoform 1

588

lsellRYYTSASGDEmvslk

168823443

helicase ARIP4

216

edtlhIVDSSESVSEddeee

168823443

helicase ARIP4

187

qevicLDSSSGSEDEkssrd

146219843

helicase SRCAP

519

seeeeTSGSSASEESesees

146219843

helicase SRCAP

1774

tltlaPASSSASLLApasvq

146219843

helicase SRCAP

1576

qasllAPASSASQALatpla

21071054

helicase-like transcription factor

396

ktavqYIESSDSEEIetsel

21071054

helicase-like transcription factor

752

irkmkLILSSGSDEEcaicl

118572606

hemicentin-1 precursor

3856

nqnsyRLLSSGSLVIispsv

118572606

hemicentin-1 precursor

4128

esirqRVLSSGSLQIafvqp

hepatocyte growth factor activator preproprotein

299

tgyrgVASTSASGLSclawn

hepatocyte nuclear factor 1-alpha

549

vftsdTEASSESGLHtpasq

hepatoma-derived growth factor-related protein 2
isoform 1
hepatoma-derived growth factor-related protein 2
isoform 1
Hermansky-Pudlak syndrome 3 protein

301

perppSSSSSDSDSDevdri

262

sssssSSSSSDSDVSvkkpp

845

ypwvhVVISSDSLADknyte

high affinity copper uptake protein 1

26

qpshhHPTTSASHSHgggds

high affinity immunoglobulin gamma Fc receptor I
precursor
histone acetyltransferase KAT7 isoform 1

72

tstpsYRITSASVNDsgeyr

134

rtptgNAPSSESDIDisspn

153085395

histone deacetylase 4

305

sgpssPNNSSGSVSAengia

13128864

4504383
256542297
48255931
48255931
19923642
4507015
10835133
5901962

histone deacetylase 6

882

leagmGKVTSASFGEestpg

148227842

histone H2A deubiquitinase MYSM1

263

etnqgEFITSDSQEAlfsks

308199413

2293

sssseMKQSSASDLVsksss

3329

isqdtSHLTSGSVSGlasss

91718902

histone-lysine N-methyltransferase 2A isoform 1
precursor
histone-lysine N-methyltransferase 2A isoform 1
precursor
histone-lysine N-methyltransferase 2C

1306

krsviRKDSSGSISEqlpcr

55741677

308199413

histone-lysine N-methyltransferase SETD1A

1029

dsdgeNDSTSDSESSsssss

197313748

histone-lysine N-methyltransferase SETD2

457

ytdnrARESSDSEEEykkty

197313748

histone-lysine N-methyltransferase SETD2

859

ykqsiGSTSSASVNHfddly

224177467

histone-lysine N-methyltransferase SETDB1 isoform1

1136

dsddiQTISSGSEGDdfedk

224177467

histone-lysine N-methyltransferase SETDB1 isoform1

403

epmfsMKTSSASALEkkqg

265
301171588

380

qmkgsGDISSDSIDHspakk

385

sdldpIEHSSESDNSvleip

970

prlnvCDKSSASIGDmekep

969

patldESSSSGSLFAtvgsr

348

ggsytQAASSDSAQGsdvsl

217035121

histone-lysine N-methyltransferase SUV39H2
isoform1
histone-lysine N-methyltransferase, H3 lysine-36 and
H4 lysine-20 specific isoform a
histone-lysine N-methyltransferase, H3 lysine-36 and
H4 lysine-20 specific isoform a
histone-lysine N-methyltransferase, H3 lysine-79
specific
HLA class I histocompatibility antigen, A-1 alpha
chain precursor
HMG box transcription factor BBX isoform 1

477

kktckKRQSSESDIEsviyt

122937319

homeobox even-skipped homolog protein 2

154

sgsaaGTTTSASGSGlgslh

homeobox protein DLX-2

285

gnypwYHQTSGSASHlqata

27477095
27477095
22094135
337752170

4758168
126090909

homeobox protein engrailed-1

37

slspgASGSSGSGSDgdsvp

7710121

homeobox protein engrailed-2

193

lgggdLSVSSDSDSSqagan

5031759

homeobox protein Hox-A11

190

atgapATSSSDSGGGggcre

7657166

homeobox protein Hox-C11

209

eeentNPSSSGSAHSvakep

4505151

homeobox protein Meis1

112

gvaggDVCSSESFNEdiavf

57863281

homeobox protein Meis3 isoform 1

100

tppggDVCSSDSFNEdiaaf

84105335

homeobox protein MOX-2

170

sggkrKSDSSDSQEGnykse

111120318

homeobox protein Nkx-6.1

128

sgsssSSSSSASASSasaaa

20070107

homeobox protein OTX1

117

kksspVRESSGSESSgqftp

28866955

homeobox protein PKNOX1 isoform 1

84

stqgsEGTTSASFDVdienf

116812644

homeobox protein PKNOX2

100

atqgsECITSASFDVdienf

122937321

homeobox protein unc-4 homolog

231

glslhSAPSSDSDSGgggls

114796624

homeodomain-interacting protein kinase 3 isoform 1

700

lapatTTLTSESVAGshrlg

hornerin

416

hssgrGQHSSGSGQSpghgq

120431738

huntingtin-associated protein 1 isoform 2

54

gqrvgSRATSGSQFLseart

257196151

immunoglobulin-like and fibronectin type III domaincontaining protein 1
importin subunit alpha-7

527

erphlQGESSESGLGlpekq

262

pvlsrLLFSSDSDLLadacw

inhibitor of Bruton tyrosine kinase

1026

veslpELLTSDSEGSyagvg

89

kvlvmEYCSSGSLLSvlesp

57864582

6912478
57863304
7661946
269954690

inhibitor of nuclear factor kappa-B kinase subunit
epsilon isoform 1
inositol 1,4,5-trisphosphate receptor type 1 isoform 1

2644

rmramSLVSSDSEGEqnelr

inositol hexakisphosphate and diphosphoinositolpentakisphosphate kinase 1 isoform 2
inositol-trisphosphate 3-kinase B

835

hvrtrLYFTSESHVHsllsv

84

sgrrrLNSSSGSGSGssgss

5031805

insulin receptor substrate 1

411

sdclfPRRSSASVSGspsdg

195947361
194272161
5031805

insulin receptor substrate 1

811

addssSSTSSDSLGGgycga

38683860

insulin receptor substrate 2

590

rqrpvPQPSSASLDEytlmr

38683860

insulin receptor substrate 2

481

hhgpgQRPSSGSASAsgsps

21361851

integrator complex subunit 12

277

stvisGNSSSASVSSsvtsg

39995084

integrator complex subunit 3

1013

naeeeSGSSSASEEEdtkpk

224831239

integrin alpha-M isoform 1 precursor

558

gavylFHGTSGSGISpshsq

4504763

integrin alpha-V isoform 1 precursor

951

qnhsySLKSSASFNViefpy

interactor protein for cytohesin exchange factors 1
isoform 1
interferon alpha-inducible protein 6 isoform a
precursor
interferon alpha/beta receptor 2 isoform a

264

kalenSFVTSESGFLnslss

30

agkkkCSESSDSGSGfwkal

500

dapsdQSDTSESDVDlgdgy

194733747
13259552
574584807

266
33457336

interferon regulatory factor 2-binding protein-like

431

ptgsgNVYSSASGVAkqmy

interferon-related developmental regulator 2

333

lprlpQLLSSESVNLriaag

interleukin-18 receptor 1 isoform 1 precursor

58

tttksWYKSSGSQEHvelnp

173

rfddiSRLSSGSQSShilvr

57242793

interleukin-3 receptor subunit alpha isoform 1
precursor
interphotoreceptor matrix proteoglycan 2 precursor

1183

pypqhPFYSSASGDViggls

57242793

197333755
4504655
13324710

interphotoreceptor matrix proteoglycan 2 precursor

505

lpvasEERTSGSHLVedgla

139394646

iroquois-class homeodomain protein IRX-5 isoform 1

39

rtdelGRSSSGSAFSpyags

401709930

IST1 homolog isoform a

343

ptasaGASTSASEDIdfddl

jouberin isoform a

272

kessvRSVSSDSHQDdeiss

junctional protein associated with coronary artery
disease
KATNB1-like protein 1

309
124

qqsrgGADSSDSQDSqqmd
a
dsrtyLVNSSDSGSSqtesp

kelch-like protein 13 isoform b

33

fkdifKKSTSGSLVEeedqh

31542701
148806881
13376013
269973863

kelch-like protein 17

242

lkqvlELVSSDSLNVpseee

195972866

38194229

keratin, type I cytoskeletal 10

569

ssgghKSSSSGSVGEssskg

15431310

keratin, type I cytoskeletal 14

431

ahlssSQFSSGSQSSrdvts

24430190

keratin, type I cytoskeletal 15

52

sassaRFVSSGSGGGygggm

119395750

keratin, type II cytoskeletal 1

17

gyrsgGGFSSGSAGIinyqr

keratin, type II cytoskeletal 2 epidermal

22

ggggfRGFSSGSAVVsggsr

109148552

keratin, type II cytoskeletal 3

530

isvvsSSTTSASAGGygggy

32567786

keratin, type II cytoskeletal 79

40

fssvtVSRSSGSGGGahcgp

47132620

118498356

kinectin isoform a

1108

kakecMAGTSGSEEVkvleh

118498356

kinectin isoform a

922

aqhnlKEASSASQFEeleiv

118498356

kinectin isoform a

595

fhsqiAAQTSASVLAeelhk

157738621

kinesin-like protein KIF13A isoform a

846

veddsSENSSESGSLevvds

157502184

kinesin-like protein KIF6 isoform 1

711

dhtkpFLQTSDSQHEwsqll

379056376

1017

dsssdESSSSESDDEcdvie

502

ggaepPGSSSGSGDDsgggs

90

arspgAWTSSESLASddgga

527122127

KN motif and ankyrin repeat domain-containing
protein 1 isoform a
KN motif and ankyrin repeat domain-containing
protein 3
KN motif and ankyrin repeat domain-containing
protein 3
Krueppel-like factor 14

305

ppltsEVESSASGSGpgpap

194248077

Krueppel-like factor 4

125

esvaaTVSSSASASSsssps

557878723

kynurenine/alpha-aminoadipate aminotransferase,
mitochondrial isoform a
L-fucose kinase

117
330

qgqmdLCVTSGSQQGlckv
f
sgsysYMTSSASEFLlsltl

157504499
157504499

63175654
388240801

lamin-B2

420

tvsraTSSSSGSLSAtgrlg

38788416

laminin subunit alpha-1 precursor

2015

gaktkELATSASQSAvstlr

38045910

laminin subunit alpha-3 isoform 1 precursor

977

fvvdvNVKSSGSVLAgqvni

167614504

laminin subunit beta-1 precursor

688

rlelpQYTSSDSDVEspytl

149158692

large proline-rich protein BAG6 isoform a

721

gslgaRAGSSESIAAfiqrl

261337171

480

evapeASTSSASQVIaptqv

289547652

latent-transforming growth factor beta-binding protein
1 isoform 3 precursor
lateral signaling target protein 2 homolog isoform 1

567

tsdkcLPHTSGSQVDtasgl

117938328

lethal(3)malignant brain tumor-like protein 1 isoform I

138

ivensSGSTSASELLkpmkk

leucine-rich repeat and calponin homology domaincontaining protein 4 isoform 1
leucine-rich repeat flightless-interacting protein 1
isoform 1

459

amhngSPKSSASQAGaaag
q
ysrrsRRNTSASDEDermsv

30181233
212276078

96

267
153792305

leucine-rich repeat-containing protein 58

339

specsSPCSSASHSStsqse

209862903

leucine-rich repeats and immunoglobulin-like domains
protein 3 isoform 1 precursor
leucine-zipper-like transcriptional regulator 1

812

adrqdGYVSSESGSHhqfvt

326

qtwevVQPSSDSEVGgaevp

ligand-dependent nuclear receptor-interacting factor 1
isoform 1
LIM domain and actin-binding protein 1 isoform 1

88

qtqisSSSTSASVQLpifqp

540

wppptELGSSGSALEegikm

14249622

LIM domain-containing protein ajuba isoform 1

126

sprssFASSSASDASkpssp

28893581

LIM homeobox transcription factor 1-alpha

16

enfqsAIDTSASFSSllgra

29171755

liprin-alpha-2 isoform a

21

pmsqrGSQSSGSDSDshfeq

29725633

lithostathine-1-alpha precursor

113

kknrrWHWSSGSLVSyksw

377

pweqpCGSSSDSDGGslgdq

1852

tdtvsIQASSGSLDDteteq

145

fpdvtKVFSSESNFIleicd

13236583

low-density lipoprotein receptor-related protein 3
precursor
low-density lipoprotein receptor-related protein 4
precursor
lutropin-choriogonadotropic hormone receptor
precursor
lys-63-specific deubiquitinase BRCC36 isoform 1

180

fqsiqAQKSSESLHGprdfw

51873064

lysosomal alpha-mannosidase isoform 1 precursor

553

psdvvIFPSSDSQAHppell

54292123

lysosomal-trafficking regulator

679

yrfqgILPSSGSEDLlwkwd

12408658

M-phase inducer phosphatase 3 isoform b

71

sgspgFFRTSGSAFSwddng

M-phase phosphoprotein 9

130

knlvkLQTSSASLAScegns

m7GpppN-mRNA hydrolase isoform 1

245

wlsrrFGDSSDSDNGfsstg

563

llsmeVSDTSDSEQGteqdw

223278413

major facilitator superfamily domain-containing
protein 6-like
MAM domain-containing protein 2 precursor

89

rlvyqITTSSESLSDpsqln

209862971

MAP kinase-activating death domain protein isoform a

134

aseegGTESSESGSSlqpls

21361101

MAP kinase-interacting serine/threonine-protein
kinase 1 isoform 1
MAP/microtubule affinity-regulating kinase 3 isoforma

195

slgssDPPTSASQVAgttgi

454

edgisSRKSSGSAVGgkgia

matrix extracellular phosphoglycoprotein isoform a
precursor
mdm2-binding protein

512

rrrddSSESSDSGSSsesdg

754

rkrlvKSESSESLLSqttgn

47717139
55743124
165905589

167555125
157384998
106067657

508083049
31542498
269846998

193083125
9910430
21630257
255683379

MDS1 and EVI1 complex locus protein EVI1 isoforma

472

psgsdLETTSGSDLEsdies

28559039

mediator of RNA polymerase II transcription subunit 1

1084

psshsQYTSSGSVSSsgsks

28559039

mediator of RNA polymerase II transcription subunit 1

1225

sskakSPISSGSGGShmsgt

102468717

mediator of RNA polymerase II transcription subunit
13
mediator of RNA polymerase II transcription subunit
13-like
meiosis arrest female protein 1 isoform 1

1964

cthilVFPTSASVQVasaty

1576

sstnpAASSSASGSSvppvs

1705

vppcpSSETSESLLSkdpve

44771211
85797660
153791873

melanoma-associated antigen B16

79

siavtTTSSSESDEAssnqe

41350320

melanoma-associated antigen D2

3

gfsykMSDTSESGAGltrfq

109826351

melanophilin isoform 2

335

hskrrGRASSESQGLgagvr

153070262

meprin A subunit alpha precursor

319

gyfmqFSTSSGSAEEaalle

13446229

mesoderm development candidate 1

222

klgvkCMSTSASALLacvre

44

spalhSWKSSDSVGVvgspe

545479030

mesoderm-specific transcript homolog protein isoform
c
metastasis suppressor protein 1 isoform 1

359

ngfshYSLSSESHVGptgag

545479030

metastasis suppressor protein 1 isoform 1

290

svnssDSRSSGSHSHspssh

methionine--tRNA ligase, mitochondrial precursor

29

edfgpRYYSSGSLSAgddac

methionine-R-sulfoxide reductase B1

109

kfvpkGKETSASQGH

359806886

24308436
7706511

268
117606353

118

psfseAHGTSGSDEShtgil

46852161

methionine-R-sulfoxide reductase B2, mitochondrial
precursor
methyl-CpG-binding domain protein 6

464

iqpslPGTTSGSLSSvpgap

87240000

methylenetetrahydrofolate reductase

19

npcleGSASSGSESSkdssr

methylmalonic aciduria and homocystinuria type D
protein, mitochondrial
methylsterol monooxygenase 1 isoform 1

35

pkafsTAGSSGSDEShvaaa

10

tnesvSIFSSASLAVeyvds

methyltransferase-like protein 12, mitochondrial
precursor
MICAL-like protein 1

152

aqnlgAVASSGSFQLlldkg

146

dvaqgEELSSGSLSEqgtgq

367

vdavtSAQTSDSLEAildfl

95147555

microsomal triglyceride transfer protein large subunit
precursor
microtubule-associated protein 1A

2500

pvtdeTPPTSASDSGssqsd

95147555

microtubule-associated protein 1A

2104

grshwDDSTSDSELEkgare

87578396

microtubule-associated protein 2 isoform 1

1798

prrlsNVSSSGSINLlespq

45120119

1168

sstpnSPASSASHHIrpstl

110

avppaPRGSSASQEEqdeel

801

riliaSQRSSASAIHppgpi

24415404

microtubule-associated serine/threonine-protein kinase
1
microtubule-associated serine/threonine-protein kinase
4 isoform b
microtubule-associated tumor suppressor candidate 2
isoform a
midasin

855

clsglLEGSSGSLVLldrgd

24415404

midasin

4485

ttwktHLLTSDSQGGnqmld

70778869

migration and invasion-inhibitory protein

227

pqlpgLRESSGSGVEedhec

21362030

mitochondrial import receptor subunit TOM40B
isoform 1
mitochondrial import receptor subunit TOM70

102

ptvvgDMDSSGSLNAqvlll

17

avvaaAVPSSGSGVGgggta

mitogen-activated protein kinase kinase kinase 4
isoform a
mitotic checkpoint serine/threonine-protein kinase
BUB1 beta
mitotic interactor and substrate of PLK1

783

efwtsADDSSASDEIrrsvi

687

thssgFSGSSASVAStssik

393

qpglrRALSSDSILSpapda

187960079

mitotic spindle assembly checkpoint protein MAD2B

110

tqpplLSISSDSLLShveql

187960073

mitotic spindle assembly checkpoint protein MAD2B

110

tqpplLSISSDSLLShveql

109689718

monoacylglycerol lipase ABHD12 isoform a

21

rcaaaGSSSSGSAAAaldad

221625538

MORC family CW-type zinc finger protein 1

721

kvlteDENTSDSDIIlvsdk

msx2-interacting protein

279

sgsrsRSSSSDSISSsssts

324120958

mucin-1 isoform 10 precursor

187

tappvHNVTSASGSAsgsas

324120956

mucin-1 isoform 9 precursor

178

tappvHNVTSASGSAsgsas

83367077

mucin-16

2030

gsstsSPYSSASLESldsti

83367077

mucin-16

9141

shpsvEEASSASFSLsspvm

83367077

mucin-16

285

istsaPLSSSASVLDnkise

83367077

mucin-16

727

istsiPLLSSASVLEdkvsa

83367077

7661548
5803157
112734863
31324577
153285408

38488767
140161498

54607135
55956904
59814247
27735067

14790190

mucin-16

2186

ltrtiSLPTSESLVSfrmnk

533112494

mucin-19 precursor

6846

pgtsvTPDSSASESEtvttk

533112494

mucin-19 precursor

431

sdsggNTWSSDSGSGgggvt

557129045

mucin-2 precursor

1314

dwineDHPSSGSDDGdretf

257471027

mucin-4 isoform a precursor

2998

tllpvTDTSSASIGHatslp

151301154

mucin-6 precursor

2175

apvhsTTLSSGSHSSlsthp

151301154

mucin-6 precursor

1640

tpthaQMATSASIHSmptgt

151301154

mucin-6 precursor

1864

ipthtQMATSASIHSmptgt

269
151301154

mucin-6 precursor

2033

itthtQMATSASIHStptgt

151301154

mucin-6 precursor

1471

tpthaQMATSASNHSaptgt

134142337

multidrug resistance-associated protein 1

210

hdpnpCPESSASFLSritfw

190343023

multidrug resistance-associated protein 6 isoform 1

618

dpgvvDSSSSGSAAGkdcit

148746189

multiple PDZ domain protein isoform 1

1810

tfplsGSSTSESLESsskkn

muscle, skeletal receptor tyrosine-protein kinase
isoform 1
myb-binding protein 1A isoform 1

252

wiengNAVSSGSIQEsvkdr

730

seegeDNRSSESEEEsegee

71774083

myc proto-oncogene protein

263

heetpPTTSSDSEEEqedee

71774083

myc proto-oncogene protein

233

qdssaFSPSSDSLLSstess

41349499

5031927
157694494

myelin proteolipid protein isoform 1

192

qsiafPSKTSASIGSlcada

525313643

myomegalin isoform 1

1660

vlsskPSSTSASQGAkaesn

372220097

myopalladin isoform a

362

eiyieGVSSSDSEGDpnkee

224994251

myotubularin-related protein 11 isoform a

597

rwlprPAISSESLADqewgl

myotubularin-related protein 13

972

nmqegLQITSASFQLikvaf

156616294

29788755

N-acetylmuramoyl-L-alanine amidase precursor

326

rrqngAALTSASILAqqvwg

270483764

Na(+)/H(+) exchange regulatory cofactor NHE-RF4
isoform 1
NAC-alpha domain-containing protein 1

374

apaspRGSSSASLVEtedps

387

frddtSAASSDSDSAsyaea

125

llassSPHTSASQSAgiigm

158

pssssSSSSSDSESDdeadv

126362967

NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 11 isoform 2
NADH dehydrogenase [ubiquinone] flavoprotein 3,
mitochondrial isoform a precursor
nck-associated protein 5 isoform 1

1353

ssgkgSLGSSGSFSSqhgsp

208022661

nck-associated protein 5-like

1314

sggppGLETSESLSDslyds

NCK-interacting protein with SH3 domain isoform 1

280

eeevaTGTTSASDDLealgt

nebulin isoform 1

2668

wlkgiGWMTSGSLEDeknk

226437579
301129187
48255924

7705266
257743023

nephrocystin-4 isoform a

330

kvvssSKTSSGSQALvlrsr

118918403

23510323

nesprin-2 isoform 1

4423

hdndtTQESSASNQAsspen

149944548

neurobeachin-like protein 2

636

kqlysFFTSSGSGFEaffta

neuroendocrine convertase 1 isoform 1 preproprotein

331

dsiytISISSASQQGlspwy

295424143

neuroendocrine convertase 1 isoform 2

284

dsiytISISSASQQGlspwy

114145479

neuroepithelial cell-transforming gene 1 protein
isoform 1
neurogenic locus notch homolog protein 3 precursor

34

gatgpSADTSGSELDgrcsl

20336242

134244285
38455396

neurogenin-1

1815

teedeADDTSASIISdlicq

16

isdldCASSSGSDLSgfltd

267844811

neuron navigator 1 isoform 1

1180

elrikRQNSSDSISSlnsit

161169013

neuron navigator 2 isoform 1

1742

dlrirRQHSSDSVSSinsat

557636663

neuron navigator 3 isoform 1

1668

dlrirRQHSSESVSSinsat

557636663

neuron navigator 3 isoform 1

1371

qsmtsLHTSSESIDLplshh

neuronal acetylcholine receptor subunit alpha-3
isoform 1 precursor
neuronal PAS domain-containing protein 3 isoform 1

423

sanltRSSSSESVDAvlsls

460

ektseSSETSDSESDskdts

21361135

NF-kappa-B inhibitor beta isoform 1

313

eksgpCSSSSDSDSGdegde

19923348

NGFI-A-binding protein 1

456

ypseaKSHSSESLGIlkdyp

NHS-like protein 2

671

iectqVQGSSESLASpstsr

19923122
260064034

254692833
47578105

nipped-B-like protein isoform A

2489

sspskENESSDSEEEvsrpr

6631100

NK-tumor recognition protein

807

esrssLDYSSDSEQSsvqat

6631100

NK-tumor recognition protein

210

nssssSESSSESELEhersr

270
6631100

NK-tumor recognition protein

914

sdkeeGEATSDSESEvseih

6631100
6631100

NK-tumor recognition protein

956

ksskqRTSTSDSEGScsnse

NK-tumor recognition protein

1196

gevgkQDSSSASLASagest

NKAP-like protein

166

evthqKSSSSDSNSEehrkk

NUAK family SNF1-like kinase 1

578

visddSVLSSDSFDLldlqe

79

enkrrRHDSSGSGHSafepl

4505379

nuclear envelope pore membrane protein POM 121
isoform 1
nuclear factor erythroid 2-related factor 1

329

emqamEVNTSASEILysapp

117320531

56090620
7662170
380692334

nuclear factor NF-kappa-B p100 subunit isoform a

709

lcplpSPPTSDSDSDsegpe

27886526

nuclear factor of activated T-cells 5 isoform a

714

ftgstASGSSGSVDLvqqvl

27886539

173

clspaSSGSSASFISdtfsp

584

gsilkSGTTSESGALsleps

26051235

nuclear factor of activated T-cells, cytoplasmic 2
isoform B
nuclear fragile X mental retardation-interacting
protein 2
nuclear pore complex protein Nup133

223

qggsfILSSSGSQLIrlipe

503774352

32698730

nuclear pore complex protein Nup153 isoform 1

967

qggfkIGVSSDSGSInpmse

33946327

nuclear pore complex protein Nup214

502

vtgepPSYSSGSDSSkaapg

33946327

nuclear pore complex protein Nup214

1868

vfgqqSSSSSGSVFGsgntg

33946327

nuclear pore complex protein Nup214

1766

passtPTSTSGSVFGaasst

21264365

nuclear pore complex protein Nup98-Nup96 isoform 1

142

ttsnpFGSTSGSLFGpssft

nuclear pore-associated protein 1

807

ppdtsTLVSSASAASlskpa

22538461

nuclear receptor corepressor 1 isoform 1

2242

ifnlpAVTTSGSVSSrghsf

331284178

nuclear receptor corepressor 2 isoform 1

1322

egrvgRAISSASIEGlmgra

405

lnqdiRGLTSASQLEqlnkr

548923888

nuclear receptor subfamily 6 group A member 1
isoform 1
nucleolar and coiled-body phosphoprotein 1 isoform 1

374

kaaesSSDSSDSDSSeddea

548923888

nucleolar and coiled-body phosphoprotein 1 isoform 1

479

apqgsRDSSSDSDSSsseee

548923888

nucleolar and coiled-body phosphoprotein 1 isoform 1

83

kkakkKASSSDSEDSseeee

548923888

nucleolar and coiled-body phosphoprotein 1 isoform 1

165

kappkKAKSSDSDSDsssed

543173111

nucleolar protein of 40 kDa isoform a

221

kkkhrDRKSSDSDSSdsesd

nucleoporin GLE1 isoform 1

73

lsetsPSSTSASALDqpsfv

239735607

nucleoredoxin-like protein 2 isoform 2

126

hcnlcLLGSSDSLALas

21327710

nucleosome assembly protein 1-like 3

54

sssstSGSSSGSGSSssssg

21327710

112421134

53729325

51317384

nucleosome assembly protein 1-like 3

25

aeeemASSTSDSGEEsdsss

312222699

O(6)-methylguanine-induced apoptosis 2 isoform 1

285

lgprkHFISSASFVSntsrw

403501448

obscurin isoform a

5588

psssiQESSSESEDGdarge

50233854

olfactory receptor 14A16

103

vsqvfLLLSSASAELllltv

7657423

olfactory receptor 1D5

49

nvliiLAISSDSHLHtpmyf

52218828

olfactory receptor 1M1

6

ssRNQTSASQFIllgls

52317243

olfactory receptor 4D2

49

niliiITVTSDSQLHtpmyf

23592222

olfactory receptor 5P2

197

vstvvLSFSSGSIIVvtvcv

23592230

olfactory receptor 5P3

201

tfeiiPAISSGSIIVatvcv

13624325

olfactory receptor 7C2

49

nlliiLTISSDSHLHtpmyf

53828729

olfactory receptor 7D2

49

nlliiLAISSDSHLHtpmyf

52353282

olfactory receptor 7D4

49

nlliiLAVSSDSHLHtpmyf

121247395

olfactory receptor 7E24

67

nlliiLAVSSDSHLHtpmyf

119220564

one cut domain family member 2

318

srerpPSSSSGSQVAtsgql

otoferlin isoform a

1387

eekkkKTQSSGSGQGseape

34740331

271
296179395

outer dense fiber protein 2-like isoform a

30

ekedlPRCTSESHLSclkqd

22547165

oxysterol-binding protein-related protein 9 isoform a

135

sspkrLIDSSGSASVlthss

21450808

PACRG-like protein isoform 1

201

ndhlkHLLTSGSLSIikski

paired mesoderm homeobox protein 2

76

aarepSGGSSGSEAApqdge

45433499

palmitoyltransferase ZDHHC18

49

apappRWSSSGSGSGsgsgs

13236524

pancreatic progenitor cell differentiation and
proliferation factor
paralemmin-1 isoform 1

5

ppsAIPSSGSLVAthdyy

60

rwlleGTPSSASEGDedlrr

122939204

parkin coregulated gene protein isoform 1

233

hlgssDPPTSASQVAeiivn

190014586

PC4 and SFRS1-interacting protein isoform 1

271

laktgVTSTSDSEEEgddqe

374093214

PDZ and LIM domain protein 5 isoform i

7706659

93141031

87196343

PDZ domain-containing protein 2

99

lptsgDLPTSASQSAkitgv

2372

skppiGRRSSGSIVSgslgh

305632788

PDZ domain-containing protein 7 isoform 1

17

dplglGDLSSGSLSSlssrg

126723564

pecanex-like protein 1

483

mhnqrGLSTSASEEAnknph

677

tsdsdTDSSSDSDSDtsegk

42560244

pentatricopeptide repeat domain-containing protein 3,
mitochondrial precursor
peptidyl-prolyl cis-trans isomerase G

215

sdsqsSSDSSDSESAteeks

42560244

peptidyl-prolyl cis-trans isomerase G

200

sssssSSSSSDSDSSsdsqs

42560244

peptidyl-prolyl cis-trans isomerase G

255

rkkskKSASSESEAEnleaq

51173720

peregrin isoform 1

958

grsprPSSSSDSDSDksted

51173720

38683855

peregrin isoform 1

1003

ndcslPRSSSDSESSsssss

194097341

period circadian protein homolog 1

659

assssYTTSSASDDDrqrtg

194097341

period circadian protein homolog 1

526

gplhsPGSSSDSNGGdaegp

12707562

period circadian protein homolog 2

499

ehlmsQTSSSDSNGHedsrr

48255929

periphilin-1 isoform 1

206

ktsrdTSPSSGSAVSsskvl

137

llassDPPTSASQSAgitdr

4505721

peroxisomal coenzyme A diphosphatase NUDT7
isoform 3
peroxisome assembly protein 12

77

lqqhyLSRTSASFSEnfygl

4505725

peroxisome biogenesis factor 1 isoform 1

1089

ssmvfLNHSSGSDDSagdge

4505725

peroxisome biogenesis factor 1 isoform 1

1073

sglqdGSSSSDSDLSlssmv

PHD finger protein 14

361

dgesdSIMSSASENStepwf

phosphatase and actin regulator 2 isoform 1

433

ltpglMGESSESFSAsedeg

phosphate carrier protein, mitochondrial isoform a
precursor
phosphatidylinositol 3,4,5-trisphosphate 5phosphatase 1 isoform a
phosphatidylinositol 4,5-bisphosphate 3-kinase
catalytic subunit beta isoform isoform 1
phospholipase D1 isoform a

296

svlnkEKGSSASLVLkrlgf

807

qhiliSIKSSDSDESygegc

519

iekaaEIASSDSANVssrgg

609

phfklFHPSSESEQGltrph

phospholipase D2 isoform PLD2A

477

yrltdLGDSSESAASqpptp

phosphoprotein associated with glycosphingolipidenriched microdomains 1
phosphorylase b kinase regulatory subunit alpha, liver
isoform
platelet-derived growth factor receptor alpha precursor

109

mqhyeEVQTSASDLLdsqd
s
pssptGTSSSDSGGHhigwg

343887372

55769548
154354968
6031192
64085167
5453894
4505873
156564407
63054864
4505781
5453870
55741447
217416392
40538728
301172762

pleckstrin homology domain-containing family H
member 1
pleckstrin homology domain-containing family H
member 2
pleckstrin homology domain-containing family M
member 1
pleckstrin homology domain-containing family S

1049
87

lfvtvLEVSSASAAHtglyt

491
620

snmpfMDESSGSDDDcssq
a
ssspfLDDSSGSEEEdssrs

225

esldsISHSSGSEDIevhhs

224

leldnIIASSDSGESietdg

272
member 1 isoform 1
221219024

1137

41322916

pleckstrin homology-like domain family B member 1
isoform a
plectin isoform 1

980

sacspDNMSSASGLDmgki
e
pshwkVLSSSGSEAAvpsvc

41322916

plectin isoform 1

4671

ygrryASGSSASLGGpesav

PML-RARA-regulated adapter molecule 1

385

lprkpPLPSSASESSlpaav

19

pgggkAQLSSASLLGaglll

156523968

poliovirus receptor-related protein 3 isoform 1
precursor
poly [ADP-ribose] polymerase 1

360

qdrifPPETSASVAAtppps

156523968

poly [ADP-ribose] polymerase 1

723

vqqavSQGSSDSQILdlsnr

205360954

302318952
11386199

polycystin-1 isoform 1 precursor

3591

vsvawLLSSSASFLAsflgw

37595528

polyhomeotic-like protein 2 isoform a

121

lvsnrQGSTSGSNVSaqapa

41349443

potassium channel subfamily T member 2 isoform 1

967

rtesqKLTTSESQISisvee

318

lrsglLNSTSDSDLVryrti

205

vdltpAAPSSESLALdevta

845

gllseDPKSSDSENSvtknp

647

ysrclRSGTSASLGAvqvpl

51702521

potassium voltage-gated channel subfamily H member
2 isoform a
potassium voltage-gated channel subfamily H member
2 isoform a
potassium voltage-gated channel subfamily H member
5 isoform 1
potassium voltage-gated channel subfamily KQT
member 4 isoform a
POU domain, class 3, transcription factor 2

13

snhysLLTSSASIVHaeppg

13375636

4557729
4557729
22024390
26638653

PR domain zinc finger protein 14

231

sgllvPPDSSGSDSLpqtld

289547573

PR domain zinc finger protein 16 isoform 1

1055

lgtsaSSPTSESDNHallde

150378478

PR domain zinc finger protein 8

283

scspaQSLSSGSGSGggggh

150378439

PR domain zinc finger protein 8

283

scspaQSLSSGSGSGggggh

pre-B-cell leukemia transcription factor 3 isoform 1

337

spttpNSGSSGSFNLpnsgd

151301228

5453852

pre-mRNA-processing factor 40 homolog A

904

gkdsgNWDTSGSELSegele

55749769

pre-mRNA-splicing factor CWC22 homolog

676

sssssASSSSESDSSdsdsd

55749769

pre-mRNA-splicing factor CWC22 homolog

709

dsssiSSHSSASANDvrkkg

27477111

pre-mRNA-splicing factor SLU7

511

kkkkhRKSSSDSDDEekkhe

pre-mRNA-splicing regulator WTAP isoform 1

286

ngsssRQRTSGSGFHregnt

395455090

prefoldin subunit 2

10

ensgrAGKSSGSGAGkgavs

222136684

12408675

prickle-like protein 1

768

swcssSSSSSDSEEEgyflg

38524620

prickle-like protein 2

780

dwcstCSSSSESDNEgyflg

47

plppqDAQTSGSLLHyllqa

4758832

pro-FMRFamide-related neuropeptide FF
preproprotein
pro-neuregulin-2, membrane-bound isoform isoform 1

39

rssssSSSSSESGSSsrsss

4758832

pro-neuregulin-2, membrane-bound isoform isoform 1

765

aardsLSLSSGSGGGsasas

4758832

pro-neuregulin-2, membrane-bound isoform isoform 1

529

slersESLTSDSQSGimlss

170016077

probable cation-transporting ATPase 13A1

538

cfdktGTLTSDSLVVrgvag

126131099

probable E3 ubiquitin-protein ligase HERC1

136

qqqhsPESSSGSADVhsvse

126131099

probable E3 ubiquitin-protein ligase HERC1

1476

egqlqQPSTSASEGGglmtr

probable G-protein coupled receptor 110 isoform 1
precursor
probable G-protein coupled receptor 112

217

agyevVGSSSASELLsaieh

1995

lpsilSGATSGSVISkspil

148271100

probable histone-lysine N-methyltransferase PRDM7

141

sgtpnLLNTSDSEQAqkpvs

118600981

377

dnvsdFSESSDSENSnkrii

88900493

probable JmjC domain-containing histone
demethylation protein 2C isoform a
probable palmitoyltransferase ZDHHC19

294

salnpPAPTSGSLQSregtp

55956910

probable tumor suppressor protein MN1

208

asfhgLPSSSGSDSHslepr

4503769

61743940
59710093

273
321117150

progesterone receptor isoform A

167857792

programmed cell death protein 1 precursor

153792074

proline-rich protein 12

153792074

proline-rich protein 12

705

yhlqsVIRTSASLDEgataa

292658793

proline-rich transmembrane protein 4 isoform 1
precursor
prostacyclin receptor

242

ppgetTSTSSASGVSgslgf

365

eplppTQQSSGSAVGtsska

prostate androgen-regulated mucin-like protein 1
precursor
protection of telomeres protein 1 isoform 1

254

mqeveHALSSGSIAAitvtv

316

sepddSFPSSGSVSLyever

4506263
54400758
98991776

333

lprdgLPSTSASAAAagaap

58

tftcsFSNTSESFVLnwyrm

1818

agggpPGSSSDSESSpgaps

295842186

protein BEAN1 isoform 1

180

dscptLDGTSDSGSGhspgr

444299649

protein CASC5 isoform 1

1750

pvypdEINSSDSINIeteek

148277064

protein CASP isoform a

693

ktaepAQPSSASGSGnsdda

8

mnpasDGGTSESIFDldyas

31083053

protein CLN8

31581524

protein cordon-bleu isoform b

1170

tcslrKVASSASEELqsfrd

protein crumbs homolog 2 precursor

655

tfglgGAPSSASFLLqelpg

112420992

protein disulfide-isomerase A4 precursor

122

ipvakIDATSASVLAsrfdv

111185957

4758304

protein Dok-7 isoform 1

334

lqevgRQSSSDSGIAtgshs

393794759

protein Dos

247

faeisPSASSDSGEGtslda

19923559

protein EMSY

765

ptiiyQDVSSESQSAtstik

21361272

protein ENL

385

nssssSDSSSDSDFEpsqnh

14149865

protein eva-1 homolog A

80

qdresSSDSSDSEDGsedtv

78191787

protein FAM102A isoform a

264

hrrntSTSSSASGGLgmtve

154350246

protein FAM104A isoform 1

128

rgnkaFCASSGSDSGgssss

154350224

protein FAM104A isoform 2

107

fqdswDTESSGSDSGgssss

284447294

protein FAM110C

254

kvrsvSVATSGSGFSrhsgg

283837793

protein FAM133A

116

sssdsSSSSSDSEDEekkqg

91206456

protein FAM133B isoform 1

190

mysedKPLSSESLSEseyie

568384749

protein FAM133B isoform 2

107

sssdsSSSSSDSEDEdkkqg

91206454

protein FAM133B isoform 2

107

sssdsSSSSSDSEDEdkkqg

568384749

protein FAM133B isoform 2

180

mysedKPLSSESLSEseyie

91206454

protein FAM133B isoform 2

180

mysedKPLSSESLSEseyie

14149789

protein FAM186B

471

slessRQVTSESQEEpweee

189027139

protein FAM189A2 precursor

375

eehmeEAITSASFLEqimap

189027135

protein FAM189A2 precursor

375

eehmeEAITSASFLEqimap

13376429

protein FAM192A

220

pglgaYSGSSDSESSsdseg

13376429

protein FAM192A

160

lagavKHKSSESGNSvkrlk

51873049

protein FAM193A isoform 1

262

sppsvSSASSGSGSSspiti

89886201

protein FAM196A

12

dtgkcILTTSESEVEpaacl

568786296

protein FAM222B isoform 1

466

ilptpNSDSSGSQDLampfh

40254997

protein FAM83A isoform a

321

pangrLSSSSGSASDrtssn

42476337

protein FAM86A isoform 1

40

sleakLRDSSDSELLrdilh

134133220

protein FAM86B1

40

sleakLRDSSDSELLrdilq

153792110

protein HEG homolog 1 precursor

514

ysessSTSSSESLNSsaprg

153792110

protein HEG homolog 1 precursor

981

tqsptTVSSSASVNScavnp

protein Hook homolog 3

449

lmplgSQESSDSLAAeivtp

protein IWS1 homolog

361

hmdrkKFHSSDSEEEehkkq

14165274
217330641

274
56711286

protein KIAA2022

434

ghlanSLETSGSFSDdssfi

145580615

protein KRI1 homolog

51

drdssSDSSSESDSSderve

145580615

protein KRI1 homolog

99

tfynrTASSSDSEEDpeale

19311006

protein phosphatase 1 regulatory subunit 14C

36

gaggsPGSSSGSGSSredsa

45387958

protein phosphatase 1 regulatory subunit 26

149944715

protein phosphatase 1H

239047414
239047414

1159

glslhDRRSSGSEESildlr

19

fmggiMAGSSGSEHGggsc

protein phosphatase Slingshot homolog 1 isoform 1

16

sptpsAASSSASNSEleags

protein phosphatase Slingshot homolog 1 isoform 1

936

ssnltRSSSSDSIHSvrgkp

150378539

protein piccolo isoform 1

1515

epydsVEESSESENSpvpqr

150378539

protein piccolo isoform 1

2594

sepgtPTDSSASQAItswpl

209969819

protein PRR14L

1017

hnqkdLLVSSGSNNSlpcgs

149158690

protein PRRC2A

579

gggstSSTSSGSFEAspvep

149192855

protein PRRC2B

1482

lpgglSGCSSGSGHSpyale

115298682

protein PRRC2C

781

dqmegSPNSSESFEHiarsa

162287219

protein prune homolog 2

1683

edarvISTSSGSDDDsvgge

162287219

protein prune homolog 2

1272

pdapaASGTSESEALishld

70980549

protein RRP5 homolog

1555

palppLAESSDSEEDekphq

170763500

protein SET isoform 1

26

ppalgPEETSASAGLpkkge

567757558

protein SETSIP

36

ppalgLEETSASAGLpkkge

55956786

protein SFI1 homolog isoform a

51

aktlsNKKSSASFGIrrelp

61102723

protein SLX4IP

192

trrdtVETSSDSVIAeiarr

341865548

protein Smaug homolog 1 isoform 1

298

lspqsSVASSGSGGSehled

145301567

protein SMG9

353

spsheSSSSSGSDEGteyyp

191250773

protein spire homolog 1 isoform a

463

aptlaELDSSESEEEtlhks

384475548

protein sprouty homolog 1

121

ststgSAASSGSNSSasseq

154355002

protein strawberry notch homolog 2 isoform 1

59

ssdsrPFMSSASFLGsqpcp

335353804

protein SZT2

1815

dhlgyDGGSSGSDSEgpndt

224548964

protein TNT

65

ssylsDTQSSESHVSsvqhp

124378039

protein transport protein Sec16A isoform 1

1125

qsssvSLVSSGSGQAavpse

112382212

protein transport protein Sec24B isoform a

138

lgsfqGAASSASHLHtsasq

protein TSSC1

174

sssqaVLASSASLEGkgqlk

protein unc-119 homolog A isoform b

208

eelsaRAGSSGSGEVgasrd

4507703
16936535
122937514

protein unc-13 homolog C

194

wkksqECVSSDSELStmkks

150456444

protein unc-79 homolog

1448

pekhsILSTSDSDSLvfepl

116268127

protein very KIND

1511

staipKASSSESLSAktcsl

170784842

protein-associating with the carboxyl-terminal domain
of ezrin isoform 1
proto-oncogene c-Fos

387

qvllgLRDTSDSIVAitlhs

367

kgsssNEPSSDSLSSptlla

protocadherin beta-7 precursor

296

lktfqINPTSGSLHLkaqld

protocadherin Fat 4 isoform 1 precursor

4840

dgipaPESSSDSDSHesftc

protocadherin gamma-A1 isoform 1 precursor

824

fsqaqRPGTSGSQNGddtgt

4885241
11036656
604723349
11056032
218505787

protocadherin-15 isoform CD2-1 precursor

1750

sesgsSSSSSESQSGgpwgy

16933557

protocadherin-16 precursor

1689

gqvtyGGVSSESFSLdpdtg

83281200

protogenin precursor

993

ngtqqLPRTSASLASgnevg

203098995

proton myo-inositol cotransporter

617

dnrlcTCGTSDSDEGryiey

193211598

puratrophin-1 isoform 1

1167

sqcpsASGSSGSDSScvsgq

275
166197666
29570782

putative homeodomain transcription factor 1

396

gpecrSSVTSDSEGAhvntl

putative Polycomb group protein ASXL1 isoform 1

205

esgspSSSSSGSLALgsaai

149944526

putative Polycomb group protein ASXL3

1327

dkqllISSSSASNLVstqyt

223972704

putative protein FAM71E2

298

tqsspKACTSASDEAtgqgh

putative RNA-binding protein 15B

84

nhrasSGRSSGSGAGgggrg

putative spermatogenesis-associated protein 31D3

157

apsvsPLASSASGAEssftl

54607124
223633944

putative transcription factor Ovo-like 1

220

yvceeCGCTSESQEGhvlhl

170932471

38570158

putative uncharacterized protein C11orf80 precursor

131

hcnlhLPGSSDSHASvprva

299473771

putative uncharacterized protein FLJ22184

209

tegprKSVSSASEHStteps

148839376

PWWP domain-containing protein 2B isoform 1

423

dcaseSACSSDSLDEarssg

289629261

PWWP domain-containing protein MUM1L1

156

ensacLLASSESDDSlyddk

544346243

R3H domain-containing protein 1 isoform a

409

rlsktGSESSGSVGSstgsl

298676510

rab effector Noc2 isoform 1

206

twargRVVSSDSDSDsdlss

31377798

rab GTPase-binding effector protein 1 isoform 1

412

aqstdSLGTSGSLQSkalgy

24308075

rab11 family-interacting protein 5

258

slgsdSTLSSASGSLayqgp

24308075

rab11 family-interacting protein 5

363

ssisgSLPSSGSLQAvssrf

186910300

rac GTPase-activating protein 1

110

iremlMCDTSGSIQLseeqk

188528644

raftlin-2

205

negtlSGQSSESGIEeelhh

ral GTPase-activating protein subunit alpha-1 isoform
1
ral GTPase-activating protein subunit beta isoform 1

905

sagssDLISSDSHSDsfsaf

722

hsrtnSGISSASGGSteptt

5803145

ralA-binding protein 1

538

grsetEEYSSESESEsedee

7657261

rap guanine nucleotide exchange factor 2

50

sshsgCSITSDSGSSslsdi

7662070

ras-specific guanine nucleotide-releasing factor
RalGPS1 isoform 1
ras-specific guanine nucleotide-releasing factor
RalGPS2 isoform 1
RCC1 and BTB domain-containing protein 1

22

satpqGSSSSDSLEGqscdy

22

ataseKSSSSESLSDkgsel

28

irkacVFGTSASEALyvtdn

receptor-type tyrosine-protein phosphatase alpha
isoform 1 precursor
receptor-type tyrosine-protein phosphatase zeta
isoform 1 precursor
receptor-type tyrosine-protein phosphatase zeta
isoform 1 precursor
receptor-type tyrosine-protein phosphatase zeta
isoform 1 precursor
receptor-type tyrosine-protein phosphatase zeta
isoform 1 precursor
receptor-type tyrosine-protein phosphatase zeta
isoform 1 precursor
receptor-type tyrosine-protein phosphatase zeta
isoform 1 precursor
recQ-mediated genome instability protein 1

80

ptyltTVNSSDSDNGttrta

635

rnaseDSTSSGSEESlkdps

999

gdgewSGASSDSEFLlpdtd

822

dgaplLPFSSASFSSelfrh

788

lnttpAASSSDSALHatpvf

533

lpphtVEGTSASLNDgsktv

1554

eesgsGQGTSDSLNEnetst

431

dnkikQTSSSDSHSLnnkil

regulating synaptic membrane exocytosis protein 1
isoform 1
regulation of nuclear pre-mRNA domain-containing
protein 2
regulator of cell cycle RGCC

1338

scdnvSAKSSDSDVSdvsai

1142

gssfdNGPSSASELAslggg

63

hlermKRRSSASVSDssgfs

21361304

regulator of G-protein signaling 14

265

resqgSLNSSASLDLgflaf

18375673

regulator of nonsense transcripts 1

150

wfcngRGNTSGSHIVnhlvr

38788333

remodeling and spacing factor 1

1245

rvhkrRLSSSESEESylskn

51226124
544711130

32441283
57242759
4506303
91208428
91208428
91208428
91208428
91208428
91208428
153791761
41054864
183396804
132626811

344925845

REST corepressor 1

51

taasgAAASSASAAAasaaa

276
10863935

reticulon-1 isoform A

473

liiesCDASSASEESpkreq

10863935

reticulon-1 isoform A

162

giesrGLFSSDSGIEmtpae

24431935

reticulon-4 isoform A

180

paapkRRGSSGSVDEtlfal

117414137

retinitis pigmentosa 1-like 1 protein

1203

tsssgVDISSGSGGSgessv

117414137

retinitis pigmentosa 1-like 1 protein

910

pnsgaSRRSSASQGAgsrgl

retinol-binding protein 3 precursor

846

dlyilMSHTSGSAAEafaht

4506453
62548864

rho guanine nucleotide exchange factor 10

1258

tqksdLSSSSGSLSLshgss

163792208

rho guanine nucleotide exchange factor 16

600

grqeqLLLSSDSASDrarwi

21361458

rho guanine nucleotide exchange factor 17

273

spayhGGHSSGSDDDrdgeg

41327769

rho guanine nucleotide exchange factor 18 isoform a

914

srgsqRWESSASFDLkqqll

295148073

rho guanine nucleotide exchange factor 28 isoform 1

1197

cpeekGGRTSESDEDkrkae

19923723

ribosomal protein S6 kinase delta-1 isoform a

159

pecstEGFSSDSDLVsltvd

34452681

RING finger protein 10

650

pafnsYTCSSDSALGptste

58331204

RING finger protein 150 precursor

406

nseqePAVSSDSDISlimam

58743365

RING finger protein 157

347

fnpiiSSQTSDSEEHpssen

94421471

RING finger protein 17 isoform 1

268

qiirtLQLTSDSELAqvssp

331028525

RING finger protein unkempt homolog

604

qsentFLGTSASHGSlglng

331028525

RING finger protein unkempt homolog

567

vnipgSLGSSASFHSaspsp

145199237

RNA exonuclease 1 homolog

546

wpsalPSLSSDSDSDsdssl

454

gtdldFDLSSDSESSseseg

470

esegtKSSSSASDGEsegkr

7661950

RNA polymerase II subunit A C-terminal domain
phosphatase isoform 1
RNA polymerase II subunit A C-terminal domain
phosphatase isoform 1
RNA polymerase-associated protein CTR9 homolog

1053

deqrkKCASSESDSDenqnk

20270337

RNA polymerase-associated protein LEO1 isoform 1

606

reeraRIYSSDSDEGseedk

67188445
67188445

20270337

RNA polymerase-associated protein LEO1 isoform 1

321

lfggaDDISSGSDGEdkppt

195976782

RNA polymerase-associated protein RTF1 homolog

96

paassDSETSDSDDEwtfgs

195976782

RNA polymerase-associated protein RTF1 homolog

165

sdsnsSSSSSDSDSSsedee

RNA-binding protein 14 isoform 1

519

laapyRTQSSASLAAsyaaq

55741709

RNA-binding protein 25

626

pissaPSVSSASGNAtpntp

93277070

RNA-binding protein 45

5

rtyEAGSSASGGGfrpgv

RNA-binding protein 47 isoform a

10

aedstAAMSSDSAAGssakv

RNA-binding protein Musashi homolog 2 isoform a

8

meangSQGTSGSANDsqhd

5454064

148833513
20373175
612407805

rootletin

1737

glteaLAQSSASLNStrdkn

158534055

round spermatid basic protein 1-like protein

113

fsagtAVPSSASASLsqpvp

roundabout homolog 1 isoform a precursor

4506569

1158

nssdrGSSTSGSQGHkkgar

RRP15-like protein

41

vledeATDTSDSEGScgsek

19923090

RUN domain-containing protein 3B isoform a

242

eeelrTLGSSGSESStpenv

19923090

RUN domain-containing protein 3B isoform a

226

tpylkYIQSSDSISSdeeel

ryanodine receptor 2

217

tlwsvAPISSGSEAAqgyli

S-adenosylmethionine synthase isoform type-1

20

lsegvFMFTSESVGEghpdk

126362983

112799847
4557737
221136781

S1 RNA-binding domain-containing protein 1

27

efssfSELSSASEEDdkeds

118442837

sal-like protein 1 isoform a

139

anksgSGTSSGSHSStapss

154146199

sal-like protein 3

365

lpsplLPQTSASGVIfpnpl

47604944

SCY1-like protein 2

917

ppttmTNSSSASNDLkdlfg

21361914

semaphorin-4A isoform 1 precursor

743

lqspkECRTSASDVDadnnc

semenogelin-2 precursor

549

qkgryKQESSESHNIviteh

4506885

277
390131986

sentrin-specific protease 1

251

qiigsDTSSSGSASIltnqe

390131986
116174746

sentrin-specific protease 1

76

psyysDNPSSDSFLGsgdlr

sentrin-specific protease 7 isoform 1

474

ettneNESTSESALLelpli

22129776

serine protease HTRA3 precursor

172

lfgrnVPLSSGSGFImseag

42542379

serine/arginine repetitive matrix protein 1

492

yrrqnQQSSSDSGSSsssed

42542379

serine/arginine repetitive matrix protein 1

350

spvrrRRRSSASLSGsssss

118572613

serine/arginine repetitive matrix protein 2

2559

sssssGSSSSDSEGSslpvq

625180297

serine/arginine repetitive matrix protein 3 isoform a

428

rslsrARSSSDSGSGrgapg

50083281

serine/arginine repetitive matrix protein 4

525

pyyrpSPSSSGSLSStsswy

50083281

serine/arginine repetitive matrix protein 4

326

srelnSGNTSDSGNSfttss

217330634

serine/threonine-protein kinase 36 isoform 1

549

tfnleRSQTSDSLQVfqeaa

187937179

serine/threonine-protein kinase LMTK1 isoform 1

909

sldslDIPSSASDGGyevfs

38016937

serine/threonine-protein kinase LMTK2 precursor

1306

rafnlHSLSSESEDEtehpv

serine/threonine-protein kinase MRCK beta

968

ahdltFRTSSASEQEtqapk

serine/threonine-protein kinase Nek5

544

marswLTATSASQDIekdlk

serine/threonine-protein kinase RIO2 isoform 1

485

rtrtlSITSSGSAVScstip

62243658

serine/threonine-protein kinase SMG1

1867

aivgtISLSSESQASgnkfs

33636698

serine/threonine-protein kinase tousled-like 1 isoform1

5

ityVQSSSGSLEGppsws

115527097
83627721
229331967

4507831

serine/threonine-protein kinase ULK1

296

pvpvpSYPSSGSGSSsssss

4507903

serine/threonine-protein kinase VRK1

57

ciylaDMNSSESVGSdapcv

296939602

serine/threonine-protein kinase WNK1 isoform 1

1455

ypsvtVSATSASAGGstatp

538918207

serine/threonine-protein kinase WNK2 isoform 1

1842

evgvgEPVSSDSGDEgprar

50845418

serine/threonine-protein kinase WNK3 isoform 1

1469

iltagKQPSSDSEFSaslag

108936953

23

dgfgvDDYSSESDVIiipsa

410

dssllCTLSSESHQEaasne

216

eknhsDSSTSESEVSsvspl

876

tntveMLVSSASAELtlqdn

106879210

serine/threonine-protein phosphatase 4 regulatory
subunit 1 isoform a
serine/threonine-protein phosphatase 4 regulatory
subunit 1 isoform a
serine/threonine-protein phosphatase 4 regulatory
subunit 2
serine/threonine-protein phosphatase 6 regulatory
ankyrin repeat subunit A isoform a
SH2 domain-containing adapter protein B

130

gvqraFSASSASGAAgccca

224926826

SH2B adapter protein 1 isoform 1

452

rpsasISPSSASIAAshfds

SH3 and cysteine-rich domain-containing protein

216

laqrtKKGSSGSGSDsphrt

SH3 and multiple ankyrin repeat domains protein 3

1385

tvssmSTLSSESGELtdtht

SH3 and PX domain-containing protein 2A

657

qaemgKNHSSASFSSsitin

SH3 domain-binding glutamic acid-rich protein
isoform a
SH3 domain-binding protein 5 isoform a

72

vikvfVATSSGSIAIrkkqq

108936953
28372531
68131557

4507247
380748963
55749544
6677929
109134336
116235472
222446609
60302875
193290128
33413418

406

nnnrgLSSSSGSGGSsksqs

SH3-containing GRB2-like protein 3-interacting
protein 1
SHC-transforming protein 4

103

tkgkhFYSSSESEEEeeshk

605

mdnslPIISSGSEVSlkqpv

shugoshin-like 1 isoform A1

370

esevsLCESSGSGDDsddly

signal peptidase complex subunit 1

14

tgctgPSETSASGAAaialp

51

dkekdSNSSSGSFNGnstnn

112421013

signal-induced proliferation-associated 1-like protein 2

signal peptide peptidase-like 3

1358

spsahCSKSSGSLDSskvyi

112421013

signal-induced proliferation-associated 1-like protein 2

1342

dlseiSSHSSGSHHSgspsa

71143119

signal-induced proliferation-associated 1-like protein 3

1305

qdplsKGGSSDSGIDttlyt

62243734

signal-transducing adaptor protein 2 isoform 1

379

lltssDPPTSASQSAgitgv

278
148762982

SKI/DACH domain-containing protein 1

379

lgsfpESCSSDSESSsysdh

148612795

small G protein signaling modulator 2 isoform 1

229

algirKRHSSGSASEdrlaa

4507101

snRNA-activating protein complex subunit 1

288

rhrqvKLDSSDSDSAsgqgq

92859678

snRNA-activating protein complex subunit 4

24

lerilDPGSSGSHVEisess

92859678

snRNA-activating protein complex subunit 4

603

aslspPKGSSASQGGskeas

320461722

sodium channel protein type 1 subunit alpha isoform 1

1132

enlntEDFSSESDLEeskek

115583667

sodium channel protein type 11 subunit alpha

19

dernfRPFTSDSLAAiekri

126362949

sodium channel protein type 3 subunit alpha isoform 1

1120

enlntEEFSSESELEeskek

sodium channel protein type 9 subunit alpha

1095

enmnaEELSSDSDSEyskvr

15529998

4506813

sodium/hydrogen exchanger 2 precursor

692

tisiaDGNSSDSDADagttv

32401447

solute carrier family 46 member 3 isoform a precursor

41

eetgnYTFSSDSNISecekn

225637473

solute carrier organic anion transporter family member
5A1 isoform 1
sorbin and SH3 domain-containing protein 1 isoform 3

163

ierrySLKSSESGLLvscfd

1098

sflqlPLGSSDSVISqlsda

194363771

sperm-specific antigen 2 isoform 1

1100

gfeipPGESSESVFSqatse

239047343

336

deavrVPSSSASENAigdpy

155029550

spermatogenesis- and oogenesis-specific basic helixloop-helix-containing protein 2 isoform 1
spermatogenesis-associated protein 31E1

1055

tlgasVRASSGSVQEdlrst

226509740

splicing factor, arginine/serine-rich 19

813

gpppkPPVSSGSGSSsssss

169234630

splicing regulator RBM11

252

nkrkrQKQTSDSDSStdnnr

63025196

SRSF protein kinase 3 isoform 1

28

sqascGPESSGSELAlatpv

61743980

stabilin-2 precursor

61

cpdgyTMITSGSVGVrdcry

51242955

STE20-related kinase adapter protein alpha isoform 1

45

trrktNDASSESIASfskqe

157785645

striated muscle preferentially expressed protein kinase
isoform 1
sulfatase-modifying factor 1 isoform 1 precursor

1920

ppsggLSSSSDSEEEeleel

355

arsqnTPDSSASNLGfrcaa

SUN domain-containing ossification factor isoform 1
precursor
suppressor of cytokine signaling 6

32

wrvccKESSSASASSyysqd

192

qeqanSLKSSASHNGdlhlh

suppressor of IKBKE 1 isoform 1

190

elrelLSISSESLQArkens

survival of motor neuron-related-splicing factor 30

59

tqpseTLASSDSFAStqpth

94

rgiqyIDLSSDSEDVvspnc

281306733

SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin subfamily A containing
DEAD/H box 1 isoform a
synaptonemal complex protein 2-like

551

rilpvFPPSSGSGHEkdqak

166706868

synaptopodin 2-like protein isoform a

329

eeedgVPPTSESELDeeafs

226342955

synaptotagmin-14 isoform 1

132

mdkdeHGSSSESEDEalgky

123173752

synaptotagmin-16

186

gddeeLSTSSDSDEEvikqf

399154127

synaptotagmin-6

270

iwkdiQYATSESVDLgeimf

45504376

synaptotagmin-6

270

iwkdiQYATSESVDLgeimf

38202246

78000163

38202250
7656940
21450785
156151379
5032113
190358532

syntaphilin

232

gdrqpGDPSSGSAEDgadsg

149363700

syntaxin-binding protein 5-like

937

rrkvvMNSSSASQEIgdhqy

149363700

syntaxin-binding protein 5-like

22

asspgSGSSSGSNSGggags

T-box transcription factor TBX21

486

eiapiRPESSDSGLGegdsk

T-box transcription factor TBX22 isoform 1

82

gsdsgYGNSSESLEEkdiqm

T-cell immunoglobulin and mucin domain-containing
protein 4 isoform 1 precursor
T-cell surface glycoprotein CD8 beta chain isoform 2
precursor
T-complex protein 1 subunit alpha isoform a

270

tshvsMWKTSDSVSSpqpga

61

wlrqrQAPSSDSHHEflalw

370

likntKARTSASIILrgand

7019549
18375603
226529863
27886639
57863257

279
58331187
33667044
8394402

T-lymphoma invasion and metastasis-inducing protein
2 isoform a
target of Nesh-SH3 precursor

485

tstetAESSSESLSSleqld

45

nlkvhINTTSDSILLkflrp

taste receptor type 2 member 4

193

slqfiINVTSASLLIhslrr

21327701

TATA-binding protein-associated factor 2N isoform 1

93

qgqqqNMESSGSQGGraps

50658061

TBC1 domain family member 1 isoform 1

569

llgssEDLSSDSESHlpeep

312837064

TBC1 domain family member 23 isoform 1

660

litfkYGNSSASGIEilaie

389565509

TBC1 domain family member 2A isoform 1

547

lqweaGEASSDSIELspisk

194018478

TBC1 domain family member 2B isoform a

324

sgdpsSEGTSGSGSVsirkp

21536371

telomerase protein component 1

1956

dgiriYKISSGSQGAqgqal

188528648

tenascin-X isoform 1 precursor

2205

gqmtvRDITSDSLSLswtvp

188528648

tenascin-X isoform 1 precursor

3271

gelavAAVTSDSVGLswtva

188528648

tenascin-X isoform 1 precursor

1073

geltvTDRTSDSLLLrwtvp

169790825

teneurin-4

2560

apktkKFASSGSVFGkgvkf

66529407

tensin-1

402

hvehtLSVSSDSGNStastk

65288071

tensin-3

389

hsdhtLSVSSDSGHStasar

38787941

519

ppppmLSVSSDSGHSstltt

58331272

tensin-like C1 domain-containing phosphatase isoform
1
terminal uridylyltransferase 7 isoform 1

1471

kecpqFKGSSGSLSSkymtq

38679909

testis-expressed sequence 2 protein isoform 1

322

shrpkALSSSASELSnlssl

11545835

testis-specific Y-encoded-like protein 2

557

gshgnNQDSSDSDNEadeas

13899233

tetratricopeptide repeat protein 25

285

ledidMLLTSGSAEGslqka

4759226

TGF-beta receptor type-1 isoform 1 precursor

185

kdliyDMTTSGSGSGlpllv

6005902

thrombospondin-3 isoform 1 precursor

18

allllCFFTSASQDLqvidl

55770862

thyroglobulin precursor

2343

rvgvfGFLSSGSGEVsgnwg

116875767

tight junction protein ZO-1 isoform a

1442

yaqpsQPVTSASLHIhskga

116875765

tight junction protein ZO-1 isoform b

1362

yaqpsQPVTSASLHIhskga

388998877

titin isoform IC

1164

vvrnkHGETSASASLleead

388998877

titin isoform IC

3321

kndygVATTSASLSVevpev

toll-like receptor 2 precursor

38

drngiCKGSSGSLNSipsgl

187608777

19718734

tonsoku-like protein

861

gdnrrPSSTSGSDSEesrpr

257467636

TPR and ankyrin repeat-containing protein 1

99

lvgvfTTMSSDSIVLqsflp

21264324

trace amine-associated receptor 1

106

htstdIMLSSASIFHlsfis

32880231

transcription cofactor vestigial-like protein 2 isoform1

46

qecnaSPSSSGSGSSsfssq

31652244

transcription factor 20 isoform 1

49

ggtggSSGSSGSGSGggrrg

31652244

transcription factor 20 isoform 1

1100

qpeeyKDWSSGSAQGviaa

13786123

transcription factor 7-like 1

78

nesenQSSSSDSEAErrpqp

13786123

transcription factor 7-like 1

51

eggeeQEPSSDSASAqrdld

296278212

transcription factor Dp-2 isoform 1

10

istpqRLTSSGSVLIgspyt

134142809

transcription factor E2F5 isoform 2

292

qqtsaTDISSGSISGdiide

transcription factor E3 isoform 1

452

pgllsLATTSASDSLkpeql

8659574
116089331

transcription factor HIVEP3 isoform a

312

pllssGLYSSGSHSSsherc

116089331

transcription factor HIVEP3 isoform a

1410

perkgTSLSSESILSlegss

40807463

transcription factor Ovo-like 2

53

dcrsdGGSSSGSGSSsagep

transcription factor SOX-4

18

teallAGESSDSGAGlelgi

38372901

transcription factor Sp1 isoform a

287

ssqavTISSSGSQESgsqpv

38372901

transcription factor Sp1 isoform a

305

pvtsgTTISSASLVSsqass

4507163

280
67010025

transcription factor Sp4

36

ennnkKPKTSGSQDSqpspl

98961135

transcription factor SPT20 homolog isoform a

426

cpvkmSHSSSGSASLsqvsp

20357585

transcription initiation factor TFIID subunit 1 isoform1

205

sekvdFSSSSDSESEmgpqe

151301171

transcription initiation factor TFIID subunit 3

409

repdpFEFSSGSESEgdift

119393899

transcriptional activator GLI3

1165

lpiqwNEVSSGSADLssskl

119393899

transcriptional activator GLI3

417

sessqNKPTSESAVSstgdp

157502209

transcriptional protein SWT1

331

feapcCSVSSESIQDadqem

530788276

transcriptional regulator ATRX isoform 1

784

gkrkrKSSTSGSDFDtkkgk

530788276

transcriptional regulator ATRX isoform 1

1942

kkgkkDSSSSGSGSDndvev

530788276

transcriptional regulator ATRX isoform 1

702

vrkkdKRNSSDSAIDnpkpn

5729790

transcriptional repressor CTCF isoform 1

608

kmrskKEDSSDSENAepdld

transcriptional repressor CTCFL isoform 12

364

hrnlcLLGSSDSHASvsgag

transducin beta-like protein 3

579

vsrgtQLLSSGSDGLvklwt

8

mvqsrLTATSASQDSpasgl

392933947
19913369
221219048

transducin-like enhancer protein 2 isoform 2

630044887

transforming acidic coiled-coil-containing protein 2
isoform a
transient receptor potential cation channel subfamily
M member 1 isoform 1
translation machinery-associated protein 16

1945

dpakdLSRSSDSEEAfetpe

694

lykamAHESSESDLVddisq

191

gelelNDESSDSDEEmtava

translational activator GCN1

107

skagvPSKSSGSAALlaltw

transmembrane and coiled-coil domains protein 1
isoform a
transmembrane and coiled-coil domains protein 2
isoform 1
transmembrane and coiled-coil domains protein 3

426

seedcSSATSGSVGAnsttg

479

kygsdDECSSASASSagags

260

sddecSSGTSGSADSngnqs

transmembrane and immunoglobulin domaincontaining protein 1 precursor
transmembrane channel-like protein 2

173

ksrhqIQQTSESFQLsitkv

139

kprssSLASSASGGEslsee

150456424

transmembrane protein 131

1085

irelkFITTSGSEFVfilna

239735596

transmembrane protein 171 isoform 1

230

ppppyFPESSASAVAespgt

354721145
153251297
54607053
190014610
54792740
188497714
45592949
94536852

transmembrane protein 25 isoform 1 precursor

277

psrhpSLISSDSNNLklnnv

548923663

31377650

transmembrane protein 40 isoform a

84

sssssSSSSSESNDEdqqpr

443287647

transmembrane protein 80 isoform 4

109

yyalyFLATSASQAGrpgar

154707844

transmembrane protein 91 isoform a

73

ppdveDMSSSDSDSDwdgg

transmembrane protein 98

120

mgsgaKMKTSASVSDiivva

transmembrane protein FLJ37396

293

eachaCRPTSASGLAslerh

75677345
472824991

transthyretin precursor

68

wepfaSGKTSESGELhgltt

57164975

4507725

treacle protein isoform b

268

dsessSEESSDSEEEtpaak

57164975

treacle protein isoform b

536

dnsesSEESSDSADSeeapa

57164975

treacle protein isoform b

920

sestaRSSSSESEDEdvipa

57164975

treacle protein isoform b

1075

dsedsSDSSSGSEEDgegpq

20127408

520

ttektSKDTSASAVAvglkq

581

tgsnhKAGSSDSHNSgrrsy

351721563

trifunctional enzyme subunit alpha, mitochondrial
precursor
trinucleotide repeat-containing gene 6B protein
isoform 1
tripartite motif-containing protein 3 isoform 1

697

nsriqVFDSSGSFLSyints

224548921

tripartite motif-containing protein 45 isoform 1

335

vefteHLLTSGSDLEilitk

45439359

triple functional domain protein

2529

dtdrmSTCSSASEQSvqstq

89276766

trophinin isoform 5

904

vcfggSPSSSGSFGGtlsts

241982729

281
89276766

trophinin isoform 5

818

isfggMPCTSASFSGgvsss

89276766

trophinin isoform 5

1074

asfgcAVSTSASFSGavsts

89276766

trophinin isoform 5

974

agfggALNTSASFGSvlnts

116256352

tuberin isoform 1

995

rsriqTSLTSASLGSadens

212720861

tubulin polyglutamylase TTLL11 isoform a

94

alstmRRGSSESELAarwea

tumor necrosis factor receptor superfamily member
1B precursor
tumor necrosis factor receptor superfamily member 27
isoform 1
tumor necrosis factor receptor superfamily member 6
isoform 1 precursor
tumor suppressor p53-binding protein 1 isoform 1

332

sssssSLESSASALDrrapt

239

esftmASCTSESHSHwvhsp

318

qtiilKDITSDSENSnfrne

663

kehhpEEGSSGSEVEeipet

tyrosine-protein kinase transmembrane receptor ROR1
isoform 1 precursor
tyrosine-protein kinase ZAP-70 isoform 1

872

tghvtSLPSSGSNQEanipl

256

clkeaCPNSSASNASgaaap

tyrosine-protein phosphatase non-receptor type 13
isoform 1
tyrosine-protein phosphatase non-receptor type 14

1654

srrdsYSDSSGSGEDdlvta

706

sdatmLIHSSESEEEeeeap

U3 small nucleolar RNA-associated protein 15
homolog isoform 1
U3 small nucleolar RNA-interacting protein 2

195

tvkmfDARTSESVLSvehgq

49

ggkmnEEISSDSESEslapr

42716283

U6 snRNA phosphodiesterase isoform 1

10

aaplvGYSSSGSEDEsedgm

40538799

4507577
314122209
4507583
213972636
134152725
31455611
18375646
34328899
50980309
4759276

ubiquilin-4

122

patpaQPSTSGSASSdagsg

260064009

ubiquitin carboxyl-terminal hydrolase 24

1377

lsssgSNCSSGSEGEpvalh

10190742

ubiquitin carboxyl-terminal hydrolase 29

586

psmklTSESSDSLVLpvepd

122937412

ubiquitin carboxyl-terminal hydrolase 45

232

stklkIFPSSDSQLDplvve

109659841

ubiquitin domain-containing protein 2

10

gcvgaQHDSSGSLNEnsegt

254939613

ubiquitin-associated protein 1-like

115

egedeAEASSGSEEEpapss

UDP-GlcNAc:betaGal beta-1,3-Nacetylglucosaminyltransferase 4
UDP-glucuronosyltransferase 2B17 precursor

82

rcppnHTVSSASLSLpsrhr

57

gheviVLTSSASILVnasks

36031016

uncharacterized protein C10orf118

725

ssmgsRSSSSGSLNArssae

13540527
4507821
24431975

uncharacterized protein C10orf12

706

pcsslGLSSSGSGDAarapk

222537761

uncharacterized protein C11orf96

114

cklrnSLDSSDSDSAl

116256458

uncharacterized protein C12orf45

141

ssqdsSENSSESEDEddsip

59710085

uncharacterized protein C16orf71

398

spessSHSSSDSEEEeeeem

190358526

uncharacterized protein C17orf59

180

seacgGAGSSGSAESgaggg

uncharacterized protein C17orf62 isoform a

174

espteLSQSSDSEAGdpasq

74271818
166295179

uncharacterized protein C17orf85

612

qievsRESSSGSEAEs

21450814

uncharacterized protein C18orf25 isoform a

65

llmelRRDSSESQLAstesd

21450814

uncharacterized protein C18orf25 isoform a

326

lneeiNIASSDSEVEivgvq

311771577

uncharacterized protein C19orf55

166

avptaVNVTSASHAVaplqe

378404903

uncharacterized protein C20orf112 isoform 1

283

hsqedDDSSSESGSGngsst

uncharacterized protein C20orf196

6

dlRDATSGSLSEessal

122937341

31542749

uncharacterized protein C2orf78

9

hwlasATQTSASIVSsslls

284520918

uncharacterized protein C3orf18 isoform 1

17

gwfssRPPTSESDLEpatdg

242332527

uncharacterized protein C5orf42

388

qdsnnSVDSSASDSDpmrqr

256574805

uncharacterized protein C6orf132

877

dhshqAEASSDSIFHsqgtp

51972226

uncharacterized protein C7orf61

132

mcswkSSVSSASVSSqvrtq

282
197304724

uncharacterized protein C8orf46

124

pvpriSVKTSASASLeatam

565671758

uncharacterized protein C9orf84 isoform 1

1129

qistlSSQSSASDLDsviqe

193804923

uncharacterized protein CXorf57 isoform 1

157

idnvhCGETSDSISLetpfr

uncharacterized protein KIAA0408

278

rstsrNFPSSDSEQAyerwk

224589077

uncharacterized protein KIAA0825 isoform 1

1265

kqictPQNSSASDNIeeq

150378498

uncharacterized protein KIAA1109

3376

estliTACSSESLVSkghfk

154090979

uncharacterized protein KIAA1210

779

rkpdaEEVSSDSENIpeegd

148806928

uncharacterized protein KIAA1211

659

akprqESPSSASALAewasi

224451032

uncharacterized protein KIAA1683 isoform a

542

avaagTPNTSGSIHEnppka

148612838

uncharacterized protein KIAA2026

1667

lslgsFPVTSASASAgaqpp

254028267

unconventional myosin-Ih

59806363

22

dfvllDAYTSESAFVdnlrk

51317366

unconventional myosin-XVIIIb

2510

ahlsdSSSSSGSIVSfksad

51317366

unconventional myosin-XVIIIb

1047

deevhVEGSSDSVVLerlca

19924159

unconventional prefoldin RPB5 interactor 1 isoform a

450

ceeatCSDTSESILEeepqe

38016919

UPF0472 protein C16orf72

216

tpgspTHVSSGSNASrrrng

257467652

UPF0606 protein KIAA1549 isoform 1

1460

pssgnEQHSSASIFEhvdri

302129637

UPF0606 protein KIAA1549L

1355

vaaepFDTSSGSVQLiaikp

307611942

UPF0764 protein C16orf89 isoform 1 precursor

393

llisrDPPTSGSQSVgl

189491632

upstream-binding protein 1 isoform LBP-1a

415

lqgqqQAASSASENGsgapy

145580584

uromodulin-like 1 isoform 1 precursor

323

sdyvvLNVTSDSFQVswrln

219842259

usherin isoform A

1453

lcnsvGCVTSASGAGqtlaa

4507809

uteroglobin precursor

16

lvtlaLCCSSASAEIcpsfq

V-set and immunoglobulin domain-containing protein
10 precursor
vacuolar protein sorting-associated protein 13B
isoform 1
vacuolar protein sorting-associated protein 13D
isoform 1
vacuolar protein sorting-associated protein 53
homolog isoform 1
vacuolar protein sorting-associated protein 54 isoform1

172

wwfqaLNSSSESFGHnltvn

2415

sqngaDDQSSASESGsqstc

2434

tpsrhRNSSSESAIVpktvk

802

pappsGAESSGSLSLtaptp

547

aspnsEPCSSDSVSEpectt

vascular endothelial growth factor receptor 1 isoform
1 precursor
vascular endothelial growth factor receptor 3 isoform
1 precursor
very long-chain specific acyl-CoA dehydrogenase,
mitochondrial isoform 1 precursor
visual system homeobox 2

961

kprldSVTSSESFASsgfqe

758

cnakgCVNSSASVAVegsed

219

aafclTEPSSGSDAAsirts

121

pldtsQTASSDSEDVsssdr

voltage-dependent T-type calcium channel subunit
alpha-1G isoform 1
von Willebrand factor A domain-containing protein 1
isoform 1 precursor
WASH complex subunit CCDC53

1579

lddviASGSSASAASeaqck

40

gdlmfLLDSSASVSHyefsr

184

esektVEESSDSESSfsd

31317272

WD repeat and FYVE domain-containing protein 3

3282

gqeaqDEDSSDSEADeqsis

31317272

WD repeat and FYVE domain-containing protein 3

2664

avvpsLTDSSESVSGqrpnt

16554629

WD repeat-containing protein 5

95

lgisdVAWSSDSNLLvsasd

WD repeat-containing protein 52 isoform 1

289

pdkeeQLTTSGSGHIkfwem

40254891
35493701
54607139
189491744
54234034
156104876
104294888
4557235
34365783
20070163
40068485
7705622

256818774

WD repeat-containing protein 70

102

ksssrDTSSSESEQSsdssd

597709787

8922301

WD repeat-containing protein 87 isoform 1

588

lwkfhDFLSSGSQNGlkfie

110735439

Werner syndrome ATP-dependent helicase

1118

sykpcDKISSGSNISkksim

153281226

Williams-Beuren syndrome chromosomal region 28

247

sllpsLSASSDSESGtvlpe

283
protein
6005948

WW domain-binding protein 4

221

lgtldESKSSDSHSDsdgeq

X-box-binding protein 1 isoform XBP1(S)

186

pmdsgGIDSSDSESDillgi

58743323

XK-related protein 7

265

pdllpALSTSASLVSlawtl

33620755

YEATS domain-containing protein 2

342

gedciYPQSSESDISdapps

72534750

YTH domain-containing protein 1 isoform 1

415

kfqgfARLSSESHHGgspih

50345873

318

sklglVIPSSGSGSGnqsid

149944640

zinc finger and BTB domain-containing protein 21
isoform L
zinc finger and BTB domain-containing protein 34

203

eeghsDRGSSGSVSEyeiqi

7662072

zinc finger and BTB domain-containing protein 39

136

arakpLTSTSESHSGtlscp

291621630

zinc finger BED domain-containing protein 6

838

sslkeGTSSSGSVDSsavdn

291621630

zinc finger BED domain-containing protein 6

207

tldvsLSPSSGSNGSfeyip

109452611

378

smapdSSGSSGSIEEpqlge

27881484

zinc finger C2HC domain-containing protein 1C
isoform a
zinc finger CCCH domain-containing protein 7B

871

ekhkeKVFTSDSDASgwafr

8923106

zinc finger CCHC domain-containing protein 10

95

sssssSSDSSASDSSsesee

118640873

8923106

zinc finger CCHC domain-containing protein 10

137

assttSSSSSDSDSDsssss

21735419

zinc finger CCHC domain-containing protein 14

434

mgvqaREESSDSAEEndrrv

170016069

zinc finger CCHC domain-containing protein 2

461

vhsffQSISSDSLHSinnlq

47717112

232

svnhlCPTSSDSLASvcsps

118498345

zinc finger FYVE domain-containing protein 9
isoform 1
zinc finger homeobox protein 3 isoform A

3173

tsglpNKPSSASLSSptpaq

291167749

zinc finger homeobox protein 4

912

qcavcNKFTSDSLEAlsvhv

37574606

zinc finger MYM-type protein 2

392

gtivaQVDSSESFQEfcsts

11968023

zinc finger protein 106 isoform 1

1439

qlevvAIDSSESGEEkpdsp

37594442

zinc finger protein 140

282

crkcgKAFSSGSELIrhqit

110815807

zinc finger protein 169

205

dtmlkGADTSESGAVirgny

222831664

zinc finger protein 184

19

lqgghNLLSSASFQEavtfk

150170718

zinc finger protein 292

2397

ikgctSVVTSESNIIrhykc

120587019

zinc finger protein 318

1619

tsstsPLNSSASQEElhqde

15812178

zinc finger protein 36, C3H1 type-like 2

464

dsylsGSLSSGSLSGsesps

15812178

zinc finger protein 36, C3H1 type-like 2

306

csssaSSCSSASAAStpsga

23097321

zinc finger protein 383

459

ckecgKAFSSGSDLIrhqgi

134133288

zinc finger protein 407 isoform 1

1027

lhcefSAHSSASLELhvkrk

381140059

zinc finger protein 451 isoform 3

171

kenlrIDSSSASQHGrdail

zinc finger protein 518B

639

vissvFSLSSGSENVpegik

154744870

58761535

zinc finger protein 574

358

ldqhlGDHSSESHFLcvdcg

7705935

zinc finger protein 639

158

ydietENNSSESLQDqtdee

289547737

zinc finger protein 641 isoform 3

93

llaagSQVSSASLGVscgpi

289547725

zinc finger protein 653

199

vagssDSSSSGSASDseesp

268607677

zinc finger protein 667

564

cnecgKAFSSGSDLIrhqrs

13376611

zinc finger protein 703

14

gsnprTPESSGSGSGgggkr

118918411

zinc finger protein 777

624

lkprpKSPSSGSGGGgpkpy

zinc finger protein 804B

232

kkvhlKLESSASVFSentee

320118854

31791053

zinc finger protein 821 isoform 1

54

qlrdqDSSSSDSEGDeeett

123701326

zinc finger protein 831

202

thlnnSRLSSESEGAgggll

zinc finger protein basonuclin-2

365

stqneYNESSESEVSptpyk

94721327

284
119709834

zinc finger protein castor homolog 1 isoform a

824

tpsllGAVSSGSAASatpdt

119709834

zinc finger protein castor homolog 1 isoform a

746

sasptSQQSSASLAAataat

zinc finger protein GLI2

356

sdtnqNKQSSESAVSstvnp

zinc finger SWIM domain-containing protein 8
isoform 1
zinc finger SWIM domain-containing protein 8
isoform 1
zinc finger transcription factor Trps1 isoform 1

1190

dsdsiSSSSSDSLGSssssg

390

tgwwySVRTSASHSSasght

400

nksipALQSSDSGDLgkwqd

86991432
122114658
122114658
90652851
28372569

zona pellucida-like domain-containing protein 1
347
rttwsPQSSSGSAVLsagpi
precursor
a
Amino acids in capitals represent the sequence that matches the searched consensus sequence for CK2 hierarchical
multisite phosphorylation. Amino acids in lower case are the surrounding sequence within the candidate protein.
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Appendix B. Phosphorylation status of candidate multisite CK2 hierarchical sequences at
the p, p+1, and p+3 positions from the PhosphoSite Plus database.
Protein Name

Sequencea

Position

pb

p + 1b

p + 3b

14-3-3 protein theta

14249338

Bromodomain and WD repeatcontaining protein 1 isoform A
bromodomain-containing protein
3
BUD13 homolog isoform 1

lrdnlTLWTSDSAGEecdaa

228

Y

Y

Y

kisrkRVCSSDSDSSlqvvk

1903

Y

Y

Y

psrlsSSSSSESGSSsssg

706

Y

Y

Y

14249338

BUD13 homolog isoform 1

prnrpRHRSSDSDLSpprrr

384

Y

Y

Y

prrrqRTKSSDSDLSpprr

400

Y

Y

Y

24307983

cap-specific mRNA(nucleoside2'-O-)-methyltransferase 1
Cell division cycle-associated 7like protein isoform 1
Centrosomal protein of 170kDa
isoform alpha
Cleavage and polyadenylation
specificity factor subunit 7
isoform 1
CREB-regulated transcription
coactivator 2
Crossover junction endonuclease
EME1 isoform 1
CUE domain-containing protein 1

setegKQHSSDSFDDafkad

62

Y

Y

Y

qviqrEDSTSESEDDsrde

195

Y

Y

Y

flqtaLLRSSGSLGHrpsqe

462

Y

Y

Y

pprahSRDSSDSADGratp

236

Y

Y

Y

lpsalNRTSSDSALHtsvmn

169

Y

Y

Y

qtqpvRLLSSESEDEeefip

83

Y

Y

Y

mtslfRRSSSGSGGGgtaga

8

Y

Y

Y

death-inducer obliterator 1
isoform a
E3 SUMO-protein ligase RanBP2

kggddHDDTSDSDSDgltlk

150

Y

Y

Y

gsemkLHDSSGSQVGtgfk

1831

Y

Y

Y

E3 ubiquitin-protein ligase
Topors isoform 1
ephrintype-A receptor 2 precursor

rtpelVELSSDSEDLgsyek

497

Y

Y

Y

rvsirLPSTSGSEGVpfrtv

897

Y

Y

Y

Epidermal growth factor receptor
kinase substrate 8
Folate transporter 1 isoform 1

nitrqNSSSSDSGGSivrd

660

Y

Y

Y

rddrgRCETSASELErmnpg

221

Y

Y

Y

tfrqrAADSSDSDGAeespa

15

Y

Y

Y

krahpEYSSSDSELDetiev

9

Y

Y

Y

109715835

GC-rich sequence DNA-binding
factor 2 isoform 1
hairy/enhancer-of-split related
with YRPW motif protein 1
isoform a
HEAT repeat-containing protein 6

ssswkRVSSSESDFSdaegg

395

Y

Y

Y

168823443

Helicase ARIP4

qevicLDSSSGSEDEkssrd

187

Y

Y

Y

21071052

helicase-like transcription factor

ktavqYIESSDSEEIetsel

396

Y

Y

Y

5901962

rtptgNAPSSESDIDisspn

134

Y

Y

Y

ytdnrARESSDSEEEykkty

457

Y

Y

Y

dsddiQTISSGSEGDdfedk

1136

Y

Y

Y

39995084

Histone acetyltransferase KAT7
isoform 1
histone-lysine Nmethyltransferase SETD2
histone-lysine Nmethyltransferase SETDB1
isoform 1
Integrator complex subunit 3

naeeeSGSSSASEEEdtkpk

1013

Y

Y

Y

15431310

keratin, type I cytoskeletal 14

ahlssSQFSSGSQSSrdvt

431

Y

Y

Y

lamin-B2

tvsraTSSSSGSLSAtgrlg

420

Y

Y

Y

microtubule-associated protein 2
isoform 1

prrlsNVSSSGSINLlespq

1798

Y

Y

Y

GI
5803227
16445436
11067749

31542537
109255228
217035102
32171215
260763969
428755338
18375617
150418007
40805104
32967311
56682953
34808710
44890065
105990528

197313748
224177467

388240801
87578396

286
27735067

Mitotic interactor and substrate of
PLK1
Myc proto-oncogene protein

qpglrRALSSDSILSpapda

393

Y

Y

Y

heetpPTTSSDSEEEqedee

263

Y

Y

Y

NADH dehydrogenase
[ubiquinone] flavoprotein 3,
mitochondrial isoform a precursor
NK-tumor recognition protein

pssssSSSSSDSESDdeadv

158

Y

Y

Y

sdkeeGEATSDSESEvseih

914

Y

Y

Y

Nuclear envelope pore membrane
protein POM121C
PC4 and SFRS1-interacting
protein isoform 1
peptidyl-prolyl cis-transisomerase
G
Pleckstrin homology domaincontaining family H member 2
Plectin isoform 1

enkrrRHDSSGSGHSafepl

79

Y

Y

Y

laktgVTSTSDSEEEgddqe

271

Y

Y

Y

rkkskKSASSESEAEnleaq

255

Y

Y

Y

ssspfLDDSSGSEEEdssr

620

Y

Y

Y

ygrryASGSSASLGGpesav

4671

Y

Y

Y

pre-mRNA-processing factor 40
homolog A
Probable JmjC domain-containing
histone demethylation protein 2C
isoform a
Protein FAM133B isoform 1

gkdsgNWDTSGSELSegele

904

Y

Y

Y

dnvsdFSESSDSENSnkrii

377

Y

Y

Y

mysedKPLSSESLSEseyie

190

Y

Y

Y

217330641

Protein IWS1 homolog

hmdrkKFHSSDSEEEehkkq

361

Y

Y

Y

145580615

Protein KRI1 homolog

tfynrTASSSDSEEDpeale

99

Y

Y

Y

149192855

Protein PRRC2B

lpgglSGCSSGSGHSpyale

1482

Y

Y

Y

191250773

Protein spire homolog 1 isoform a

aptlaELDSSESEEEtlhk

463

Y

Y

Y

31377798

aqstdSLGTSGSLQSkalgy

412

Y

Y

Y

38788333

Rab GTPase-binding effector
protein 1 isoform 1
Remodeling and spacing factor 1

rvhkrRLSSSESEESylskn

1245

Y

Y

Y

24431935

reticulon-4 isoform A

paapkRRGSSGSVDEtlfal

180

Y

Y

Y

serine/threonine-protein kinase
RIO2 isoform 1
snRNA-activating protein
complex subunit 1
Suppressor of IKBKE1 isoform 1

rtrtlSITSSGSAVScstip

485

Y

Y

Y

rhrqvKLDSSDSDSAsgqgq

288

Y

Y

Y

elrelLSISSESLQArken

190

Y

Y

Y

qgqqqNMESSGSQGGraps
y
llgssEDLSSDSESHlpeep

93

Y

Y

Y

569

Y

Y

Y

kdliyDMTTSGSGSGlpllv

185

Y

Y

Y

vrkkdKRNSSDSAIDnpkpn

702

Y

Y

Y

gkrkrKSSTSGSDFDtkkgk

784

Y

Y

Y

kmrskKEDSSDSENAepdld

608

Y

Y

Y

57164975

TATA-binding protein-associated
factor 2N isoform 1
TBC1 domain family member 1
isoform 1
TGF-beta receptor type-1 isoform
1 precursor
Transcriptional regulator ATRX
isoform 1
Transcriptional regulator ATRX
isoform 1
Transcriptional repressor CTCF
isoform 1
Treacle protein isoform b

dnsesSEESSDSADSeeapa

536

Y

Y

Y

57164975

Treacle protein isoform b

sestaRSSSSESEDEdvipa

920

Y

Y

Y

21450814

lneeiNIASSDSEVEivgvq

326

Y

Y

Y

aaclsRQASSDSDSIlslk

2110

Y

Y

N

nekngTGQSSDSEDLpvldn

1107

Y

Y

N

267844811

Uncharacterized protein C18orf25
isoform a
Adenomatous polyposis coli
protein isoform a
AT-rich interactive domaincontaining protein 4A isoform I
Neuron navigator 1 isoform 1

elrikRQNSSDSISSlnsit

1180

Y

Y

N

161169013

Neuron navigator 2 isoform 1

dlrirRQHSSDSVSSinsat

1742

Y

Y

N

71774083
48255924
6631100
526479837
190014586
42560244
217416392
41322916
151301228
118600981
91206456

229331967
4507101
156151379
21327701
50658061
4759226
530788276
530788276
5729790

306922386
115334677

287
557636663

Neuron navigator 3 isoform 1

dlrirRQHSSESVSSinsat

1668

Y

Y

N

periphilin-1 isoform 1

ktsrdTSPSSGSAVSsskvl

206

Y

Y

N

Phospholipase D1 isoform a

phfklFHPSSESEQGltrph

609

Y

Y

N

Tumor suppressor p53-binding
protein 1 isoform 1
tyrosine-protein kinase ZAP-70
isoform 1
Vacuolar protein sortingassociated protein 13D isoform 1
CLIP-associating protein 2
isoform 1
Constitutive coactivator of PPARgamma-like protein 1 isoform a
DCC-interacting protein 13-alpha

kehhpEEGSSGSEVEeipet

663

Y

Y

N

clkeaCPNSSASNASgaaap

256

Y

Y

N

tpsrhRNSSSESAIVpktvk

2434

Y

Y

N

kslqtYLKSSGSVASlpqsd

543

Y

N

Y

kaegsSTASSGSQLAegkg

509

Y

N

Y

rpptaRTSSSGSLGSestnl

426

Y

N

Y

disco-interacting protein 2
homolog B
Insulin receptor substrate 2

dactpPDTSSASEDEgslrr

144

Y

N

Y

rqrpvPQPSSASLDEytlmr

590

Y

N

Y

m7GpppN-mRNA hydrolase
isoform 1
nipped-B-like protein isoform A

wlsrrFGDSSDSDNGfsstg

245

Y

N

Y

sspskENESSDSEEEvsrpr

2489

Y

N

Y

Nuclear receptor corepressor 2
isoform 1
Protein phosphatase Sling shot
homolog 1 isoform 1
Protein PRRC2C

egrvgRAISSASIEGlmgra

1322

Y

N

Y

ssnltRSSSSDSIHSvrgkp

936

Y

N

Y

dqmegSPNSSESFEHiarsa

781

Y

N

Y

24308075

rab11 family-interacting protein 5

ssisgSLPSSGSLQAvssrf

363

Y

N

Y

51242955

STE20-related kinase adapter
protein alpha isoform 1
SWI/SNF-related matrixassociated actin-dependent
regulator of chromatin subfamily
A containing DEAD/Hbox 1
isoform a
Tight junction protein ZO-1
isoform a
Uncharacterized protein
C10orf118
YTH domain-containing protein 1
isoform 1
actin-binding LIM protein 2
isoform 1
A-kinase anchor protein 11

trrktNDASSESIASfskqe

45

Y

N

Y

rgiqyIDLSSDSEDVvspnc

94

Y

N

Y

yaqpsQPVTSASLHIhskga

1442

Y

N

Y

ssmgsRSSSSGSLNArssae

725

Y

N

Y

kfqgfARLSSESHHGgspih

415

Y

N

Y

drnkeTRTSSESIISvpa

278

Y

N

N

rslseEVESSESGELpevdv

1175

Y

N

N

AP-1 complex subunit beta-1
isoform a
Bifunctional glutamate/prolinetRNA ligase
Clathrin interactor 1 isoform 1

kslppRTASSESAESpetap

598

Y

N

N

igqniSSNSSASILEsksly

815

Y

N

N

nkdkyVGVSSDSVGGfryse

162

Y

N

N

eagseEEGSSASGLAkvkel

668

Y

N

N

119943108

Clustered mitochondria protein
homolog
Disks large homolog 3 isoform b

qeqgvTSNTSDSESSskgqe

293

Y

N

N

291621657

dmX-like protein 2 isoform 1

lakasEGASSESLLSvpgqk

928

Y

N

N

164607124

Fanconi anemia group I protein
isoform 1
histone-lysine Nmethyltransferase 2C
inositol-trisphosphate 3-kinase B

aktkmANKTSDSLLSmkfv

799

Y

N

N

krsviRKDSSGSISEqlpcr

1306

Y

N

N

sgrrrLNSSSGSGSGssg

84

Y

N

N

LIM domain-containing protein
ajuba isoform 1

sprssFASSSASDASkpssp

126

Y

N

N

48255929
4505873
213972636
31455611
54607139
333440449
39652628
6912242
55749758
38683860
31542498
47578105
331284178
239047414
115298682

190358532

116875767
36031016
72534750
194272196
7706457
260436862
62241042
307078123
87162455

91718902
194272161
14249622

288
193083125

MAP/microtubule affinityregulating kinase 3 isoform a
nephrocystin-4 isoform a

edgisSRKSSGSAVGgkgia

454

Y

N

N

kvvssSKTSSGSQALvlrsr

330

Y

N

N

Nucleolar protein of 40kDa
isoform a
Nucleosome assembly protein 1like 3
RNA-binding protein Musashi
homolog 2 isoform a
Transcription factor Sp4

kkkhrDRKSSDSDSSdsesd

221

Y

N

N

sssstSGSSSGSGSSssssg

54

Y

N

N

meangSQGTSGSANDsqhd
p
ennnkKPKTSGSQDSqpspl

8

Y

N

N

36

Y

N

N

Transcription initiation factor
TFIID subunit 3
Transforming acidic coiled-coilcontaining protein 2 isoform a
Uncharacterized protein C11orf96

repdpFEFSSGSESEgdift

409

Y

N

N

dpakdLSRSSDSEEAfetpe

1945

Y

N

N

cklrnSLDSSDSDSAl

114

Y

N

N

Zinc finger CCHC domaincontaining protein 2
3'-5' exoribonuclease 1

vhsffQSISSDSLHSinnlq

461

Y

N

N

tkgskFITSSASDFSdpvyk

55

N

Y

Y

skelvSSSSSGSDSDsevdk

11

N

Y

Y

ktvngKAESSDSGAEseeee

183

N

Y

Y

kkkgkGTNSSDSEELsage

1151

N

Y

Y

spqrrGPLTSGSDEEnvalp

201

N

Y

Y

23943920

Activated RNA polymerase II
transcriptional coactivator p15
acyl-CoA-binding domaincontaining protein 5 isoform 1
AT-rich interactive domaincontaining protein 4B isoform 1
Cytoplasmic dynein 1 light
intermediate chain 2 isoform 1
Cytosolic phospholipase A2

tkhivSNDSSDSDDEshepk

433

N

Y

Y

148539628

Disks large homolog 1 isoform1

eqmmnSSISSGSGSLrtsqk

569

N

Y

Y

61835148

Fragile X mental retardation
syndrome-related protein 1
isoform a
histone-lysine Nmethyltransferase SUV39H2
isoform 1
HMG box transcription factor
BBX isoform 1
Nuclear factor NF-kappa-Bp100
subunit isoform a
Nuclear pore complex protein
Nup214
Nucleolar and coiled-body
phosphoproteins 1 isoform 1
Poly[ADP-ribose]polymerase 1

sekaiNGPTSASGDDisklq

583

N

Y

Y

qmkgsGDISSDSIDHspakk

380

N

Y

Y

kktckKRQSSESDIEsviyt

477

N

Y

Y

lcplpSPPTSDSDSDsegpe

709

N

Y

Y

vtgepPSYSSGSDSSkaapg

502

N

Y

Y

kkakkKASSSDSEDSseeee

83

N

Y

Y

qdrifPPETSASVAAtppp

360

N

Y

Y

Potassium voltage-gated channel
subfamily H member 2 isoform a
PREDICTED:HLA class I
histocompatibility antigen, A-2
alpha chain isoform X1
pre-mRNA-splicing factor SLU7

lrsglLNSTSDSDLVryrti

318

N

Y

Y

ggsysQAASSDSAQGsdvsl

348

N

Y

Y

kkkkhRKSSSDSDDEekkhe

511

N

Y

Y

Regulator of cell cycle RGCC

hlermKRRSSASVSDssgf

63

N

Y

Y

Rho guanine nucleotide exchange
factor 10
RNA-binding protein 14 isoform1

tqksdLSSSSGSLSLshg

1258

N

Y

Y

laapyRTQSSASLAAsyaaq

519

N

Y

Y

RNA polymerase-associated
protein LEO1 isoform 1
tonsoku-like protein

reeraRIYSSDSDEGseedk

606

N

Y

Y

gdnrrPSSTSGSDSEesrpr

861

N

Y

Y

U3 small nucleolar RNAinteracting protein 2

ggkmnEEISSDSESEslapr

49

N

Y

Y

23510323
543173111
21327710
20373175
67010025
151301171
630044887
222537761
170016069
31543184
217330646
203098629
332164768
5453634

301171588
217035121
117320531
33946327
548923888
156523968
4557729
578841487
27477111
132626811
62548864
5454064
20270337
187608777
4759276

289
55742689

Actin filament-associated protein
1-like 1 isoform 1
Ankyrin repeat and LEM domaincontaining protein 2
AT-rich interactive domaincontaining protein 4B isoform 1
bromodomain-containing protein
4 isoform long
Calsenilin isoform 1

krlsqEKQTSDSDSVgvgdn

347

N

Y

N

ascrdKATTSGSNSIsvraf

628

N

Y

N

ndrkaEFPSSGSNSVlntpp

1012

N

Y

N

ssdssSDSSSDSDSStddse

492

N

Y

N

stapqGSDSSDSELElstvr

61

N

Y

N

Dentin sialophosphoprotein
preproprotein
Disks large-associated protein 4
isoform a
FCH domain only protein 2
isoform a
gamma-tubulin complex
component 5 isoform a
interleukin-3 receptor subunit
alpha isoform 1 precursor
Melanophilin isoform 2

sdssdSNSSSDSDSSdsd

576

N

Y

N

tsqsgLSNSSDSLDSstrpp

607

N

Y

N

aesssSISSSASLSAantpt

513

N

Y

N

kmsdnASASSGSDQGpssrq

533

N

Y

N

rfddiSRLSSGSQSShilvr

173

N

Y

N

hskrrGRASSESQGLgagvr

335

N

Y

N

95147555

microtubule-associated protein1A

grshwDDSTSDSELEkgare

2104

N

Y

N

114145479

gatgpSADTSGSELDgrcsl

34

N

Y

N

eksgpCSSSSDSDSGdegde

313

N

Y

N

kaaesSSDSSDSDSSeddea

374

N

Y

N

93141031

Neuroepithelial cell-transforming
gene 1 protein isoform 1
NF-kappa-B inhibitor beta
isoform 1
Nucleolar and coiled-body
phosphoproteins 1 isoform 1
paralemmin-1 isoform 1

rwlleGTPSSASEGDedlrr

60

N

Y

N

87196343

PDZ domain-containing protein 2

skppiGRRSSGSIVSgslgh

2372

N

Y

N

45387958

glslhDRRSSGSEESildlr

1159

N

Y

N

170763500

Protein phosphatase 1 regulatory
subunit 26
Protein SET isoform 1

ppalgPEETSASAGLpkkge

26

N

Y

N

384475548

Protein sprouty homolog 1

ststgSAASSGSNSSasseq

121

N

Y

N

vikvfVATSSGSIAIrkkqq

72

N

Y

N

algirKRHSSGSASEdrlaa

229

N

Y

N

esetnQNSSSDSEAErrppp

58

N

Y

N

llmelRRDSSESQLAstesd

65

N

Y

N

rqagaPGGSSGSGGSpelsa

591

N

N

Y

akssgNSSSSGSGSGstsag

14

N

N

Y

dlsriSLESSASLEGslskf

1449

N

N

Y

ngiggCSSSSDSGSAekrrr

175

N

N

Y

tptqpESFSSGSQDVhqkrv

168

N

N

Y

seseeSQDSSDSIGSsqkah

43

N

N

Y

etytpPDTSSASEDEgslrr

136

N

N

Y

lshgeVKGTSGSLADvfant

199

N

N

Y

82659109

SH3 domain-binding glutamic
acid-rich protein isoform a
Small G protein signaling
modulator 2 isoform 1
Transcription factor 7-like 2
isoform 1
Uncharacterized protein C18orf25
isoform a
angiomotin-like protein 2
isoform1
aspartyl/asparaginyl betahydroxylase isoform a
C-myc promoter-binding protein
isoform 1
CREB/ATF bZIP transcription
factor
CREB-regulated transcription
coactivator 1 isoform 1
Cyclic AMP-dependent
transcription factor ATF-1
disco-interacting protein 2
homolog A isoform a
disco-interacting protein 2
homolog B
E3 ubiquitin-protein ligase UBR4

kekekDGETSGSQEDqlcta

3382

N

N

Y

385428859

Epidermal growth factor receptor

ergtpGPDSSGSLGSgeftg

370

N

N

Y

148664230
332164768
19718731
7305199
89001107
34335253
226371723
156616297
13324710
109826351

21361135
548923888

6677929
148612795
226371764
21450814
522838240
14589866
221307568
88900495
148596965
4885073
45827692
55749758

290
substrate 15-like 1 isoform 1
239049440

FCH domain only protein 1
isoform a
fos-related antigen 2

taepsRFSSSDSDFDdeepr

343

N

N

Y

rssssGDQSSDSLNSptlla

313

N

N

Y

ngsdsESETSESDDDspprp

357

N

N

Y

etnqgEFITSDSQEAlfsk

263

N

N

Y

rmramSLVSSDSEGEqnelr

2644

N

N

Y

195972866

General transcription factor IIE
subunit 1
Histone H2A deubiquitinase
MYSM1
Inositol 1,4,5-trisphosphate
receptor type 1 isoform 1
keratin, type I cytoskeletal 10

ssgghKSSSSGSVGEssskg

569

N

N

Y

119395750

keratin, type II cytoskeletal 1

gyrsgGGFSSGSAGIinyqr

17

N

N

Y

microtubule-associated
serine/threonine-protein kinase 4
isoform b
Pentatricopeptide repeat domaincontaining protein 3,
mitochondrial precursor
pre-mRNA-splicing regulator
WTAP isoform 1
Rho guanine nucleotide exchange
factor 18 isoform a
RNA polymerase II subunit ACterminal domain phosphatase
isoform 1
sentrin-specific protease 1

avppaPRGSSASQEEqdeel

110

N

N

Y

tsdsdTDSSSDSDSDtsegk

677

N

N

Y

ngsssRQRTSGSGFHregnt

286

N

N

Y

srgsqRWESSASFDLkqqll

914

N

N

Y

esegtKSSSSASDGEsegkr

470

N

N

Y

psyysDNPSSDSFLGsgdlr

76

N

N

Y

Survival of motor neuron-relatedsplicing factor 30
TBC1 domain family member 2B
isoform a
T-box transcription factor TBX22
isoform 1
Tumor necrosis factor receptor
superfamily member 6 isoform 1
precursor
Uncharacterized protein C17orf59

tqpseTLASSDSFAStqpth

59

N

N

Y

sgdpsSEGTSGSGSVsirkp

324

N

N

Y

gsdsgYGNSSESLEEkdiqm

82

N

N

Y

qtiilKDITSDSENSnfrne

318

N

N

Y

seacgGAGSSGSAESgaggg

180

N

N

Y

Zinc finger and BTB domaincontaining protein 34
Zinc finger protein 106 isoform 1

eeghsDRGSSGSVSEyeiqi

203

N

N

Y

tgslnHKASSDSAASfevvr

418

N

N

Y

Zinc finger protein 318

tsstsPLNSSASQEElhqde

1619

N

N

Y

4885245
144922725
148227842
269954690

38488767
38683855
21361159
41327769
67188445
390131986
5032113
194018478
18375603
4507583
190358526
149944640
11968023
120587019
a

Amino acids in capitals represent the sequence that matches the searched consensus sequence for CK2 hierarchical
multisite phosphorylation. Amino acids in lower case are the surrounding sequence within the candidate protein.
b

Y, phosphorylated; N, not phosphorylated.
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Appendix C. Candidate sequences in the human proteome that match the proline-directed
CK2 hierarchical consensus sequence.
GI

Protein Name

121583483
117168250
10863929
32313587
111955084
48314820
24119277
94557301
33186925
21493022
21493022
27363457
7705981
62988361
50897850
145275198
289577109
166064001
58218977
29826319
4502199
22035550
117956409
11345484
168823435
4503273
157671951
37620163
37620163
46519147
46519147
140161500
18254476
56676397
134948558
134948558
38683807

1-phosphatidylinositol 3-phosphate 5-kinase isoform2
1-phosphatidylinositol 4,5-bisphosphate
phosphodiesterase epsilon-1 isoform 1
2-5A-dependent ribonuclease
24-hydroxycholesterol 7-alpha-hydroxylase
5-azacytidine-induced protein 1 isoform a
5-oxoprolinase
5-phosphohydroxy-L-lysine phospho-lyase isoform 2
5'-AMP-activated protein kinase catalytic subunit
alpha-1 isoform 1
5'-AMP-activated protein kinase subunit gamma-2
isoform a
A-kinase anchor protein 12 isoform 1
A-kinase anchor protein 12 isoform 1
aarF domain-containing protein kinase 4 isoform a
ABI gene family member 3 isoform 1
absent in melanoma 1 protein
actin filament-associated protein 1-like 2 isoform 1
ADAMTS-like protein 3 precursor
ADP-ribosylation factor-binding protein GGA3
isoform 1
ADP-ribosylation factor-like 17-like isoform b
adropin precursor
alpha-adducin isoform a
amphiregulin preproprotein
amyloid beta A4 precursor protein-binding family A
member 2 isoform a
amyotrophic lateral sclerosis 2 chromosomal region
candidate gene 8 protein
AN1-type zinc finger protein 3
androglobin
angiotensin-converting enzyme isoform 1 precursor
anion exchange protein 3 isoform 1
ANKHD1-EIF4EBP3 protein
ANKHD1-EIF4EBP3 protein
ankyrin repeat and KH domain-containing protein 1
isoform 1
ankyrin repeat and KH domain-containing protein 1
isoform 1
ankyrin repeat and SAM domain-containing protein
1A
ankyrin repeat and SOCS box protein 5
ankyrin repeat domain-containing protein 11
ankyrin repeat domain-containing protein 12 isoform
1
ankyrin repeat domain-containing protein 12 isoform
1
ankyrin repeat domain-containing protein 17 isoform
a

Position

Sequencea

1538
785

rqgeeskiSAMDASPrnispglq
cnrsleTDEEDSPsegnss

395
260
8
1064
145
528

qevavkTFCEGSPraqrev
diveteTSKENSPnyglll
mkgtraigSVPERSPagvdlslt
vrvviprgSILDPSPeaavvggn
hayhghlsSLIDISPykfrnldg
sltssvTSLDSSPvdltpr

129

sfsgifrsSSKESSPnsnpatsp

247
1389
125
260
758
207
26
587

eetlkreqSHAEISPpaesgqav
iidgakevSSLEGSPppclgqee
grlqseggSGLDSSPflseanae
vfqrppTLEELSPpppdee
fglgkkkeSQPEMSPalhlmqnl
dnrllcykSSKDHSPqldvnllg
hsplpqTTAEKSPgayflp
mkvklqppSGTELSPfspiqppa

108
42
642
58
243

lcgvtgTNDEASPgsltsy
hsrsadvdSLSESSPnsspgpcp
aatfkpTLPDLSPdepsea
vtsrsemsSGSEISPvsempsss
slsmtsitSASEASPehgpepgp

574

qlqpryTSPDESPavvsvn

123
1524
333
169
2084
737
2084

rscgtdsqSENEASPvkrprlle
prtrspTILETSPrlirka
vaeeffTSLELSPmppefw
qkakfsigSDEDDSPglpgraav
tqeeaqpsSVSDLSPmsmpfasn
pqepdrTSQENSPallgvq
tqeeaqpsSVSDLSPmsmpfasn

737

pqepdrTSQENSPallgvq

525

qllctagqSHPDGSPqqgachka

66
746
146

ygvtqgqgSWADRSPlheaasqg
snkaekerSLKEKSPkeeklrly
allmqmTARDNSPdstpnh

1570

pvysdsTIQEASPnfekay

2258

pfgpfsTLFENSPtsahaf

292
379317153
21264337
22748653
31745180
38569405
56549668
51479158
51479158
10337613
72256200
164664508
14043024
629266065
114431248
7661958
7661958
183396783
125988395
87299628
7705638
4507339
394953947
13124765
227497884
387157909
191251777
49472835
148727368
223029436
223029436
14249338
14249338
14249338
210147453
210147453
209862787
209862787
148596944
118600977
347446676
145309304
16445393
4757956
16753221

AP-5 complex subunit beta-1
arf-GAP with Rho-GAP domain, ANK repeat and PH
domain-containing protein 3
arrestin domain-containing protein 1
aryl hydrocarbon receptor nuclear translocator-like
protein 2 isoform 1
arylsulfatase B isoform 1 precursor
AT-rich interactive domain-containing protein 2
ataxin-1
ataxin-1
B-cell CLL/lymphoma 7 protein family member A
isoform a
B-cell CLL/lymphoma 9 protein
B-cell lymphoma 3 protein
BAG family molecular chaperone regulator 3
basement membrane-specific heparan sulfate
proteoglycan core protein isoform a precursor
basic helix-loop-helix domain-containing protein
KIAA2018
bcl-2-associated transcription factor 1 isoform 1
bcl-2-associated transcription factor 1 isoform 1
BCL-6 corepressor isoform a
bifunctional arginine demethylase and lysylhydroxylase JMJD6 isoform 1
biorientation of chromosomes in cell division protein
1-like 1
bolA-like protein 1 precursor
brachyury protein isoform 1
brachyury protein isoform 2
brain-enriched guanylate kinase-associated protein
brain-enriched guanylate kinase-associated protein
breast cancer anti-estrogen resistance protein 3
isoform 1
breast carcinoma-amplified sequence 1
bridging integrator 2
bromodomain and PHD finger-containing protein 3
BTB/POZ domain-containing protein 18
BTB/POZ domain-containing protein 18
BUD13 homolog isoform 1
BUD13 homolog isoform 1
BUD13 homolog isoform 1
C2 calcium-dependent domain-containing protein 4C
C2 calcium-dependent domain-containing protein 4C
C2 calcium-dependent domain-containing protein 4D
C2 calcium-dependent domain-containing protein 4D
C2 domain-containing protein 3
C3 and PZP-like alpha-2-macroglobulin domaincontaining protein 8
C7orf55-LUC7L2 protein
cadherin EGF LAG seven-pass G-type receptor 3
precursor
cadherin-12 preproprotein
cadherin-16 isoform 1 precursor
cadherin-22 precursor

257
76

egerslTAREHSPeearel
gsldpksdSAMEPSPspapqaqp

192
243

lhadvenqSGKDTSPvvasllqk
vakvkeqlSSFDISPreklidak

381
625
85
403
97

gfdvwkTISEGSPspriel
stsvvrvdSVPDVSPapspagip
lhkalsTGLDYSPpsaprs
levqqaTHREASPstlndk
hddnsnqsSIADASPikqenssn

1033
368
273
2044

hdaiktvaSSDDDSPparspnlp
katrpastSQPDPSPdrsantsp
frssvqgaSSREGSParsstplh
ariqvvvlSASDASPppvkiess

352

csqpprTAGDSSPmsisks

216
528
1370
122

sgdiwpglSAYDNSPrsphspsp
dareksTFREESPlrikmi
frkrpepsSDYDLSPakqepkpf
kyyieymeSTRDDSPlyifdssy

1278

atlehsTNLDSSPslssvt

117
304
243
547
343
352

tpaqwrenSQLDTSPpclggnkk
hrnnspTYSDNSPaclsml
sqqpgysqSYSDNSPaclsmlqs
gsrdslepSSMEASPemhpaarl
drkppaTTYEGSPrfakat
gcklppqsSGVDTSPcpnspvfr

311
463
983
443
621
369
385
401
267
219
174
143
1672
415

kkdpedTGAEKSPttsadl
gtasprTSLEVSPnpeppe
prsrscseSEGERSPqqeeetgm
spdhpvvkSEFESSPelvekepm
ssldtpqrSYGDLSPpcsnwvet
kqspghqdSDSDLSPprnrprhr
rnrprhrsSDSDLSPprrrqrtk
rrrqrtksSDSDLSPprrsqppg
hgslsaddSTPDASPgsrrrltr
sggesdtgSSAESSPfgspllsr
hslspekaSSADTSPhsprragp
rapdsdtaSSPDSSPfgsprpgl
ccvsfaTADESSPvytqvv
ayvgkvelSYPDGSPaegvtvqi

418
3294

lascdrdrSSRDRSPrdrdrkdk
tprsatshSISELSPdsevprse

170
343
175

dgpyvaTVPEMSPvgayvl
cpprdptvSIPELSPpgtevtrl
flhgpyigSVAELSPtgtsvmqv

293
189571674
189571674
14589891
76880478
62388890
14149742
4505677
29826341
29826341
5729758
162329608
115529445
115529445
116008447
23097238
145699139
217416347
157743265
15718706
188497718
11034811
119964726
5729765
130980075
52145312
118150654
171184451
70608155
48717495
27545323
27545323
40255020
29244924
22748877
31563537
270132810
105990535
57222570
57222570
83035129
154090997
299829223

cadherin-23 isoform 1 precursor
cadherin-23 isoform 1 precursor
cadherin-3 preproprotein
calcitonin gene-related peptide 1 isoform alphaCGRP preproprotein
calcium-activated potassium channel subunit alpha-1
isoform a
calcium-binding and coiled-coil domain-containing
protein 1 isoform 1
calcium/calmodulin-dependent 3',5'-cyclic nucleotide
phosphodiesterase 1B isoform 1
calmodulin-binding transcription activator 2 isoform1
calmodulin-binding transcription activator 2 isoform1
calpain-9 isoform 1
cAMP-specific 3',5'-cyclic phosphodiesterase 4A
isoform 1
cAMP-specific 3',5'-cyclic phosphodiesterase 4C
isoform PDE4C1
cAMP-specific 3',5'-cyclic phosphodiesterase 4C
isoform PDE4C1
CAP-Gly domain-containing linker protein 2 isoform
1
carbohydrate sulfotransferase 13 precursor
cartilage intermediate layer protein 2 precursor
caskin-2 isoform a
caspase recruitment domain-containing protein 11
caspase-8 isoform B precursor
catenin alpha-3 isoform a
catenin delta-2 isoform 1
cation-independent mannose-6-phosphate receptor
precursor
cell growth regulator with RING finger domain
protein 1
centromere protein J
centrosomal protein C10orf90
centrosomal protein kizuna isoform 1
centrosome-associated protein 350
cGMP-inhibited 3',5'-cyclic phosphodiesterase A
isoform 1
chondroitin sulfate glucuronyltransferase isoform 1
precursor
chondroitin sulfate synthase 2 isoform 1
chondroitin sulfate synthase 2 isoform 1
chromatin modification-related protein MEAF6
isoform 1
chromodomain-helicase-DNA-binding protein 6
class E basic helix-loop-helix protein 22
CLIP-associating protein 1 isoform 1
CMRF35-like molecule 9 isoform 1 precursor
coagulation factor V precursor
codanin-1
codanin-1
coiled-coil domain-containing protein 108 isoform 1
coiled-coil domain-containing protein 13
coiled-coil domain-containing protein 141

1861
2738
570
29

nlpmniTISENSPvssfva
pqyqllTVPEHSPrgtlvg
rqvlniTDKDLSPhtspfq
slhaapfrSALESSPadpatlse

922

ftppgmdrSSPDNSPvhgmlrqp

71

fvwssvpeSTTDGSPihtsvqfq

508

asgitnqmSIDELSPceeeapps

857
536
287
151

fsvtsaysSAPDGSPppaplpas
lspalsTITDFSPewsype
wgqvewngSWSDSSPewrsvgpa
esflyrsdSDYDMSPktmsrnss

125

esflyrsdSDYELSPkamsrnss

577

qqgdrereSGLDISPmcdkhtas

36

sssaavaaSSKEGSPlhkqssgp

150
1065
719
477
186
209
690
1658

ahapgrlpSLADFSPaeinrrlr
hnygvyTVTDQSPrlakei
qeqpapqpSGGDPSPpqernlpe
ngqeaddsSTSEESPedskyflp
eefskersSSLEGSPdefsngee
deiagaraSLKENSPllhsicsa
tnaviiphSGWENSPlqddrkiq
ecsvrngsSIVDLSPlihrtggy

10

aavflvTLYEYSPlfyiav

725
535
617
1647
569

tedrergiSSREDSPqvcddkgp
kksedpTTPEPSPaapspa
kiaseasfSSSEGSPlsrhenkk
krrghhddSDEEASPekttlsta
hraltytqSAPDLSPqiltppvi

728

epglvqkfSLRDCSPrlseelyh

300
403
122

gdhegvhySHLELSPgepvqegd
yfteqhafSCADGSPrcplrgad
repgsgTESDTSPdfhnqe

1380
141
759
223
1687
342
228
1657
468
1421

dsraaqdgSDPDKSPwpvssalt
srgsvaesSGGEQSPdddsdgrc
csrdtsreSSRDTSPargfppld
ppmqldstSAEDTSPalssgssk
kssegkTYEDDSPewfked
rrmvtakdSDPELSPavldsles
scvpssqpSALDTSPwglglppg
preeseTSEEKSPnkwgpv
nkgvgegsSGREVSPaytqfled
rllsnvTVMEGSPvtleve

294
226246554
226246554
75677376
7661690
73486666
110735435
507116137
183583553
295849303
540344553
115298678
178557739
178056552
168229161
16975496
112420992
259013213
156142182
14211949
114205399
116642889
4557439
33350932
5453754
52630425
50593110
51317380
182507165
4503257
117553586
148539840
58530840
11641269
94967023
148528998
594140514
291621657
4557719
4504191
153792012
5174501
289547596
5453932
24475814
27597059
170763515
408684411

coiled-coil domain-containing protein 168
coiled-coil domain-containing protein 168
coiled-coil domain-containing protein 62
coiled-coil domain-containing protein 9
collagen alpha-1(IX) chain isoform 1 precursor
collagen alpha-3(V) chain preproprotein
collagen alpha-5(VI) chain isoform 1 precursor
collagen alpha-5(VI) chain precursor
complement C2 isoform 3
complement C2 isoform 4
complement C3 precursor
complement C4-B preproprotein
condensin complex subunit 1
coronin-7 isoform 1
cortactin-binding protein 2
crumbs homolog 2 precursor
CUB and sushi domain-containing protein 1
precursor
CXXC-type zinc finger protein 1 isoform 1
cyclic AMP-responsive element-binding protein 3like protein 3
cyclic nucleotide-gated cation channel beta-1 isoform
a
cyclic nucleotide-gated cation channel beta-3
cyclin-dependent kinase 3
cytoplasmic dynein 1 heavy chain 1
cytoplasmic protein NCK1 isoform 1
cytoplasmic protein NCK2 isoform A
cytosolic 5'-nucleotidase 1B isoform 1
D-glucuronyl C5-epimerase
dapper homolog 3
death domain-associated protein 6 isoform a
dedicator of cytokinesis protein 5
deleted in malignant brain tumors 1 protein isoform a
precursor
desmoplakin isoform I
dipeptidase 2 precursor
disabled homolog 2-interacting protein isoform 1
dmX-like protein 1
dmX-like protein 1 isoform 1
dmX-like protein 2 isoform 1
DNA ligase 1 isoform 1
DNA mismatch repair protein Msh6
DNA polymerase zeta catalytic subunit isoform a
DNA-binding protein Ikaros isoform 1
DNA-binding protein SATB2
DNA-directed RNA polymerase II subunit RPB11-a
DNA-directed RNA polymerase III subunit RPC8
isoform a
dnaJ homolog subfamily C member 9
Double sex- and mab-3-related transcription factorA1
Down syndrome cell adhesion molecule isoform 2

4788
969
623
387
330
1275
1889
18
456
27
379
1115
1063
83
1579
1145
3390

tsappqvfSITEHSPlskrkepq
qtlstqTILENSPcpmmdp
ekasivlpSQDDFSPtsklqrll
petpqpTSPETSPketpmq
pgadglTGPDGSPgsigsk
gppgdpgvSGIDGSPgekgdpgd
iitatmefSALDISPtvfafder
liiwteTLADQSPgpgpvy
qflcsgTQEDESPckgesg
sgsaratgSGVERSPsaaifsfe
dlmvfvTNPDGSPayrvpv
lsqqqadgSFQDLSPvihrsmqg
qlrllfTMLEKSPlpivrs
chsdlvTDLDFSPfddfll
innlrmpvSQKEVSPlsshqtte
ecslnvTCLDGSPceggsp
sskvnaTFSEASPvelklt

307
392

ddhglpwmSDTEESPfldpalrk
prpeadTTREESPgspgad

594

lidpdvTSDEESPkpspak

155
286
141
256
84
161
589
164
558
1507
45

kklvegdlSSPEASPqtakptav
talahpyfSSPEPSPaarqyvlq
sqlrvlTLSEDSPyetlhs
vmqnnpltSGLEPSPpqcdyirp
lgktrrktSARDASPtpstdaey
srtpstspSLHDSSPpplsgqps
hinqlqllSTIDESPvfkefvkr
iyaserpkSLGDASPsapevvga
eqpeelTLEEESPvsqlfe
kwfevkqiSTEEISPlenaietm
evpldpTVAEGSPfpsest

2614
460
28
1902
1206
943
103
88
1614
383
355
79
155

sssfsdTLEESSPiaaifd
taklpakwSVSESSPhmapvlav
gsrrslpgSLSEKSPsmepsaat
assfldTSKDCSPssplkl
llrsvdlvSSVDGSPpfpvslsw
vpgqknvdSSPETSPsvspmphs
atspennaSLSDTSPmdsspsgi
vapaapTSCDFSPgdlvwa
qnssqldnSVSDDSPiffsdpgf
lskaklvpSEREASPsnscqdst
avkpeptnSSVEVSPdiyqqvrd
iiirvqTTPDYSPqeaftn
irfrvvdeSFVDTSPtgpssada

85
285
1234

vydeqgTVDEDSPvltqdr
lsphpgeqSGGEESPrslsssdl
shpyptviSEFEASPdsfsyrip

295

21359935
38372911
38372911
42764683
238231453
157779137
39930351
256542310
19115954
217416452
239048792
94536811
61676188
61676188
261823980
217416388
21040269
148839382
15147333
15147337
19923497
7662358
304555610
148806925
148596928
38569394
60498978
50959176
29294651
87298935
31377575
156104874
499591691
221316650
13449287
34577114
218505680
10835013
37574042
41872448
24307883
4758316
221316747
4826659
21361861

precursor
Down syndrome cell adhesion molecule-like protein1
dual specificity protein phosphatase 16
dual specificity protein phosphatase 16
dual specificity protein phosphatase 6 isoform a
dual specificity protein phosphatase 7
dymeclin
dynamin-binding protein
dynein heavy chain 17, axonemal
dynein heavy chain 5, axonemal
dynein intermediate chain 2, axonemal isoform 1
E3 ubiquitin-protein ligase CHFR isoform 1
E3 ubiquitin-protein ligase HECW1 isoform a
E3 ubiquitin-protein ligase HUWE1
E3 ubiquitin-protein ligase HUWE1
E3 ubiquitin-protein ligase MARCH1 isoform 1
E3 ubiquitin-protein ligase NEURL1B
E3 ubiquitin-protein ligase RNF133 precursor
E3 ubiquitin-protein ligase RNF169
E3 ubiquitin-protein ligase TRIM37
E3 ubiquitin-protein ligase UBR5
echinoderm microtubule-associated protein-like 4
isoform a
ectonucleotide pyrophosphatase/phosphodiesterase
family member 4 precursor
EF-hand calcium-binding domain-containing protein
13 isoform A
EGF, latrophilin and seven transmembrane domaincontaining protein 1 precursor
electrogenic sodium bicarbonate cotransporter 1
isoform 1
elongator complex protein 1
EMILIN-2 precursor
endoplasmic reticulum-Golgi intermediate
compartment protein 2
endoribonuclease Dicer isoform 1
engulfment and cell motility protein 3
ENTH domain-containing protein 1
envoplakin
eomesodermin homolog isoform 1
ephrin type-A receptor 1 precursor
epidermal growth factor-like protein 8 precursor
ERC protein 2
ERI1 exoribonuclease 2 isoform 1
estrogen receptor beta isoform 1
ethanolamine-phosphate phospho-lyase isoform 1
ETS domain-containing protein Elk-4 isoform a
ETS translocation variant 4 isoform 1
ETS translocation variant 5
exophilin-5
F-actin-capping protein subunit beta isoform 1
Fanconi anemia group D2 protein isoform a

1298
368
611
194
232
133
1424
3864
2400
479
190
655
2849
2823
38
10
338
424
794
1165
727

pgsgqpapSEYETSPeqlfyria
psvpsvqpSLLEDSPlvqalsgl
sdradsrrSWHEESPfekqfkrr
rdpnsaTDSDGSPlsnsqp
elpssaTESDGSPvpssqp
elqlhfTYEEKSPgnyssd
tlsaslnpSNSESSPsrcpsdpd
grsvefskSYEESSPstsiffil
ngmvfmssSILDWSPilegflkk
sqlgttTLLEVSPglstlq
dlfptasaSSTEPSPagrersss
gdthpstgSESDSSPrqggdhsc
sdaltavsSQLEGSPmdtsslas
sgeaetTQMELSPaptits
dasqtsTLNEKSPgrsasr
gntvhrTLPDPSPparlla
spseeeTNNEVSPagtsdk
rslqkqTSYEASPrilkkw
skgdcqTLSEGSPgssqsg
mvcpsgTNPDDSPlyvlcc
ghssyiTHLDWSPdnkyim

263

idhsyyTLIDLSPvaailp

292

lqeqyedvSITEGSPlneitsdr

149

llqevyrnSVTDLSPtdiityie

1063

pflsdskpSDRERSPtflerhts

517
514
114

eedvflavSHSEFSPrsvihhlt
lqmtnnTGAELSPpgaaal
glvyepTVFDLSPqqkewq

1249
479
284
1695
668
659
184
11
560
510
144
336
456
486
598
204
618

yldgnankSTSDGSPvmavmpgt
gepcseTAQDFSPmffgqd
gadavpTLSENSPsgqrdv
silepeTGKDMSPyeaykr
rrrlspsnSSNENSPsikcedin
ktvaikTLKDTSPggqwwn
lgvdgrTCMEGSPepptsa
gsartiTNLEGSPsrsprl
iheekpTSSDCSPvrsssw
gckssiTGSECSPaedsks
hayhghlsSLIEISPykfqkgkd
aptlviTSSDPSPlgilsp
seedtvplSHLDESPaylpelag
edtlplTHFEDSPaylldm
hvksselvSQQDSSPvevhinke
qmekdeTVSDCSPhianig
tsllqlvhSCSEQSPqasalyyd

296
122937382
122937382
28875786
116063562
145309324
145309324
4758362
10190674
4503701
24476013
348605235
60498989
38348219
228480211
42476118
157738667
189217917
50962882
31088934
33286436
330864753
19923777
157739942
101943240
101943240
7705387
208022632
205277386
115647981
116805340
21361716
31083099
4504805
334724470
71979663
51093832
339276000
343478299
109715835
109715835
31317303
146219843
4885395
4504421
194394143
71725341

fas-binding factor 1
fas-binding factor 1
FCH and double SH3 domains protein 1
FERM domain-containing protein 4A
FH2 domain-containing protein 1
FH2 domain-containing protein 1
fibroblast growth factor 11
fibroblast growth factor 23 precursor
fibroblast growth factor 4 precursor
focal adhesion kinase 1 isoform a
forkhead box protein P1 isoform 1
forkhead box protein P4 isoform 1
forkhead box protein R2
four and a half LIM domains protein 1 isoform 1
FYN-binding protein isoform 1
FYVE and coiled-coil domain-containing protein 1
FYVE, RhoGEF and PH domain-containing protein 2
G patch domain-containing protein 8
gametocyte-specific factor 1-like isoform 1
gametogenetin
gamma-interferon-inducible protein 16 isoform 1
GAS2-like protein 1 isoform a
gem-associated protein 5 isoform 1
general transcription factor 3C polypeptide 1 isoform
1
general transcription factor 3C polypeptide 1 isoform
1
general transcription factor II-I repeat domaincontaining protein 1 isoform 1
girdin isoform 1
glucosamine--fructose-6-phosphate aminotransferase
[isomerizing] 1 isoform 2
glutamine and serine-rich protein 1
glycine--tRNA ligase precursor
Golgi phosphoprotein 3-like
Golgin subfamily A member 8A
Golgin-45
GRB2-associated and regulator of MAPK protein
isoform 1
growth factor receptor-bound protein 14
GTPase-activating protein and VPS9 domaincontaining protein 1
guanine nucleotide exchange factor DBS isoform a
H(+)/Cl(-) exchange transporter 3 isoform a
HEAT repeat-containing protein 6
HEAT repeat-containing protein 6
heat shock 70 kDa protein 12B isoform 1
helicase SRCAP
hemoglobin subunit theta-1
hepatic leukemia factor
hepatocyte nuclear factor 3-beta isoform 1
hepatocyte nuclear factor 4-alpha isoform HNF4
alpha 7

174
1086
429
772
865
699
212
211
113
26
393
51
133
95
208
1244
214
1075
133
505
718
600
618
1839

pvtqskTASDKSPstvrdq
wcsqppTGLDPSPlhlhar
rrlsearlSQRDLSPtaedaels
mnanysTLAEDSPskarqr
dvvapkrgSLKEASPgaskpgsa
eetsqlTLSDFSPmelesv
myqepslhSVPEASPssppap
ascsqelpSAEDNSPmasdplgv
gahadtrdSLLELSPvergvvsi
tkthlgTGMERSPgamerv
vssvtlskSASEASPqslphtpt
revttgadSNGEMSPaellhfqq
kvveslpsSSSEQSPlqkqgihs
ilcnkcTTREDSPkckgcf
kpplstenSHEDESPmknvsssk
pdssgsgtSQGEPSPalspaspg
aaellaTWTDKSPlfqevl
snigtgrgSEGDCSPedknsvta
vcendtkeSARETSPqkilrpgq
spapapTVAEPSPpvsapa
kkdilnpdSSMETSPdfff
prsqalssSSDEGSPcpgmggpl
yvhnlkTVIESSPespvti
pqarplegSSSEDSPpegqapps

2072

vveevevpSSLDESPmafyeptl

509

ldiiqvTVPDPSPtseemt

1559
100

lvnnkdttSFEDISPqgvsddss
ahtrwaTHGEPSPvnshpq

1510
270
26
462
350
794

kwkeefssSQSDSSPeihtsssd
nvkspiTGNDLSPpvsfnl
kkmeseedSNWEKSPdnedsgds
rlltepgdSAKDASPggghhqag
rildpvTCKESSPdnpffe
lhlqlaprSCGDGSPwqppadls

217
63

vsfateTNGEISPtqilqm
ldrliiTSAEASPaeccqh

1094
725
679
467
15
2796
44
101
439
13

psgsaqclSSSESSPgsavlsns
sprplklrSILDMSPftvtdhtp
sdagsaagSTYEPSPmrlealqv
vslmtlTLKDPSPktraca
glqglyigSSPERSPvpsppgsp
gspsvrsmSGPESSPpiggpcea
fpatktyfSHLDLSPgssqvrah
engippspSQHDHSPhppglqpa
gpvtnkTGLDASPlaadts
aplgapveSSYDTSPsegtnlna

297
188497754
21396500
5901962
169234807
308199413
7662046
91199543
210032580
197313748
197313748
50659082
217035121
24497526
19923391
31377777
5174681
7657214
61676186
122937243
122937243
71164886
379030637
7706607
41281583
194272161
5031805
31657140
74271834
4504721
4504725
4757734
289666748
4557669
28610147
209862765
8393638
21704283
7662260
223468659
148664209
32140182
109288006
148277102
7705574
55741641
91825557

hexokinase-1 isoform HKI
HIRA-interacting protein 3 isoform 1
histone acetyltransferase KAT7 isoform 1
histone deacetylase 7 isoform a
histone-lysine N-methyltransferase 2A isoform 1
precursor
histone-lysine N-methyltransferase 2B
histone-lysine N-methyltransferase 2E
histone-lysine N-methyltransferase SETD1B
histone-lysine N-methyltransferase SETD2
histone-lysine N-methyltransferase SETD2
histone-lysine N-methyltransferase SUV420H1
isoform 1
HMG box transcription factor BBX isoform 1
homeobox protein Hox-B1
homeobox protein Hox-D3
homeobox protein Nkx-2.8
homeobox protein SIX1
hormonally up-regulated neu tumor-associated kinase
hypermethylated in cancer 1 protein isoform 1
inactive dual specificity phosphatase 27
inactive dual specificity phosphatase 27
inactive serine/threonine-protein kinase VRK3
isoform 1
inactive ubiquitin carboxyl-terminal hydrolase 17like protein 4
inner nuclear membrane protein Man1 isoform 1
inositol hexakisphosphate and diphosphoinositolpentakisphosphate kinase 2
inositol-trisphosphate 3-kinase B
insulin receptor substrate 1
insulin receptor-related protein precursor
integral membrane protein GPR155 isoform 1
interferon regulatory factor 1
interferon regulatory factor 3 isoform 1
interferon-inducible protein AIM2
interleukin-34 isoform 1 precursor
interleukin-4 receptor subunit alpha isoform a
precursor
interleukin-6 receptor subunit beta isoform 1
precursor
iporin
junctional adhesion molecule A precursor
junctophilin-3
kelch repeat and BTB domain-containing protein 11
kelch repeat and BTB domain-containing protein 2
kelch-like protein 10
keratin-associated protein 10-10
keratin-associated protein 13-1
keratin-associated protein 24-1
killer cell lectin-like receptor subfamily F member 1
kinase D-interacting substrate of 220 kDa
kinesin light chain 3

880
400
51
234
762

srimhqTVKELSPkcnvsf
kgrtrsssSSSDGSPeakggkag
rssarlsqSSQDSSPvrnlqsfg
rrrpaeTLGDSSPsssstp
mrtrsgrlSSSELSPltppssvs

2023
951
1122
128
705
526

shggpgdsSEEESSPtsryihfp
ntmhfeniSSPESSPeikrrtys
ssessefeSSSESSPsssedeee
igdtlsTAEESSPpksrve
tsddsvTGSELSPlvkacm
qnpvrgahSQGESSPctyitrrs

72
292
182
56
215
338
385
1048
1030
53

eqdvgeTEDDESPeqrarr
sdqstcTSPEASPssvts
nscatageSCEDKSPpgpaskrv
ghypssdeSSLETSPpdssqrps
ggkplmssSEEEFSPpqspdqns
nvtypnriSLEDLSPsvvlhmte
kssseetgSSEDPSPpgghlegy
ffrrtpesSEREESPepqrpnwa
rstynetsSSREESPepyffrrt
qgskrglnSSFETSPkkvkwsst

35

afaeiqrtSLPEKSPlssetrvd

143
974

llgfssdeSDVEASPrdqagggg
rsrktaTNDEESPlsvssp

865
999
583
570
138
117
101
136
213

rlkairTTLEVSPffkche
mqmscprqSYVDTSPaapvsyad
vraitlTTEEDSPhqgaqs
vvepgnTAFEESPapvnep
akskakrkSCGDSSPdtfsdgls
vnsgvgdfSQPDTSPdtngggst
svtkpkplSQAEMSPaasaairn
nvqqglTDVEVSPkvesvl
aqcyntTWSEWSPstkwhn

819

qqyfkqncSQHESSPdishfers

568
153
417
43
588
324
120
68
34
187
1465
496

plrvsvgdSSQEFSPiqeaqqdr
gnravltcSEQDGSPpseytwfk
ariariTAKEFSPsfqhre
slgaslcfSSGEESPpqslasaa
ctvgklypSCLEESPwkpptylf
drwvnvTCEEESPrayhga
pvcfvpTCSESSPsccqqs
weptscqtSYVESSPcqtscyrp
pvtssvtlSSSDLSPtfghclps
slkmtwTWVDGSPidskif
idysssgvSTNDASPldpiteed
kaprtlsaSTQDLSPh

298
41327691
387942373
5032013
148612877
21955174
37655157
32481206
38788416
194328809
57165355
216548085
45331215
238908508
288541295
66392157
66392157
289547512
289547512
16904383
34222199
54607118
4507181
165905589
312032467
87080813
190684667
226442779
45504380
33946291
122937404
508083049
4505245
33457311
212275945
565671710
24111244
13376306
78042577
270483742
13491174
22218341
122891870
352962167
21686999

kinesin-like protein KIF16B isoform 2
kinesin-like protein KIF18B isoform 1
kinesin-like protein KIF20A
kinesin-like protein KIF2A isoform 1
kinesin-like protein KIFC2
Krueppel-like factor 6 isoform A
lactase-phlorizin hydrolase preproprotein
laminin subunit alpha-1 precursor
latent-transforming growth factor beta-binding
protein 3 isoform 1 precursor
latrophilin-1 isoform 1 precursor
leucine zipper protein 1
leucine zipper putative tumor suppressor 2
leucine-rich repeat and death domain-containing
protein 1
leucine-rich repeat-containing protein 15 isoform a
precursor
leucine-rich repeat-containing protein 16C
leucine-rich repeat-containing protein 16C
leucine-rich repeat-containing protein 37A precursor
leucine-rich repeat-containing protein 37A precursor
leucine-rich repeat-containing protein 7
leucine-rich repeat-containing protein 8D
leucine-rich repeats and immunoglobulin-like
domains protein 1 precursor
leukosialin precursor
LIM domain and actin-binding protein 1 isoform 1
liprin-beta-1 isoform 1
LON peptidase N-terminal domain and RING finger
protein 1
lung adenoma susceptibility protein 2 precursor
lysine-specific demethylase 3A
lysine-specific demethylase 4B
lysophosphatidylcholine acyltransferase 1
lysophospholipid acyltransferase 1
M-phase phosphoprotein 9
macrophage mannose receptor 1 precursor
magnesium-dependent phosphatase 1 isoform 1
male-specific lethal 3 homolog isoform a
MAM and LDL-receptor class A domain-containing
protein 1 precursor
MAM domain-containing
glycosylphosphatidylinositol anchor protein 1
precursor
MAP6 domain-containing protein 1
MAP7 domain-containing protein 1
MAP7 domain-containing protein 2 isoform 1
MARCKS-related protein
matrix metalloproteinase-21 preproprotein
melanoma inhibitory activity protein 3 precursor
melanoma-associated antigen 10
metalloendopeptidase OMA1, mitochondrial
precursor

1298
446
861
134
161
114
1916
206
1194

ltlskhTICEFSPffkkgv
eramegnsSDQEQSPededegpa
lprtptcqSSTDCSPyarilrsr
sssaqqngSVSDISPvqaakkef
pspdgsTSQEESPshftav
dvssessdSSEELSPtakftsdp
skqgktqrSQQELSPvssf
tslingrpSADDLSPklleftsa
ptsqsesnSFWDTSPlllgkppr

1395
391
305
123

ganlrdspSYPDSSPegpsealp
asvskhTARELSPqhkrer
traspdssSCGERSPppppppps
nflsheTVGEVSPqvseen

285

nrltlfgnSLKELSPgifgpmpn

1414
1117
1360
561
688
240
969

lppqptepSSPERSPpspatdqr
strgprTDLETSPgaaprt
spsqgafsSLGDLSPqenpflev
itpeskTEVELSPtmketp
nsvssgTYSDYSPsqassg
tlpkhvstSSDEGSPsastpmin
pngpepggSDQEHSPhhqcsrta

69
369
354
362

tsalppstSINEGSPlwtsigas
lspdsrasSLSESSPpkamkkfq
slldaqgfSDLEKSPsptpvmgs
hsvmeesqSLNEPSPkqseeipe

366
277
632
499
230
389
729
166
303
1249

rdlvddTNGERSPkm
tlvskqakSCSEASPsmcpvqsv
svvkqeasSDEEASPfsgeedvs
ypdqthfeSCAETSPapipngfc
nwkrkgfhSLPEPSPtgavihkl
lektfislSSTDVSPnqsntsne
spsegfTWSDGSPvsyenw
kaqtgplrSSLEESPfea
esatstnrSQEELSPsppllnps
gdvavddiSFQDCSPllsperkc

454

kgravvTVREGSPaelqce

161
457
699
35
33
1672
110
214

arvitthtSGWDSSPgagfqvpe
arlsasTASELSPkskarp
pvskeeliSIPEFSPvsemipgv
gqenghvkSNGDLSPkgegespp
slfhsrdrSDLEPSPlrqakpia
gsfgpspvSGGECSPpltveppv
dqsdegssSQKEESPstlqvlpd
fvvfyfTHLEVSPitgrsk

299
58219056
238859557
118918413
33188445
95147555
153945728
153945728
153945728
45120119
112363080
112363080
150170729
150170729
148727255
148727255
301898343
282847398
85838511
52421790
336020360
59814247
24431958
89257348
31542699
14790190
65301117
256600257
308736985
83367077
83367077
83367077
83367077
83367077
71774083
60498973
226423889
5174543
153792294
4557896
226437579
74271814
110624785

methyltransferase-like protein 10
MHC class II regulatory factor RFX1
MICAL C-terminal-like protein
microtubule-actin cross-linking factor 1 isoform a
microtubule-associated protein 1A
microtubule-associated protein 1B
microtubule-associated protein 1B
microtubule-associated protein 1B
microtubule-associated serine/threonine-protein
kinase 1
microtubule-associated serine/threonine-protein
kinase 2
microtubule-associated serine/threonine-protein
kinase 2
microtubule-associated serine/threonine-protein
kinase 3
microtubule-associated serine/threonine-protein
kinase 3
microtubule-associated serine/threonine-protein
kinase 4 isoform a
microtubule-associated serine/threonine-protein
kinase 4 isoform a
mitogen-activated protein kinase kinase kinase 12
isoform 1
mitogen-activated protein kinase kinase kinase 15
mitogen-activated protein kinase kinase kinase 2
mitogen-activated protein kinase kinase kinase 9
isoform 1
mitogen-activated protein kinase kinase kinase
kinase 4 isoform 5
mitotic checkpoint serine/threonine-protein kinase
BUB1 beta
monocarboxylate transporter 2
motor neuron and pancreas homeobox protein 1
isoform 1
MPN domain-containing protein isoform 1
msx2-interacting protein
mucin-1 isoform 1 precursor
mucin-12 precursor
mucin-13 precursor
mucin-16
mucin-16
mucin-16
mucin-16
mucin-16
myc proto-oncogene protein
myelin transcription factor 1-like protein
myocardin isoform 1
myocyte enhancer factor 2B isoform b
myopalladin isoform a
myotubularin
NAC-alpha domain-containing protein 1
NACHT, LRR and PYD domains-containing protein
1 isoform 5
NACHT, LRR and PYD domains-containing protein

108
117
144
3832
1197
1723
1568
1687
946

fgfsniTGIDYSPsaiqls
amraseTVSEASPgstasq
gkdrswTGQELSPlagedr
vnqfweTYEELSPwieetr
spedtqslSLSEESPsketsldv
dlselisvSQVEASPstssahtp
ssfpepTTDDVSPslhaev
itengpTEVDYSPsdmqds
prslssnpSSRDSSPsrdyspav

1083

phsqssnpSSRDSSPsrdflpal

918

vsesshTESDSSPpmtvrr

929

prslssnpSSRDSSPsrdpspvc

984

ytvhhvvwSVEDGSPaqeaglra

931

hslssdpsSSRDSSPsrdssaas

1665

sgkkndttSARELSPsslkmnks

798

sdgeegTASEPSPsgtpev

500
341
610

irrfkkTIIEHSPrqerln
idnptlTVMDISPpsrspr
tlgqkelaSGDEGSPqrrekang

557

vspvsrshSFSDPSPkfahhhlr

568

lktsesitSNEDVSPdvcdeftg

216
383

knktgkTEDDSSPkkiktk
vhaassdcSSEDDSPpprpshqp

175
299
239
282
139
235
10574
968
4257
9747
239
463
476
340
475
432
1353
1046

qlhtpaTAADESPasegee
sdssdsssSSSDDSParsvqsaa
thgryvppSSTDRSPyekvsagn
pttfqswpSSKDTSPapsgttsa
tmvpsetqSNNEMSPttednqss
psfgtlysSFLDLSPkgtpnsrg
ttaslvsrSGAERSPviqtldvs
aapqstTWPETSPrfktgl
vtnmeaTSSEYSPipghtk
lspvssTLLDSSPssplpv
spssdsllSSTESSPqgspeplv
agrrdnmrSYEDQSPrqlpgedr
agslpdTFNDASPsfglhp
rrspggTSPERSPgtarar
ewyregTLIEDSPdfrilq
hgdknhTDADRSPiflqfi
peqqededSLEEDSPralgsgqh
piaeiagkSHEESSPevvpvell

324

iisesrseSLDDGSPctdwyqel

300

38093637
38093637
126362967
126362967
208022661
4502169
315259111
4758822
118918403
32261318
5453810
41393547
21314632
291084505
19923348
254692833
118600963
195972909
150010577
312283682
350529396
27886539
209862845
19743903
45545405
93141039
157694511
194394141
46048234
28212272
50659095
33391150
33391150
38788260
399124757
56549107
194306541
194306541
5454016
14149740
14210532
41152072
156766064
27436910
93141033

13
Nance-Horan syndrome protein isoform 1
Nance-Horan syndrome protein isoform 1
nck-associated protein 5 isoform 1
nck-associated protein 5 isoform 1
nck-associated protein 5-like
NEDD8-activating enzyme E1 regulatory subunit
isoform a
NEDD8-MDP1 protein
nephrin precursor
nesprin-2 isoform 1
netrin receptor UNC5B isoform 1 precursor
netrin-3 precursor
neuroblastoma-amplified sequence
neutral amino acid transporter A isoform 1
NF-kappa-B-repressing factor isoform 1
NGFI-A-binding protein 1
NHS-like protein 2
nik-related protein kinase
NMDA receptor synaptonuclear signaling and
neuronal migration factor isoform a
non-receptor tyrosine-protein kinase TNK1 isoform
2
NT5C1B-RDH14 protein isoform 1
nuclear factor 1 C-type isoform 1
nuclear factor of activated T-cells, cytoplasmic 2
isoform B
nuclear factor of activated T-cells, cytoplasmic 4
isoform 1
nuclear receptor ROR-alpha isoform a
nuclear receptor subfamily 5 group A member 2
isoform 1
nuclear respiratory factor 1
nucleolar complex protein 2 homolog
nucleolar pre-ribosomal-associated protein 1
nucleolar protein 8 isoform a
nucleolar protein 9 isoform 1
nucleolar RNA helicase 2 isoform 1
nucleoplasmin-2 isoform 1
nucleoplasmin-2 isoform 1
nucleosome-remodeling factor subunit BPTF
isoform 2
nurim isoform 5
optineurin
oxidation resistance protein 1 isoform 1
oxidation resistance protein 1 isoform 1
oxygen-regulated protein 1
oxysterol-binding protein-related protein 5 isoform a
oxysterol-binding protein-related protein 6 isoform a
palmitoyltransferase ZDHHC5
paraneoplastic antigen-like protein 5
partner and localizer of BRCA2
PAX-interacting protein 1

739
1383
1316
594
490
102

ftsmatydSFLEKSPsdkadtss
tqgnvdeaSLKESSPsddsiisp
gnsltrqnSSTESSPnkapsapm
tfdelhieSSDEKSPsdvslaad
nsripcrnSGSDGSPspllarrg
elnsdvsgSFVEESPenlldndp

183
1140
156
250
193
638
501
166
401
1066
839
52

kaqtgplrSSLEESPfea
teaepyyrSLRDFSPqlpptqee
nqpslddvSVVDSSPassppakk
vyvnggwsSWAEWSPcsnrcgrg
dgsgllafSMQDSSPpgldldss
geididsiSYEELSPpdeepakn
veaipnckSEEETSPlvthqnpa
tsqqansqSTPEPSPsqtfpesv
lsaglyrqSSEEHSPngltsdns
vtstpqadSEREASPlgssvepg
nwlaasesSSEEESPvtgrrsqs
dhlladaySGHDGSPemqpapqn

408

etgdpiTVIEGSPdstiwk

103
330
327

srtpstspSLHDSSPpplsgqps
sspvkkTEMDKSPfnspsp
ppkmwkTSPDPSPvsaaps

776

satpfgTDMDFSPprppyp

262
235

fpycsfTNGETSPtvsmae
haalppTDYDRSPfvtspi

38
29
1491
611
311
83
153
190
647

tytehsmlSADEDSPsspedtsy
sgfdseseSESENSPqaetrear
lflptlltSDGEESPdsqvkeal
khedpsiiSMEDGSPyvngslge
igylstrgSSVDGSPlllflrdq
kakkkeepSQNDISPktkslrkk
dededadiSLEEQSPvkqvkrlv
keeeeiraSVRDKSPvkkakata
dnttnaTSEETSPsegrsp

55
12
147
342
1570
265
202
526
372
58
221

pcagagraSGPEVSPgsqtllpp
qplsclTEKEDSPsestgn
yvpdpeyvSSVESSPslspvspl
lsedvfTESELSPireelv
mvktmetgSYSESSPdlkkciks
rdgepgTSPDASPsslcgl
sfhifpstSTAESSPaanvsvmd
lvptgpTHREPSPvrydnl
pqatvqarSFSDSSPqtiqgglp
tveeqdclSQQDLSPqlkhsepk
tdeksspaSSQEGSPsgdqqfsp

301
300797388
87196343
532164741
126723564
126723564
51173720
81295809
48255929
45439327
221316602
4758896
7019499
56788370
18034775
28557677
4505921
22027648
22027648
7662022
34452732
194353959
307691174
30089916
63055049
45505139
283436112
256017245
6005830
55749621
221139728
237820622
40254442
26665869
315221121
315221121
194306631
116006951
148612879
112807221
34452725
253683544
253683544
20149500
157074214

PCNA-interacting partner
PDZ domain-containing protein 2
PDZ domain-containing protein MAGIX isoform a
pecanex-like protein 1
pecanex-like protein 1
peregrin isoform 1
pericentrin
periphilin-1 isoform 1
periplakin
peroxisomal carnitine O-octanoyltransferase isoform
1
peroxisomal membrane protein PEX14
peroxisome proliferator-activated receptor gamma
coactivator 1-alpha
PH and SEC7 domain-containing protein 4
PHD finger protein 20
PHD finger protein 6 isoform 1
phenylethanolamine N-methyltransferase
phosphatidate phosphatase LPIN1 isoform 1
phosphatidate phosphatase LPIN1 isoform 1
phosphatidate phosphatase LPIN2
phosphatidylinositol 3,4,5-trisphosphate-dependent
Rac exchanger 1 protein
phosphatidylinositol 4-phosphate 3-kinase C2
domain-containing subunit gamma
phosphatidylinositol 4-phosphate 5-kinase type-1
gamma isoform 1
phosphofurin acidic cluster sorting protein 1
phosphoglucomutase-2
phosphoinositide 3-kinase adapter protein 1
phospholipase B1, membrane-associated isoform 1
precursor
phospholipase DDHD2 isoform 1
plakophilin-3
pleckstrin homology domain-containing family G
member 3
pleckstrin homology domain-containing family M
member 2
pleckstrin homology domain-containing family N
member 1 isoform a
plexin-B1 precursor
POC1 centriolar protein homolog B isoform a
POC1B-GALNT4 protein isoform 1
POC1B-GALNT4 protein isoform 1
poly(rC)-binding protein 3 isoform 1
polycystic kidney disease protein 1-like 2 isoform a
precursor
polyhomeotic-like protein 3
polypeptide N-acetylgalactosaminyltransferase 12
polypeptide N-acetylgalactosaminyltransferase 4
POM121-like protein 2
POM121-like protein 2
porphobilinogen deaminase isoform 1
potassium channel subfamily U member 1

326
1703
228
414
2281
1081
48
202
1667
304

sqegvvalSTTDISParpkshai
ttevtsasSAMENSPlskvarhf
eprkgvvpSWPDRSPdpggpevt
sthiesilSEHEESPkagtksgr
irlkagrnSWKDWSPqegmeghv
lgrgagwlSEDEDSPldaldlvw
rkgsavdaSVQEESPvtkedsal
pvqslkTSRDTSPssgsav
vvihpdTGRELSPeeahra
iqssllvySMEDSSPhvtpedys

259
121

spaavnhhSSSDISPvsnestss
tdgdvtTDNEASPssmpdg

463
566
193
1
231
319
223
833

pgprpspaSSQEGSPqlqhhssg
seeisdTSQEPSPpkafav
gtdemessSYRDRSPhrsspsdt
waqkvglSGADRSPnagaapds
pqsasypnSDREWSPtpspsgsr
hsessdTFSDQSPtlvgga
hsgdhyplSDGDWSPlettypqt
llslgprlSLCEDSPmvtltvdn

1314

seavqqTVEESSPvylgek

533

ttlsstslSIPERSPsetseqpr

528
209
210
460

plsertnsSDSERSPdlghstqi
pwpqawddSLIDSSPllhnpsas
lddrvaTEAEFSPedspsv
kgfsvgTGKETSPnaflnq

11
706
949

vqsqqeqlSQSDPSPspnscssf
hlieklpgSVGEKSPpaevlvni
ehsppkpsSAGEMSPqrfffnps

328

igkkkksrSDEEASPlhpacsqk

553

pdapqlvsSAREGSPepwlpltd

722
24
153
24
284
687

gapstaTASDISPgaspsl
ghkaaiTSLDLSPngkqla
stllrtihSVLETSPavllkeii
ghkaaiTSLDLSPngkqlg
aqnlmgqsSGLDASPpasthelt
dillrvTMGEDSPvamfsw

269
157
156
486
910
12
830

ttvtsskiSQRDPSPesnkkges
stllrtvySVLETSPdilleevi
stllrtihSVLETSPavllkeii
dttwppstSQADRSPmppdppap
esgiimTGPDMSPtsgafs
ngnaaaTAEENSPkmrvir
tigslqidSSSDPSPsvseetpg

302
27436974
24497462
289547573
156938331
578796196
578796550
530420159
530376621
530415050
530415050
530415512
530391425
530417278
578796399
530360450
578838355
254826809
144922665
4885323
5803025
145309309
442796413
153792074
51093874
223671861
54400758
4885075
91208420
15721939
39545580
223972612
75677363
334085258
157671937
157671937
210032790
210147567
213512168
296531322
94721334
116812620
29825823
56711286
145580588

potassium voltage-gated channel subfamily B
member 2
potassium voltage-gated channel subfamily C
member 4 isoform a
PR domain zinc finger protein 16 isoform 1
pre-mRNA-processing factor 39
PREDICTED: cell wall protein AWA1-like
PREDICTED: neurotrimin-like
PREDICTED: phosphomannomutase 1 isoform X2
PREDICTED: protein furry homolog-like isoform
X1
PREDICTED: protein Wiz isoform X1
PREDICTED: protein Wiz isoform X1
PREDICTED: relA-associated inhibitor isoform X1
PREDICTED: serine/threonine-protein kinase
WNK2 isoform X3
PREDICTED: uncharacterized aarF domaincontaining protein kinase 4 isoform X1
PREDICTED: uncharacterized protein C11orf89-like
PREDICTED: uncharacterized protein KIAA1751
isoform X1
PREDICTED: uncharacterized protein KIAA2022
isoform X1
prematurely terminated mRNA decay factor-like
probable G-protein coupled receptor 123 isoform 1
probable G-protein coupled receptor 37 precursor
probable G-protein coupled receptor 75
probable ubiquitin carboxyl-terminal hydrolase FAFX isoform 3
progestin and adipoQ receptor family member 6
isoform 4
proline-rich protein 12
proline-rich protein 19
properdin precursor
prostate androgen-regulated mucin-like protein 1
precursor
protein atonal homolog 1
protein bassoon
protein CASC3
protein cereblon isoform 1
protein cramped-like
protein ERGIC-53-like precursor
protein FAM124A isoform 1
protein FAM135A isoform a
protein FAM135A isoform a
protein FAM184B
protein FAM194B
protein FAM205A
protein FAM219A isoform 1
protein FAM63B isoform a
protein FAM98C
protein HID1
protein KIAA2022
protein kintoun isoform 1

616

scatdfTETERSPlpppsa

521

tsprdsTCSDTSPpareeg

135
41
220
12
19
20

gweqilTDVEVSPqegcit
teimnvTEMEQSPddspnv
ldtamaevSAPEQSPkagwllpf
elrsqqplSLEDASPltycasls
prtgrcsiSTDDCSPssgtfief
sgdvvldtSTEESSPrlvkmkrl

1261
629
17
1642

aaagifwaSDVEPSPlnlssgpe
eeedvvltSEMDFSPengvfspl
ciagvrgpSGPDGSPpssvqygl
vmeqgtssSMTESSPrsmlgydr

209

grlqseggSGLDSSPflseanae

457
915

trppptvrSILELSPqpknfnrt
tvhaivttSDLELSPsevdfgyc

1066

tpdkfrhsSLSEMSPpdtpslsp

1903
441
591
490
37

almngvTEIERSPllewlp
peyayhipSSLDGSPrssrtdsp
ndneytTELELSPfstirr
ysiynsspSQEESSPcnlqpvns
qnqtsspdSSNENSPatppdeqg

50

kalgsvrsSAQEPSPihscstts

1819
320
319
102

gggppgssSDSESSPgapseder
sspllprtSVLDWSPsppsplps
cpvdgewdSWGEWSPcirrnmks
gsnwegTNTDPSPsgfsst

336
1121
357
431
484
250
543
648
996
514
41
813
96
159
132
647
1066
449

ktsprshrSDGEFSPhshysdsd
emeelhrsSCSEYSPspsldsea
rsrrleqtSVRDPSPeadapvlg
lptipdTEDEISPdkvilc
ppaadalqSSGESSPesapgega
dvlsfltfSLSEPSPevppqpfl
papstsTLTDSSPqlpcdt
ltsinslpSDDELSPdenskksv
synftssiSWYESSPkpqiqafl
qnktrpTGAEESPqelgrq
teveldeeSLQDESPfspegesl
tsqsviTEMEPSPveipae
lvvpnkgySSLDQSPdekplval
ssagglssSCSDPSPpgespsld
atrllclrSLLDPSPrpplgegv
slepepqqSLEDGSPakgepsqa
tpdkfrhsSLSEMSPpdtpslsp
rhagsppgSVEEPSPggenspgg

303
358679311
28144916
187761379
51702245
88702791
332634572
194394139
28626517
150378539
150378539
162287219
257743447
211904177
203098098
257467639
55749600
157739945
116256338
283837842
7662316
148664232
67190163
9256602
538260588
13787217
148886692
11128039
8850232
14277675
14589916
157426847
41352721
222418631
50557646
21361647
24308043
29570782
153792780
312261259
54607124
116812577
8922692
379030635
336455088
299473771
189217411
7662234

protein LAP2 isoform 1
protein lin-37 homolog
protein maestro isoform c
protein MANBAL
protein Mdm4 isoform 1
protein MRVI1 isoform a
protein notum homolog precursor
protein phosphatase 1 regulatory inhibitor subunit
16B isoform 1
protein piccolo isoform 1
protein piccolo isoform 1
protein prune homolog 2
protein RD3
protein shisa-6 homolog isoform 1 precursor
protein Shroom3
protein SOGA1 isoform 1
protein spire homolog 2
protein TANC2
protein transport protein Sec31A isoform 1
protein unc-13 homolog A
protein VPRBP isoform 1
protein-glutamine gamma-glutamyltransferase 6
isoform 1
proteoglycan 4 isoform A precursor
protocadherin beta-10 precursor
protocadherin beta-9 precursor
protocadherin Fat 2 precursor
protocadherin Fat 3 precursor
protocadherin gamma-A11 isoform 1 precursor
protocadherin gamma-A12 isoform 1 precursor
protocadherin gamma-C3 isoform 1 precursor
protocadherin-10 isoform 1 precursor
protocadherin-19 isoform a precursor
proton-coupled amino acid transporter 1
proton-coupled amino acid transporter 2
protrudin isoform a
putative adenosylhomocysteinase 2 isoform a
putative adenosylhomocysteinase 3 isoform a
putative Polycomb group protein ASXL1 isoform 1
putative Polycomb group protein ASXL2
putative RNA exonuclease NEF-sp isoform 1
putative RNA-binding protein 15B
putative RNA-binding protein Luc7-like 2 isoform 1
putative sodium-coupled neutral amino acid
transporter 7
putative ubiquitin carboxyl-terminal hydrolase 17like protein 1
putative uncharacterized protein C20orf78
putative uncharacterized protein FLJ22184
PX domain-containing protein 1
rab11 family-interacting protein 3 isoform 1

851
196
24
2
90
331
102
470

svdlgiskSTEDLSPqksgpvgs
qgtpddepSEPEPSPstliyrnm
esshlaTTRESSPpesgtg
etkkkrSDLDFSPpevpeptf
ellgrqsfSVKDPSPlydmlrkn
gkqllkTGWEGSPlprspt
llntsvTCNDGSPagyylk
adatppwsSYKEQSPqtllelkr

1516
1854
614
68
235
436
1172
422
1818
526
1485
302
191

pydsveesSESENSPvpqrkrrt
emeelhrsSCSEYSPsiesdpeg
ripptpmnSLVESSPsteepasl
swlastprSTYDLSPierlqled
ahceretiSAIDTSPkentpvrs
ieeqlhTVLEKSPensppv
vssmsefeSLLDCSPylaggdar
aemeemntSEEEESPcgevtlkr
plkpayerSCDELSPvsptqggy
kdsdqvaqSDGEESPaaeeqllg
gvglkkTFLEKSPdlqslr
mfvelsnsSWSEMSPwvigtnyt
edilniclSILDRSPghqnnpat

512
354
354
3436
383
355
354
664
257
245
14
38
8
84
165
846
559
220
4
352
36

kepaptTTKEPSPttpkep
livssfsnSVAENSPetplavfk
liisslsnSVAENSPgivlavfk
qlnystTVQENSPigskvl
fekevydvSISEFSPpgvvvaiv
ititssinSILENSPpgtviall
vvltslasSVPENSPrgtliall
sttatltvSVTEDSPearaefps
fdqpvytvSLPENSPpgtlviql
fsestyavSVPENSPpntpvirl
rnedyhdySSTDVSPeespsegl
lenkdsTFLDESPsesagl
mqtseregSGPELSPsvmpeapl
saasytdsSDDEVSPrekqqtns
saasytdsSDDETSPrdkqqkns
dpvnvtpsSTPESSPtdclqnra
mkeplaTLVDQSPeslkrk
flltkcngSIADNSPlfgldcem
rdtaSERDSSPsgrgssss
lascdrdrSSRDRSPrdrdrkdk
pcvdtapkSEWEASPggldrgtt

35

afaeiqrtSLPEKSPlssetrvd

54
215
127
396

aamapsitSSEDSSPsqrdkkdl
svssasehSTTEPSPaarrrpsa
rsevvlTFFERSPldqvlk
hfedygegSEAELSPetlcngql

304
4758532
5803145
119392077
224809578
40353729
56550077
38505170
301897977
121114304
91208428
18677729
10863935
24431935
172072597
172072597
7661858
7661858
7662208
40548322
186928844
95091875
7662086
21361458
21361458
50843837
50843837
50959191
34452681
297206763
22538405
8400718
325120986
612407805
157412245
221307578
72534652
116256479
7706089
115298663
134031945
33469966
31542785
47578099
39777608
189163501
545746387

ral guanine nucleotide dissociation stimulator-like 2
isoform 1
ralA-binding protein 1
rap guanine nucleotide exchange factor 5
rap1 GTPase-activating protein 1 isoform a
ras and Rab interactor 3
ras-related protein Rab-40A
ras-specific guanine nucleotide-releasing factor 2
RE1-silencing transcription factor
receptor-type tyrosine-protein kinase FLT3
receptor-type tyrosine-protein phosphatase zeta
isoform 1 precursor
relaxin receptor 2 isoform 1
reticulon-1 isoform A
reticulon-4 isoform A
retinoblastoma-like protein 2
retinoblastoma-like protein 2
rho GTPase-activating protein 11A isoform 1
rho GTPase-activating protein 11A isoform 1
rho GTPase-activating protein 26 isoform a
rho GTPase-activating protein 27 isoform a
rho GTPase-activating protein 31
rho GTPase-activating protein 6 isoform 1
rho guanine nucleotide exchange factor 11 isoform 1
rho guanine nucleotide exchange factor 17
rho guanine nucleotide exchange factor 17
rho guanine nucleotide exchange factor 40
rho guanine nucleotide exchange factor 40 isoform 1
rho guanine nucleotide exchange factor 5
RING finger protein 10
RING finger protein 39 isoform 1
RNA binding protein fox-1 homolog 1 isoform 1
RNA-binding motif, single-stranded-interacting
protein 1 isoform a
RNA-binding protein 10 isoform 5
rootletin
RUN and SH3 domain-containing protein 1 isoform
a
RUN domain-containing protein 3A isoform 1
runt-related transcription factor 3 isoform 1
RWD domain-containing protein 4
SCAN domain-containing protein 1 isoform 1
SCL-interrupting locus protein isoform 1
SCO-spondin precursor
sec1 family domain-containing protein 1 isoform a
sec1 family domain-containing protein 2
selenoprotein N isoform 1 precursor
semaphorin-4B precursor
serine protease inhibitor Kazal-type 5 isoform a
precursor
serine-rich coiled-coil domain-containing protein 2
isoform 1

583

wpsvssldSALESSPslhspadp

28
359
275
395
153
792
855
204
1498

gsgltrtpSSEEISPtkfpglyr
gmhrrhTVDEYSPqkknka
qtseeelfSTNEESPafveflef
rrrvservSLEDQSPgmaaegdq
aerlgvTFFEVSPlcnfni
pldlsrglSSPEQSPgtveenvd
swllkesvSTEDLSPpspplpke
vlcdsqgeSCKEESPavvkkeek
vssdsqTGMDRSPgkspsa

318
474
860
2
963
669
632
694
139
1066
661
332
1638
1507
259
1468
560
701
124
93
395

ldlssnTITELSPhlfkdl
iiescdasSASEESPkreqdspp
qireteTFSDSSPieiide
ndrgshSGGDQSPpppppppa
elnkdrTSRDSSPvmrsss
tgkgekcfSERDFSPlqtqtfnr
gkvkltepSYLEDSPeenlfetn
pmptssTSSDSSPvrsvag
paeldevgSWEEVSPataavrtk
qggvpgpeSSKESSPsvqdstsp
sstdsnkaSSGDISPydnnspvl
gvflryifSQADPSPllfylcae
elvpfdsdSDDESSPspsgtlqs
scaaptlnSCPEPSPevwvcnsd
pvrgspTDAEGSPglsrvr
slapetldSSGDVSPgprnspsl
petasaplSMDDPSPcgtsemcp
gspsfcvgSLEEDSPfpsfaqml
wgtppaTGTEASPtacpcc
lyppaqTHSEQSPadtsaq
qqvaveTSNDHSPytfqpn

24
1477
107

dagrgggeSLQEASPrladhgss
sgeglnspSTLECSPgsqppspg
pgcssslsSCSDLSPdespvsvy

229
364
22
38
677
3544
297
464
473
812
1005

hsaessTSEDNSPehpylp
fsmvagssSGGDRSPtrmlasct
rsiyegdeSFRELSPvsfqyrig
perncvgsSLPEASPpapepssp
dmgscsphSNIEPSPvarppshm
pcgqpcprSCQDLSPgsvcqpgs
nrvnleesSGVENSPagarpkrk
kpvtqrTNEDYSPeellil
grtlreTVLESSPiltlln
krplsiqdSFVEVSPvcprprvr
ekpshvraSQEEDSPdsfsslds

496

pdtdyragSSFELSPsdssdgty

305
118572613
118572613
118572613
118572613
118572613
118572613
118572613
118572613
166295194
166295194
47132591
4507831
151301204
151101459
194294554
194294554
120587025
226817313
224586793
229892306
222352170
50843820
7662126
112421013
4506967
40217823
46358066
90577167
303304956
291490690
37622907
4506975
4506975
186910315
306774092
589908390
7661700
23111038
145275189
112382250
218749820
145699133
46240864
32699054

serine/arginine repetitive matrix protein 2
serine/arginine repetitive matrix protein 2
serine/arginine repetitive matrix protein 2
serine/arginine repetitive matrix protein 2
serine/arginine repetitive matrix protein 2
serine/arginine repetitive matrix protein 2
serine/arginine repetitive matrix protein 2
serine/arginine repetitive matrix protein 2
serine/threonine-protein kinase Chk1 isoform 1
serine/threonine-protein kinase Chk1 isoform 1
serine/threonine-protein kinase N1 isoform 1
serine/threonine-protein kinase ULK1
serine/threonine-protein kinase ULK4
serine/threonine-protein phosphatase 6 regulatory
subunit 1
SET-binding protein isoform a
SET-binding protein isoform a
SH3 and multiple ankyrin repeat domains protein 1
SH3 and multiple ankyrin repeat domains protein 2
isoform 1
SHC-transforming protein 3
shugoshin-like 2 isoform 1
sialidase-2
sickle tail protein homolog isoform 1
signal-induced proliferation-associated 1-like protein
1 isoform 1
signal-induced proliferation-associated 1-like protein
2
ski oncogene
SLIT and NTRK-like protein 5 precursor
SLP adapter and CSK-interacting membrane protein
isoform 1
small G protein signaling modulator 1 isoform 1
smoothelin-like protein 1
sodium bicarbonate transporter-like protein 11
isoform 1
sodium channel protein type 5 subunit alpha isoform
a
solute carrier family 12 member 2 isoform 1
solute carrier family 12 member 2 isoform 1
solute carrier family 12 member 3 isoform 1
solute carrier family 12 member 8
solute carrier family 22 member 24 isoform 2
sorbin and SH3 domain-containing protein 1 isoform
2
sorting nexin-2 isoform 1
specifically androgen-regulated gene protein isoform
1
spectrin beta chain, non-erythrocytic 1 isoform 1
speriolin-like protein isoform 1
sperm flagellar protein 2 isoform 1
sperm-associated antigen 17
spindle and kinetochore-associated protein 2 isoform
1

1477
1615
1556
1381
870
1652
1265
415
325
295
565
538
373
843

prtpsrgrSECDSSPepkalpqt
praapraqSGSDSSPepkapapr
psaspqerSESDSSPdskaktrt
qstrssghSSSELSPdavekagm
qsvtpqrrSCFESSPdpelksrt
rgpspegsSSTESSPehppksrt
selkemstSNFESSPeveerpav
speklpqsSSSESSPpspqptkv
qpeprtglSLWDTSPsyidklvq
sgfskhiqSNLDFSPvnsassee
eklnlgTDSDSSPqkssrd
grsprpgsSAPEHSPrtsglgcr
ptprtsTAVEVSPgedmth
hqppqtTEGEKSPeplglp

375
510
23
1016

kregysadSAQEASParqnvssa
mvmtppTCTDHSPsrklpe
asecpeggSESDSSPdgpgrgpr
rkgmlvkqSNVEDSPektcsipi

439
1086
344
1681
1728

pqawpaavSSAESSPrkdlfdmk
kskkrkTSIDPSPeshevm
dlqsmgTGPDGSPlfgcly
ikqlenTISEMSPkalvdt
laqmkpysSSKDSSPtlaskvdq

1647

gkefmdTTGERSPspltgk

388
71
89

pwspavsaSEKELSPhlpalird
scenrgiiSLSEISPprfpiyhl
plpprnwpSLEDSSPqeapsqpp

909
303
54

laslavttSANEVSPvsssgvty
vasgqtspSASESSPsdvpqspp
gflrktwiSEHENSPtmsqngyf

458

rgvdtvsrSSLEMSPlapvnshe

574
938
26
225
275
235

acklnfdfSSCESSPcsyglmnn
lqgqeellSSQEKSPgtkdvvvs
rftistllSSDEPSPpaaydssh
ellqnnTLPDYSPgesfft
piivlflsSWYEQSPhslpvsea
epdltgavSSTDSSPllnevsss

32
499

edlftstvSTLESSPsspepasl
lssylsTEKDASPktstsl

2159
97
1807
464
98

ngateqrtSSKESSPipsptsdr
lcshaplsSEDDTSPgcaapsqa
qrsehvqgSDGERSPsrhteekk
teedlvppSLREPSPradgldhr
qklqkqTDLELSPltkeek

306
40789229
7661952
10047104
4507117
41281898
215820650
21361863
55742730
485836756
394582088
19557691
19557702
19557702
27545326
26190608
40353727
40353727
15011902
4502643
27477070
54607014
114688046
156231067
45597175
115511020
153946395
157384973
122937400
66529407
7706708
21264578
21264580
238859655
237648959
4885491
150170672
23312394
389565493
41281981
4503641
378925625
76880480
56550035
38505226
17998698
110347463

splicing factor, arginine/serine-rich 15 isoform 1
squamous cell carcinoma antigen recognized by Tcells 3
SS18-like protein 2
stannin
stAR-related lipid transfer protein 13 isoform 1
stAR-related lipid transfer protein 8 isoform a
stonin-2 isoform 1
storkhead-box protein 2
stromal interaction molecule 1 isoform 1 precursor
suppressor of cytokine signaling 2
surfeit locus protein 4
surfeit locus protein 6 isoform 1
surfeit locus protein 6 isoform 1
SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin subfamily B member 1
isoform a
synaptojanin-2 isoform 1
synaptopodin isoform A
synaptopodin isoform A
synaptotagmin-like protein 2 isoform a
T-complex protein 1 subunit zeta isoform a
TATA-binding protein-associated factor 172
TBC1 domain family member 25
TBC1 domain family member 4 isoform 1
TBC1 domain family member 8
TBC1 domain family member 9B isoform a
telomerase-binding protein EST1A isoform 1
tenascin precursor
tenascin-R precursor
teneurin-3
tensin-1
testis-expressed sequence 264 protein isoform 1
precursor
tetraspanin-1
tetraspanin-2
tetratricopeptide repeat protein 31
thioredoxin domain-containing protein 16 isoform 1
precursor
thrombopoietin receptor precursor
thrombospondin type-1 domain-containing protein
7A precursor
tigger transposable element-derived protein 3
tight junction protein ZO-3 isoform 1
TIR domain-containing adapter molecule 1
tissue factor isoform 1 precursor
titin isoform 1
TLR4 interactor with leucine rich repeats precursor
transcription cofactor vestigial-like protein 3
transcription factor E2F8
transcription factor GATA-5
transcription factor HIVEP2

151
73

pvaenvTNNEGSPpppvkv
dgdeyamaSSAESSPgeyeweyd

65
1
328
871
301
56
700
24
149
132
68
283

nliylaTIADASPtstska
ngpevhgSIMDHSPttgvvtvi
kglpcsgkSSGESSPsehsssgv
vlqlcssySAAELSPpgpalael
isslnrtpSVTEASPwratnpfl
asrgymTSGDVSPismspi
nhgldkahSLMELSPsappggsp
rsqwgtagSAEEPSPqaarlaka
mfagvpTMRESSPkqymql
iqeargqgSAKELSPaalekrrr
kaaehkakSLGEKSPaasgarrp
vdqfewdmSEKENSPekfalklc

570
251
275
487
334
89
566
599
439
950
481
1940
795
976
1440
100

pqlsgatdSQDDSSPadifavgf
giqapggtSQMERSPmlerrhfg
kapapqppSLPDRSPrpqrhims
ssrdrqqgSEEEPSPvlktlers
acggvalnSFDDLSPdclghagl
trqeptseSSMEDSPtterlnfd
spssssppSTQEASPtgdmavgs
fersnslaSEKDYSPgdsppgtp
mssqnseeSEKEKSPlmhpdalv
aahyftedSSSEASPlasdldlf
qlhfldTDDEVSPtswgds
vgpdttsySLADLSPsthytaki
sssvniTWSDPSPpadrli
splstffrSSPEDSPiipetqvl
tlpdfskySMPDNSPetrakvkf
rcavgsilSEGEESPspelidly

158
45
205
26

cgftnyTDFEDSPyfkens
fggaikelSSEDKSPeyfyvgly
gepkasttSDGDESPpsspgnpv
ifymptvnSLPELSPqkyfstlq

203
513

alqrphsaSALDQSPcaqptmpw
chipcpTECEVSPwsawgp

162
283
356
284
10318
412
179
348
46
2100

tsqaqlplSLKDFSPedvfgcae
lvnippavSDSDSSPledisdla
pcpptpTTPETSPpppppp
crkagvgqSWKENSPlnvs
ekitivTQREESPppavpe
ddqqlqngSCADPSPsasltadr
vtgppgtfSAADPSPwpghnlhq
kpafkwTGPEISPntsgss
vpsmlsylSGCEPSPqppelaar
eaalrremSQRDVSPrrhlsprr

307
116089331
5902104
109637791
109637791
109637791
109637791
109637791
109637791
109637791
119393899
194328729
19913369
221136834
347360922
630044887
109638745
4506137
30089937
14150104
262399371
150378481
122937189
118421085
116805348
27436877
44680122
45439359
50658079
213972636
429325228
219689113
4755140
113722125
156104895
358356428
21536466
595582408
33356177
18375646
153792150
260064009
188497648
109134332
157739864

transcription factor HIVEP3 isoform a
transcription factor SOX-10
transcription factor TFIIIB component B'' homolog
transcription factor TFIIIB component B'' homolog
transcription factor TFIIIB component B'' homolog
transcription factor TFIIIB component B'' homolog
transcription factor TFIIIB component B'' homolog
transcription factor TFIIIB component B'' homolog
transcription factor TFIIIB component B'' homolog
transcriptional activator GLI3
transcriptional activator Myb isoform 1
transducin beta-like protein 3
transducin-like enhancer protein 6 isoform 1
transformation/transcription domain-associated
protein isoform 1
transforming acidic coiled-coil-containing protein 2
isoform a
transforming growth factor beta-1-induced transcript
1 protein isoform 1
transmembrane gamma-carboxyglutamic acid
protein 2 precursor
transmembrane protein 132A isoform b precursor
transmembrane protein 175
transmembrane protein 201 isoform 1
transmembrane protein 236
transmembrane protein FAM155A
treslin
trinucleotide repeat-containing gene 6A protein
tripartite motif-containing protein 59
tripartite motif-containing protein 7 isoform 1
triple functional domain protein
tubulin polyglutamylase TTLL5
tumor suppressor p53-binding protein 1 isoform 1
twist-related protein 2
two pore calcium channel protein 1 isoform 1
type I inositol 3,4-bisphosphate 4-phosphatase
isoform a
type II inositol 1,4,5-trisphosphate 5-phosphatase
precursor
type II inositol 3,4-bisphosphate 4-phosphatase
tyrosine-protein kinase receptor Tie-1 isoform 2
tyrosine-protein kinase receptor UFO isoform 1
precursor
tyrosine-protein kinase SgK223
tyrosine-protein phosphatase non-receptor type 11
isoform 1
tyrosine-protein phosphatase non-receptor type 13
isoform 1
ubiquitin carboxyl-terminal hydrolase 17
ubiquitin carboxyl-terminal hydrolase 24
ubiquitin carboxyl-terminal hydrolase 37
ubiquitin carboxyl-terminal hydrolase 44
ubiquitin conjugation factor E4 B isoform 1

990
7
962
1017
1042
1096
1123
1205
1778
39
578
72
22
2352

pharemrrSASEQSPnvshsahm
pSEVELSPvgseeprc
etdlkaTGNESSPrektpe
etdlnaTGRESSPrektpe
eidleeTEREVSPqengle
eidleeTEREISPqengle
qtdlkaTGREISPrektpe
etdleeTEREISPqengpe
rrvgeeTVGDNSPssvvee
kavassttSNEDESPgqtyhrer
frtpaikrSILESSPrtptpfkh
edqediTAFDLSPdnevlv
stspcpgiSNSESSPtlnyqgil
nfiqailtSLIEKSPdakilrav

191

qkssfsfsSGIDQSPgmspvplr

186

ptqppvvsSTNEGSPsppeptgk

18

lymaltTCLDTSPseetdq

336
58
555
343
108
1875
1744
240
448
1739
906
1677
38
125
4

chraglTEPDSSPlelsef
vmilpvTHTEISPeqqfdr
geapttpsSSDEHSPhngslftm
yltririfSAFEMSPf
pswpallaSMGESSPaaqahrll
dedvdvlpSTVEDSPfsrafsrr
ltgqkpplSTWDNSPlrigggwg
lelmaltiSLQEESPlkflekvd
gqywavTSPERSPlscghl
nhkdslsvSSNDASPpasvaslq
thlssvTTSDLSPgpchhs
sgkrklitSEEERSPakrgrksa
rkrryskkSSEDGSPtpgkrgkk
dsqapslsSGGESSPsspahnwe
gkvetTAREHSPrhgara

82

pvsrdfTLEEVSPdgelyi

490
153
32

kkppspksSTEESSPqdqppvmr
sgiysaTYLEASPlgsaff
cmaprgTQAEESPfvgnpg

799
555

apvpfpsgSTEDVSPsgpqqppp
ysladqTSGDQSPlppctp

2104

eertedTDCDGSPlpeyft

35
2071
456
166
269

afaeiqrtSLPEKSPlssearvd
edlslsapSSPEISPqssprphr
ktwktepvSGEENSPdisatray
mgkifrTWFEQSPigrkkq
sfgasslsSLYESSPaptpsfws

308
542133148
32307148
36031016
282847388
38348310
222144283
125628665
207028635
568215110
71274152
242332527
375493555
124028515
154689866
57863293
57863293
149363685
197245440
154090979
112734870
223633988
71274186
148612838
148727311
299782489
156119615
54606888
34147384
149944410
149944410
70608185
42544121
53832007
148536844
329663531
21361077
114431244
54124343
5901892
13324688
216548378
102470001
24308444
40255272

ubiquitin-associated protein 2 isoform 1
UDP-N-acetylglucosamine--peptide Nacetylglucosaminyltransferase 110 kDa subunit
isoform 1
uncharacterized protein C10orf118
uncharacterized protein C10orf62
uncharacterized protein C11orf53
uncharacterized protein C11orf95
uncharacterized protein C16orf86
uncharacterized protein C1orf226 isoform 1
uncharacterized protein C20orf62
uncharacterized protein C2orf71
uncharacterized protein C5orf42
uncharacterized protein C9orf173 isoform a
uncharacterized protein C9orf84 isoform 1
uncharacterized protein KIAA0232
uncharacterized protein KIAA0930 isoform a
uncharacterized protein KIAA0930 isoform a
uncharacterized protein KIAA0947
uncharacterized protein KIAA1107
uncharacterized protein KIAA1210
uncharacterized protein KIAA1522 isoform 1
uncharacterized protein KIAA1671
uncharacterized protein KIAA1755
uncharacterized protein KIAA2026
uncharacterized protein LOC389690
uncharacterized protein LOC401236
unconventional myosin-IXa
UPF0258 protein KIAA1024
UPF0366 protein C11orf67
UPF0501 protein KIAA1430
UPF0501 protein KIAA1430
UPF0524 protein C3orf70
vacuolar protein sorting-associated protein 13C
isoform 1A
voltage-dependent L-type calcium channel subunit
alpha-1F isoform 1
voltage-dependent P/Q-type calcium channel subunit
alpha-1A isoform 1
voltage-dependent R-type calcium channel subunit
alpha-1E isoform 2
voltage-dependent T-type calcium channel subunit
alpha-1I isoform a
von Willebrand factor C and EGF domain-containing
protein precursor
WASH complex subunit FAM21A
WD repeat and HMG-box DNA-binding protein 1
isoform 1
WD repeat-containing protein 11
WD repeat-containing protein 47 isoform 1
WD repeat-containing protein 88
WD repeat-containing protein 92 isoform 1
xin actin-binding repeat-containing protein 1 isoform
1

426
681

vlshldfkSQPEPSPvlsqlsqr
fmdyiiTDQETSPaevaeq

734
17
210
364
141
286
110
1222
1766
114
557
1111
266
278
1467
1334
332
697
1689
1188
942
280
71
1780
553
43
258
253
214
573

sgslnarsSAEDRSPentgssva
rketsecpSDKDKSPeshkakne
pdeeadtgSLHDPSPwvkedgsi
sasaagapSSQDLSPpdvkeeag
lqeeepedSQSEPSPsakqhkka
lspislaeSWEDGSPppqartss
safasgsfSHFEDSPyillhvvl
yesqlgqnSSSEESPkkdtepgs
lcdsgiteSSSEYSPvirvktst
tryqvpspSVRESSPhphysigc
keacslTLQEESPivhink
prthfrpiSASELSPgggsesef
aemavsrvSTGDTSPcgteedss
dtspcgTEEDSSPaspmhe
agcipvTSAEKSPeashtg
asitmasfSSEDCSPqgewtile
isknlveiSLDDESPknpqkkal
pavvpgpvSTTDASPqspptpqt
dntwmfkdSTEEKSPrkeesdee
egtdsqTSLEDSPqtspla
kqtdyvddSTKELSPrkkaklst
lttpswTQQEQSPekaflf
mgslpgTISENSPspsern
trvkptTQSEVSPlfagtd
gslsqlhkSDCDSSPehnltkia
twdwreTGTEHSPgvqpad
tvtdvsplSTPDISPlqsfelgi
peesedTVTDVSPlstpdi
teegaelsSEEDYSPesswepde
lkikfeTNPEDSPadqtli

12

seggkdTTPEPSPangagp

2122

rgnnlsTISDTSPmkrsas

1075

vhisnkTDGEASPlkeaei

2017

qatgsdTSLDASPsssags

901

llteasalSMMDPSPsktpitll

349
955

fappklTDEDFSPfgsggg
talsrtTNNEKSPiikpli

616
375
457
324
207

knfptiTALEWSPshnlks
mlentechSIYEESPersdtpvd
dtssssssSERENSPpprgskdd
vtlstqpiSSLDWSPdkrglcvc
ldrlgsrpSLQEQSPlelrseiq

309
282394051
282394051
28269693
87116683
87116683
114842410
410812199
21735419
291167749
157676340
222831664
56699475
126723501
120587019
24307925
72255571
188536004
188536004
188536004
24429588
7662092
124286830
289547725
337298801
21361146
46094072
31791053
123701326
166795262
94721327
94721327
119709834
223890230
122114658
292494919
29789072
a

XK-related protein 5
XK-related protein 5 isoform a
xylosyltransferase 1 precursor
zinc finger C3H1 domain-containing protein
zinc finger C3H1 domain-containing protein
zinc finger CCCH domain-containing protein 11A
zinc finger CCCH-type domain-containing-like
zinc finger CCHC domain-containing protein 14
zinc finger homeobox protein 4
zinc finger protein 142
zinc finger protein 184
zinc finger protein 202
zinc finger protein 277
zinc finger protein 318
zinc finger protein 32
zinc finger protein 451 isoform 1
zinc finger protein 469
zinc finger protein 469
zinc finger protein 469
zinc finger protein 532
zinc finger protein 536
zinc finger protein 618
zinc finger protein 653
zinc finger protein 691 isoform 1
zinc finger protein 76
zinc finger protein 770
zinc finger protein 804B
zinc finger protein 831
zinc finger protein AEBP2 isoform a
zinc finger protein basonuclin-2
zinc finger protein basonuclin-2
zinc finger protein castor homolog 1 isoform a
zinc finger protein ZFPM2
zinc finger SWIM domain-containing protein
KIAA0913 isoform 1
zinc finger with UFM1-specific peptidase domain
protein
ZZ-type zinc finger-containing protein 3

596
553
536
188
122
732
733
278
890
1066
116
168
52
1710
66
593
2983
413
2161
1250
708
590
204
33
390
526
709
1396
83
366
677
51
394
1158

lapfpdTMADISPilgtgp
ataevatsSQQEGSPatlqtahs
aesffhTVLENSPhcdtmv
gsgfsssqSWREPSPprkssksf
psvrmpssSLSESSPrpsfwers
slvlpptqSSSDSSPpevsgpss
slvlpltqSSSDSSPpevsgpss
salayrTQMDTSPailmps
ddlsllTAGELSPyisdpa
krgtpqTQPDVSPlsngds
vsapepdiSEEELSPevivekhk
elqdpvqsSTPEQSPeettqspd
espggtTTLEGSPsvpcif
ssfqsdTSRDISPekseld
kspdskTLQEDSPgvrqrv
kpssaiTVIDHSPansspr
apaddsssSLGDVSPeppslere
fpgqayraSGVDTSPgppdtela
vqattdTGAEDSPvappsl
dnqqenkpSHEDESPdgavsdrk
ggglsqtgSAQEDSPhpsspsss
glaketfgSLEETSPppcwnsvt
dssssgsaSDSEESPegqpvkaa
ssegsemgSEKEQSPephlpeeg
eqqqleaaSAAEESPppkrpria
lkrheqTHNEKSPyaslcq
qsclsrysSSLDTSPssmsslrs
remdkrTVKDISPsagehg
gggeaeTMSEPSPesasqa
tqneynesSESEVSPtpykndqt
mshdnhchSQEEMSPgmsvkdfs
vekradagSHTEGSPsqprdqer
psgklpreSDMEHSPsatedslq
dssapeTTSDSSPtlsrrp

467

ewilnyysSEGEGSPkvvctskp

129

clrseapnSSEEDSPiksdkesv

Amino acids in capitals represent the sequence that matches the searched consensus sequence for CK2 hierarchical
multisite phosphorylation. Amino acids in lower case are the surrounding sequence within the candidate protein.
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Appendix D. Phosphorylation status of candidate proline-directed CK2 hierarchical
sequences at the p and p+5 positions from the PhosphoSite Plus database.
GI
121583483
111955084
21493022
21493022
29826319
11345484
157671951
37620163
46519147
134948558
56549668
51479158
72256200
164664508
14043024
7661958
7661958
183396783
7705638
13124765
387157909
49472835
14249338
14249338
14249338
210147453
16753221
32171241
217416347
118150654
171184451
48717495
40255020
333440451
7661690

Protein Name

Peptide Sequencea

Position

pb

p+5b

1-phosphatidyl inositol 3-phosphate 5kinase isoform 2
5-azacytidine-induced protein 1 isoform
a
A-kinase anchor protein 12 isoform 1
A-kinase anchor protein 12 isoform 1
alpha-adducin isoform a
AN1-type zinc finger protein 3
Anion exchange protein 3 isoform 1
ANKHD1-EIF4 EBP3 protein
Ankyrin repeat and KH domaincontaining protein 1 isoform 1
Ankyrin repeat domain-containing
protein 12 isoform 1
AT-rich interactive domain-containing
protein 2
ataxin-1
B-cell CLL/lymphoma 9 protein
B-cell lymphoma 3 protein
BAG family molecular chaperone
regulator 3
bcl-2-associated transcription factor 1
isoform 1
bcl-2-associated transcription factor 1
isoform 1
BCL-6 corepressor isoform a
bolA-like protein 1 precursor
brain-enriched guanylate kinaseassociated protein
Breast cancer anti-estrogen resistance
protein 3 isoform 1
Bridging integrator 2
BUD13 homolog isoform 1
BUD13 homolog isoform 1
BUD13 homolog isoform 1
C2 calcium-dependent domaincontaining protein 4C
cadherin-22 precursor
cAMP-specific 3',5'-cyclic
phosphodiesterase 4B isoform 1
caskin-2 isoform a
Centrosomal protein Kizuna isoform1
centrosome-associated protein 350
Chondroitin sulfate
glucuronyltransferase isoform 1
precursor
Chromatin modification-related protein
MEAF 6 isoform 1
CLIP-associating protein 2 isoform 2
coiled-coil domain-containing protein 9

rqgeeskiSAMDASPrnispglq

1538

N

Y

mkgtraigSVPERSPagvdlslt

8

N

Y

eetlkreqSHAEISPpaesgqav
iidgakevSSLEGSPppclgqee
sdaatfkpTLPDLSPdepsealg
rscgtdsqSENEASPvkrprlle
qkakfsigSDEDDSPglpgraav
vppqepdrTSQENSPallgvqkg
vppqepdrTSQENSPallgvqkg

247
1389
642
123
169
737
737

Y
Y
N
Y
Y
Y
Y

Y
Y
Y
Y
N
Y
Y

qmallmqmTARDNSPdstpnhp

146

N

Y

stsvvrvdSVPDVSPapspagip

625

Y

Y

iglhkalsTGLDYSPpsaprsvp
hdaiktvaSSDDDSPparspnlp
katrpastSQPDPSPdrsantsp
frssvqgaSSREGSParsstplh

85
1033
368
273

N
Y
N
Y

Y
Y
Y
Y

nldareksTFREESPlrikmia

528

Y

Y

sgdiwpglSAYDNSPrsphspsp

216

Y

Y

frkrpepsSDYDLSPakqepkpf
tpaqwrenSQLDTSPpclggnkk
gsrdslepSSMEASPemhpaarl

1370
117
547

Y
N
N

Y
Y
Y

gcklppqsSGVDTSPcpnspvfr

352

N

Y

gtgtasprTSLEVSPnpeppekp
kqspghqdSDSDLSPprnrprhr
rnrprhrsSDSDLSPprrrqrtk
rrrqrtksSDSDLSPprrsqppg
hgslsaddSTPDASPgsrrrltr

463
369
385
401
267

Y
Y
Y
Y
N

Y
Y
Y
Y
Y

flhgpyigSVAELSPtgtsvmqv
esflyrsdSDYDLSPkamsrn

175
139

N
Y

Y
Y

qeqpapqpSGGDPSPpqernlpe
kiaseasfSSSEGSPlsrhenkk
krrghhddSDEEASPekttlsta
epglvqkfSLRDCSPrlseelyh

719
617
1647
728

N
Y
Y
Y

Y
N
Y
N

ekrepgsgTESDTSPdfhnqene

122

Y

Y

csreasreSSRDTSPvrsfqpla
papetpqpTSPETSPketpmqpp

535
387

N
Y

Y
Y

311
178056552
5453754
52630425
182507165
58530840
148528998
291621657
5174501
4504191
38372911
42764683
148839382
148596928
156104874
221316747
24476013
60498989
330864753
101943240
208022632
347659028
4504805
50962882
109715835
4885395
197313748
197313748
5901962
71164886
7706607
41281583
5031805
4504725
387942373
5032013
148612877
91825557
66392157
66392157
197333706

Condensing complex subunit 1
Cytoplasmic protein NCK1 isoform 1
Cytoplasmic protein NCK2 isoform A
Dapper homolog 3
Desmoplakin isoform I
dmX-like protein 1
dmX-likeprotein 2 isoform 1
DNA-binding protein Ikaros isoform1
DNA mismatch repair protein Msh6
Dual specificity protein phosphatase 16
Dual specificity protein phosphatase 6
isoform a
E3 ubiquitin-protein ligase RNF169
Electrogenic sodium bicarbonate
cotransporter 1 isoform 1
envoplakin
exophilin-5
Focal adhesion kinase 1 isoform a
Forkhead box protein P4 isoform 1
gamma-interferon-inducible protein 16
isoform 1
General transcription factor 3C
polypeptide 1 isoform 1
Girdin isoform 1
glucosamine--fructose-6-phosphate
aminotransferase [isomerizing] 1
isoform 1
Golgin-45
G patch domain-containing protein 8
HEAT repeat-containing protein 6
Hemoglobin subunit theta-1
histone-lysine N-methyltransferase
SETD2
histone-lysineN-methyltransferase
SETD2
Histone acetyltransferase KAT7
isoform 1
inactiveserine/threonine-protein kinase
VRK3 isoform 1
Inner nuclear membrane protein Man1
isoform 1
Inositol hexakisphosphate and
diphosphoinositol-pentakisphosphate
kinase 2
Insulin receptor substrate 1
Interferon regulatory factor 3 isoform 1
kinesin-like protein KIF18B isoform1
kinesin-like protein KIF20A
kinesin-like protein KIF2A isoform 1
Kinesin light chain 3
leucine-rich repeat-containing protein
16C
leucine-rich repeat-containing protein
16C
leucine-rich repeat-containing protein
8D

dsqlrllfTMLEKSPlpivrsnl
vmqnnpltSGLEPSPpqcdyirp
lgktrrktSARDASPtpstdaey
iyaserpkSLGDASPsapevvga
irsssfsdTLEESSPiaaifdte
yrassfldTSKDCSPssplklda
vpgqknvdSSPETSPsvspmph
lskaklvpSEREASPsnscqdst
rsvapaapTSCDFSPgdlvwakm
sdradsrrSWHEESPfekqfkrr
ldrdpnsaTDSDGSPlsnsqpsf

1063
256
84
164
2614
1902
943
383
88
611
194

Y
N
N
Y
Y
N
Y
N
N
Y
N

N
Y
Y
N
N
Y
Y
Y
Y
N
Y

lnrslqkqTSYEASPrilkkweq
pflsdskpSDRERSPtflerht

424
1063

N
Y

Y
Y

kisilepeTGKDMSPyeaykrgi
hvksselvSQQDSSPvevhinke
sstkthlgTGMERSPgamervlk
revttgadSNGEMSPaellhfqq
kkdilnpdSSMETSPdfff

1695
598
26
51
718

N
N
N
Y
Y

Y
Y
Y
Y
N

pqarplegSSSEDSPpegqapp

1839

N

Y

lvnnkdttSFEDISPqgvsdd
giahtrwaTHGEPSPvnshpqr

1559
100

Y
N

Y
Y

vlrildpvTCKESSPdnpffe
snigtgrgSEGDCSPedknsvta
sdagsaagSTYEPSPmrlealqv
fpatktyfSHLDLSPgssqvrah
meigdtlsTAEESSPpksrvelg

350
1075
679
44
128

Y
Y
Y
N
Y

Y
Y
N
Y
Y

lmtsddsvTGSELSPlvkacml

705

N

Y

rssarlsqSSQDSSPvrnlqsfg

51

Y

N

qgskrglnSSFETSPkkvkwsst

53

Y

Y

llgfssdeSDVEASPrdqagggg

143

Y

N

lprsrktaTNDEESPlsvsspeg

974

N

Y

mqmscprqSYVDTSPaapvsya
vnsgvgdfSQPDTSPdtngggst
eramegnsSDQEQSPededegpa
lprtptcqSSTDCSPyarilrsr
sssaqqngSVSDISPvqaakkef
kaprtlsaSTQDLSPh
prstrgprTDLETSPgaaprtrk

999
117
446
861
134
496
1117

N
N
N
Y
Y
Y
N

Y
Y
Y
Y
Y
N
Y

lppqptepSSPERSPpspatdqr

1414

N

Y

tlpkhvstSSDEGSPsastpmin

240

N

Y

312
216548085
165905589
33457311
78042577
147903302
13491174
352962167
122891870
238859557
95147555
148727255
85838511
336020360
59814247
67189007
208022661
126362967
315259111
118918403
21314632
19923348
254692833
150010577
350529396
27886539
45545405
157694511
46048234
50659095
56549107
194306541
41152072
27436910
51173720
81295809
48255929
45439327
56788370
18034775
28557677
34452732

Leucine zipper protein 1
LIM domain and actin-binding protein
1 isoform 1
magnesium-dependent phosphatase 1
isoform 1
MAP7 domain-containing protein 1
MAP7 domain-containing protein 3
isoform 1
MARCKS-related protein
melanoma-associated antigen 10
Melanoma inhibitory activity protein 3
precursor
MHC class II regulatory factor RFX1
microtubule-associated protein 1A
microtubule-associated
serine/threonine-protein kinase 4
isoform a
mitogen-activated protein kinase kinase
kinase 2
mitogen-activated protein kinase kinase
kinase kinase 4 isoform 5
Mitotic check point serine/threonineprotein kinase BUB1 beta
mucin-1 isoform 2 precursor
nck-associated protein 5-like
nck-associated protein 5 isoform 1
NEDD8-MDP1 protein
nesprin-2 isoform 1
Neutral amino acid transporter A
isoform 1
NGFI-A-binding protein 1
NHS-like protein 2
non-receptor tyrosine-protein kinase
TNK1 isoform 2
Nuclear factor 1C-type isoform 1
Nuclear factor of activated T-cells,
cytoplasmic 2 isoform B
Nuclear receptor subfamily 5 group A
member 2 isoform 1
Nucleolar complex protein 2 homolog
Nucleolar protein 8 isoform a
Nucleolar RNA helicase 2 isoform 1
optineurin
Oxidation resistance protein 1 isoform1
Palmitoyl transferase ZDHHC5
Partner and localizer of BRCA2
Peregrin isoform 1
Pericentrin
periphilin-1 isoform 1
periplakin
PH and SEC7 domain-containing
protein 4
PHD finger protein 20
PHD finger protein 6 isoform 1
Phosphatidylinositol 3,4,5trisphosphate-dependent Rac exchanger

seasvskhTARELSPqhkrerlr
lspdsrasSLSESSPpkamkkfq

391
369

N
Y

Y
Y

kaqtgplrSSLEESPfea

166

Y

N

prarlsasTASELSPkskarp
vnvevfcnTSMEASPkagvgma

457
319

Y
Y

Y
Y

gqenghvkSNGDLSPkgegespp
dqsdegssSQKEESPstlqvlpd
gsfgpspvSGGECSPpltveppv

35
110
1672

Y
N
N

N
Y
Y

egamraseTVSEASPgstasqtg
spedtqslSLSEESPsketsldv
sgkkndttSARELSPsslkmnk

117
1197
1665

N
N
N

Y
Y
Y

sdidnptlTVMDISPpsrsprap

341

N

Y

vspvsrshSFSDPSPkfahhhlr

557

Y

Y

lktsesitSNEDVSPdvcdeftg

568

N

Y

thgryvppSSTDRSPyekvsagn
nsripcrnSGSDGSPspllarrg
tfdelhieSSDEKSPsdvslaad
kaqtgplrSSLEESPfea
nqpslddvSVVDSSPassppakk
veaipnckSEEETSPlvthqnpa

230
490
594
183
156
501

Y
N
N
Y
N
Y

Y
Y
Y
N
Y
Y

lsaglyrqSSEEHSPngltsdn
vtstpqadSEREASPlgssvepg
rmetgdpiTVIEGSPdstiwkgq

401
1066
408

Y
N
N

Y
Y
Y

gisspvkkTEMDKSPfnspspqd
gippkmwkTSPDPSPvsaapska

330
327

Y
Y

Y
N

lnhaalppTDYDRSPfvtspism

235

N

Y

sgfdseseSESENSPqaetrear
khedpsiiSMEDGSPyvngslge
kakkkeepSQNDISPktkslrkk
shqplsclTEKEDSPsestgngp
eslsedvfTESELSPireelv
prlvptgpTHREPSPvrydnlsr
tveeqdclSQQDLSPqlkhsepk
lgrgagwlSEDEDSPldaldlvw
rkgsavdaSVQEESPvtkedsal
erpvqslkTSRDTSPssgsav
sivvihpdTGRELSPeeahragl
pgprpspaSSQEGSPqlqhhssg

29
611
83
12
342
526
58
1081
48
202
1667
463

N
Y
Y
N
N
Y
Y
Y
N
N
N
Y

Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y

pcseeisdTSQEPSPpkafavtr
gtdemessSYRDRSPhrsspsdt
llslgprlSLCEDSPmvtltvdn

566
193
833

N
Y
Y

Y
N
N

313

30089916
55749621
221139728
237820622
148612879
20149500
530372498
15721939
296531322
29825823
358679311
28144916
88702791
28626517
150378539
203098098
257467639
55749600
157739945
41349439
148886692
24308043
153792780
116812577
5803145
119392077
24431935
47519562
7661858
7661858
95091875
50843837
8400718
325120986
72534652
116256479
33469966
39777608

1 protein
Phosphofurin acidic cluster sorting
protein 1
Pleckstrin homology domain-containing
family G member 3
Pleckstrin homology domain-containing
family M member 2
Pleckstrin homology domain-containing
family N member 1 isoform a
polyhomeotic-like protein 3
Porphobilinogen deaminase isoform 1
PREDICTED: microtubule-associated
protein 4 isoform X23
Protein CASC3
Protein FAM219A isoform 1
Protein HID1
Protein LAP2 isoform 1
proteinlin-37 homolog
Protein Mdm4 isoform 1
Protein phosphatase 1 regulatory
inhibitor subunit 16B isoform 1
Protein piccolo isoform 1
Protein Shroom 3
Protein SOGA1 isoform 1
Protein spire homolog 2
Protein TANC2
Protein transport protein Sec31A
isoform 1
Protocadherin Fat3 precursor
Putative adenosyl homocysteinase 3
isoform a
Putative Polycomb group protein
ASXL2
Putative RNA-binding protein Luc7like 2 isoform 1
ralA-binding protein 1
Rap guanine nucleotide exchange factor
5
reticulon-4 isoform A
reticulon-4 isoform E
Rho GTPase-activating protein 11A
isoform 1
Rho GTPase-activating protein 11A
isoform 1
Rho GTPase-activating protein 6
isoform 1
Rho guanine nucleotide exchange factor
40
RNA-binding motif, single-strandedinteracting protein 1 isoform a
RNA-binding protein 10 isoform 5
runt-related transcription factor 3
isoform 1
RWD domain-containing protein 4
sec1 family domain-containing protein
1 isoform a
semaphorin-4B precursor

plsertnsSDSERSPdlghstqi

528

Y

Y

ehsppkpsSAGEMSPqrfffnp

949

N

Y

igkkkksrSDEEASPlhpacsqk

328

Y

N

pdapqlvsSAREGSPepwlpltd

553

N

Y

ttvtsskiSQRDPSPesnkkge
sgngnaaaTAEENSPkmrvirvg
kkkpcsetSQIEGSPtefleekm

269
12
70

N
N
N

Y
Y
Y

rsrrleqtSVRDPSPeadapvlg
lvvpnkgySSLDQSPdekplval
slepepqqSLEDGSPakgepsqa
svdlgiskSTEDLSPqksgpvg
qgtpddepSEPEPSPstliyrnm
ellgrqsfSVKDPSPlydmlrkn
adatppwsSYKEQSPqtllelkr

357
96
647
851
196
90
470

Y
N
N
Y
N
N
N

Y
Y
Y
Y
Y
Y
Y

pydsveesSESENSPvpqrkrrt
pfieeqlhTVLEKSPensppvkp
vssmsefeSLLDCSPylaggdar
aemeemntSEEEESPcgevtlkr
plkpayerSCDELSPvsptqggy
kdsdqvaqSDGEESPaaeeqllg

1516
436
1172
422
1818
526

N
N
N
N
Y
Y

Y
Y
Y
Y
Y
Y

fekevydvSISEFSPpgvvvaiv
saasytdsSDDETSPrdkqqkn

383
165

N
Y

Y
N

tnmkeplaTLVDQSPeslkrk

559

N

Y

lascdrdrSSRDRSPrdrdrkdk

352

N

Y

gsgltrtpSSEEISPtkfpglyr
ilgmhrrhTVDEYSPqkknkalf

28
359

Y
Y

Y
N

eaqireteTFSDSSPieiidefp
eaqireteTFSDSSPieiidefp
tgkgekcfSERDFSPlqtqtfnr

860
654
669

N
N
Y

Y
Y
Y

gkvkltepSYLEDSPeenlfetn

632

N

Y

sstdsnkaSSGDISPydnnspvl

661

N

Y

tlpvrgspTDAEGSPglsrvrtv

259

N

Y

gqqqvaveTSNDHSPytfqpnk

395

N

Y

dagrgggeSLQEASPrladhg
fsmvagssSGGDRSPtrmlasct

24
364

N
N

Y
Y

rsiyegdeSFRELSPvsfqyrig
nrvnleesSGVENSPagarpkrk

22
297

N
N

Y
Y

krplsiqdSFVEVSPvcprprvr

812

Y

Y

314
118572613
118572613
118572613
118572613
118572613
118572613
118572613
118572613
166295194
166295194
47132591
4507831
120587025
229892306
50843820
7662126
4506967
4506975
194733749
112382250
32699054
40789229
21361863
485836756
394582088
19557691
19557702
19557702
40353727
40353727
27477070
114688046
115511020
66529407
4503641
378925625
109637791

serine/arginine repetitive matrix protein
2
serine/arginine repetitive matrix protein
2
serine/arginine repetitive matrix protein
2
serine/arginine repetitive matrix protein
2
serine/arginine repetitive matrix protein
2
serine/arginine repetitive matrix protein
2
serine/arginine repetitive matrix protein
2
serine/arginine repetitive matrix protein
2
serine/threonine-protein kinase Chk1
isoform 1
serine/threonine-protein kinase Chk1
isoform 1
serine/threonine-protein kinase N1
isoform 1
serine/threonine-protein kinase ULK1
SH3 and multiple ankyrin repeat
domains protein 1
shugoshin-like 2 isoform 1
Sickle tail protein homolog isoform 1
signal-induced proliferation-associated
1-like protein 1 isoform 1
skioncogene
Solute carrier family 12 member 2
isoform 1
Sorbin and SH3 domain-containing
protein 2 isoform 1
Spectrin beta chain, non-erythrocytic 1
isoform 1
Spindle and kinetochore-associated
protein 2 isoform 1
Splicing factor, arginine/serine-rich 15
isoform 1
stonin-2 isoform 1
Stromal interaction molecule 1 isoform
1 precursor
Suppressor of cytokine signaling 2
Surfeitlocus protein 4
Surfeitlocus protein 6 isoform 1
Surfeitlocus protein 6 isoform 1
Synaptopodin isoform A
Synaptopodin isoform A
TATA-binding protein-associated
factor 172
TBC1 domain family member 4
isoform 1
telomerase-binding protein EST1A
isoform 1
tensin-1
Tissue factor isoform 1 precursor
Titin isoform 1
Transcription factor TFIIIB component

qstrssghSSSELSPdavekagm

1381

Y

Y

prtpsrgrSECDSSPepkalpqt

1477

Y

Y

praapraqSGSDSSPepkapapr

1615

Y

Y

rgpspegsSSTESSPehppksrt

1652

Y

Y

speklpqsSSSESSPpspqptkv

415

N

Y

selkemstSNFESSPeveerpav

1265

N

Y

psaspqerSESDSSPdskaktrt

1556

N

Y

qsvtpqrrSCFESSPdpelksrt

870

Y

N

qpeprtglSLWDTSPsyidklvq

325

N

Y

sgfskhiqSNLDFSPvnsassee

295

Y

N

sveklnlgTDSDSSPqkssrdpp

565

Y

Y

grsprpgsSAPEHSPrtsglgcr
asecpeggSESDSSPdgpgrgpr

538
23

Y
Y

Y
N

tskskkrkTSIDPSPeshevmer
qtikqlenTISEMSPkalvdtsc
laqmkpysSSKDSSPtlaskvdq

1086
1681
1728

Y
N
N

Y
Y
Y

pwspavsaSEKELSPhlpalird
lqgqeellSSQEKSPgtkdvvv

388
938

N
N

Y
Y

qtyrplskSHSDNSPnafkda

197

N

Y

ngateqrtSSKESSPipsptsdr

2159

Y

N

miqklqkqTDLELSPltkeekta

98

N

Y

aapvaenvTNNEGSPpppvkv

151

Y

Y

isslnrtpSVTEASPwratnpfl
nhgldkahSLMELSPsappggsp

301
700

Y
N

Y
Y

rsqwgtagSAEEPSPqaarlaka
ksmfagvpTMRESSPkqymqlg
iqeargqgSAKELSPaalekrrr
kaaehkakSLGEKSPaasgarrp
giqapggtSQMERSPmlerrhfg
kapapqppSLPDRSPrpqrhim
trqeptseSSMEDSPtterlnfd

24
149
132
68
251
275
89

N
Y
Y
N
N
N
N

Y
N
Y
Y
Y
Y
Y

fersnslaSEKDYSPgdsppgtp

599

Y

N

tpqlhfldTDDEVSPtswgdsrq

481

Y

Y

tlpdfskySMPDNSPetrakvkf
crkagvgqSWKENSPlnv
teekitivTQREESPppavpeip
vietdleeTEREISPqengpeev

1440
284
10318
1205

Y
Y
Y
Y

Y
N
Y
N

315
B'' homolog
630044887 Transforming acidic coiled-coilqkssfsfsSGIDQSPgmspvplr
191
N
Y
containing protein 2 isoform a
109638745 Transforming growth factor beta-1ptqppvvsSTNEGSPsppeptgk
186
N
Y
induced transcript 1 protein isoform 1
118421085 Treslin
dedvdvlpSTVEDSPfsrafsrr
1875
N
Y
116805348 Trinucleotide repeat-containing gene
ltgqkpplSTWDNSPlrigggwg
1744
N
Y
6A protein
213972636 Tumor suppressor p53-binding protein
sgkrklitSEEERSPakrgrksa
1677
Y
Y
1 isoform 1
595582408 tyrosine-protein kinase SgK223
apvpfpsgSTEDVSPsgpqqppp
799
N
Y
33356177 tyrosine-protein phosphatase nonikysladqTSGDQSPlppctptp
555
Y
Y
receptor type 11 isoform 1
260064009 Ubiquitin carboxyl-terminal hydrolase
edlslsapSSPEISPqssprphr
2071
N
Y
24
188497648 Ubiquitin carboxyl-terminal hydrolase
ktwktepvSGEENSPdisatray
456
Y
Y
37
36031016 Uncharacterized protein C10orf118
sgslnarsSAEDRSPentgssva
734
N
Y
207028635 Uncharacterized protein C1orf226
lspislaeSWEDGSPppqart
286
N
Y
isoform 1
57863293 Uncharacterized protein KIAA0930
tgdtspcgTEEDSSPaspmherv
278
Y
Y
isoform a
57863293 Uncharacterized protein KIAA0930
aemavsrvSTGDTSPcgteed
266
N
Y
isoform a
223633988 Uncharacterized protein KIAA1671
dntwmfkdSTEEKSPrkeesdee
1689
N
Y
34147384 UPF0366 protein C11orf67
srtwdwreTGTEHSPgvqpadvk
43
N
Y
42544121 Vacuolar protein sorting-associated
sllkikfeTNPEDSPadqtlivq
573
Y
Y
protein 13C isoform 1A
54124343 WASH complex subunit FAM21A
nlfappklTDEDFSPfgsggglf
349
Y
Y
216548378 WD repeat-containing protein 47
mlentechSIYEESPersdtpvd
375
Y
N
isoform 1
5901892 WD repeat and HMG-box DNAkstalsrtTNNEKSPiikplipk
955
N
Y
binding protein 1 isoform 1
40255272 xinactin-binding repeat-containing
ldrlgsrpSLQEQSPlelrseiq
207
Y
N
protein 1 isoform 1
87116683 Zinc finger C3H1 domain-containing
psvrmpssSLSESSPrpsfwer
122
N
Y
protein
87116683 Zinc finger C3H1 domain-containing
gsgfsssqSWREPSPprkssksf
188
N
Y
protein
410812199 Zinc finger CCCH-type domainslvlpltqSSSDSSPpevsgp
733
N
Y
containing-like
222831664 Zinc finger protein 184
vsapepdiSEEELSPevivekhk
116
Y
Y
120587019 Zinc finger protein 318
tsssfqsdTSRDISPekseldlg
1710
N
Y
24307925 Zinc finger protein 32
eqkspdskTLQEDSPgvrqrvye
66
N
Y
188536004 Zinc finger protein 469
fpgqayraSGVDTSPgppdtela
413
N
Y
337298801 Zinc finger protein 691 isoform 1
ssegsemgSEKEQSPephlpeeg
33
N
Y
122114658 Zinc finger SWIM domain-containing
sidssapeTTSDSSPtlsrrplr
1158
N
Y
protein KIAA0913 isoform 1
29789072 ZZ-type zinc finger-containing protein
clrseapnSSEEDSPiksdkesv
129
Y
Y
3
a
Amino acids in capitals represent the sequence that matches the searched consensus sequence for CK2 hierarchical
multisite phosphorylation. Amino acids in lower case are the surrounding sequence within the candidate protein.
b

Y, phosphorylated; N, not phosphorylated.

316

Title:

Author:

Versatile Strategy for
Biochemical, Electrochemical
and Immunoarray Detection of
Protein Phosphorylations

Logged in as:
Michelle Gabriel

Sanela Martić, Michelle Gabriel,
Jacob P. Turowec, et al

Publication: Journal of the American
Chemical Society
Publisher:

American Chemical Society

Date:

Oct 1, 2012

Copyright © 2012, American Chemical Society

PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you because
no fee is being charged for your order. Please note the following:

Permission is granted for your request in both print and electronic formats, and
translations.
If figures and/or tables were requested, they may be adapted or used in part.
Please print this page for your records and send a copy of it to your publisher/graduate
school.
Appropriate credit for the requested material should be given as follows: "Reprinted
(adapted) with permission from (COMPLETE REFERENCE CITATION). Copyright
(YEAR) American Chemical Society." Insert appropriate information in place of the
capitalized words.
One-time permission is granted only for the use specified in your request. No additional
uses are granted (such as derivative works or other editions). For any other uses, please
submit a new request.

Copyright © 2015 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement. Terms and Conditions.
Comments? We would like to hear from you. E-mail us at customercare@copyright.com

317
JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Sep 12, 2015

This Agreement between Michelle Gabriel ("You") and John Wiley and Sons ("John Wiley
and Sons") consists of your license details and the terms and conditions provided by John
Wiley and Sons and Copyright Clearance Center.

License Number

3706350499493

License date

Sep 12, 2015

Licensed Content Publisher

John Wiley and Sons

Licensed Content Publication Wiley Books
Licensed Content Title

Protein Kinase CK2

Licensed Content Author

Lorenzo A. Pinna

Licensed Content Date

Jan 1, 2013

Pages

480

Type of use

Dissertation/Thesis

Requestor type

University/Academic

Format

Print and electronic

Portion

Figure/table

Number of figures/tables

2

Original Wiley figure/table
number(s)

Figure 1 and Figure 3

Will you be translating?

No

Title of your thesis /
dissertation

Chemical Biology Approaches to Investigate the Activity and
Substrate Specificity of Protein Kinase CK2

Expected completion date

Oct 2015

Expected size (number of
pages)

320

Requestor Location

Michelle Gabriel
Department of Biochemistry
The University of Western Ontario
London, ON N6A 3K7
Canada
Attn: Michelle Gabriel

Billing Type

Invoice

Billing Address

Michelle Gabriel
Department of Biochemistry
The University of Western Ontario

318
MICHELLE A. GABRIEL
EDUCATION

The University of Western Ontario,
London, Canada
Doctor of Philosophy, Biochemistry
Supervisor: Dr. David. W. Litchfield
The University of Western Ontario,
London, Canada
Bachelor of Science, Honors Specialization in
Genetics and Biochemistry
Supervisor: Dr. Frederic Marsolais

PUBLICATIONS

2009 – Present

2004 – 2009

Peer-reviewed papers
St-Denis N, Gabriel M, Turowec JP, Gloor GB, Li SS, Gingras AC
and Litchfield DW. (2015) Systematic investigation of hierarchical
phosphorylation by protein kinase CK2. J. Proteomics. 118:49-62.
Turowec JP, Vilk G, Gabriel M and Litchfield DW. (2013)
Characterizing the convergence of protein kinase CK2 and caspase3 reveals isoform-specific phosphorylation of caspase-3 by CK2α':
implications for pathological roles of CK2 in promoting cancer cell
survival. Oncotarget. 4:560-571.
Martic S, Gabriel M, Turowec JP, Litchfield DW and Kraatz HB.
(2012) Versatile strategy for biochemical, electrochemical and
immunoarray detection of protein phosphorylations. J. Am. Chem.
Soc. 134:17036-17045.
Gabriel M, Telmer PG and Marsolais F. (2012) Role of
asparaginase variable loop at the carboxyl terminal of the alpha
subunit in the determination of substrate preference in plants.
Planta. 235:1013-1022.
Marsolais F, Pajak A, Yin F, Taylor M, Gabriel M, Merino DM,
Ma V, Kameka A, Vijayan P, Pham H, Huang S, Rivoal J, Bett K,
Hernandez-Sebastia C, Liu Q, Bertrand A and Chapman R. (2010)
Proteomic analysis of common bean seed with storage protein
deficiency reveals up-regulation of sulfur-rich proteins and starch
and raffinose metabolic enzymes, and down-regulation of the
secretory pathway. J. Proteomics. 73:1587-1600.

319
Book Chapter
Gabriel M and Litchfield DW. (2013) Protein Kinase CK2: At the
Crossroads of Pathways Controlling Cell Proliferation and Survival
in Protein Kinase CK2. Ed. Pinna PA. John Wiley & Sons, Inc. pp
169-189.
PRESENTATIONS Invited Oral Presentation
Gabriel M, French A, Turowec J, LeBlanc D, Fess S, Gyenis L and
Litchfield DW. (2013) Chemical Biology Approaches to Perform
Unbiased Evaluation of CK2 and CK2 Inhibitors. 7th International
Conference on Protein Kinase CK2. Lublin, Poland. September 10 –
13, 2013.
Poster Presentations
Gabriel M, French A. and Litchfield DW. (2014) A chemical
biology approach to systematically monitor substrate specificity and
selectivity of protein kinase CK2. 10th Conference on Signalling in
Normal and Cancer Cells. Banff, Canada. March 23-27, 2014
Gabriel M, Martic S, Labib M, Litchfield DW and Kraatz HB.
(2010) Detection of Erk1-catalyzed phosphorylation reaction:
comparative analysis of electrochemical biosensor and traditional
assays. Nanoscience and Nanotechnology Workshop. London,
Canada. May 16 – 18, 2010.
Gabriel M, Pajak A. and Marsolais F. (2007) Structure-function
relationship of plant L-asparaginase. Society of Plant Physiologists
Eastern Regional Meeting, London, Canada. December 3, 2007.
SCHOLARSHIPS
AND AWARDS

Ontario Graduate Scholarship (OGS)
$15 000

September 2013 –
August 2014

Canadian Institute of Health Research (CIHR)
Banting and Best Canada Graduate Scholarship
(CGS-D)
$35 000/year

September 2011 –
August 2013

Ontario Graduate Scholarship (OGS)
$15 000

September 2010 –
August 2011

Canadian Institute of Health Research Strategic
Training Program in Cancer Research and
Technology Transfer (CIHR-STP CaRTT)
$18 900

September 2009 –
August 2011

320

Natural Sciences and Engineering Research
Council (NSERC) Alexander Graham Bell
Canadian Graduate Scholarship (CGS-M)
$17 500

September 2009 –
August 2010

Natural Sciences and Engineering Research
Council (NSERC) Undergraduate Student
Research Award (USRA)
$4 500

May 2007 –
August 2007

Western Scholarship of Excellence
$2 000
WORK
EXPERIENCE

September 2004

Research Assistantships
Graduate research assistant
Supervisor: Dr. D. Litchfield
Department of Biochemistry, University of
Western Ontario

September 2009 –
Present

Student research assistant
Supervisor: Dr. F. Marsolais
Southern Crop Protection Food Research
Centre, Agriculture and Agri-Food Canada

September 2007 –
August 2009

Student research assistant
Supervisor: Dr. M. Mann
Department of Biochemistry, University of
Western Ontario and Children’s Health
Research Institute

January – August
2007

Teaching Assistantships
Biochemistry 3380G: Biochemistry Laboratory
Biochemistry 2280A: Biochemistry and
Molecular Biology

!

January 2012 –
April 2014
September 2011 –
December 2014

